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1. INTRODUCTION 
Colorectal cancer (CRC) is one of the most common causes of death in Western countries. 
In the vast majority of patients, it presents as a sporadic disease. Around 20% of patients 
exhibit unspecific familial clustering. In up to 5% of the patients, CRC occurs in the context of 
a monogenic condition caused by highly penetrant germline mutations. The hereditary forms 
can be divided into two major groups: the more frequent Lynch syndrome or hereditary non-
polyposis colorectal cancer (HNPCC), and the various gastrointestinal polyposis syndromes. 
Relatives of patients with a hereditary type of CRC have a high lifetime risk of gastrointestinal 
tumors and a syndrome-specific spectrum of extraintestinal malignancies (Aretz 2010). 
Frequent gastrointerstinal endoscopic surveillance is advised for patients and persons at risk 
and has improved the prognosis considerably (van der Meulen-de Jong et al. 2011).  
Colorectal adenomatous polyposes are cancer predisposition syndromes, characterized by 
the occurrence of dozens to thousands of adenomatous polyps, which, if not detected early 
and removed, invariably result in CRC. So far, two different inherited forms can be delineated 
by molecular genetic analysis: the autosomal dominant Familial Adenomatous Polyposis 
(FAP) caused by heterozygous germline mutations in the tumor suppressor gene (TSG) APC 
on chromosome 5q22, and the autosomal recessive MUTYH-Associated Polyposis (MAP) 
caused by biallelic germline mutations of the base excision repair (BER) gene MUTYH on 
chromosome 1p34 (Aretz et al. 2013; Aretz et al. 2006). In FAP, the vast majority of 
mutations are truncating point mutations and large deletions (www.lovd.nl/APC) while the 
mutation spectrum in MAP is dominated by missense mutations (www.lovd.nl/MUTYH).  
Nowadays, conventional methods including Sanger sequencing and deletion/duplication 
analysis by MLPA are widely used for the detection of germline mutations of the APC and 
MUTYH genes in adenomatous polyposis patients. However, in up to 50% of patients, APC 
and MUTYH mutations cannot be identified by these methods although a genetic cause is 
likely. A reason for this failure might be that mutations in these genes are overlooked by 
routine molecular methods. However, even if these patients do not carry a germline mutation 
in known genes, the presence of dozens or more colorectal adenomas argues in favor of an 
underlying genetic predisposition. Following the discovery of MUTYH in 2002, which has 
become a known gene for up to 25% of APC mutation-negative patients with adenomatous 
polyposis, it is reasonable to assume that there might be yet unidentified causative genes 
awaiting discovery. Identification of new genetic causes of as yet unexplained disease is 
important. Once the causative genes are known, we could further understand the 
pathophysiology of the disease and improve medical care of the families regarding 
differential diagnosis, estimating the recurrence risks, and predictive testing of persons at risk 
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Germline copy number variants (CNVs) have been recognised as an important form of 
structural genetic variation, which also predisposes to human disease (Feuk et al. 2006; 
Krepischi et al. 2012b). Genome-wide CNV analysis does not require a priori hypothesis 
about the pathophysiological properties of the responsible genes and can thus be applied to 
those cases where other methods for identifying causal genes such as linkage analysis or 
candidate gene approaches are not feasible or promising. During recent years, genome-wide 
copy number analysis has been used to uncover new predisposing genes in various inherited 
conditions including familial cancer syndromes (Chen et al. 2013; Lucito et al. 2007; 
Venkatachalam et al. 2011). It is reasonable to ask whether CNVs, in particular heterozygous 
deletion CNVs, might also be part of the mutation spectrum in yet unidentified genes 
underlying unexplained adenomatous polyposis syndromes  
Next generation sequencing (NGS) refers to high throughput sequencing technologies. The 
NGS allows faster and more comprehensive diagnostics in genetically heterogeneous 
conditions. It can be used to sequence whole genome, whole exome, as well as specific 
genes of interest to discover novel causing disease mutations (Gilissen et al. 2012). 
This thesis was intended to identify novel causative genes responsible for monogenic 
adenomatous polyposis syndromes by the application of a SNP array based CNV analysis 
and a targeted Next Generation Sequencing (NGS) approach to a large and well-
characterized cohort of unrelated patients with etiologically unexplained colorectal 
adenomatous polyposis. 
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2. BASIC PRINCIPLES 
2.1. Hereditary Colorectal Cancer 
Colorectal cancer (CRC) is one of most common forms of cancer and a major cause of 
cancer-related death in the world. The etiological factors and pathogenic mechanisms 
underlying CRC development appear to be complex and heterogeneous. CRC often begins 
as a polyp on the surface of the colon mucosa. Most polyps remain benign, but some have 
the potential to turn cancerous, in particular adenomatous polyps (adenomas). The removal 
of colon polyps at the time of colonoscopy considerably reduces the subsequent risk of colon 
cancer (Tuohy et al. 2010). 
Depending upon the genetics and the etiology of the disease, CRC is usually categorized 
into sporadic, familial, and hereditary CRC. Sporadic CRC occurs in about 70% of patients, 
with no apparent evidence of the disorder being inherited. Up to 30% of CRC patients have a 
positive family history, which suggests a genetic contribution, but less than 6% of them show 
the trait in a monogenic (hereditary) form (Fearon 2011). Two major hereditary syndromes 
known so far are hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome and 
the various gastrointestinal polyposis syndromes. These two forms of hereditary cases are 
found only in 3-5% of all CRC (Daley 2010), however, they are also characterized by a broad 
syndrome-specific extracolonic tumor spectrum.  
Lynch syndrome is an autosomal dominant inherited cancer predisposition syndrome caused 
by germline mutations of mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) or the 
EPCAM gene upstream of MSH2. The majority of germline mutations have been identified in 
the MLH1 gene on chromosome 3p21 and the MSH2 gene on chromosome 2p16. Mutations 
in any of these genes prevent the proper repair of DNA replication errors. As abnormal cells 
continue to divide, the accumulated errors can lead to uncontrolled cell growth and possibly 
cancer. The EPCAM gene is not a MMR gene itself but specific 3´deletions of EPCAM lead 
to inactivation of the downstream MSH2 gene (Kuiper et al. 2011). 
The gastrointestinal polyposes, which account for about 1% of all CRC cases, can be 
categorized histologically into adenomatous polyposis and hamartomatous polyposes (Figure 
2.1). The latter include Peutz-Jeghers syndrome, familial juvenile polyposis syndrome, 
hyperplastic polyposis, and Cowden’s syndrome. The two main hereditary adenomatous 
polyposis syndromes are familial adenomatous polyposis (FAP) and MUTYH-associated 
polyposis (MAP). FAP, the best known and most frequent inherited form of gastrointestinal 
polyposis, is an autosomal dominant syndrome, caused by germline mutations in the APC 
gene. The classical (typical) form is characterized by the development of hundreds of 
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adenomas in the second decade of life. MAP is an autosomal recessive inheritance, 
described for the first time in 2002, and caused by biallelic germline mutations in the base-
excision repair (BER) gene MUTYH. It is responsible for about 20% of adenomatous 
polyposis cases without an APC mutation (Aretz et al. 2006; Mongin et al. 2012), or up to 0.3% 
of CRC patients (Nieuwenhuis et al. 2012). Although APC and MUTYH are the major causes 
of colorectal adenomatous polyposis, in up to 50% of patients no germline mutations in these 
two genes can be detected. 
 
Figure 2.1. Genetic etiology of colorectal cancer 
 
2.1.1. Differential diagnosis 
The different types of hereditary CRC can be distinguished from each other by clinical and 
histopathologic findings, the mode of inheritance, and molecular genetic analysis. To 
diagnose an adenomatous polyposis, the presence of at least 10-20 synchronous colorectal 
adenomas is required. Adenomatous polyposis can be classified as FAP if an APC germline 
mutation is identified. The larger the number of adenomas found the greater the likelihood to 
identify an APC-related FAP (Jasperson et al. 2010). Genetic screening for MUTYH 
mutations is usually done if no APC mutation is identified as MAP is suspected in those 
cases as the most important differential diagnosis. In those cases the family history usually 
does not show an autosomal dominant pattern. Hamartomatous polyps represent 
developmental malformations that affect the epithelial glands and the underlying lamina 
propria, where the mucosal components are arranged abnormally but the epithelial cells are 
not dysplastic. Patients manifest numerous nonadenomatous lesions. The conditions for 
differential diagnosis are summarized in table 2.1. 
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Table 2.1. Differential diagnosis of inherited CRC 
Syndrome Clinical features Gene defects 
HNPCC 
CRC without polyps; other cancers include 
endometrial, ovarian, and stomach cancer; 
occasionally brain tumors 
MSH2, MLH1, PMS2, 
MSH6 
FAP 
Multiple adenomatous polyps (> 100) and 
carcinomas of colorectum; duodenal polyps and 
carcinomas; fundic gland polyps in the stomach; 
congenital hypertrophy of retinal pigment 
epithelium 
APC 
Attenuated FAP < 100 polyps and/or late onset manifestation APC (predominantly 
5´and 3’ mutations) 
Gardner syndrome 
phenotypic variant of FAP, desmoids tumors 
and mandibular osteomas 
APC 
Turcot’s syndrome 
phenotypic variant of FAP, colorectal polyposis 
brain tumors (mostly medulloblastomas) 
APC 
MUTYH-associated 
polyposis 
Multiple adenomatous GI polyps MUTYH (autosomal 
recessive) 
Peutz-Jeghers syndrome 
Hamartomatous polyps throughout GI tract and 
mucocutaneous pigmentation 
STK11, LKB1 
Cowden‘s syndrome 
Multiple hamartomatous polyps in GI tract and 
various extraintestinal lesions (breast cancer, 
endometrial cancer, thyroid cancer) 
PTEN 
Juvenile polyposis 
syndrome 
Multiple juvenile polyps with predominance in 
colon and stomach 
BMPR1A, SMAD4 
Hyperplastic polyposis 
syndrome 
≥ 30 hyperplastic polyposis throughout colon 
Genetic cause 
unknown 
CRC, colorectal cancer; FAP, familial adenomatous polyposis; GI, gastrointestinal; HNPCC, hereditary 
nonpolyposis colorectal cancer.  
 
2.1.2. Adenoma-carcinoma sequence 
The majority of CRCs develop over more than 10 years from benign pre-neoplastic lesions. 
Adenomas are the most common form of premalignant precursor lesions. A multistep model 
of carcinogenesis for the development of CRC has been described by Vogelstein et al. 
(1988), known as adenoma-carcinoma sequence. Adenomas arise as the result of the 
accumulation of genetic and epigenetic changes that transform normal glandular epithelial 
cells into benign neoplasia, followed by invasive carcinoma and eventually metastatic cancer.  
Mutations in a number of oncogenic driver genes (tumor suppressor genes, oncogenes, DNA 
repair genes) have been implicated in the development of CRC. Mutations in the APC gene 
appear to be one of the earliest events in colorectal tumorigenesis. Beyond the defects in the 
Wnt-APC-beta-catenin signaling pathway (see section 2.2.1), other mutations must occur for 
the cell to become cancerous. Several major molecular abnormalities may be induced on 
transition from normal epithelium to carcinoma (Figure 2.2). One important driver is the TP53 
gene, located on chromosome 17p, which normally monitors cell division and kills cells if they 
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have severe DNA defects (apoptosis). Mutations of the TP53 gene are commonly seen in 
CRC (Vogelstein et al. 1988; Vogelstein et al. 2013). 
 
Figure 2.2. Adenoma-carcinoma development: an early initiating mutation occurs in the APC gene, 
followed by activation of oncogenes such as KRAS, leading to adenomatous polyp formation. 
Together with methylation alterations, some adenomas progress and become an adenocarcinoma. 
Mutations of TP53 and deletions of chromosome 18q are commonly found in carcinomas. 
 
2.1.3. Knudson two-hit hypothesis 
In 1971, Alfred Knudson proposed the two-hit hypothesis to explain the early onset of an 
inherited form of retinoblastoma at multiple sites. Although one allele is mutated in the 
germline, the other, normal, allele is still sufficient to protect against tumorigenesis. If a 
second hit (mutation) to the wildtype allele copy occurs somatically, the gene is completely 
inactivated, so that cancer can develop (Knudson 2001). The chance for a germline mutation 
carrier to obtain a second somatic mutation is much greater than the chances for a non-
carrier to get two somatic hits in the same cell. This hypothesis serves as the basis for the 
understanding of how mutations of tumor suppressor genes (TSG), which usually cause 
autosomal dominant inherited cancer syndromes, drive cancer. 
However, the two-hit model of the APC gene that initiates colorectal tumorigenesis does not 
necessarily result in complete loss of function. Mutant APC proteins probably retain some 
function and the two hits are co-selected to produce an optimal level of Wnt activation. In 
addition, a three-hit hypothesis has been introduced by Segditsas et al. (2009). They showed 
that a heterozygous deletion of APC represents an effective third hit in cases where the 
germline mutation is located at the very 5´end of the gene.  
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2.2. Genetics of adenomatous polyposis syndromes 
2.2.1. Familial adenomatous polyposis (FAP) 
Familial Adenomatous Polyposis (FAP) (MIM# 175100) is an autosomal dominant cancer 
predisposition syndrome, characterized by the development of hundreds of adenomatous 
polyps of the colorectum and caused by high-penetrant germline mutations in the 
Adenomatous Polyposis Coli (APC) gene (Groden et al. 1991). It is estimated to occur in 1 of 
10,000 individuals and in both genders equally. Adenomas usually occur within the second 
decade (average age of 16 years) and become symptomatic during the third decade of life. If 
not removed, the likelihood to progress to CRC is high. The average age of colon cancer 
diagnosis in untreated individuals is 39 years (Petersen et al. 1991). Attenuated FAP (AFAP) 
is a mild form of FAP with less than hundred colorectal adenomas and/or late onset of 
adenoma development. Usually, both adenoma formation and CRC occur 10-15 years later 
compared to classical FAP.  
APC is a tumor suppressor gene located on chromosome 5q22 and a central player of the 
Wnt-signaling pathway. It interacts with the adherens junction proteins and β-catenin. 
Mutations of APC cause aberrant accumulation of β-catenin, which moves into the nucleus, 
then binds T cell factor-4 (Tcf-4), causing increased transcriptional activation of target genes 
(Figure 2.3). This results in activation of the Wnt-signaling pathway and contributes to 
tumorigenesis by altering the relative adhesiveness of colonic epithelial cells and 
misregulating the integrity of cadherin-catenin complexes. APC also plays a role in 
controlling cell cycle by inhibiting the progression of cells from G0/G1 to the S phase, helping 
to suppress tumorigenesis. Furthermore, APC stabilizes microtubules, thus promoting 
chromosomal stability. Inactivation of APC can lead to defects in mitotic spindles and 
chromosomal mis-segregation, with the resulting aneuploidy leading to CRC (Galiatsatos and 
Foulkes 2006). Mutant APC proteins could alter β-catenin-mediated cell-cell signaling in a 
dominant-negative effect (Dihlmann et al. 1999). However, it is likely that this dominant-
negative effect alone is not sufficient to produce a tumor, and that additional mutations, such 
as ras-activating mutations, loss of p53 function, or loss of the wild-type allele may be 
required for tumor formation.  
The APC gene consists of 15 coding exons and encodes a protein of 2,843 amino acids 
(Groden et al. 1991; Kinzler et al. 1991). In normal tissue, several isoforms of APC 
messenger RNA (mRNA) are generated as a result of alternative splicing. To date, more 
than 1,500 different APC germline mutations have been identified in FAP patients 
(www.hgmd.org; www.lovd.nl/APC). The vast majority is predicted to result in truncated 
proteins due to nonsense or frameshift mutations, mutations in highly conserved splice sites, 
or large deletions. Around 60% of mutations occur in exon 15. Two APC hot spot mutations 
are at codons 1061 and 1309 and account for around one third of the identified mutations 
(Fearon 2011). 
Basic Principles 
 
8 
 
Figure 2.3. Model of the canonical Wnt signaling pathway. Left: The APC protein aligns with other 
proteins such as glycogen synthase kinase 3β (GSK3β) to form a destruction complex. This complex 
phosphorylates -catenin, leading to degradation of -catenin. Thus no -catenin can move into the 
nucleus. Right: Inactivation of APC can lead to the accumulation of -catenin. When free -catenin is 
increased, the -catenin can enter the nucleus and activate the transcription of TCF-regulated target 
genes. (Figure adapted from www.boundless.com/biology/cancer-and-disease/genetic-basis-for-
cancer/cancer-development-is-a-multi-step-process/) 
Differences in phenotypic expression are partly related to the location of the mutation within 
the APC gene (Figure 2.4). Most of the correlations between the mutation site and the clinical 
phenotype (genotype-phenotype correlation) have been proved to be significant and 
consistent (Friedl and Aretz 2005). Mutations in the middle part of the gene are associated 
with ‘classical FAP’ with early onset of 100-1000 polyps. Severe FAP usually co-occurs with 
mutations of the APC gene between codons 1250-1464, which is a mutation cluster region. 
The mild form of FAP is usually caused by mutations in the extreme 5’ end or the 3′ half of 
APC or in the alternatively spliced region of exon 9 (Jones et al. 2002). Mutations in the 3' 
half of the gene are usually associated with extra-intestinal manifestations such as desmoids. 
Desmoid tumors generally occur in FAP patients with mutations downstream of codon 1400 
(Heinen 2010).The presence of congenital hypertrophy of the retinal pigment epithelium 
(CHRPE) appears restricted to patients with inherited mutations between codons 311 and 
1465.  
Two phenotypic variants of APC-associated polyposis syndromes are Gardner syndrome 
and Turcot syndrome (Table 2.1). They can occur in any individual with FAP (Gardner and 
Richards 1953). Gardner syndrome is characterized by colonic polyposis together with 
osteomas and soft tissue tumors (desmoids, fibromas). Turcot syndrome is defined as the 
association of colonic polyposis and central nervous system (CNS) tumors.  
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Figure 2.4. APC mutation spectrum and corresponding clinical outcome (genotype-phenotype 
correlations). Classical FAP is associated with mutations in codons 157-1595, excluding the mutation 
cluster region (codon 1250-1464), which is found in FAP patients with severe colorectal phenotype. A 
milder form of FAP is associated with APC mutations in three regions: 1) 5’ end of the gene; 2) the 
alternative splice region in exon 9; and 3) the 3’ part of the gene. CHRPE is associated with mutations 
between codons 311-1465. Desmoid tumors are related to a mutation beyond codon 1400. 
 
2.2.2. MUTYH-associated polyposis (MAP) 
MUTYH-associated polyposis (MAP) (MIM# 608456) is the most important differential 
diagnosis of FAP. It is the first known polyposis syndrome with a recessive mode of 
inheritance. MAP is caused by biallelic MUTYH mutations and is characterized by ten to a 
few hundred colorectal adenomas at around 50 years of age. The risk of untreated MAP 
patients to develop CRC is around 80% at age of 60 years approximately. 
MUTYH is a base excision repair (BER) gene located on chromosome 1p34.1. Mutations of 
BER genes lead to an increase of G:C to T:A transversions (Moriya and Grollman 1993). The 
role of MUTYH or the MutY homolog gene in polyposis was discovered in 2002 by Al-Tassan 
et al. By studying eleven tumors in three affected siblings without inherited mutations of APC, 
they found that 15 out of 18 somatic mutations are G:C to T:A transversions (Al-Tassan et al. 
2002). This finding led to the suspicion that the MUTYH protein may be deficient in these 
patients. Many functional studies of this protein as well as mutation screening in many 
patient cohorts could clarify this hypothesis. 
The MUTYH gene consists of 16 exons and encodes a protein of 546 amino acids. It 
encodes a DNA glycosylase enzyme involved in oxidative DNA damage repair. The MUTYH 
glycosylase corrects the intermediate mutational state (incorporation of an A opposite to oG ) 
during DNA replication before cell division, and thus prevent the accumulation of DNA 
mutations which might predispose to tumorigenesis. This function is known as BER (Figure 
2.5). When BER in the cell is impaired due to MUTYH inactivation, mutations in other genes 
such as APC build up, leading to cell overgrowth and possibly tumor formation. To date, 
more than 300 unique variants of MUTYH have been reported in the LOVD database. Most 
are specific missense mutations, along with small deletions, duplications, and insertions. Two 
most common missense mutations in the Caucasian population are Tyr179Cys and 
Gly396Asp. These two mutations have not been identified in Far Eastern Asian populations; 
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thus, they probably represent founder effects from a common European ancestor (Aretz et al. 
2013).  
 
Figure 2.5. Base excision repair (BER) pathway; oxidative stress can induce a formation of 8-
oxoguanine (8-oxoG) in DNA (
o
G) resulting in a G:C to T:A transversion mutation after replication in 
the case of an unrepaired 8-oxoG lesion. MutM (OGG1) and MutY (MUTYH) can repair the 
intermediate mutation states. The MutM (OGG1) will correct the 8-oxoG, and then a repair process will 
take place. Or if A is misincorporated opposite the 8-oxoG as a consequence of inaccurate replication, 
MutY (MUTYH) will remove it and resynthesis will be accomplished.  
 
2.2.3. Mutation negative adenomatous polyposis 
In up to 50% of patients with adenomatous polyposis, no APC or MUTYH germline mutation 
can be identified in routine diagnostics. However, the occurrence of dozens or hundreds of 
colorectal polyps strongly argues for an underlying genetic predisposition. One possibility to 
explain mutation-negative adenomatous polyposis is the limitation of present routine 
diagnostics methods, which leads to overlooking mutations in both genes. Aretz et al. (2007a) 
and Hes et al. (2008) reported mosaic mutations in the APC gene in a substantial number of 
FAP patients with an empty family history, in whom no APC mutation was identified by 
routine screening methods, because the signal of the mutated allele was very low. Moreover, 
there might be additional mutations in non-scanned parts (non-coding regions) of the genes, 
which have not been discovered with present methods. 
The high number of adenomas and the early age at onset cannot be explained convincingly 
by non-genetic/environmental factors. Thus, it is likely that a yet unknown inherited 
predisposition is underlying the unexplained adenomatous polyposis cases, either as a 
monogenic trait or in a more oligogenic/multifactorial way which means, a fairly large number 
of mutated genes may contribute to disease, each with only a small effect that is difficult to 
uncover. As the majority of unexplained adenomatous polyposis patients are sporadic cases, 
monogenic subtypes are likely to be autosomal recessive.  
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2.3. Human genome variation  
The human genome consists of about 3.2 billion base pairs (bp), and it is currently estimated 
that about 21,000 protein coding genes are encoded in the human DNA (Genome Reference 
Consortium). Protein-coding sequences make up only about 1-2% of the human genome.  
Genomic variations have different forms: 1) Single nucleotide polymorphisms (SNP); 2) 
tandem repeats; and 3) structural variants including deletions, duplications, translocations, 
and inversions (Ku et al. 2010). All types of genetic variation can also occur as rare and high 
penetrant mutations which may cause human disease. 
 
Figure 2.6. Graph explaining the expected allele frequency and penetrance of rare and common 
diseases. The majority of Mendelian diseases are caused by very rare variants with high penetrance 
(McCarthy et al. 2008). 
A common variant is often defined as having a minor allele frequency (MAF) of more than 1% 
in the general population. Conversely, the definition of rare variant refers to a variant with a 
MAF of less than 1% (Ionita-Laza and Ottman 2011; Lefevre et al. 2012). Variants found 
frequently in the human genome and may or may not have an impact on the phenotype are 
also called ‘polymorphisms’. Mendelian (monogenic) diseases are usually caused by a rare 
variant with high penetrance. However, some mutations observed in autosomal recessive 
conditions such as Cystic Fibrosis or MAP, have an MAF of > 1%. In contrast to Mendelian 
disorders, multifactorial diseases are caused by several common variants with low 
penetrance (common disease - common variant hypothesis) (McCarthy et al. 2008). 
Penetrance is defined as the proportion of mutation carriers that express the related 
phenotype (Figure 2.6). 
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2.3.1. Single nucleotide polymorphisms (SNPs) 
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation 
characterized by single-base exchanges at a specific DNA site and are distributed 
throughout the genome. The human genome contains at least 11 million SNPs that occur 
with a minor allele frequency (MAF) of at least 1% (International-HapMap-Consortium 2005). 
They are estimated to occur at a frequency of approximately one per 300 nucleotides. 
Therefore, for every 300 nucleotides, the average nucleotide identity at one position will differ 
between any two copies of that chromosome at a substantial frequency throughout a 
population. A wide variety of approaches for genotyping SNPs have been developed, one 
approach being Micro-array technology (Carter 2007). SNP genotyping is important in human 
genetic studies because a specific SNP allele can be implicated as an associated causative 
factor in human genetic disorders and can be used as genetic marker for genetic-mapping 
studies. 
 
2.3.2. Tandem repeats 
Tandem repeats are repeats of a nucleotide pattern and can be divided into two classes, 
short tandem repeats (STRs) and variable number tandem repeats (VNTRs). STRs or 
microsatellites are repeats typically composed of 2-7 nucleotides. These markers are 
abundant, equally distributed throughout the genome and are highly polymorphic compared 
with other genetic markers. STRs have become popular DNA markers; the number of 
repeats in STR markers can be highly polymorphic among individuals, which makes STRs 
effective in the identification of genes underlying monogenic conditions by linkage analysis. 
VNTRs, also known as minisatellites, consist of repetitive sequences of more than eight 
bases (commonly 10 – 60 base pairs).  
 
2.3.3. Structural variations 
Variants comprising more than a single nucleotide are broadly defined as structural 
variations. They include insertions, deletions, translocations, duplications and inversions 
(Figure 2.7). The sizes of structural variants range from the microscopic level, e.g., 
chromosomal aberrations, to the copy number variant level, which is on the order of ≥ 1 kb. 
One of the smallest structural variants are ‘indels’, which are defined as either an insertion or 
deletion of nucleotides up to 50 bases in length (Montgomery et al. 2013). Next to SNPs, 
indels are the second most abundant form of genetic variation. It has been estimated that 
there are 1-2 million short indels segregating at low to high frequency in modern human 
populations. The vast majority of indels occur in short tandem repeats. Many of these indels 
map to functionally important sites within human genes and are likely to influence human 
traits and diseases (Mullaney et al. 2010). 
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Several studies suggest that structural variants account for at least 70% of all variant bases 
in the human genome, and for any given individual, structural variations constitute between 
~0.5% to 1% of the genome (Alkan et al. 2011). All these variations likely contribute to both 
human diversity and disease susceptibility due to altered gene dosage levels, disruption of 
proximal or distant regulatory regions, or by affecting the coding sequence. 
 
Figure 2.7. The schema represents types of structural variants compared to the reference genome 
(upper line); deletion, insertion, duplication, inversion, and translocation. (Figure adapted from Alkan et 
al. (2011)). 
 
Copy number variation (CNV)  
Copy number variation (CNV) is a major part of human genetic variation (Cook and Scherer 
2008) and an important class among the other types of structural variation (Feuk et al. 2006). 
As humans have two copies of each autosomal chromosome, a deletion or a duplication of 
one allele alters the number of copies, and this phenomenon is called copy number variation 
(Freeman et al. 2006). Thus, CNVs include gains (insertions or duplications) and losses 
(deletions or null alleles) of genomic regions. By definition, the term refers to DNA regions ≥ 
1 kb in length. The majority of CNVs are 1-10 kb in length. 
Mechanisms of CNV formation 
Three major mechanisms have been proposed to cause genomic rearrangements in the 
human genome: (1) Non-allelic homologous recombination (NAHR) is well known, mostly 
mediated by low-copy repeats (LCRs) with recombination hotspots, gene conversion, and 
apparent minimally efficient processing segments; (2) non-homologous end joining (NHEJ); 
and (3) Fork Stalling and Template Switching (FoSTeS) models, both of which are 
responsible for non-recurrent rearrangements (Gu et al. 2008). 
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1 Non-allelic homologous recombination (NAHR), also called ‘Hotspots inside low-copy 
repeats’, is often caused by LCRs. LCRs are segmental duplications which are defined as 
regions longer than 10 kb with over ~97% sequence identity. LCRs can cause genomic 
instability and either mediate or stimulate CNV formation. When LCRs are located at a 
distance less than 10 MB from each other, they can lead to misalignment in both meiosis and 
mitosis, and mediate non-allelic homologous recombination (NAHR), which can result in 
unequal crossing-over. When two LCRs are located on the same chromosome in the same 
direction, NAHR between them causes a duplication and/or a deletion (Figure 2.8). When 
they are on the same chromosome but in opposite directions, NAHR results in an inversion 
of the fragment flanked by them. Prominent examples of disease causing CNVs mediated by 
LCRs are a number of well known human microdeletion syndromes such as Angelman 
syndrome, DiGeorge syndrome, or Williams-Beuren syndrome. Non-homologous 
recombination events that underlie changes in copy number also allow for generation of new 
combinations of exons between different genes by translocation, insertion, or deletion, so 
that proteins might acquire new domains, and hence new or modified activities (Hastings et 
al. 2009). 
 
Figure 2.8. Nonallelic homologous recombination (NAHR): a1 and a2) Genomic rearrangements 
resulting from low-copy repeat (LCR) recombinations. Black arrows represent LCRs and the direction 
of the arrowhead indicates the orientation of LCRs. Letters indicate the flanking sequences. Thin 
diagonal lines refer to recombination events with results identified by numbers 1, 2, and 3. b) 
Schematic representation of reciprocal duplications and deletions mediated by interchromosomal (left), 
interchromatid (middle) and intrachromatid (right) NAHR using LCR pairs in direct orientation. 
Interchromosomal and interchromatid NAHR between LCRs in direct orientation result in reciprocal 
duplication and deletion, whereas intrachromatid NAHR only creates deletion (Figure adapted from Gu 
et al. (2008)). 
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2 Non-Homologous End Joining (NHEJ) is one of the two major mechanisms for repairing 
DNA double strand breaks (DSB); it is used to explain duplications (Lee et al. 2006). 
Random breakage can cause large inverted duplications, and repeated cycles could lead to 
amplification of the inverted repeat. The breakage-fusion-bridge cycle has been linked to the 
formation of amplification and is believed to play a major role in amplification in cancer. In 
contrast to NAHR, NHEJ does not require LCRs to mediate the recombination but may also 
be stimulated by genome architecture. When a DSB is detected, then both broken DNA ends 
are bridged, modified, and finally ligated (Figure 2.9) (Lieber 2008). 
3 Fork Stalling and Template Switching (FoSTeS) is the third major mechanism for human 
genomic rearrangement (Lee et al. 2007) and might be a major mechanism for duplication 
CNVs. The mechanism is based on DNA replication errors. During DNA replication, the DNA 
replication fork stalls at one position; one replication fork with a lagging strand invades and 
anneals to another replication fork in physical proximity at the 3' end and starts the DNA 
synthesis. The priming results in a 'join point' rather than a breakpoint and can result in 
complex rearrangements. Depending on the location of the new fork, a deletion or a 
duplication will occur (Gu et al. 2008). 
 
Figure 2.9. Genomic rearrangement mechanisms: a) Non-homologous end-joining (NHEJ); a double-
stranded DNA break (DSB) occurs and is repaired via NHEJ mechanism. The two thick lines depict 
two DNA strands with DSB, the thin segments in the middle represent the modifications, through 
which the ends have gone before the final ligation. Ku is a DNA end-binding protein; once Ku is bound 
to the DNA end it can improve the binding equilibrium of the nuclease (Artemis-DNA-Pkcs), 
polymerases ( and ), and ligase (XRCC-DNA ligase IV) of NHEJ. b) Fork stalling and template 
switching (FosTes); after the original stalling of the replication fork (dark blue and red, solid lines), the 
lagging strand (red, dotted line) invades and anneals to a second fork (purple and green, solid lines) 
followed by DNA synthesis (green, dotted line). After the fork disengages, the original fork (dark blue 
and red, solid lines) with its lagging strand (red and green, dotted lines) could invade a third fork (gray 
and black, solid lines). Dotted lines represent newly synthesized DNA. Serial replication fork 
disengaging and lagging strand invasion could occur several times before resumption of replication on 
the original template (Figures adapted from Lee et al. (2007) and Gu et al. (2008)). 
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Functional impact of CNVs and disease association 
Nowadays, large-scale duplications and deletions are thought to be a normal part of genetic 
variation. Like SNPs, CNVs have become important in genetic diversity as they play a role in 
genetic susceptibility to common diseases including cancers (Ionita-Laza et al. 2009; 
Krepischi et al. 2012b; Stankiewicz and Lupski 2010). In hereditary cancer syndromes, rare 
large heterozygous deletions in several known cancer-predisposing genes such as APC, 
BRCA1, BRCA2, RB1 and TP53 substantially contribute to the germline mutation spectrum 
(Kuiper et al. 2010). Thus, common and rare CNVs play important pathogenic roles, from 
causative high penetrant CNVs (mostly deletions) in rare genomic disorders to intermediate 
or low penetrant CNVs in complex multifactorial diseases (Fanciulli et al. 2010). 
Consequently and similar to SNPs and rare point mutations, common and rare CNVs should 
be considered separately as they may play different roles in cancer predisposition (Shlien 
and Malkin 2009). In line with the definition of SNPs, common CNVs shared by > 1% of the 
population are also referred to as copy number polymorphisms (CNPs), however, the term 
‘CNPs’ is not consistently used. CNPs correspond mostly to ancestral events and segregate 
in the population with different allele frequencies (McCarroll et al. 2008; Redon et al. 2006).  
CNVs and gene expression: Changes in copy number might change the expression levels 
of genes included in the affected region, thus allowing transcription levels to be higher or 
lower (Hastings et al. 2009). By gene expression analysis, around 76% of genes affected by 
copy number alteration had expression patterns that correlated with the gene copy number 
(Fanciulli et al. 2010; Henrichsen et al. 2009; McCarroll et al. 2006; Orozco et al. 2009; 
Stranger et al. 2007). 
Partial gene duplications might be more deleterious than full gene duplications as they may 
introduce a frameshift into the transcript or produce a dominant negative isoform when they 
are ordered in a tandem position, either of which may decrease protein function. Likewise, a 
chromosomal rearrangement resulting from CNVs can cause a ‘positional effect’, i.e., the 
absence of the natural regulatory region or the conjunction with a different regulatory element 
can change the expression of the respective gene (Kleinjan and van Heyningen 1998). 
Stranger et al. (2007) reported a gene expression study in HapMap lymphoblast cells 
showing that half the effects of known CNVs are caused by gene disruption or by affecting 
regulatory or other functional regions, not by altering gene dosage. For example, a deletion 
that moves an enhancer within functional distance of a gene can increase expression of that 
gene, while a duplication that moves an enhancer further away may decrease gene 
expression (Figure 2.10). These effects lead to difficulties in predicting functional 
consequences of CNVs.  
Notably, 53% of genes whose expression was influenced by CNVs had the corresponding 
CNV outside of the actual gene, suggesting that many CNVs could affect important 
regulatory sequences that are situated at a distance from the actual target gene (Ionita-Laza 
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et al. 2009). Large de novo CNVs, which encompass many genes and/or regulatory 
sequences, are thought to likely be disease causative (de Smith et al. 2008).  
 
Figure 2.10. Illustration of mechanisms of CNVs leading to malfunction of genes. Squares represent 
genes, ovals represent promoters, and bent arrows represent the direction of transcription (Figure 
adapted from Lee and Scherer (2010)).  
In general, large deletions are supposed to cause more severe phenotypes compared to 
large duplications since the loss of a copy has more dramatic effects than the gain of a copy 
in dosage sensitive genes CNVs that are intragenic or involve a single exon may have 
functional consequences that are similar to point mutations, behaving much like classical 
Mendelian dominant or recessive traits. In addition, a deletion may result in 
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haploinsufficiency for a dosage-sensitive gene. A duplication may create imbalances due to 
excess product of the duplicated genes, or, when intragenic, may alter the structure of a 
product and thereby its function (Lee and Scherer 2010). Alternatively, CNVs that overlap 
genes can result in fusion genes that may have phenotypic consequences. 
CNVs and cancer: Rare germline CNVs such as deletions and amplifications can cause 
monogenic genetic disorders including hereditary cancer syndromes (Lucito et al. 2007). So 
far, more than 30% of approximately 100 known cancer genes predisposing to hereditary 
tumor syndromes have been observed to include deleterious CNVs; most of them are 
heterozygous deletions, which disrupt single exons up to the whole gene (Krepischi et al. 
2012b; Kuiper et al. 2010). Common germline CNVs are supposed to lead to low penetrance 
cancer predisposition. Shlien and Malkin (2010) reported 49 cancer-related genes involving 
common CNVs, most of which presumably have low penetrance and exert only a small 
contribution to cancer risk. Although common low penetrant CNVs are only modest 
contributors to cancer individually, their combined impact on cancer predisposition must be 
taken into account in estimating cancer risks. 
CNVs and colorectal cancer: Although most highly penetrant genes are frequently affected 
by point mutations, CNVs, in particular deletions, contribute significantly to the mutation 
spectrum of known genes underlying hereditary CRC syndromes: in FAP, Lynch syndrome, 
or Peutz-Jeghers syndrome, around 5-30% of the underlying germline mutations represent 
herterozygous deletions (Aretz et al. 2005; Krepischi et al. 2012b; Kuiper et al. 2010; Lucci-
Cordisco et al. 2005; Shlien and Malkin 2009). Monogenic cancer syndromes such as Lynch 
syndrome can also be caused by germline CNVs outside the relevant genes such as micro-
deletions of the EPCAM gene upstream of MSH2 which causes a transcriptional read-
through and epigenetic silencing of MSH2 (Kuiper et al. 2010). 
Although CNVs are a significant submicroscopic form of genetic variation, their influence on 
phenotypic variability, including disease susceptibility, remains incompletely understood and 
needs to be investigated further. 
  
2.4. Identification of causative genes in human disease 
It is important to identify the genes implicated in hereditary diseases, since this knowledge 
can lead to improvements in differential diagnosis, estimating recurrence risks, disease 
prevention (surveillance), and treatment. To localize disease predisposing genes, different 
methods can be applied. The usual process to identify highly penetrant causative genes is 
linkage analysis in DNA samples of family members affected and not affected with the 
disease. This approach can only be applied if multiple affected family members are present 
and available and when the disease status of the family members can be clearly asessed. 
Homozygosity mapping is another traditional approach to identify the causative gene for 
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autosomal recessive conditions in consanguineous families. Since the completion of the 
Human Genome Project, family-based analysis has shifted to hypothesis-free research 
including genome-wide CNV analysis. Most recently, high-throughput sequencing 
technologies, in particular exome and genome sequencing, are increasingly used to identify 
pathogenic mutations in new genes underlying Mendelian disorders (Gilissen et al. 2012; 
Goldstein et al. 2013).  
In multifactorial/polygenic (complex) diseases, genome-wide linkage analysis and SNP-
based association studies of candidate genes were used to uncover the genetic basis. 
However, these methods were replaced recently by genome-wide association study (GWAS) 
and next generation sequencing (NGS) studies to identify common low penetrant and rare 
moderate penetrant variants, which constitute the genomic architecture of genomic 
predisposition. 
Below, the most common methods for localizing or directly identifying disease-predisposing 
genes are outlined in more detail. 
 
2.4.1. Homozygosity mapping 
Homozygosity mapping is an important tool to identify the causative gene in autosomal 
recessive conditions in consanguineous families. In most situations, the power for the 
detection of recessive genes is lower compared to autosomal dominant genes because 
recessive diseases usually are found only in a single sibship, often with just sporadic 
appearance, while dominant traits tend to occur in many generations of larger family 
pedigrees.  
 
Figure 2.11. Illustration of the basic principles of homozygosity mapping. The genomic region is 
represented by a straight grey line with markers indicated by small bars. Regions of autozygosity 
(homozygous with two identical‐by‐descent alleles) are in black. Considering four patients who are 
affected by the same recessive disorder, because of inbreeding, each patient might have several 
autozygous regions over the genome. However, they share a region of autozygosity, where the 
disease locus is likely to map. Patients will all be homozygous at the markers located in this region. 
(Figure adapted from www.els.net/WileyCDA/ElsArticle/refId-a0005407.html) 
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The basic concept of homozygosity mapping is to trace the inheritance of the same 
chromosomal region from an ancestor via two consanguineous heterozygous parents and 
hence homozygosity in the patients; thus, the disease region must be homozygous in all 
affected family members (Figure 2.11). However, detection of identical regions and 
homozygosity by descent (HBD) when family data are not available, or when relationships 
are unknown, is still a challenge (Zhang et al. 2011). Making use of population data from 
high-density SNP genotyping may allow detection of regions HBD from recent common 
founders in singleton patients without genealogy information. However, the homozygous 
regions may include dozens or hundereds of candidate genes. If the affected family 
members are more distantly related, the homozygous regions will be reduced regarding 
number and size. 
 
2.4.2. Loss of heterozygosity (LOH) analysis 
A region derived from each parent, which contains different alleles of a genetic variant, is 
said to be heterozygous. However, one parental copy of a region can sometimes be lost due 
to non-disjunction during mitosis, segregation during recombination, or deletion of a 
chromosome segment, which results in the region having just one copy. That single copy 
cannot be heterozygous and therefore the region shows a “loss of heterozygosity” (LOH). To 
demontrate heterozygosity, genetic markers such as microstellites or SNPs can be used. 
LOH becomes critical when the remaining allele contains a point mutation that renders the 
gene inactive. This alteration is a common genetic occurrence in cancers where a tumor 
suppressor gene (TSG) is affected. The LOH of a TSG, often examined by genotyping 
microstallite markers flanking the gene in normal tissue compared to tumor tissue, is an 
important marker for loss of the second (wildtype) allele in tumor tissue. The deletion of the 
wildtype allele is the second hits’ required for TSG inactivation and is believed to be one of 
the key steps in the carcinogenesis of tumors such as CRC. Analysis of LOH is important in 
cancer research for localizing potential TSGs (Paulson et al. 1999). There have been several 
reports of LOH in candidate TSGs in CRC, which relate to chromosomes 7, 8, 18, 20, and 22 
(Eldai et al. 2013; Therkildsen et al. 2013; Yam et al. 2013).  
Microsatellite markers, also known as short tandem repeats (STRs), are polymorphic DNA 
loci consisting of 2-6 repeated nucleotide sequences. The number of repeat units varies in 
the population. LOH using microsatellite markers is used for screening of tumor samples by 
comparing suspected cancerous tissue and healthy tissue from the same individual. Another 
approach for analyzing LOH is SNP array genotyping to compare SNP genotypes between 
tumor DNA samples and patient-matched germline DNA samples obtained from normal (non-
tumor) tissue. SNP array genotyping data is also useful for the delineation of minimally lost 
regions that indicate the presence of important TSGs.  
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With SNP array genotyping data, it is possible to identify copy-neutral LOH. The LOH is 
called copy-neutral because no net change in the copy number occurs in the affected 
individual. Other names for copy-neutral LOH are acquired uniparental disomy (UPD) or 
gene conversion. In UPD, a person receives two copies of a chromosome, or part of a 
chromosome, from one parent and no copies from the other parent due to errors in meiosis I 
or meiosis II. 
 
2.4.3. Linkage analysis 
Linkage is the tendency for genes and other genetic markers to be inherited together 
because of their location near one another on the same chromosome. The biological basis 
for linkage analysis is recombination caused by crossing-over during meiosis. The smaller 
the physical distance between two genetic loci on a chromosome, the lower the frequency of 
recombination is between the markers, which means that the probability that they are 
separated by recombination is low. In contrast, the recombination rate is higher (no linkage) if 
two loci are at opposite ends on a chromosome (Goldstein et al. 2001). Linkage analysis is a 
traditional approach to search for a disease gene, used to investigate in a family with several 
affected persons to see if some of a set of markers (microstellites, SNPs) co-segregate with 
the phenotype. The co-segragating markers are assumed to be close to a neighboring 
disease causing gene (Figure 2.12). Linkage studies require no prior information regarding 
the causative gene, however, the results are influenced by the distance of the markers to the 
causative region (recombination events), the ability to clearly recognize the phenotype of a 
proband, and the correctness of the reported relationships between family members.  
 
Figure 2.12. The co-segregation of an autosomal dominant disease trait and alleles at 3 polymorphic 
marker loci (A, B, C). The disease is transferred from I:1 to II:1 by the black allele which contains the 
haplotype 1-2-4 of the markers A, B, and C. Recombination events are shown in the third generation. 
Marker C shows recombination in III:4, III:6 with no phenotype and marker A shows one recombination 
in the unaffected individual III:10. The affected III:3, III:7 demonstrate that the disease trait shows 
linkage to markers A and B, and the causative gene is located within haplotype block B. (Figure 
adapted from Pulst (1999)). 
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Genome-wide linkage analysis is a powerful tool for localizing genes for diseases following 
Mendelian patterns in families (Goldstein et al. 2001). Microsatellite markers are used as 
tools for tracking the not yet identified gene. Approximately 400-500 microsatellite markers 
distributed over the whole genome are examined for genetic mapping. They are based on 
the observation that genes that reside physically close on a chromosome remain linked 
during meiosis but the regions identified are often large and include many candidate genes. 
After the identification of a putative locus, the region that could possibly contain a causal 
variant is smaller and easier to systematically study. 
 
2.4.4. Genome-wide association study (GWAS) 
Genome-wide association studies (GWAS) aim to identify common genetic variants that 
might underlie multifactorial, genetically complex disease where a combination of various low 
or moderate penetrance susceptibility alleles and environmental factors cause the phenotype. 
A GWAS requires no prior information regarding potential causative genes but is based on 
the “common disease – common variant” hypothesis. Depending on the type of control 
individuals/genotypes used, two different approaches are distinguished, family-based or 
case-control association methods (Ioannidis et al. 2010). In GWAS, to achieve 
comprehensive coverage and adequate statistical power to detect unknown disease variants 
through linkage disequilibrium (LD), a large number of genetic markers are required 
spanning the whole genome as well as a large number of patients and controls. 
In an association analysis, unrelated case and control individuals are compared regarding 
the frequencies of alleles or genotypes of a single marker. Fortunately, the existence of LD 
significantly reduces the number of SNPs to a set of representative tagSNPs that needs to 
be genotyped in a GWAS. Genomic regions of interest may also be investigated by 
haplotype analysis, in which a handful of alleles transmitted together on the same 
chromosome are tested for association with disease; in this case, the loci which are jointly 
considered are located within a small genomic region, often confined to the neighborhood of 
a single gene (Braun and Buetow 2011). 
Genetic variants which are identified to be statiscally associated with a disease may directly 
increase susceptibility to a condition, or the associated marker alleles may be linked to 
nearby causative alleles. More often than not, the markers do not themselves play a role but 
instead are in LD to the real causative markers. Additionally, they might modify the 
expression of a nearby gene as most of them are located in regulatory regions. Significant 
frequency differences of SNPs between patients and controls are interpreted as being due to 
an original disease mutation having occurred generations ago and a paucity of recombination 
between disease and neighboring marker loci. Most markers used in GWAS have no effect 
on the amino acid sequence of a protein since they are silent variants or are located in 
intergenic or intronic regions with no obvious connection with protein expression. 
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In recent years the use of genome-wide SNP microarrays (SNP arrays) has exploded due to 
the rise of large numbers of GWAS. This strategy has been very successful in identifying 
new genetic loci for various human complex traits (see updated GWAS catalog: 
www.ebi.ac.uk/fgpt/gwas/). Most of the genes and loci identified have not previously been 
thought to be associated with their respective diseases.  
 
2.4.5. Copy number variation (CNV) analysis 
Copy number variation (CNV) is an important form of structural variation. Redon et al. (2006) 
published the first CNV map, which collected 1447 copy number variable regions, covering 
360 Mb (12%) of the human genome. The CNV regions cover more nucleotide content per 
genome than SNPs; 10% of known genes contain CNVs. Since then, several studies of 
CNVs with high-throughput technologies have been performed to increase the knowledge of 
CNV distributions, sizes, frequencies, and other population-genetic parameters (Conrad et al. 
2010; Cooper et al. 2008; Jakobsson et al. 2008; Mills et al. 2011). The number of CNVs 
reported in the Database of Genomic Variants (DGV, http://projects. tcag.ca/variation/), a 
catalog of human genomic structural variation, is increasing continuously. In 2008, Perry et al. 
(2008) reported that CNV regions have been estimated to cover 18% of the human genome. 
One year later, Zhang et al. (2009) showed that CNVs cover 29.7% of the human genome. In 
June of 2013, DGV reported a number of 184,148 CNVs by including 53 studies. CNVs are 
found in every chromosome including sex chromosomes (Figure 2.13).  
Detection of CNVs 
Traditional approaches to identify CNVs (large deletions and duplications) employ 
chromosome analysis and targeted approaches such as karyotyping and fluorescence in situ 
hybridization (FISH), segregation analysis of polymorphic marker alleles, quantitive PCR, 
RNA analysis, multiplex ligation-dependent probe amplification (MLPA). Nowadays, high-
throughput technologies enabling genome-wide discovery of CNVs are broadly used. They 
can be divided into two categories: hybridization-based and sequence-based approaches 
(see section 2.4.6). In large-scale genetic studies, hybridization-based technology is the 
primary method for CNV detection (Pinto et al. 2011). Several genome-wide studies of copy-
number variation using hybridization-based methods have been published (Conrad et al. 
2006; Cooper et al. 2008; Pinto et al. 2007; Redon et al. 2006). The two main types of 
microarrays are comparative genomic hybridization (CGH) arrays and single nucleotide 
polymorphism (SNP) arrays, also called genotyping arrays. 
In a typical array-CGH experiment, total genomic DNAs are extracted from patients and 
references and differentially labeled with two fluorescent dyes, green and red. The two sets 
of DNA probes are hybridized together to an array (Figure 2.14A). Fluorescence signals are 
measured separately for the test and the reference samples with two different color channels. 
For a given probe, the relative intensity of the test versus reference signals reflects a noisy 
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measurement of the relative DNA amount (Pinkel and Albertson 2005). With proper 
normalization, the data usually take the form of log ratio (LogR) of test and reference 
intensities at each probe, linearly ordered according to the physical locations of probes along 
the genome. The generated CNV profile falls into a wide range of coverage and resolution. 
Although array-CGH can detect deletions or duplications in very small segments of 
chromosomes, it cannot detect copy number neutral differences associated with loss of 
heterozygosity (LOH). 
 
Figure 2.13. Genome-wide view of CNVs. Blue bars indicate reported CNVs. Red bars indicate 
reported inversion breakpoints. Green bars indicate segmental duplications. (Figure adapted from 
Database Genome Variants (hg 18)). 
SNP arrays were originally designed for high-density genotyping projects with hundreds of 
thousands to millions of probes (e.g. in GWAS). On a SNP genotyping array, each SNP 
allele is represented by probes approximately 25 bp long. In contrast to the CGH array, the 
SNP array is oligonucleotide specific to known SNPs. They do not require reference DNA 
from a healthy person. A DNA sample from an individual is pre-processed and hybridized to 
a commercial chip. Alleles of each SNP have been defined (Figure 2.14B). Due to the high 
density of SNPs in the human genome, the density of oligonucleotide probes on genotyping 
arrays is very high, which enables the arrays to be used for CNV detection (Carter 2007). 
Final genotype calls and raw measurements obtained from the genotyping array have been 
used to construct CNV data. 
CNV detection using SNP arrays 
For CNV detection, signal intensities of the match and mismatch probes are compared with 
values from another individual (or group of individuals) and the relative copy number per 
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locus is determined (Yau and Holmes 2008). Highly standardized processing procedures 
help to reduce the variance of ratios calculated from independent hybridizations. Further 
noise reduction can be achieved by taking length and GC content of the probes into account. 
Different algorithms have been developed for the detection of CNVs in array intensity data 
such as PennCNV, QuantiSNP, and CNV partition (Carter 2007; Dellinger et al. 2010; Pinto 
et al. 2011; Valsesia et al. 2013).  
 
Figure 2.14. Basic principle of array CGH and SNP array analysis. A) In array CGH, patient and 
control DNAs are labeled in different colors and co-hybridized to the array. Yellow dots on the slide 
indicate equal copy number for control and patient DNA. Red dots indicate the loss of DNA material in 
the patient. Computational analysis shows spectral imbalance which represents gain/loss of test DNA 
material. B) In a SNP array, only patient DNA is labeled and hybridized to the array. Copy number 
analysis is based on signal intensity; the intensity of each oligonucleotide is compared to the intensity 
of the same oligonucleotide in a set of standard controls. 
The accuracy of CNV boundaries derived from SNP arrays is influenced by multiple factors 
such as DNA quality, markers density, sophisticated algorithms, statistical methods, batch 
effects, and differences between experiments. QuantiSNP is a computational framework for 
detecting regions of copy number variation from BeadArray SNP genotyping data using an 
Objective Bayes Hidden-Markov Model (OB-HMM) (Colella et al. 2007). It provides 
probabilistic quantification of state classifications and significantly improves the accuracy of 
segmental aneuploidy identification and mapping, relative to analytical tools (GenomeStudio, 
Illumina), as demonstrated by validation of breakpoint boundaries. 
The array-based approaches can only detect simple duplications or deletions, but are unable 
to infer more complex but copy-neutral structural variations, such as balanced inversions or 
translocations that can also affect genome function (Tuzun et al. 2005). These technologies 
show some drawbacks such as hybridization noise and limited coverage of the genome, 
which can lead to false interpretation of results. Thus, identified CNVs still need to be 
confirmed by such traditional methods as FISH, MLPA, or qPCR (see section 3.13.) 
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2.4.6. High-throughput sequencing 
High-throughput sequencing, also called next generation sequencing (NGS), can be used to 
sequence entire genomes (whole genome sequencing; WGS) or may be constrained to 
specific areas of interest, including all 21,000 coding genes (whole exome sequencing; WES) 
or small numbers of individual genes (targeted sequencing) to describe common and rare 
human genetic variation and to discover novel mutations and disease causing genes. 
Compared to conventional Sanger sequencing, NGS allows faster and more comprehensive 
diagnostics in genetically heterogeneous conditions and can be more sensitive to identify 
low-level mosaicism. Depending on the coverage (read depth) and other quality parameters, 
NGS data can also be used for the detection of submicroscopic copy number changes 
(sequence-based approach). It is able to provide a very detailed map of genome-wide 
structural variants as small as 500 bp (Mills et al. 2011) (Figure 2.15). Although a rather low 
coverage is a current limitation to identify copy numbers (Zhao et al. 2013), further 
improvements of the sequencing technology and analytical tools will allow the detection of 
almost all known types of genetic variation by NGS in the near future.  
However, since tens of thousands of genomic variants can be identified in each exome, the 
prioritization and interpretation of these variants are challenging. It is important to carefully 
consider strategies for efficiently and robustly prioritizing pathogenic variants. Many 
bioinformatics tools have been and are being developed to prioritize candidate disease 
variants from disease gene loci. The combination of prediction results with phenotypic and 
pedigree data as well as data from databases might be the best approach to determine the 
potential cause of the disease under investigation (Gilissen et al. 2012; Pabinger et al. 2013).  
 
Figure 2.15. Types of genome alterations that can be detected by NGS. Left: point mutations (A to C), 
small insertions and deletions (indels) (deletions shown by a dashed line). Middle: changes in read 
depth (comparing to a normal control) is used to identify copy number changes. Grey boxes represent 
absent or decreased reads. Right: paired-ends that map to different genomic loci (chromosome 1 and 
5) represent rearrangements. (Figure adapted from Meyerson et al. (2010)). 
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2.5. Validation of functionally relevant candidate genes 
After promising candidate genes have been identified, the next step is to find evidence for 
their clinical relevance, i.e., to validate whether mutations or a certain mutation type in these 
genes are indeed causative. There is no single best step to success, but using multiple 
approaches can improve the accuracy of validation and confirm the potential causality of 
candidate genes. To verify plausible candidate genes, there are several approaches as 
described below and a few important criteria: 1) the mutation spectrum and type of mutations 
(missense mutations versus truncating mutations or mutations encompassing whole gene 
versus hotspot mutations); 2) the frequency in population-based controls; 3) in-silico 
prediction tools; 4) the inheritance model (biallelic mutation versus heterozygous mutation). 
 
2.5.1. Recurrent findings 
A gene affected by recurrent mutations is defined as a gene that harbors frequent mutations 
more than expected by chance. For example, recurrent mutations in the APC gene are 
common among FAP patients but rare or absent in healthy controls. For a given gene, the 
higher the number of mutations found in a specific patient group but not in controls, the 
greater is the likelihood that the gene is causative. Therefore, the simplest way to confirm 
causality is to look for additional mutations in large patient groups. However, germline 
mutations in recently identified genes causative for Mendelian conditions seem to be very 
rare (Meindl et al. 2010; Palles et al. 2013). Thus, mutation-negative patient groups for 
established familial tumor syndromes seem to be genetically very heterogeneous and, 
therefore, large patient cohorts are needed to validate a predisposing gene by finding 
recurrent mutations.  
 
2.5.2. Segregation analysis 
Investigating patterns of co-segregation of a mutation among affected family members is 
another powerful strategy to potentially increase the likelihood of a mutation being 
pathogenic. Co-segregation indicates causality for the phenotype or at least LD between 
markers and a pathogenic mutation in the respective gene (linkage marker). To be effective, 
reliable family histories associated with a pedigree are important. The more clearly affected 
family members are available, the more significant is the result. Phenotype misclassification, 
late onset phenotypes, mild phenotypes, and wrong parternity can lead to wrong 
interpretation. Segregation analysis is not effective for identifying low to moderately penetrant 
causative genes since in this scenario there is no clear relationship (co-segregation) between 
the presence of the variant in question and the development of the phenotype. 
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2.5.3. Gene expression in relevant target tissues 
Expression analysis is widely used to study whether a gene of interest is up-/downregulated. 
A promising candidate gene should be expressed in normal tissues which are relevant to the 
phenotype and the expression pattern should be consistent with the pathophysiological 
hypothesis of the involved genes and mutation types. For example, TSGs should be 
downregulated in the tumor tissue whereas oncogenes should be upregulated. The 
expression of candidate genes can be tested by RT-PCR, Northern blotting, Western blotting, 
in situ hybridization against mRNA in tissue sections, and expression arrays (Strachan and 
Read 1999).  
 
2.5.4. Candidate gene approach 
The candidate gene approach, in contrast to genome-wide approaches, focuses on 
associations between genetic variation within pre-specified genes of interest and the 
phenotype. In many organisms from animals to humans, candidate gene approaches have 
been ubiquitously applied in gene-disease research, genetic association studies, biomarker 
and drug target selection (Tabor et al. 2002; Zhu and Zhao 2007).  
The first critical step in conducting candidate gene studies is the choice of a suitable 
candidate gene that may plausibly play a relevant role in the process or disease under 
investigation. The selection of specific candidate genes is based on gene’s functions and 
pathways, which should be related to the biological mechanisms of the disease (Kwon and 
Goate 2000). However, the main disadvantage of the selection process is that it requires 
information from existing well-known physiological, biochemical or functional processes. This 
approach is not really suited to identify novel causative genes as it is limited by the reliance 
on existing biological knowledge. 
In the context of presumed Mendelian phenotypes, the candidate gene approach is used to 
look for recurrent mutations in patients to confirm the causality of candidate genes. However, 
in the past many candidate genes have been proposed according to functional assumptions 
or pathways involved, but few of them have been successfully verified and ultimately brought 
to endpoint usage (Zhu and Zhao 2007). 
 
2.5.5. Pathway enrichment analysis/network analysis 
Enrichment analysis is a statistical method to see whether candidate genes identified in a 
group of patients are more frequent (overrepresented) in a certain established pathway or a 
functional network than expected by chance. An objective of pathway-based approaches is 
to connect the functional level of genes with a phenotype as the idea is that genes do not 
work alone but interact with other genes in functional networks. Instead of looking for a 
recurrent mutation in one gene, this approach aims to look for recurrent mutations in a 
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pathway, i.e., a set of genes (Emmert-Streib and Glazko 2011). The overrepresentation of 
candidate genes in a specific pathway might mean that these genes act together and are not 
affected in the patients just by chance.  
Enrichment analysis helps to interpret data in the context of biological processes, pathways, 
and networks. The primary result is an enrichment score, which reflects the degree to which 
a gene set is overrepresented. The magnitude of the increment depends on the correlation of 
the genes with the phenotype. There are several web-based tools to analyze enrichment, i.e., 
the Database for Annotation, Visualization, and Integrated Discovery (DAVID), Gene 
Ontology (GO) enrichment analysis, which are used to discover enriched functionally related 
gene groups. The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a well-known web-
based tool for pathway enrichment analysis. Network analysis offers the potential for greater 
power of discovery and natural connections to biological mechanisms. It can confirm genes 
and proteins associated with the etiology of a specific disease and can help to understand 
mechanisms of disease (Ramanan et al. 2012). 
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2.6. Scope of the thesis 
The main aim of this thesis was to identify new high penetrant causative genes in a large and 
well-characterized cohort of unrelated patients with clinically verified, etiologically 
unexplained colorectal adenomatous polyposis, a precancerous condition which is supposed 
to have a strong hereditary basis. 
Prior to the comprehensive and laborious application of genome-wide techniques such as 
SNP-array based CNV analysis and targeted next generation sequencing of candidates we 
performed a systemic APC transcript analysis to uncover mutations in deep intronic regions 
of the APC gene which cannot be identified by routine diagnostics.  
Afterwards, a high-resolution genome-wide CNV analysis was performed, followed by 
stringent filter steps to select for rare CNVs in protein coding genes which are supposed to 
result in truncating mutations, assuming a monogenic disease model. 
Subsequently, various methods were applied to examine the causal relevance of the 
candidate genes including co-segregation analysis, network and pathway analysis, 
expression analysis, data mining, and recurrent germilne point mutation and somatic point 
mutation analyses. 
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3. MATERIALS AND METHODS 
This chapter provides detailed technical information on how this thesis was carried out. It 
starts with lists of databases and tools, followed by a description of available patients and 
how their data were analyzed. 
 
3.1. Databases 
- 1000 Genomes; A Deep Catalog of Human Genetic Variation: 
www.1000genomes.org 
- APC Mutation database: www.lovd.nl/APC 
- BDGP (Berkeley Drosophila Genome Project): www.fruitfly.org/seq_tools/splice.html 
- BLAT: http://genome.ucsc.edu/cgi-bin/hgBlat  
- COSMIC (Catalogue of somatic mutations in cancer): 
http://cancer.sanger.ac.uk/cancer genome /projects/cosmic/  
- DAVID (Database for Annotation, Visualization and Integrated Discovery) 
Bioinformatics Resources 6.7: http://david.abcc.ncifcrf.gov/  
- dbSNP (The Single Nucleotide Polymorphism database): www.ncbi.nlm.nih.gov/SNP/  
- DGV (Database of Genomic Variants): 
http://dgvbeta.tcag.ca/dgv/app/home?ref=NCBI36 /hg18 
- Ensembl Genome Browser: Archive EnsEMBL release 54 - May 2009: 
http://may2009. archive.ensembl.org/index.html 
- ESEfinder program Release 2.0: http://rulai.cshl.edu/tools/ESE2/  
- EVS (Exome Variant Server): http://evs.gs.washington.edu/EVS/ 
- GENATLAS: http://genatlas.medecine.univ-paris5.fr/  
- GeneCards: www.genecards.org/ 
- GeneCodis (Gene annotations co-occurrence discovery): 
http://genecodis.cnb.csic.es/  
- GWAs Catalog (A Catalog of Published Genome-Wide Associations Studies): 
www.genome.gov/gwastudies/ 
- HGMD (Human Gene Mutation Database): http://hgmd.org 
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- KEGG (Kyoto Encyclopedia of Genes and Genomes ): www.genome.ad.jp/kegg 
- LOVD (Leiden Open Variation Database): www.lovd.nl/2.0/ 
- MutationTaster: www.mutationtaster.org 
- NCBI (National Center for Biotechnology Information): www.ncbi.nlm.nih.gov 
- OMIM® (Online Mendelian Inheritance in Man®): http://omim.org/  
- PolyPhen-2: http://genetics.bwh.harvard.edu/pph2/ 
- PUBMED: http://pubmed.com/ 
- SIFT (Sorting Intolerant from Tolerant): http://sift.jcvi.org/  
- STRING (Search tool for the retrieval of interacting genes/proteins): http://string-
db.org/newstring_cgi/  
- UCSC Genome Bioinformatics: http://genome.ucsc.edu  
- UNIGENE: EST profile: www.ncbi.nlm.nih.gov/unigene  
- UniSTS Integrating Markers and Maps database: www.ncbi.nlm.nih.gov/unists 
- VARBANK: https://anubis.ccg.uni-koeln.de/varbank/  
 
3.2. Devices 
Concentration measurement device 
- NanoDrop® ND‐1000 Spectrophotometer, Peqlab Biotechnology GmbH 
Agarose gel electrophoresis 
- UV imaging system (BioRad Gel Doc™) 
- Electrophoresis horizontal gel chamber (Biorad) 
Genotyping systems  
- iScan System, Illumina® Inc. 
- MassARRAY™ Nanodispenser, SAMSUNG Techwin Co. Ltd. For Sequenom® 
- MassARRAY™ Compact Analyzer, Bruker Daltonics Inc. for Sequenom® 
Pipetter robot systems  
- Biomek® Laboratory Automation Workstations NX MC and NX S8G, Beckman 
Coulter GmbH 
Sequencing devices  
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- Automatic 16-capillary sequencing device 3130xl Genetic Analyzer (Life 
Technologies, Carlsbad, CA) 
- ABI 3500xl Genetic Analyzer (Life Technologies, Carlsbad, CA) 
Thermocyclers  
- MJ Research PTC-200 Thermal Cycler 
- ABI Prism 7900HT Fast Real-Time PCR System (Life Technologies, Carlsbad, CA) 
 
3.3. Software 
- 3130xl Data Collection Software v3.0, Life Technologies 
- Biomek Software 3.2, Beckman/Coulter, Fullerton, California, USA 
- Cartagenia Bench Lab CNVTM software, Cartagenia, Leuven, Belgium 
- Chromas v2.21, Technelysium Pty Ltd, Australia 
- DesignStudio: Truseq Custom Enrichment: http://designstudio.illumina.com/  
- Genecodis 2.0: Gene annotations co-occurrence discovery: 
http://genecodis.cnb.csic.es/  
- GenomeStudio v2011.1, Illumina, San Diego, California, USA 
- GenomeStudio Genotyping Analysis Module v1.9.4 
- Human GenoTyping Tools: www.mysequenom.com/Tools  
- Illumina DesignStudio: http://designstudio.illumina.com/ 
- Illumina Genome Viewer v1.9.0 
- Illumina Realtime Analysis® (RTA) software 
- Ingenuity pathway analysis: www.ingenuity.com/products/ipa  
- Integrative Genome viewer: www.broadinstitute.org/igv/  
- NanoDrop ND-100 v3.3.0, Biotechnologie GmbH, Erlangen 
- PLIGU (Patienten und Laborinformationssystem für genetische Untersuchungen)  
- Primer3 v.0.4.0: http://frodo.wi.mit.edu/primer3/input.htm 
- QuantiSNP v1.1 and 2.2 (Colella et al., 2007): https://sites.google.com/site/quantisnp/  
- R software version 3.0.2: www.r-project.org/ 
- Sequence Detection Software; SDS 2.2.2, Life Technologies 
- SeqPilot v4.0.1, JSI medical systems GmbH, Germany 
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- Sequencing Analysis Software v5.2.0, Life Technologies Corporation, Carlsbad, 
California, USA 
- Sequenom’s MassARRAY Designer software 
- SNP Annotation and Proxy Search (SNAP): www.broadinstitute.org/mpg/snap/ 
- Typer v3.4 and v4.0, Sequenom 
 
3.4. Commercial reagents 
- 100 bp DNA ladder (BioEngland) 
- 5 x Big Dye Terminator v1.1 sequencing buffer (Life Technologies) 
- Agencourt AMPure® XP PCR purification kit (Beckman Coulter) 
- Agencourt CleanSEQ® dye-terminator removal kit (Beckman Coulter) 
- Amplitaq Gold® PCR Master Mix (Life Technologies) 
- Big Dye ready reaction mix v3.1 (Life Technologies) 
- DyeEx 2.0 Spin kit (Qiagen) 
- Expand 20 kbPlus PCR system (Roche Diagnostics GmbH, Mannheim, Germany) 
- First strand cDNA of human adult colon mucosa (Amsbio) 
- HighPure PCR Product Purification Kit (Roche Diagnostics) 
- Human MTC Panel I & II (Clontech) 
- Infinium II Whole-Genome Genotyping Kit (Illumina Inc.)  
- PAX gene blood RNA kit (Qiagen) 
- Power SYBR Green® PCR Master Mix (Life Technologies)  
- QIAamp DNA FFPE tissue kit (Qiagen) 
- QIA quick PCR purification kit (Qiagen) 
- REDTaq ReadyMix PCR Reaction Mix with MgCl2 (Sigma Alrich)  
- SEQUENOM iplex Gold Chip and Reagent Kit (Sequenom) 
- Super Script First-Strand Synthesis System for qRT-PCR (Invitrogen) 
- TaqMan gene expression assays: Human CTNNB1 and Human MUTYH (Life 
Technologies) 
- TaqMan endogenous controls: Human Cyclophilin (hu-CYC) and Human Beta-2-
microglobulin (hu-2M)( Life Technologies) 
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- TaqMan® gene expression master mix (2X) (Life Technologies) 
- TruSeq® Custom Enrichment kit (Illumina Inc.) 
- TruSeq® DNA HT Sample Preparation Kit (Illumina Inc.) 
 
3.5. Study samples 
3.5.1. Initial patient cohort 
Patients or blood/DNA samples were primarily referred from all parts of Germany to the 
Institute of Human Genetics, Bonn, or the Medical Genetics Center (MGZ), Munich, Germany, 
because typical or attenuated adenomatous polyposis was suspected. All patients were 
screened during routine diagnostics for germline mutations in the APC and MUTYH genes by 
complete Sanger sequencing of the coding regions and the flanking exon-intron boundaries 
(~30-40 bp) as described (Aretz et al. 2006). MLPA analysis (MRC-Holland, Amsterdam, 
Netherlands) was performed to screen for large genomic deletions or duplications of the APC 
gene.  
Table 3.1. Clinicopathological and genetic features of the patients included 
Study project 
CNV 
analysis 
Targeted NGS 
Phenotype FAP FAP HNPCC Total 
No. of patients 229 145 47 192 
Gender (male/female) 132/97 83/62 22/25 105/87 
Mean age at diagnosis (years) 
Range (years) 
45 
12-78 
46 
12-78 
52 
30-86 
47 
47-82 
No. of colorectal adenomas 
< 100 adenomas 
> 100 adenomas 
Multiple/numerous polyps 
unknown 
 
142 (62%) 
42 (18%) 
42 (18%) 
3 (1%) 
 
99 (68%) 
20 (14%) 
24 (17%) 
2 (1%) 
  
Colorectal cancer 77 (34%) 55 (38%) 41 (87%) 96 (49%) 
Extracolonic lesions * 
yes 
no 
 
34(15%) 
195 (85%) 
 
18 (12%) 
127 (88%) 
  
 
Family history 
Familial 
Sporadic 
Unclear/unknown 
 
34 (15%) 
188 (82%) 
7 (3%) 
 
19 (13%) 
123 (85%) 
3 (2%) 
 
47 (100%) 
 
66 (34%) 
123 (64%) 
3 (2%) 
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All index patients with no detectable germline mutation in the APC or MUTYH genes were 
contacted by clinical geneticists of the Institute of Human Genetics, Bonn, either directly or 
via their responsible clinician and asked to participate in the present study. Clinical 
information and family history of patients were obtained during genetic counseling sessions, 
from a questionnaire, through telephone interviews and from medical records. Patients were 
asked to enrol in the study and to give their informed consent. Missing medical notes and 
histopathology records were requested from general practitioners, medical specialists, 
hospitals, and institutes. Affected relatives were informed about the study by the patients and 
were asked to participate in the study. The study was approved by the ethics review board of 
the Faculty of Medicine, University of Bonn, Germany. 
 
3.5.2. NGS validation cohort 
192 patients (87 females, 105 males) were selected for the study. One hundred of them 
came from the CNVs study cohort. Forty-five adenomatous polyposis patients and an 
additional 47 subjects with suspected Lynch syndrome (Table 3.1) were subsequently 
included. In this latter group, the Amsterdam I or II criteria for Lynch syndrome (Vasen et al. 
1991; Vasen et al. 1999) were met; the tumors showed microsatellite stability and normal 
immunohistochemistry. Moreover, no mutations in APC, MUTYH, EPCAM, and mismatch 
repair genes (MLH1, MSH2, MSH6, PMS2) could be identified by extensive mutation 
screening including Sanger sequencing, MLPA, and transcript analysis. The recruitment 
process and inclusion criteria of these patients into the study were the same as with the initial 
patient cohort. 
 
3.5.3. Heinz Nixdorf RECALL (HNR) study controls 
The Heinz Nixdorf RECALL (Risk Factors, Evaluation of Coronary Calcium and Lifestyle) 
cohort study (HNR controls) is an ongoing longitudinal study taking place at the University 
Hospital of Essen, and analyzes the population-based incidences of cardiovascular diseases 
(www.recall-studie.uni-essen.de/). The entire sample comprises about 4,800 men and 
women aged from 45 years to older.  
Samples used in this study are of German descent and were chosen according to their 
genotyping chip. Using the same platform can exclude sampling biases and the use of 
platform-specific references makes it possible to account for platform-specific artifacts, thus 
this study included only samples which were hybridized on the Omni-1Quad SNP-array. 
According to the inclusion criterion that the the standard deviation of the logR ratio must be 
lower than 0.3, 531 HNR controls (255 females, 276 males) were included in the CNV study. 
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3.5.4. GWAS replication study  
To replicate the results of a GWAS in unexplained adenomatous polyposis, recently 
performed by the research group (results not shown here, and not yet published), the most 
promising SNPs were genotyped in a large group of Dutch patients and controls, provided by 
our collaborators at Leiden University, The Netherlands. DNA samples from 950 subjects 
comprising 379 adenomatous polyposis patients with no APC or MUTYH germline mutation, 
and 570 anonymous controls were analyzed. Age at diagnosis of patients vary from 4-82 
years (median 52) while ages of the control cohort varied from less than ten up to 88 years 
(median 44), The basic characteristics and colorectal phenotype of the patient cohort is 
summarized in table 3.2. 
Table 3.2. Clinicopathological and genetic features of the patients 
Study cohort Patient 
Number of sample 380 
Gender (male/female) 219/160 (unknown 1) 
Median age at diagnosis (years) 
Range (years) 
52 
4-82 
Pathological report 
polyps < 10 
polyps 10-50 
polyps 50-100 
polyps > 100 
Not available 
 
68 (18%) 
194 (51%) 
58 (15%) 
35 (9%) 
25 (7%) 
Family history 
Familial 
Sporadic 
 
204 (54%) 
176 (46%) 
 
3.6. DNA and RNA preparations 
3.6.1. DNA extraction using desalting method 
Using a standard salting-out procedure, genomic DNA was extracted from peripheral EDTA-
anticoagulated blood samples (Miller et al. 1988). Ten ml of EDTA treated blood was 
transferred into a 50 ml Falcon tube and cell lysis buffer (saturated NaCl [6M]) was added up 
to 45 ml and mixed well. The tube was incubated on ice for 15 minutes before being 
centrifuged for 15 minutes at 1500 rpm and 4oC. Supernatant was discarded and pellet was 
air-dried for 5-10 minutes. Five ml of nuclear lysis buffer (10mM Tris-HCl pH 8.2, 400 mM 
NaCl, 2mM Na2EDTA, pH 8.2) was added into the tube, followed by 250 µl of protein lysis 
buffer (10 mg/ml proteinase K). The solutions were mixed well, then 250 µl of 10% SDS was 
added and incubated overnight at 37oC to complete the lysis reaction. Two ml of saturated 
NaCl was added into the sample tube and centrifuged at 4000 rpm for 10 minutes at room 
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temperature. Supernatant was transferred to a new 50 ml Falcon tube and mixed with 5 ml 
isopropanol. A visible DNA strand was removed with a spatula and transferred to a 1.5 ml 
microcentrifuge tube containing 70%EtOH to dehydrate the DNA strand. The dried DNA was 
transferred to a new 1.5 ml microcentrifuge tube containing 200-500 µl of TE-4 buffer. The 
DNA was incubated at room temperature at least 2 hours to dissolve the DNA completely 
before quantitation. It can then be stored at 4oC for months. 
 
3.6.2. Formalin fixed paraffin embedded (FFPE) tissue DNA isolation 
Adenomas were obtained during an operation and were fixed and preceded follow standard 
formalin-fixation and paraffin-embedding procedures and the tissue blocks were kept at room 
temperature. 
The formalin fixed paraffin embedded (FFPE) tissues were cut with a thickness of 10 micron. 
One section of each block was stained with Hematoxylin and Eosin (H&E) to indicate the 
tumor location. Up to 8 sections with a surface area of tumor up to 250 mm2 were combined 
in one preparation. DNA was extracted with the QIAamp DNA FFPE tissue kit (Qiagen) 
followed the manufacturer’s protocol. Briefly, paraffin was dissolved in xylene, then sample 
was lysed with proteinase K and incubated at 90 oC to reverse formalin crosslinking. DNA 
was binded to a membrane provided in the kit while residual contaminants were washed 
away. Then the DNA was eluted from the membrane and kept at 4oC. 
 
3.6.3. RNA extraction using the PAX gene kit 
RNA was extracted from approximately 2.5 ml of venous blood collected in a PAXgene Blood 
RNA Tube (Becton Dickinson) containing RNA stabilization reagent. In principle, the PAX 
gene blood RNA kit (Qiagen) uses a membrane-based isolation and purification system in 
the form of a ‘spin column’. The PAXgene Shredder spin column is used to homogenize the 
cell lysate and remove residual cell debris. The PAXgene RNA spin column with silica 
membrane will bind to RNA whereas contaminants pass through the membrane. All reagents 
for RNA reactions were provided in the kit. The RNA extraction protocol is described in the 
manufacturer’s handbook. Briefly, before starting the RNA extraction process, all equipment 
and the working area must be cleaned with 99% chloroform to reduce contamination with 
RNases. Whole blood was collected in the PAX gene blood RNA tube and incubated at room 
temperature overnight to complete the blood cells lysis. The pellet was washed and 
resuspended. The resuspended pellet was incubated in optimized buffers together with 
proteinase K to bring about protein digestion. After an additional centrifugation through the 
PAXgene Shredder spin column, the supernatant of the flow-through fraction was transferred 
to a fresh microcentrifuge tube. Ethanol was added to adjust binding conditions, and the 
lysate was applied to a PAXgene RNA spin column. Remaining contaminants were removed 
in several efficient wash steps. Between the first and second wash steps, the membrane was 
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treated with DNase I to remove trace amounts of bound DNA. After the wash steps, RNA 
was eluted in elution buffer and heat-denatured at 65oC. The reaction was stopped by 
immediately placing it on ice. The RNA was quantified by UV absorbance (260/280 nm) and 
stored at -70oC. 
 
3.6.4. Determination of concentration and quality 
A spectrophotometer is commonly used to determine the concentration of nucleic acid based 
on the Beer-Lambert equation. The Beer-Lambert law provides a relationship between the 
amount of the light absorbed and the concentration of the absorbing molecule. The 
absorbance is used to convert optical density (OD) to concentration. The value of 1 unit of 
OD is equivalent to 50ng/µl for DNA and 40 ng/µl for RNA. The DNA concentrations and 
purity are commonly determined by measuring the ratio of the UV absorbance at 260 nm and 
280 nm. Based on the fact that OD for DNA at 260 nm is twice that at 280 nm, the cleaned 
DNA has an OD-260/OD-280 ratio of between 1.8 and 2.0, and around 2.1 for an RNA 
sample. 
For this thesis, the measurement was performed with a Thermo Scientific NanoDrop™ ND-
1000 Spectrophotometer, which requires only 1 µl of DNA for the measurement. 
 
3.6.5. First-strand cDNA synthesis 
cDNA represents a more convenient way to work with the coding sequence because RNA is 
very unstable, fragile, and easily degraded. First strand cDNA synthesis, or reverse 
transcription (RT), is a process, which transcribes single-stranded RNA into complementary 
DNA (cDNA). It is facilitated by a reverse transcriptase enzyme, RNA-dependent DNA 
polymerase, which is typically of Avian Myeloblastosis Viral (AMV) origin. This step is a 
required procedure prior to amplification by DNA polymerases. 
There are three different types of primers: 1) oligo-dT primer is used when the mRNAs have 
a poly-A tail; it anneals to all mRNA simultaneously. 2) Sequence-specific primer can be 
used to produce specific cDNA from a particular mRNA. 3) Random primer is able to produce 
pieces of cDNA scattered all over the mRNA. For this thesis, random primers were used to 
generate first-strand cDNA. 
One µg of RNA from lymphocytes was reverse transcribed into a first cDNA strand by 
random hexamer-primed reverse transcription. This was achieved with the Super Script First 
Strand Synthesis System for qRT-PCR (Invitrogen) according to the protocol provided by the 
manufacturer as outlined below. 
One µg of RNA was diluted in 8 µl of DEPC-treated water. One µl of 10 mM dNTP mix and 
one µl of Random hexamers (50 ng/µl) were added to the tube, followed by brief 
centrifugation and incubation at 65oC for 5 minutes, then immediately placed on ice for 2 
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minutes. In a separate tube, 2X reaction mix was prepared. Volume and concentration are 
shown in table 3.3. 
The 2X RT reaction mix was added to the RNA tube, which was then incubated at room 
temperature or 25°C for 2 minutes. One µl of SuperScript II RT was added into each tube 
and tubes were incubated at room temperature for another 10 minutes, temperature was 
increased to 42°C for 50 minutes, and the reaction was terminated after 15 minutes at 70°C 
temperature. After termination, the reaction material was immediately cooled down on ice, 
and then briefly centrifuged. One µl of RNase H was added to remove remaining template 
RNA. The reaction mix was incubated at 37°C for 20 minutes. The first-strand cDNA was 
either immediately used for qPCR or stored at -20°C. 
Table 3.3. Solutions and concentrations for reaction mix preparation 
Solution Volume 
10X RT buffer 2 µl 
25 mM MgCl2 4 µl 
0.1 M DTT 2 µl 
RNaseOUT (40 U/µl) 1 µl 
Total volume 9 µl 
 
3.7. Polymerase Chain Reaction (PCR) 
3.7.1. Basic principle 
The Polymerase Chain Reaction (PCR), invented by Kary Mullis in 1983, is a technique for 
amplifying specific target DNA. The basic principle is the cyclic change of different 
temperatures to promote an enzymatic amplification of specific DNA. To start the reaction the 
temperature is raised to 95°C to melt double-stranded DNA into single strands. The 
temperature is then lowered to 50-60°C to allow primers to bind to target DNA. Thus the 
polymerase enzyme has somewhere to bind and can begin synthesizing a complementary 
sequence of the DNA strands with deoxynucleotide triphosphates (dNTPs). The optimal 
temperature for the polymerase is 72°C, which allows the enzyme to work fast. The melting 
of double strand DNA is called “Denaturation step”, while the binding of primer is called 
“Annealing step”, and the synthesizing of the complementary sequence is called “Extension 
step”. These three steps are repeated 30 to 40 times and the amount of DNA is increased 
exponentially. At the end of the amplification, the product can be detected on an agarose gel. 
 
3.7.2. Primer design 
In this thesis, Primer3 (V.0.4.0), an online program tool (http://frodo.wi.mit.edu/primer3 
/input.htm), was used to design primers for quantitative real-time PCR (qPCR), Sanger 
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sequencing, and expression analysis. DNA sequences were called by the Ensembl Genome 
Browser; release 54 – May 2009, based on the NCBI reference sequence [RefSeq] build 36. 
The length of primers was set at 18-27 bases, melting temperature was 57-61oC, and GC 
content was 20-60%. When the software was unable to design proper primers, they were 
designed manually following these criteria: 
- Length: 18-22 bp 
- Melting temperature: 58-60oC, Tm should not be higher than 2oC 
- GC content: 40-60% 
- GC clamp: put GC at 3’ end if possible, avoid > 2 GC sequences in the last 5 bases at 
the 3’ end 
- avoid a repeat of > 4 di-nucleotides 
- avoid polymorphism 
Amplicon length for PCR was set at 400-600 bp while the length for the quantitative PCR 
product was set at 120-150 bp and the length for Sanger sequencing was at most 500 bp. 
Primers and amplicons were blasted on the UCSC Genome Browser to verify the 
specifications. The primers were then synthesized at Metabion (Martinsried, Germany) in 
standard quality. 
 
3.7.3. PCR reaction components 
Reagent Volume (µl) Final concentration 
10x PCR buffer with MgCl2 2.5 1X 
10x dNTP mix (10 mM each) 0.5 0.4 µM each 
Taq polymerase [5 U/µl) 0.2 1 U/reaction 
DNA [10 ng/µl] 2 20 ng/reaction 
10 µM For primer 1 0.4 µM 
10 µM Rev primer 1 0.4 µM 
H2O 17.8  
Total 25  
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3.7.4. Cycling step 
Reaction Temperature Duration Cycle 
Initial denaturation 95°C 5 min 1 X 
Denaturation 95°C 30 sec  
35 X Annealing 56°C 30 sec 
Extension 72°C 1 min 
Final extension 72°C 10 min 1 X 
Storage 4°C  1 X 
 
3.7.5. Agarose gel electrophoresis 
Agarose is a polysaccharide which, after solidifying, forms a three-dimensional network that 
allows for migration of DNA molecules in a buffer. Briefly, if an anode is attached to the 
system, negatively charged DNA migrates through the agarose pores based on the effect of 
molecular sieving. The DNAs can then be separated according to their sizes as short 
molecules move faster and thereby further than long molecules. 
2-20 µl of PCR product was loaded on 2% agarose gel. A 100 bp-DNA ladder (BioEngland) 
was used as a molecular weight marker. The electrophoresis system was set at 120 volt and 
run for 1.30 hours to separate the PCR product. The result of a gel electrophoresis run was 
analyzed after ethidium bromide staining using a UV imaging system (BioRad Gel Doc™) 
and visualized with (BIORAD). 
 
3.7.6. PCR product purification  
QIA Quick PCR Purification: After specificity and quantity of the products were checked by 
running agarose gel electrophoresis, the amplified PCR product was purified using the QIA 
quick PCR purification kit (Qiagen). This purification is based on the silica-membrane spin 
column. All purification steps, that is, DNA binding to the filter membrane, washing steps, and 
the DNA elution were performed step by step following the company manual. The cleaned 
product was used for validation of the mutation by Sanger sequencing. 
AmPure purification: Agencourt AMPure XP PCR purification kit was used to purify PCR 
product. It is based on Solid Phase Reversible Immobilization (SPRI®) with magnetic bead-
based technology. DNAs bind to the magnetic beads and the beads are adhered to the walls 
by a magnetic plate while other molecules such as primer dimers, dNTPs, and so on are 
washed away. After washing steps, the DNA is eluted and detached from the beads. 
Before using, the AmPure bottle was gently shaken to resuspend the magnetic particles, 
then 36 µl of AmPure buffer containing the magnetic beads in solution was added into the 
PCR reaction and well mixed by pipetting up and down 10 times. The PCR reaction plate 
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was placed on the magnetic plate for 5-10 minutes to separate beads from solution and 
supernatant was discarded. Two-hundred µl of 70% EtOH was added into the reaction and 
incubated at room temperature for 30 seconds, then the supernatant was discarded and this 
washing step was repeated for a total of 2 washes. The purified PCR product was air-dried 
for 20-30 minutes to completely remove ethanol and dissolved in 40 µl of elution buffer (TE-4). 
Purification PCR product from agarose gel: The specific band PCR product on the gel 
was removed from the gel and purified with the High Pure PCR Product Purification Kit 
(Roche Diagnostics). All processes were performed following manufacturer’s protocol as 
described. To excise the specific band, we used only a new blade. Binding buffer was added 
into a fresh 1.5 ml microcentifuge tube which contained the excised specific agarose gel, and 
incubated at 56oC for 15 minutes to melt the gel, followed by adding isopropanol. Then the 
product was transferred into a filter tube and was centrifuged at 13000 rpm for 1 minute, then 
supernatant was discarded. The rest of the product mix was transferred into the filter tube 
and the centrifuge step was repeated. After discarding the supernatant, the filter tube was 
filled with washing buffer, centrifuged, and supernatant discarded twice before contents were 
transferred to a new 1.5 ml microcentrifuge tube. Sixty ul of elution buffer was added into the 
filter tube and the filter tube was incubated at room temperature around 10 minutes to 
complete the elution before being centrifuged at 13,000 rpm for 1 minute. Purified DNA in the 
1.5 ml microcentrifuge tube was stored at 4oC and the filter tube was discarded. 
 
3.8. Sanger sequencing 
3.8.1. Basic principle 
Sanger sequencing, developed by Fred Sanger et al. in the mid 1970’s, is a tool to detect the 
alteration of nucleotides of a DNA sequence (Sanger and Coulson 1975). It is the most 
reliable method for detecting sequence variations. The sequencing reactions are analogous 
to the PCR reactions for replicating DNA. The template DNA pieces are replicated, 
incorporating normal nucleotides, but occasionally and at random di-deoxynucleotides 
(ddNTPs) are taken up. The Sanger technique uses ddNTPs, which are essentially the same 
as nucleotides except they contain a hydrogen group instead of a hydroxyl (-OH) group at 3’ 
carbon. Because they lack a 3' OH, nothing can be added to the chain once a ddNTP has 
been added; therefore, the replication is stopped. Sooner or later all of the copies will get 
terminated by the ddNTPs, but each time the enzyme makes a new strand; the place where 
it was stopped will be random. Because of their different lengths, running at different rates 
during electrophoresis, their order can be determined.  
Each type of ddNTP emits colored light of a characteristic wavelength. The color band is 
recorded on a simulated image and interpreted by a computer program, which automatically 
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prints out a chromatogram as well as the sequence. The colors represent the four bases: 
blue is C, black is G, red is T, and green is A. 
 
3.8.2. Reaction components 
Reagent Volume (µl) 
5x Big Dye Terminator v1.1 sequencing buffer 3.75 
Big Dye ‐ ready reaction mix v3.1 0.5 
5 µM Primer For/Rev 1 
Purified PCR product 1 
H2O 13.75 
Total 20 
 
3.8.3. Cycling step 
Reaction 
Temperature 
(oC) 
Duration 
Number of 
cycle 
Initial denaturation 96 1 min 1 X 
Denaturation 96 10 sec 
25 X Annealing 50 5 sec 
Extension 60 4 min 
Storage 12  1 X 
 
3.8.4. Cycle sequencing product cleaning 
DyeEx 2.0 Spin Kit (Qiagen): The DyeEx 2.0 Spin kit (Qiagen) with prehydrated DyeEx gel-
filtration material was used to remove unbounded ddNTPs from the sequencing reaction 
before loading the tagged products onto a capillary sequencer. When sequencing reaction 
mixtures are applied to DyeEx columns, dye terminators diffuse into the pores and are 
retained in the gel-filtration material, while labeled DNA fragments are excluded and 
recovered in the flow-through. 
A quick centrifugation step was applied to remove storage buffer from the column, the 
sequencing samples were loaded, and a second centrifugation step was performed at 3000 
rpm for 3 minutes to remove unincorporated dye terminators. Samples were then ready for 
loading onto a capillary sequencer. 
CleanSEQ purification: CleanSEQ® is the Agencourt dye-terminator removal kit. As is the 
AMPure kit, it is based on SPRI® paramagnetic bead technology, where the nucleic acids 
are immobilized onto paramagnetic micro particles using specific buffer conditions. 
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Ten µl of CleanSEQ buffer, containing magnetic beads, was added into each reaction, 
followed by 62 µl of 85% EtOH, and then mixed by pipetting up and down 7 times. The PCR 
reaction plate was placed on the magnetic plate for 3 minutes to separate beads from 
solution, and then supernatant was discarded. One-hundred µl of 85% EtOH was added into 
the reaction and incubated at room temperature for 30 seconds and then the supernatant 
was discarded. These washing steps are to remove unincorporated dyes, nucleotides, salts 
and contaminants. The purified product was air-dried for 10-20 minutes to completely remove 
ethanol before adding 40 µl of H2O into the reaction. 
 
3.8.5. Capillary electrophoresis 
Capillary sequencing is an accurate nucleic acid analysis. DNA passes through the detection 
cell and a laser beam simultaneously illuminates the capillaries from both sides of the array. 
To accomplish this, light from a single laser source is split using optical elements to form a 
dual pathway. The emitted fluorescent light is collected, separated by wavelength, and 
focused onto a charge-coupled device (CCD). When the fluorescent light has been collected 
and dispersed across the CCD, the data are transferred to the instrument computer where 
they are transformed by chemometric algorithmic processing into 4-dye electropherograms. 
This thesis used an automated 16-capillary sequencing device, 3130xl Genetic Analyzer (Life 
Technologies). One µl of purified product was diluted in 9 µl H2O before it was put into the 
sequencer. 
 
3.9. APC transcript analysis 
To uncover aberrant transcripts, which might be caused by intronic mutations outside the 
routinely screened regions, we performed a systematic mRNA analysis of the APC gene in 
125 apparently unrelated mutation negative patients with clinically verified adenomatous 
polyposis and negative APC and MUTYH mutation. 
 
3.9.1. Primer design 
Primers of coding regions of the APC gene were designed with the primer 3 online tool (see 
section 3.7.2). The cDNAs were fragmented into 5 overlapping fragments spanning exons 1-
15A (c.-138 to c.2625) (Figure 3.1).  
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Figure 3.1. Schematic overview of the APC gene (coding exons 1-15A) and the five overlapping 
fragments used for cDNA analysis 
 
3.9.2. cDNA analysis 
Specific fragments of cDNA from 125 included patients were amplified using 5 primer pairs 
(Table A1). The PCR reactions and cycles are described in section 3.7. Twenty µl of PCR 
products were loaded on agarose gel to check sizes of amplified products in comparison with 
the commercial marker, 100 bp-DNA ladder (BioEngland), and to compare the pattern of the 
bands with those in 10 anonymous controls. 
If the patient’s agarose gel illustrated the pattern and the size of the product differently from 
those in the control cohort, the specific different bands on the gel were cut out of the gel and 
purified (see section 3.7.6.) for re-amplification with the same primer pair to increase the 
yield of the product. The re-amplified product was cleaned with the QIA Quick PCR 
Purification Kit (Qiagen) (see section 3.7.6.) before being tagged with fluorescent dyes for 
sequencing. 
 
3.9.3. Sanger sequencing 
Both forward and reverse primers were used for cycle sequencing. The capillary 
electrophoresis was performed on an ABI 3500xl Genetic Analyzer (Life Technologies). For 
details, see section 3.8. 
 
3.9.4. Data analysis  
The sequencing results were visualized using Chromas software version 2.21 (Technelysium 
Pty Ltd, Australia) and SeqPilot software version 4.0.1 (JSI medical systems GmbH, 
Germany). The cDNA bases were numbered according to the APC reference sequence in 
GenBank NM_000038.5, where +1 corresponds to the A of the ATG translation initiation 
codon. All abnormal results were confirmed at the genomic level in an independent 
experiment.  
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3.9.5. Genomic DNA analysis 
If an exonised intronic insertion or exonic deletion was detected, the corresponding region 
was sequenced at the genomic DNA level with primers flanking that particular region (Table 
A2).  
 
3.9.6. Haplotype analysis 
A haplotype refers to a set of alleles at genetic markers (microsatellites, SNPs) that are 
inherited together on a chromosome. The haplotype “phase” refers to the determination of a 
haplotype or the placement of alleles together along a chromosome. Affected family 
members are likely to share the same haplotype.  
In this thesis, haplotype analysis was performed with a panel of seven microsatellite markers 
flanking the APC region. The order of markers on chromosome 5q is: CEN – D5S134 – 
D5S492 – D5S1965 – APC – D5S346 – D5S656 – D5S2001 – D5S421 – TEL. They span 
around 2.8 Mb. The primer sequences are given in table A3.  
For each microsatellite analysis, primers were picked from the UniSTS Integrating Markers 
and Maps database (www.ncbi.nlm.nih.gov/unists). Five ng of genomic DNA was amplified 
with forward primer labelled with FAM fluorescent dye and with the specific unlabeled 
reverse primers and Amplitaq Gold® PCR Master Mix using standard protocol. The 
annealing temperature was adjusted following the melting temperature of primers. The PCR 
amplicons were analyzed and separated by size with capillary electrophoresis. The expected 
size of the products is given in table A3. 
 
3.9.7. In-silico analysis 
Splicing efficiencies of the normal and mutant sequences were calculated using the splice 
prediction program NNSPLICE 0.9 from BDGP (the Berkeley Drosophila Genome Project; 
www.fruitfly.org/seq_tools/splice.html) and with the method of Shapiro and Senapathy (1987). 
The influence of base substitutions on a putative Exonic Splicing Enhancer (ESE) site was 
checked with the ESEfinder program (Cartegni et al. 2003). The location of inserted 
sequences at the genomic level was determined by BLAST analysis. 
 
3.10. Genome-wide SNP array hybridization 
3.10.1. Genotyping based on BeadArray Technology (Illumina®) 
The basic principle of DNA microarrays is a binding or hybridization assay. Applications of 
the arrays are diverse, such as SNP detection and scoring, gene expression and mutation 
analysis of large genes. They have been used extensively for linkage disequilibrium studies 
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for investigating genetic associations with disease, for genome wide association studies 
(GWAS), and for copy number variation (CNV) studies. 
The Illumina BeadArray technology is based on 3 micron silica beads in microwells (Fearon 
2011). Each bead is covered with hundreds of thousands of copies of a specific 
oligonucleotide that act as the capture sequences in the reaction. The target is amplified, 
hybridized on the array, and fluorescently labeled. The array is read by exciting the 
fluorescence signal with a laser scanning each spot or imaging the entire array (Figure 3.2).  
For this thesis, the Human Omni 1-Quad Bead chip (Illumina) was used to identify copy 
number changes in all samples. The chip contains 1,140,419 markers including both SNP 
and CNV probes; 618,959 of them are SNP probes with 10 kb of RefSeq genes and 32,110 
markers are nonsynonymous SNPs (NCBI annotated). The average genomic distance 
between adjacent markers is 2.4 kb. The log R deviation is below 0.30.  
 
3.10.2. Protocol 
Amplification, hybridization, and extension steps were performed following the protocols of 
Infinium® HD Assay Super, recommended by the manufacturer (Illumina) as described 
below.  
Briefly, each whole genome amplification reaction requires 200 ng of DNA (4 µl of 50 ng/µl 
DNA) and enables up to 1000-fold amplification. The amplified DNA was enzymatically 
fragmented using end-point fragmentation and was then precipitated with isopropanol at 4oC. 
The precipitated DNA was resuspended in hybridization buffer and then hybridized onto a 
BeadChip. The loaded BeadChip was incubated overnight at 48oC. The amplified and 
fragmented DNA samples anneal to locus-specific 50-mers (covalently linked to one of up to 
one million bead types) during hybridization. Unhybridized and non-specifically hybridized 
DNA was washed away. The BeadChip was labeled with ddNTPs; dinitrophenol (DNP)-
labeled ddNTPs (C/G), and biotin-labeled ddNTPs (A/T), to extend the primer hybridized to 
the DNA. This step is known as ‘single base extension’. The haptens are stained with 
Strepavadin or anti-DNP immunoglobulin. Signal amplification is used in combination with 
anti-strapavadin or antibody to the anti-DNP immunoglobulins conjugated to a fluorescent 
reporter (Figure 3.2). The iScan Reader (Illumina) was used to scan the BeadChip. The 
reader uses a laser to excite the fluorophore of the single-base extension product on the 
beads of the beadchip. Light emissions from the fluorophore are recorded in high-resolution 
images. Data from these images were analyzed with the GenomeStudio Genotype Module 
(Illumina) and export to a file containing the SNP locus, genotypes and quantified fluorescent 
signal intensities (Xraw, Yraw). 
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Figure 3.2. Illustration of Single Base Extension and staining steps: after hybridization (A), ddNTPs 
are labeled (B), and stained with fluorescent dyes (C). The fluorescence signals are recorded and the 
intensity is analyzed by a software tool (D). (Pictures adapted from http://barleyworld.org/sites/ 
default/files/illuminasnpgenotyping.pdf) 
 
3.10.3. Bead decoding 
Decoding is achieved by a series of sequential hybridizations. Oligonucleotides are usually 
80 bases long. The decoding process (Gunderson et al. 2004) uses the first 50 bases of the 
oligonucleotide for detection of the beads while the remaining 30 bases are complementary 
to the genomic target sequence. The 3' end of the complementary sequence of the 
oligonucleotide ends at a position before the analyzed SNPs. Each bead type is defined by a 
unique DNA sequence, which is recognized by a complementary decoder. The fluorescence 
signal is read by imaging the entire array. If one assigns a number to each state – 0 to blank, 
1 to green, and 2 to red, then each cycle of the process generates one of three digits. The 
array is then dehybridized and the rehybridization process is repeated until there is sufficient 
data to unambiguously determine the identity of each bead. 
 
3.10.4. Quality control of raw data 
The GenomeStudio Genotyping Module v2011.1 (Illumina Inc) was used for the analysis of 
the genotyping assay collected by the iScan system (Figure 3.3). This module enables 
efficient genotyping data normalization, genotype calling, clustering, data intensity analysis, 
loss of heterozygosity (LOH) calculation, and copy number variation (CNV) analysis. The 
software calculated a SNP call rate, which represents the percentage of the number of 
markers detected by the scanner. For efficient CNV identification, we set a call rate threshold 
of ≥ 97%. 
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Figure 3.3. Genoplots from GenomeStudio Genotyping Analysis Module with data of a SNP marker (A) 
with 3 different genotypes (red = AA, purple = AB, blue = BB) and data of CNV markers (B and C) 
showing only 1 genotype each. Genotypes are called for each sample (dot) by their signal intensity 
(norm R) and allele frequency (Norm Theta) relative to canonical cluster positions (dark shading) for a 
given SNP marker. 
 
3.11. Identification of putative CNVs 
3.11.1. Final reports 
Genome Studio Files were divided into two sets according to the dates at which blood 
samples were received. The first Genome Studio file contains data of 181 patients and 531 
controls (total n = 732). The second file contains data of 229 patients and 531 controls, 
including the samples of the first file (total n = 760). 
To call putative CNVs, two final reports were created by the Illumina GenomeStudio 
Genotyping module v2011.1 (Illumina Inc.). The first final report was created from the first 
Genome Studio file for 181 patients and 531 controls and the second report was created 
from the second Genome Studio file for the additional 48 patients. The final report indicates 
position, log R ratio (LRR), and B Allele Frequency (BAF) of all markers. 
 
3.11.2. CNV calling 
QuantiSNP calculation: QuantiSNP (version 1.1 and 2.2, https://sites.google.com/site/ 
quantisnp/) was used for CNV detection. Introduced by Colella et al. (2007), QuantiSNP is a 
computational tool for the detection of copy number variation from BeadArrayTM SNP 
genotype data. It applies a Hidden Markov Model (HMM) consisting of hidden and observed 
states that represent the unknown copy number of probes in a sample and their normalized 
intensity measurements in the array. A Bayes Factor provides a probability measure of the 
strength of evidence, based on the data, for the presence of a copy number variant in a 
region versus the hypothesis that there is no variant (i.e. that the called CNV is an artifact). 
The higher the log Bayes factor is, the more likely the CNV is a true positive. In contrast, a 
CNV with a low log Bayes factor tends to be a false positive. The recommended threshold for 
true versus false positive is BF = 30. For the QuantiSNP calculation, two specific values are 
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of importance; allelic intensity ratio (B-allele frequency, BAF) and signal intensities (log R 
ratio, LRR). 
 
Figure 3.4. Illustration of B Allele frequency and Log R ratio of a deletion CNV. The BAF shows loss of 
heterozygosity and LRR shows the intensity lower than 0. 
 
Figure 3.5. Illustration of BAF and LRR of a duplication CNV.  
B-allele frequency (BAF): The B-allele frequency (BAF) provides information on the 
genotype of each SNP marker, depending on whether a red (Cy5) or green (Cy3) 
fluorescence-labeled nucleotide has been incorporated during the single-base extension on 
each bead oligonucleotide. If the genotype is homozygous B/B or hemizygous B/-, the BAF is 
~1 whereas if the genotype is A/A or A/-, the BAF is ~0, and if the scanner detects a mixed 
color, the genotype is a heterozygote A/B and the BAF is ~0.5. For a heterozygous deletion 
(only 1 allele present), the BAF will be either ~1 or ~0, which corresponds to homozygosity 
(Figure 3.4). For a duplication (3 copies), the possible homozygous genotypes are BBB or 
AAA, for which the BAF will be 1 or 0, respectively. Other possible genotypes are BBA or 
AAB, which lead to BAF values of ~0.67 and ~0.33, respectively (Figure 3.5). Homozygous 
deletions result in a failure of the BAF to cluster. Thus, the BAF may be used to accurately 
assign copy numbers from 0 to 4 in diploid regions of the genome (Cooper et al. 2008). It 
also allows detection of copy-neutral events such as segmental uniparental disomy 
(segmental UPD) or whole-chromosome UPD and identity by descent (IBD), which occurs 
when a segment of one chromosome is replaced by the other allele without a change in copy 
number (Peiffer et al. 2006). 
Some markers are not SNP markers but CNV markers. The latter give no information about 
the BAF because they are not polymorphisms. The BAF of these markers is always as if a 
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homozygous allele were present. Since the BAF alone is not able to unequivocally identify 
copy number changes, a second value is necessary to evaluate the copy number. 
Log R ratio (LRR): The Log R ratio (LRR) is a measure of total florescence signal intensity 
measured at every probe. The LRR value for each SNP is calculated as LRR = log2 
(Rsubject/Rexpected), in which Rexpected is computed through linear interpolation of canonical 
genotype clusters obtained from a set of reference samples (Wang and Bucan 2008). The 
log normalized scale ranges from -1 to 1 and is proportional to the copy number at that locus. 
The log2 of normal copy number (diploid) is 0; if the LRR is below 0, the intensity of the 
subject is lower than expected. In contrast, the LRR increases with a gain of copy number. 
The standard deviation of the LRR should not be above 0.30 so unacceptable background 
noise for reliable CNV detection can be avoided. 
 
3.12. CNV analysis 
3.12.1. Known candidate gene survey 
Before performing filtering steps, all called CNVs were checked whether any of the patients 
carry a deletion or a duplication in known polyposis genes or other CRC related genes (Table 
3.4) Genomic positions are based on Ensembl genome Browser release 54 (NCBI build 36, 
hg 18). 
 
3.12.2. Filtering CNVs 
Two different types of filters were applied: 1) those that are technical in nature to minimize 
the number of false-positive CNVs (section 3.12.2.1 – 3.12.2.5), and 2) filters that are based 
on the etiological relevance of the CNV (section 3.12.2.6 – 3.12.2.8). The latter refers to the 
preferred disease model we considered. This thesis focussed on highly penetrant CNVs, with 
both dominant and recessive models of inheritance. 
3.12.2.1. CNV length 
The DGV reports that 95% of CNVs are shorter than 100 kb. Since the majority of CNVs are 
1-10 kb in length and tend to be benign CNVs, variants in the 10-50 kb range are considered 
more important for research (Pinto et al. 2011). Therefore, this thesis set the minimum size 
for inclusion at ≥ 10 kb for CNV length (Engels et al. 2009). Nevertheless, the minimum size 
for duplication inclusion was set at 20 kb to reduce the number of false positive. 
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Table 3.4. Established causative genes or candidate genes for (hereditary) colorectal tumors  
Gene Chro Start 
position 
Stop 
position 
Disease/pathway/susceptibility 
APC 5q22.2 112101483 112209834 Familial adenomatous polyposis (FAP) 
APC2 19p13.3 
1401148 1424243 
Wnt signalling pathway, depletion of intracellular beta-
catenin 
AXIN1 16p13.3 277441 342465 Regulator of canonical Wnt signaling pathway 
AXIN2 17q24 60955145 60988202 Regulator of beta-catenin pathway 
BMPR1A 10q22.3 88506376 88674925 Juvenile polyposis syndrome 
BRAF 7q34 140080751 140271033 Known oncogene, somatic mutations in CRC 
BUB1B 15q15 38240530 38300627 Gastrointestinal adenomas and carcinomas 
CDH1 16q22.1 67328696 67426943 Hereditary diffuse gastric cancer 
CHEK2 22q12.1 27413731 27467822 Susceptibility gene for HNPCC 
CTNNB1 3p21 41211405 41256943 Central protein of canonical Wnt signaling pathway 
EGFR 7p12 55054219 55242524 Known oncogene 
EPCAM 2p21 47425801 47467661 Lynch syndrome/HNPCC 
FAM123B Xq11.2 63321722 63342349 Regulator of canonical Wnt signaling pathway 
FBXW7 4q31.3 
153461860 153675622 
Frequently mutated in CRC and colorectal adenomas, 
Cyclin E degradation 
GREM1 15q13.3 30797497 30814158 Member of BMP pathway, susceptible gene for CRC 
GSK3B 3q13.3 
121028238 121295954 
Involved in canonical Wnt signaling pathway, interact with 
APC, beta-catenin 
KRAS 12p12.1 25249449 25295121 Oncogene, frequently mutated in CRC 
MAP2K4 17p12 11864866 11987865 Frequently mutated in CRC, MAPK pathway 
MLH1 3q21.3 37009845 37067341 Lynch syndrome/HNPCC 
MSH2 2p21 47483710 47563871 Lynch syndrome/HNPCC 
MSH6 2p16 47863725 47887596 Lynch syndrome/HNPCC 
MUTYH 1p32-34 45567501 45578729 MUTYH-associated polyposis (MAP) 
NRAS 1p13.2 115051108 115061038 Frequently mutated in CRC 
PDGFRA 4q12 54790204 54859168 Frequently mutated in CRC 
PIK3CA 3q26.3 180349005 180435189 Cowden syndrome, frequently mutated in CRC 
PMS2 7p22.2 5979396 6015263 Lynch syndrome/HNPCC 
POLD1 19q13.3 55579420 55613082 Candidate CRC gene for hereditary multiple adenomas 
POLD2 7p13 44120811 44129655 Candidate for hereditary multiple adenomas/CRC 
POLD3 11q14 73981277 74031413 Candidate for hereditary multiple adenomas/CRC 
POLD4 11q13 66875597 66877593 Candidate for hereditary multiple adenomas/CRC 
POLE 12q24.3 131710421 131774018 Hereditary multiple adenomas/CRC 
POLE2 14q21 49180028 49224685 Candidate for hereditary multiple adenomas/CRC 
POLE3 9q33 115209342 115212773 Candidate for hereditary multiple adenomas/CRC 
POLE4 2p12 75039283 75050366 Candidate for hereditary multiple adenomas/CRC 
PPP2R1B 11q23 111102842 111142379 
MAPK pathway, candidate TSG, frequently mutated in 
CRC 
PTEN 10q23.31 89613175 89718511 Cowden’s syndrome 
PTPRJ 11p11.2 47958686 48148969 Candidate CRC gene 
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Gene Chro Start 
position 
Stop 
position 
Disease/pathway/susceptibility 
SFRP1 8p11.21 
41238640 41286149 
Modulator of Wnt signaling pathway, epigenetic loss in 
early colorectal adenomas and CRC 
SMAD2 18q21.1 43613464 43711510 TGF-beta signaling pathway, frequently mutated in CRC 
SMAD4 18q21.1 46810581 46865409 Juvenile polyposis syndrome  
SOX9 17q24.3 67628756 67634147 Frequently mutated in CRC 
STK11 19p13.3 1156798 1179434 Peutz-Jeghers syndrome 
TCF7L2 10q25.3 114700201 114916073 
Frequently mutated in CRC, target transcription of Wnt 
signaling pathway 
TP53 17p13.1 7512445 7531642 Li-Fraumeni syndrome 
UBC 12q24.3 
123962147 123965530 
Regulation of various cell signaling pathways by 
ubiquitination 
WIF1 12q14.3 63730674 63801383 Inhibitor of Wnt signaling pathway 
 
3.12.2.2. Number of markers 
To reduce the signal-to-noise ratio, as had been done in previous studies, the number of 
consecutive probes was set at  5 for a deletion (Engels et al. 2009; Pinto et al. 2011) and at 
 7 for a duplication (Venkatachalam et al. 2011). 
3.12.2.3. Log Bayes Factor  
The Log Bayes Factor represents the confidence for a CNV. It is calculated by the 
QuantiSNP software based on LRR and BAF, where higher values indicate higher statistical 
reliability. The percentage of false positive CNVs with Log BF lower than 20 is higher than 60% 
(Priebe et al. 2012), thus minimizes the number of false positive CNV calls; the critical Log 
Bayes Factor for a deletion and duplication was set at  20 and  30, respectively. 
3.12.2.4. Segmental duplications 
Segmental duplications are genomic regions with high sequence identity (greater than or 
equal to 90%) to more than one genomic locus and have been mapped in the human 
genome. Segmental duplications make up approximately 5% of the human genome. They 
can appear on the same or different chromosomes (Bailey et al. 2002). Copy number 
changes mediated by segmental duplications may be benign in the human population (Itsara 
et al. 2009). A segmental duplication represents an obstacle for the design of specific 
primers for validating a CNV by qPCR methods. In analogy to Itsara et al. (2010) who 
excluded segmental duplications and hotspot enrichment from the analysis to avoid 
ascertainment bias in the results, we also removed putative CNVs in segmental duplication 
regions. 
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3.12.2.5. Visual inspection on Genome Viewer (Illumina) 
The remaining CNVs were inspected for their LRR, BAF, types of probes, and pattern of 
probes using Genome Viewer software (Illumina). This inspection allowed removing false 
positive CNVs from the study. A CNV was excluded if all markers are CNV probes, or the 
majority of probes is located in intronic regions while the last or first probe is located in 
isolation. An example of a false positive CNV visualized by the Genome Viewer is shown in 
figure 3.6. 
 
Figure 3.6. GenomeViewer illustrating the pattern of a false positive heterozygous deletion called by 
QuantiSNP. The CNV is located on chr15: 41924943-41935434; length 10492 bp, Max Log BF 26, 
and involves 17 probes (red dots). All except the last single, right-sided probe are CNV markers, 
clustering together in a candle-shaped way. The clustered group of CNV probes is located in the 
intronic region of WDR76 whereas the exon of the gene (blue circle) is located between the last 2 
probes. 
3.12.2.6. Comparison to the Database of Genomic Variants (DGV) 
For overlaps with known CNVs, the Cartagenia Bench software set the criteria to filter out 
common CNVs if there was 100% overlap with variants reported and the number of observed 
CNVs was ≥ 3% in the control population. After this in-silico filtering step, the remaining 
CNVs were manually inspected on the DGV (http://projects.tcag.ca/ variation/?source= hg18). 
In this thesis, the definition of a common CNV is a CNV which has been reported as a 
deletion/duplication in at least 1% of study samples in at least two large-scale studies such 
as those of Redon et al. (2006), Pinto et al. (2007), Jakobsson et al. (2008), Shaikh et al. 
(2009), and Conrad et al. (2010). The sample sizes of these studies are hundreds to 
thousands. On the other hand, reports with only a few samples were not used in 
consideration of classifying a CNV as common or rare. For example, the DGV reports a 
deletion on chromosome 15:40160584-40195058, shown in figure 3.7 (whole region). 
Common deletions in the region have been reported by many groups but in all except one 
report, the deletion is located outside a gene (red bars, right side). A deletion 
(chr15:40167556-40174721) involving PLA2G4D, has been reported in one study only 
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(Korbel et al. 2007) (red bar, left side). The deletion was found in one of two samples. The 
PLA2G4D gene is a reverse strand; the 5’UTR and the first exon were deleted. The 
duplication (blue bar, whole region), found in one of 47 control samples, has been reported 
by Sharp et al. (2006).  
 
Figure 3.7. Database of Genomic Variants (DGV) reports deletions and duplications on chromosome 
15:40160584-40195058. Red bars represent deletions, blue bars represent duplications. 
3.12.2.7. Comparison to HNR controls 
After filtering CNVs with the above criteria, 531 Heinz Nixdorf RECALL (HNR) study controls 
that were genotyped on the same array and showed log R ratio deviation ≤ 0.30 were used 
for exclusion of common CNVs. CNVs of HNR controls were called with QuantiSNP as had 
been done in the patient cohort. Called CNVs smaller than 1 kb were excluded from the 
study because they are defined as ‘indels’, not ‘CNVs’. The patients’ CNVs were compared 
against the controls’ CNVs and were removed from the study if they were present in more 
than 1 control individual (frequency > 0.2%) and either partly or completely overlap with 
those in controls (Figure 3.8). CNVs found more than once in the control cohort were 
described to be common CNVs. 
 
Figure 3.8. Definitions of the position of CNVs used for comparing between patient CNVs (CNVs of 
interest) and control CNVs (blue bars). Patient CNVs completely covered by control CNVs (left) or 
partly overlapping the control CNVs (right) were considered to be found in the control cohort. 
3.12.2.8. Gene content 
CNVs were checked against Ensembl genome browser 54 to exclude non-genic CNVs and 
genic CNVs disrupting only an intronic part (containing no coding sequence). Only the CNVs 
containing protein coding genes were included. 
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3.13. CNV validation 
3.13.1. Quantitative PCR (qPCR) 
Real-Time quantitative polymerase chain reaction (qPCR) is similar to a simple PCR except 
for its ability to monitor the progress of the PCR as it occurs in real time. The PCR product is 
measured after each round of amplification while with traditional PCR, the amount of PCR 
product is measured only at the end of amplification. The amplified product is measured 
based on fluorescent label. Two common methods for the detection of products in 
quantitative PCR are 1) non-specific fluorescent dyes that intercalate with any double-
stranded DNA and 2) sequence-specific DNA probes consisting of oligonucleotides that are 
labeled with a fluorescent reporter which permits detection only after hybridization of the 
probe with its complementary sequence. They all link the amplification of DNA to the 
generation of fluorescence which can simply be detected with a camera during each PCR 
cycle. Hence, as the number of gene copies increases during the reaction, so increases the 
fluorescence. 
Quantitative PCR can be used to quantify nucleic acids by two common methods: relative 
quantification and absolute quantification. Relative quantification is based on internal 
reference genes to determine fold-differences in expression of the target gene. The 
quantification is expressed as the change in expression levels of mRNA interpreted as 
complementary DNA. Absolute quantification gives the exact number of target DNA 
molecules by comparison with DNA standards using a calibration curve. It is therefore 
essential that the PCR of the sample and the standard have the same amplification efficiency. 
Relative quantification is easier to carry out than absolute quantification as it does not require 
a calibration curve: the amount of the studied gene is compared to the amount of a control 
housekeeping gene. 
 
3.13.2. CNV validation by qPCR using SYBR Green I 
SYBR Green I is a DNA-intercalating (DNA minor-groove binding) dye, which is able to 
nonspecifically bind to double stranded DNA to detect a PCR product during PCR cycles. 
SYBR Green I exhibits little fluorescence when it is free in solution, but its fluorescence 
intensity increases up to 1,000-fold when it binds double-stranded DNA (Figure 3.9). 
To validate the copy number of putative CNVs, qPCR using SYBR Green was performed on 
an ABI Prism 7900HT Fast Real-Time PCR System (Life Technologies) with exact amounts 
of DNA samples. For each CNV, three primer pairs were designed using the online program 
Primer3. The primers were put in coding regions (if possible) at the beginning, in the middle, 
and at the end of each CNV. All primer sequences are presented in Tables A4 and A5. Three 
housekeeping genes (BNC1, CFTR, RPP38) were used as internal controls for normalization 
(Table A6). The reason for using housekeeping genes is to correct for non-specific variation. 
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Four anonymous healthy controls were used for assessment of the variability in copy number. 
Each assay was run in triplicate and contained a no template control (NTC). 
 
Figure 3.9. Illustration of the SYBR Green I binding to double-stranded DNA in real-time PCR. The 
fluorescence signal is increased in proportion to the amount of the target DNA amplified. (Figure 
adapted from www.gene-quantification.de/real-time-pcr-guide-bio-rad.pdf) 
Reaction components 
The Power SYBR Green I PCR Master Mix (Life Technologies) is supplied in 2X 
concentration. The mix contains SYBR Green I Dye, AmpliTaq Gold DNA Polymerase, 
dNTP, passive reference (ROX™ dye), and optimized buffer components. The passive 
reference provides an internal reference for data normalization, which is necessary to correct 
well-to-well fluorescence fluctuations. In total 10 µl of each reaction contains 20 ng of 
template DNA. Reagents for each reaction were provided as shown in table 3.5. 
Table 3.5. Amount and final concentration of qPCR reagents per reaction 
Reagent Volume 
(µl) 
Final 
concentration 
2X Power SYBR® Green I 
PCR Master Mix 
5 1X 
For primer [10 pmol/µl] 0.2 0.2 µM/reaction 
Rev primer [10pmol/µl] 0.2 0.2 µM/reaction 
Genomic DNA [10ng/µl] 2 20 ng/reaction 
H2O 2.6  
Total 10  
Cycling step 
The conditions for amplifications were started with a temperature of 50°C for 2 minutes, then 
denaturation at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and a 
combined annealing and extension step at 60°C for 60 seconds, followed by melting 
temperature curve analysis. 
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3.13.3. Data analysis 
Absolute quantification was used to determine the absolute copy number. The dissociation 
stage was performed to recognize the presence of unspecific product because SYBR GreenI 
binds to any double-stranded DNA including nonspecific double-stranded DNA sequences, 
which leads to false positive signals. A multi-peak might be caused by unspecific products or 
an unspecific primer elongation or primer dimer or SNPs (Figure 3.10). In this case, primers 
were redesigned. 
The signals from the PCR amplification were detected by Sequence Detection Software 
(SDS) version 2.2.2 (Life Technologies). Results were expressed in terms of the threshold 
cycle (Ct) value, which was calculated with SDS 2.2.2 using standard settings for Ct and 
autobaseline (Figure 3.11). 
 
Figure 3.10. The dissociation curves represent the specific product (left) and the unspecific product 
(right) which leads to a false Ct result. The X axis represents temperature (°C) and the Y axis 
represents derivative of log. 
 
3.13.4. Copy number calculation (2−ΔΔCT method) 
Since the assays were done in triplicate, an average of the Ct was calculated in all assays. 
The standard deviation (SD) must not be higher than 0.20 to ensure the reliability of the Ct 
value. Assays with SD higher than 0.20 were repeated. 
The delta delta Ct (2-Ct) method was used to identify the copy number. This method directly 
compares the Ct values between patients and controls. The first step is normalization and 
Ct was generated by subtracting the Ct of the target from the Ct of the reference (Ct = Ct 
CNV – Ct Ref Gene). Then the Ct of the case was compared to the Ct of the control (Ct 
= Ct patient - Ct control). The copy number was then calculated with the formula; CN = 2 x 
2-Ct (Livak and Schmittgen 2001). 
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Figure 3.11. The amplification plots show (left) the difference between the Ct value of a PCR product 
with a normal copy number (dark green) and the Ct value of a PCR product with loss of a copy 
number (light green), and (right) the difference of the Ct value between the normal copy number (dark 
blue) and the Ct value of a gain of copy number (blue). The x-axis represents the cycle of the PCR. 
The y-axis represents the normalization of the fluorescence signal between the reporter signal and the 
baseline signal (Rn). The red line is the threshold at which the reaction reaches fluorescence 
intensity above background. 
 
3.14. Co-segregation analysis 
To see whether or not the CNV segregates with the phenotype of family members, and 
based on whether the DNA of patients’ family members is available, the copy number was 
evaluated by qPCR with the same primer set as was used for validation of the CNV in the 
probands. qPCR (see section 3.13) was performed to check whether the CNV of the index 
patient was also present in affected relatives or absent in non-affected relatives.  
 
3.15. Gene expression analysis 
3.15.1. Gene expression in human colon cDNA 
To check whether the identified candidate genes are known to be expressed in colon tissue, 
two publicly available databases were used: the EST profiles reported in the UniGene 
database (www.ncbi.nlm.nih.gov/unigene), and RNA expression data from normal human 
tissues reported in GeneCards (www.genecards.org). Genes were considered to be 
expressed if the value of transcripts per million (TPM) was > 0. To exclude false negative 
results in the accessed databases, the expression of candidate genes with reported non-
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expression in human colon tissue was examined using commercial first strand cDNA of 
human adult colon mucosa (Amsbio). Genes which are unexpressed in human colon cDNA 
were removed from the list of candidates. 
 
3.15.2. PCR and agarose gel electrophoresis 
PCR Ready First Strand cDNA Human adult normal colon tissue (Amsbio) [2.5 ng/µl] was 
used for this study. REDTaq ReadyMix PCR Reaction Mix with MgCl2 (Sigma Alrich) was 
used for semi-quantitaive PCR (Pasternack et al. 2008). A primer pair for each gene was 
designed and synthesized as described in section 3.7. Amplicon length was set at 400-600 
bp and, if possible, primers were put in exon-exon boundaries and the exon must be present 
in every isoform when there is more than one isoform. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an endogenous control, and positive control cDNA for 
the analysis was taken from Human MTC Panels I & II (Clontech) (placenta, liver, stomach, 
esophagus, and testis), hair follicle, and peripheral blood leukocytes. A new primer pair was 
designed to repeat the test in case no band showed up on the gel and, in particular, no 
positive tissue was available. 
PCR reaction components 
Before preparing the reaction, primers were diluted 1:10 in H2O to a working concentration of 
10 µM. Reagents used for PCR reaction preparations are described in table 3.6. The PCR 
cycle is described in section 3.7. 
The PCR product was checked with a 2% agarose gel electrophoresis. If PCR products 
obtained on cDNA showed a visible band on the control tissue (e.g. placenta or testis) but 
not on the colon tissue, the primer was assumed to work well but the candidate gene was not 
expressed in colon. If the product is not present on any tissue, the gene is either not 
expressed in both, control tissues and colon tissue, or the primer is not working. In the latter 
scenario, a new primer pair was designed and the test was repeated to confirm the result. 
Table 3.6. Reagents used for the PCR reactions 
Reagents Volume (µl) Final concentration 
2X REDTaq 12.5 1X 
10 µM Forward primer 1 0.4 µM 
10 µM Reverse primer 1 0.4 µM 
[2.5 ng/µl]Template cDNA 1 2.5 ng/reaction 
H2O 9.5  
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3.16. Network analysis  
To further prioritize our candidate genes, a network and pathway analysis was performed in 
collaboration with Prof. Dr. Holger Fröhlich at the Bonn-Aachen International Center for 
Information Technology in Bonn. The network analysis was performed twice. For the first 
analysis, protein-protein interaction was performed to compare our candidate genes and 
established polyposis genes, published candidate genes for colorectal cancer, and putative 
disease genes from a polyposis GWAS (unpublished data). The second analysis was 
performed via the Steiner Tree algorithm (Sadeghi and Frohlich 2013). Network analysis, 
pathway analysis, and enrichment analysis were carried out according to KEGG pathway 
and GO terms (biological process) with the conditional hyper-geometric test approach 
(Falcon and Gentleman 2007) in both CNV candidate genes and known candidate genes. All 
human genes were employed as statistical background. 
The pathway analysis of 180 candidate genes was also performed by an online Ingenuity 
pathway analysis tool (www.ingenuity.com/products/ipa). This online tool evaluates the set of 
input genes as to whether there are known relationships between the genes and biofunctions 
with subcategory of diseases, and cellular functions in the Ingenuity Knowledge Base. The 
probability that each biological function and/or disease assigned to that data set is due to 
statistical chance was calculated by a right-tailed Fischer’s Exact Test. Overrepresentation of 
the molecules in a given process was considered to be statistically significant when P < 0.05. 
The over-represented functional or pathway processes are those with more focus molecules 
than expected by chance (Mitra et al. 2012). 
 
3.17. Candidate gene prioritization 
To select the most promising candidate genes for further work-up, many conditions and 
criteria were applied to prioritize candidate genes as described below. 
 
3.17.1. Frequency of finding 
Candidate genes present in more than one patient were included for further study and 
prioritized as being most interesting genes. 
 
3.17.2. Segregation analysis 
When DNA from any family member of the study patients was available, the copy number of 
the candidate CNV region identified in the study patient was examined in the relatives to 
prove whether the CNV co-segregates with the phenotype or not. If the CNV co-segregated 
with the phenotype, the genes in the CNV would be further studied and ranked as top 
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prioritization. If the CNV did not segregate with the phenotype, the CNV might not be 
causative or is assumed to have a low to moderate penetrance. 
 
3.17.3. Data mining 
Another approach we used to rank our candidates was text mining by access through 
relevant databases and literature of individual genes to maximize the chance of identifying 
relevant genes (Moreau and Tranchevent 2012). Many online databases such as COSMIC 
(Catalogue of somatic mutations in cancer), DAVID (Database for Annotation, Visualization 
and Integrated Discovery), GENATLAS (http://genatlas.medecine.univ-paris5.fr/), GeneCards 
(www.genecards.org/), Gene Codis (Gene annotations co-ocurrence discovery), the GWAS 
catalog (A Catalog of Published Genome-Wide Associations Studies), Human Gene Mutation 
Database (HGMD), the KEGG database (Kyoto Encyclopedia of Genes and Genomes), 
OMIM (Online Mendelian Inheritance in Man), PUBMED (http://pubmed.com/), and STRING 
(Search Tool for the Retrieval of Interacting Genes/Proteins) were used for compiling all 
relevant information of the candidate genes including functions, pathways, related 
phenotypes, gene interactions, tissue specification, GWA studies, and publications. 
 
3.18. TaqMan® gene expression analysis 
3.18.1. Basic principle 
The TaqMan-based detection probe uses a fluorogenic probe and represents a more 
specific quantitative detection method than SYBR Green I. The latter is an intercalator dye, 
which is able to detect both specific and non-specific products, whereas fluorogenic probes 
amplify only a specific product and enable the development of a real-time detection method. 
The probes are dual labeled; a reporter fluorescence dye (VIC or FAM) labels on the 5’ end 
and a non-fluorescent quencher (NFQ) and minor groove binder (MGB) are at the 3’ end of 
the probe. The fluorophore is a molecule that emits light of a certain wavelength after having 
first absorbed light of a specific but shorter wavelength. The quencher is a molecule that 
accepts energy from a fluorophore in the form of light and dissipates this energy in the form 
of light. The MGBs increase the melting temperature (Tm) without increasing probe length. 
The fluorophore is excited by the machine and passes its energy via FRET (Fluorescence 
Resonance Energy Transfer) to the quencher (Cardullo et al. 1988). If the target sequence is 
present, the probe anneals downstream from one of the primer sites and is cleaved by the 5' 
nuclease activity of Taq DNA polymerase as this primer is extended. Additional reporter dye 
molecules are cleaved from their respective probes with each cycle, resulting in an increase 
in fluorescence intensity proportional to the amount of amplicon produced (Figure 3.12). The 
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increase in florescence occurs only if the target sequence is complementary to the probe and 
is amplified during PCR. Therefore, without specific amplification a sequence is not detected. 
 
Figure 3.12. Schematic of the FRET method.1) A fluorescent reporter (R) dye and a quencher (Q) are 
attached to the 5’ and 3’ ends of a TaqMan probe respectively. 2) The reporter dye emission is 
quenched. 3) The DNA polymerase cleaves the reporter dye during each PCR cycle. And 4) the 
reporter dye separates from the quencher and emits its fluorescence. (Figure adapted from 
www.appliedbiosystems.com/absite/us/en/home/applications-technologies/real-time-pcr/taqman-and-
sybr-green-chemistries.html) 
 
3.18.2. Relative quantitative PCR (RT-PCR) 
Duplex real-time PCR allows the amplification of two target sequences in a single reaction. 
Two assays must have a different specific probe labeled with a unique fluorescent dye, 
resulting in different observed colors for each assay. Typically one probe is used to detect 
the target gene, another probe is used to detect an endogenous control. The endogenous 
control is necessary for normalization of each sample to adjust for differences in total DNA 
content.  
This study was performed to quantify the expression of CTNNB1 or MUTYH. TaqMan gene 
expression assays for this study were designed and generated by Life Technologies. Each 
assay was composed of specific primers and probes for CTNNB1 or MUTYH. Human 
Cyclophilin and Human Beta-2-microglobulin (hu2M) (Life Technologies) were used as 
endogenous controls. The assays for reference genes were labeled with VIC while the 
assays for the target genes were labeled with FAM. Ten anonymous healthy controls (5 
males, 5 females) were used for the statistical comparison. 
Each assay was run in triplicate. Each run contained a no-template control (NTC). For valid 
Ct values, the standard deviation (SD) of each assay must not be higher than 0.20. 
 
3.18.3. Reaction components 
Reagents, volume and final concentrations for a duplex qPCR reaction are presented in table 
3.7. CTNNB1 assay was combined with hu2M while MUTYH was combined with the 
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Cyclophilin A assay. Exact pipetting is a crucial requirement for this experiment as even the 
smallest change in the amount of template could lead to wrong results.  
Table 3.7. Reagents used for TaqMan gene expression study 
Reagent 
Volume 
(µl) 
Final 
concentration 
TaqMan® Gene Expression Master Mix (2X) 5 1X 
TaqMan® Gene Expression Assay (20X FAM) 0.5 1X 
TaqMan® Endogenous Control (20X VIC) 0.5 1X 
cDNA (50 ng RNA equivalent/µl) 2 
100 ng RNA 
equivalent/reaction 
RNase-free water 2  
Total 10  
 
3.18.4. Cycling step 
The qPCR was performed on an ABI Prism 7900HT Fast Real-Time PCR System (Life 
Technologies) with standard amplification programs as for qPCR using SYBR Green I. The 
amplifications were started at 50°C for 2 minutes, then denaturation at 95°C for 10 minutes, 
followed by 40 cycles at 95°C for 15 seconds, and a combined annealing and extension step 
at 60°C for 60 seconds. Melting temperature curve analysis is not needed for TaqMan 
assays. 
 
3.18.5. Data analysis 
The Comparative CT (CT) method (relative quantification) was used to analyze changes in 
gene expression in a target sample relative to a reference gene. The original amount of 
transcript was then obtained from that normalized Ct value by calculating 1/(2xCt). A 
reasonable value of the result was obtained by multiplying it with an arbitrary factor of 
100,000,000. 
To determine differences in gene expression level between a patient and controls, statistical 
significance was analyzed by R software version 3.0.2 using a two-sided Wilcoxon test. The 
Wilcoxon test is a non-parametric statistical test to compare two independent samples. The 
statistical difference was considered significant when the p-value was less than 0.05.  
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3.19. Targeted next generation sequencing  
3.19.1. Basic principle 
Next generation sequencing (NGS) refers to high throughput sequencing technologies that 
have emerged during the last decade. Each platform is different in its methods of clonal 
amplification of short DNA fragments as a genomic library template and how these fragment 
libraries are subsequently sequenced through repetitive cycles to provide a nucleotide 
readout. The sequencing is conducted in either a stepwise iterative process or in a 
continuous real-time manner. By virtue of the highly parallel process, each clonal template is 
sequenced individually and can be counted among the total sequences generated 
(Myllykangas et al. 2011). In principle, there are three major steps: sample preparation, 
sequencing by collection of images, and data analysis. 
The sample preparation steps generally involve random breakage of genomic DNA and 
product filtering into a sub-pool of suitable fragment sizes (50–400 bases). Filtered fragments 
are further processed into a library by applying adapters, through ligating containing a 
universal primer motif, to the ends of each fragment. A successful amplification of the DNA 
fragments results in one clonal product per bead, or a cluster in case using a glass slide. 
Beads and clusters produce an amplified signal, representing the average of the original 
molecule during the sequencing step (Figure 3.13).  
 
Figure 3.13. Illumina sample procedure. Double strand DNA is fragmented and ligated with an 
adaptor, then clusters are generated by bridge amplification, and sequencing is performed during 
synthesis (Figure adapted from Rizzi et al. (2012)). 
The development of algorithms and software that are able to determine the success of the 
experiment and turn data into manageable results is crucial for interpreting the increasing 
piles of generated sequences. In principle, the NGS analysis pipeline consists of 4 major 
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steps; 1) read cleaning or raw data analysis: this first step is to discard failed reads and 
collect only cleaned reads; 2) read mapping: this step is to align the reads against a 
reference genome; 3) variant calling: to detect genetic variations such as SNPs, 
deletions/insertions, and CNVs; 4) variant annotation: this step is linking the variants to 
biological information, i.e. to specific genes and transcripts to determine the functional 
consequences such as the mutation type, and to appropriate databases.  
 
3.19.2. Library preparation, target enrichment, and sequencing 
In this study, the targeted NGS was performed in collaboration with the Cologne Center for 
Genomics (CCG). 192 DNA samples (validation cohort) were enriched with the TruSeq® 
Custom Enrichment kit (Illumina). The oligonucleotide probes were designed by means of the 
Illumina DesignStudio (http://designstudio.illumina.com/). One µg genomic DNA extracted 
from leukocytes with standard protocols was fragmented using sonication technology 
(Bioruptor) and fragments were end repaired and adapter ligated using the TruSeq® DNA HT 
Sample Preparation Kit (Illumina). Custom capture of targeted regions was performed on 
pools of 12 indexed libraries with the TruSeq enrichment protocol (Illumina). The captured 
DNA was sequenced by an Illumina HiSeq2000 sequencer with 2x100bp paired-end reads 
achieving 30x coverage for at least 96% of targeted bases. Data were filtered using Illumina 
Realtime Analysis® (RTA) software. 
 
3.19.3. Alignment, genotype calling, and variant annotation 
Primary data were filtered according to signal purity using the Illumina Realtime Analysis 
(RTA) software version 1.8. Subsequently, the reads were mapped to the human genome 
reference build GRCh37 with the BWA version alignment algorithm (Li and Durbin 2009). 
GATK version 1.6 (McKenna et al. 2010) was used to remove duplicated reads, perform local 
realignment around known indels from the 1000 Genomes Pilot, and recalibrate base quality 
scores. Variant calling was performed using SAMtools version 0.1.7 (Li et al. 2009) for InDel 
detection. Scripts developed in-house at the CCG were applied to detect point mutations and 
overlaps with known variants. The sequences were stored and further analyzed in a user-
friendly database (VARBANK, version 2.6) developed by CCG, Germany 
(http://varbank.ccg.uni-koeln.de/). 
 
3.19.4. Data analysis and filter 
The annotated sequences were processed through the VARBANK pipeline to detect protein 
changes, affected donor and acceptor splice sites, and overlaps with known variants. 
Acceptor and donor splice site mutations were analyzed with a Maximum Entropy mode (Yeo 
and Burge 2004), and filtered for effect changes. In particular, filtering was performed for 
high-quality, rare (MAF < 0.01) autosomal variants using allele frequencies from the 1000 
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Genomes database and the Exome Variant Server. Filtering was also performed against an 
inhouse-database containing variants from 511 exomes from epilepsy patients in order to 
exclude pipeline-related artifacts (MAF < 0.02). The cDNA bases were numbered according 
to the gene reference sequence in GenBank, where 1 corresponds to the A of the ATG 
translation initiation codon. All relevant information of the pre-filtered variants was 
downloaded as an excel sheet and afterwards further filtered and analysed. 
 
3.19.5. Validation of results 
All variants were visually inspected with the VARBANK Read Browser to exclude obvious 
false positive variants and artifacts. Afterwards, only rare truncating mutations (nonsense 
mutations, insertions, deletions, and splice site mutations) were confirmed by Sanger 
sequencing. To evaluate the functional impact of missense and splice site mutations on the 
structure and function of a protein, four in-silico tools (Polyphen-2, Mutation Taster, SIFT, 
and BDGP) were applied. 
 
3.20. Genotyping based on MassExtend Reaction (Sequenom®) 
3.20.1. Basic principle 
The Sequenom MassArray MALDI-TOF (matrix-assisted laser desorption/ionization time-of-
flight) system is a compact mass spectrometer. The MALDI-TOF MS has been used for 
genotyping a limited set of SNPs in a large number of individuals by analysis of the mass of 
single base extension oligonucleotides specific to the SNP of interest. The Sequenom 
MassARRAY iPLEX SNP typing platform uses MALDI-TOF MS coupled with single-base 
extension PCR for high throughput multiplex SNP detection, which is capable of multiplexing 
up to 40 SNPs per single reaction. The homogeneous assay consists of PCR amplification of 
the target, followed by incubation with shrimp alkaline phosphatase (SAP) to inactivate 
unincorporated nucleotides (Figure 3.14). Then a primer is hybridized adjacent to the SNP of 
interest, extended through the SNP by a single ddNTP under standard thermocycling 
conditions, followed by reaction termination. The mass of the primer extension product is 
analyzed and used to determine the sequence of the nucleotide at the SNP site. 
 
3.20.2. Selection of the genotyped SNPs 
From a recently performed GWAS in 178 unexplained adenomatous polyposis patients and 
536 HNR control individuals based on genotyping data from the above mentioned SNP array 
experiments, the most promising SNPs were selected for a replication study using the 
Sequenom platform for genotyping. The most promising SNPs were mainly selected by a 
top-down approach, i.e. including the SNPs with the highest association according to p-
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values. 140 SNPs showed p-values < 10-4, and odds ratios of 0.284-4.326. All 140 SNPs 
showed appropriate clustering on GenomeStudio (Figure 3.15). The number of SNPs for 
genotyping was reduced from 140 to 119 by exclusion of SNPs which are in strong LD (r ≥ 
0.8) with each other, i.e. which are located on the same haploblock. From all SNPs in LD, 
only two were included to reduce their number. 
 
Figure 3.14. Sequenom® MassARRAY® MALDI-TOF MS SNP genotyping schematic. The target is 
PCR amplified followed by SAP incubation to inactivate unincorporated nucleotides. During the iPLEX 
Gold reaction, an internal primer is extended through the SNP by a single ddNTP. The mass of the 
primer extension product is determined by MALDI-TOF MS to determine the sequence of the 
nucleotide at the SNP site. (Figure adapted rom iPLEX Gold Application Guide, Sequenom) 
 
Figure 3.15. Cluster plot of SNP rs1329428 showed three genotypes; AA (horizontal, red dots), BB 
(vertical, blue dots), and AB (diagonal, purple dots). A plot normalized values (right figure) shows clear 
genotypes calling. 
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3.20.3. DNA preparation 
Ten µl of DNA (20 ng/µl) was prepared and delivered in 96-well plates by our collaborators. 
Before dilution, the DNAs were randomly measured regarding concentration using a Thermo 
Scientific NanoDrop™ ND-1000 Spectrophotometer. The DNAs were diluted to 5 ng/µl as 
working concentration, then 2 µl of the working DNAs were transferred to a 384-well PCR 
plate and air-dried overnight before the PCR step. Each PCR plex included one no-template 
control (NTC) and duplicate DNA samples. 
 
3.20.4. Assay and primer design  
The Human Genotyping Tools Online (www.mysequenom.com) was used to retrieve flanking 
sequences of all 119 SNPs and to check positions of proxy SNPs, which could lead to a 
problem when designing primers. Forward and reverse PCR primers as well as extension 
primers for single base extension were automatically designed. The optimal amplicon size 
was set at 80 to 120 bp. A 10-mer tag (5′-ACGTTGGATG-3′) was added to the 5′ end of each 
PCR primer to avoid confusion in the mass spectrum, and SBE primers were 5′ tailed with 
non-homologous sequences varying in length to create large enough mass differences 
between the different SBE products to be detected by MALDI-TOF MS. 
In this study, the software was not able to design primers for four of the SNPs (rs10148733, 
rs4236975, rs4967946, and rs11709614); therefore these SNPs were replaced by proxy 
SNPs. To search for suitable proxy SNPs, the SNP Annotation and Proxy Search (SNAP) 
online tool (Broad Institute) (www.broadinstitute.org/mpg/snap/) was used with the HapMap 
release 21 SNP dataset. The r2 threshold was set at 1. Three SNPS, rs10148733, rs4236975, 
and rs4967946, were replaced by rs60455014, rs4236978, and rs12935619, respectively. 
Nevertheless, there was no proxy SNP available for rs11709614: thus, this SNP was 
genotyped with the TaqMan Genotype assay instead (see section 3.21). 
To design the multiplex genotype assay, Sequenom’s MassARRAY Designer software was 
used. Each plex is able to contain up to 40 SNPs. The range of weight was set at 4300-9000 
Da and the minimum peak separation was set at 30 to reduce ambiguity of peaks. The 118 
SNPs were divided into four plex’s; information on all SNPs, plexes and primers used in the 
experiments are given in Table A7. 
 
3.20.5. PCR step 
The PCR assay pool plexes consisted of the multiplexed forward and reverse PCR 
oligonucleotide primers for each reaction present together in one multiplexed assay pool. 
PCR was performed in 5 μl reaction volumes containing 0.5 U of Taq polymerase, 5-10 ng of 
genomic DNA, 100 nM of PCR primers, and 500 μM of dNTPs. 
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PCR cycle 
Step Temperature (°C) Duration Number of cycle 
Initial denaturation 95 15 min 1X 
Denaturation 95 20 sec 
45X Annealing 56 30 sec 
Extension 72 1 min 
Final extension 72 3 min 1X 
 
3.20.6. Digestion step  
Shrimp alkaline phosphatase (SAP) dephosphorylates unincorporated dNTPs by cleaving the 
phosphate groups from the 5’ termini. To remove remaining unincorporated dNTPs, PCR 
products were treated with 0.5 U SAP by incubation at 37°C for 40 minutes, followed by 
enzyme inactivation by heating at 85°C for 5 minutes. 480 reactions of reagents were 
prepared for robot pipetting into 384 well-plate. 
Reagent Volume (µl) 480 reactions (µl) 
Shrimp Alkaline Phosphatase (SAP) buffer 0.17 81.6 
SAP enzyme 0.3 144 
H2O 1.53 734.4 
Total 2 960 
 
3.20.7. Extension primer adjustment 
Adjusting the concentrations of oligos to equilibrate signal-to-noise ratios was performed to 
increase signal-to-noise ratios, which tend to decrease in multiplex experiments. Eventually, 
the signals become indistinguishable from noise, resulting in calling errors (Figure 3.16). A 
general method to adjust extension primers is to divide the primers into a low mass group 
and a high mass group. All primers in the high mass group are doubled in concentration with 
respect to those in the low mass group. 
In this study, mass groups were generated using the primer adjustment tool of the Typer 
software version 3.4 and 4.0. The primers were sorted by weight into four groups, with the 
highest mass group diluted to 14 μM, the second and third highest groups to 11.6 μM and 
9.3 μM, respectively, and the last group with the lowest mass diluted to 7 μm. 
 
3.20.8. Extension step  
The primer extension or iPLEX reaction is a method for detecting single-base polymorphisms 
or small insertion/deletion polymorphisms in amplified DNA. 
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Figure 3.16. Spectra of adjusted and non-adjusted oligos in an assay pool (Figure adapted from 
Sequenom’s iPLEX Gold Application Guide). 
Two μl of an iPLEX Gold extension reaction cocktail, containing extend primer, buffer, 
enzyme, and mass-modified ddNTPs, was added to the purified PCR products. During the 
iPLEX reaction, the primer was extended by one mass-modified nucleotide depending on the 
allele and the design of the assay. 
Reagent Volume (µl) 480 reactions (µl) 
10X I-PLEX buffer plus 0.2 96 
I-PLEX termination mix 0.2 96 
UEP primers mix 0.94 451.2 
I-PLEX enzyme 0.041 19.68 
H2O 0.619 297.12 
Total 2 960 
Extension step cycle 
Step Temp (oC) Duration Number of cycle 
Initial denaturation 94 30 sec 1X 
Denaturation 94 5 sec 1X 
40X Annealing 52 5 sec 
5X 
Extension 80 5 sec 
Final extension 72 3 min 1X 
 
3.20.9. Clean up reaction 
Each extension product was diluted with 16 µl of water before desalting of the products with 
6 µg of CLEAN resin (Sequenom). The plate was turned upside down for 10 minutes to mix-
Materials and Methods 
 
73 
shake products and resin, then centrifuged at 4000 rpm for 7 minutes before dispensing the 
cleaned extension product on a chip using a Nanodispenser. 
 
3.20.10. Dispensing DNA on a chip  
The MassARRAY Nanodispensor was used to dispense reaction products. Approximately 20 
nl of the product was dispensed onto a 384-format SpectroCHIP (Sequenom). Calibrant 
solution was spotted onto the chip at 10 positions before the chip was transferred to the 
Mass Spectrometer. 
 
3.20.11. Mass spectrometry 
The array was placed into a Mass Spectrometer and each spot was then shot with a laser 
under vacuum by the MALDI-TOF method. MALDI-TOF MS analysis was performed on a 
MassARRAY Compact Analyzer (Sequenom). Data acquisition was automatically performed 
by SpectroAcquire, with ten laser shots per raster position and a threshold of five good 
spectra per sample pad. Once the sample molecules were vaporized and ionized, they are 
transferred electrostatically into a time-of-flight mass spectrometer (TOF-MS), where they 
were separated from the matrix ions, individually detected based on their mass-to-charge 
(m/z) ratios, and analyzed. Detection of an ion at the end of the tube was based on its flight 
time, which was proportional to the square root of its m/z. 
 
3.20.12. Data analysis 
Quality control was monitored by including a duplicate sample and a negative control in each 
384-well plate. The data were automatically analyzed with MassARRAY Typer Software 
version 3.4 and then were manually checked. Genotyping calls were viewed in call cluster 
plots, and peak intensities were reviewed in each respective sample spectrum. Sample call 
rate and SNP call rate were set at  90%. Samples were repeated if  10% of SNPs in the 
plex failed or if  50% of SNPs in the plex showed up as aggressive or moderate or no call. 
 
3.21. TaqMan® SNP genotyping/allelic discrimination 
3.21.1. Basic principle 
TaqMan SNP genotyping is suitable for genotyping a small number of SNPs in a large cohort. 
The TaqMan SNP genotyping assay amplifies and detects specific SNP targets via two 
allele-specific fluorescent probes. One probe labeled with VIC dye for the detection of allele 1 
and the other probe labeled with FAM dye to detect the other allele. The perfect matched 
probe is hybridized to the target whereas the mismatched probe is degraded by Polymerase. 
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By exciting the reporter, the emission of the released reporter can be measured (Figure 3.17). 
Moreover, a minor groove binder (MGB) probe can increase the differences in melting 
temperature values between matched and mismatched probes, which allows for more 
accurate allelic discrimination (Life Technologies). 
 
Figure 3.17. Allelic discrimination using TaqMan SNP genotyping probes. (Figure adapted from Perkin 
Elmer Biosystems) 
 
3.21.2. DNA preparation 
Two µl of working DNA [5ng/µl] (see section 3.20.2) were transferred onto a 384-well 
TaqMan plate. As in genotyping with the Sequenom platform, each PCR plate contains one 
no-template control (NTC) and each assay contains duplicate DNA samples.  
 
3.21.3. Primer and probe design 
SNP genotype assay mixes for rs11709614 and rs10823418 were pre-designed and 
commercially provided by Life Technologies. Each assay contained sequence-specific 
forward and reverse primers to amplify the SNP of interest and two allele-specific TaqMan® 
MGB probes containing distinct fluorescence to detect specific SNP targets. One was labeled 
with VIC dye to detect allele 1 and the other was labeled with FAM dye to detect allele 2. The 
probes used in this study are presented in table 3.8. 
Table 3.8. TaqMan probes and fluorescent dyes labeled on each allele 
SNP ID Location (NCBI Build 37) VIC FAM 
rs11709614 Chr.3:24081772 A G 
rs10823418 Chr.10:71439191 C T 
 
3.21.4. PCR step 
The reaction needs only three components: 10 ng of genomic DNA, TaqMan genotype 
master mix, and SNP genotype assay mix, which was prepared with 10 µl/reaction. Because 
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a robot was used for pipetting, 110 reactions of master mix were prepared for 96 PCR 
reactions. 
Reagent Volume (µl) 
Final 
concentration 
2X TaqMan genotype master mix 2.5 1X 
40X TaqMan genotype assay mix 0.125 1X 
H2O 0.375  
DNA [5 ng/µl] 2 10 ng 
Total volume 5  
PCR cycle 
Step Temperature (oC) Duration Number of cycle 
Enzyme activation 95 10 min 1X 
Denaturation 92 15 sec 
40X 
Annealing/Extension 60 1 min 
 
3.21.5. Allelic discrimination data analysis 
After PCR amplification, an allelic discrimination plate read was performed on the ABI Prism 
7900HT Fast Real-Time PCR System (Life Technologies) and analyzed by SDS 2.2.2 
software (Life Technologies). Fluorescence intensities were measured during the plate read. 
The SDS software plotted results of the allelic discrimination based on the fluorescence 
signals from each well, and showed a scatter plot of alleles 1 versus 2. 
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4. RESULTS 
4.1. Transcript analysis of the APC gene 
To identify deep intronic APC mutations, a systematic APC messenger RNA (mRNA) 
analysis was undertaken in 125 unrelated patients with unexplained adenomatous polyposis 
meeting the inclusion criteria. The majority of patients were sporadic cases (54%). Clinical 
details of the patients are summarized in table 4.1. 
Table 4.1. Baseline data and phenotypic characteristics of the 125 polyposis patients. 
No. of patients 125 patients  
Gender (male/female) 75/50 
Range of age at diagnosis  
Median age at diagnosis 
20-78 years     
45 years 
No. of colorectal adenomas 
< 100 adenomas 
> 100 adenomas 
Multiple/numerous polyps 
 
66 patients (53%) 
27 patients (22%) 
32 patients (25%) 
Colorectal cancer 39 patients (31%) 
Family history 
Familial 
Sporadic 
Unclear/unknown 
 
20 patients (16%) 
68 patients (54%) 
37 patients (30%) 
 
4.1.1. Agarose gel electrophoresis 
The size and pattern of PCR products from five overlapping fragments spanning the 5’UTR 
to exon 15A (c.-138 to c.2625) of the APC gene were visualized on an agarose gel. Eight of 
125 patients (6%) showed an aberrant transcript pattern in one fragment on the gel. The 
agarose gel of PCR product of fragment 2 clearly revealed two additional bands in five 
unrelated patients (FAP715, 732, 1333, 1383, and 1668). The bands were approximately 720 
bp and 780 bp, exceeding the length of the expected wildtype (600 bp) (Figure 4.1). The 
PCR product of fragment 4 revealed an insertion of around 80 bp in three patients (FAP64, 
640, 1708) (Figure 4.2).  
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Figure 4.1. Agarose gel representing PCR products of fragment 2 from 5 patients (lanes 1-5) and 
controls (lanes 7-9). Primers were located in exon 3 (forward) and exon 8 (reverse). All five patients 
showed two additional bands at around 720 bp and 780 bp compared to controls. M is the DNA 
marker ladder 100 bp (Invitrogen).  
 
Figure 4.2. Agarose gel representing PCR products of fragment 4 from 3 patients (lanes 1-3) and 
controls (lanes 5-7). The primers were located in exon 10 (forward) and exon 14 (reverse). An 
additional band around 590 bp was detected in patients but not in controls. M is the DNA marker 
ladder 100 bp (Invitrogen). 
 
4.1.2. Sanger sequencing of aberrant transcripts and genomic DNAs 
Aberrant patterns on an agarose gel were excised, purified, re-amplified, and sequenced on 
a 3130xl Genetic Analyzer (Life Technologies). Sequencing of the specific gel bands showed 
different out-of-frame insertions analyzed by visual inspection with DNA Sequencing Analysis 
Software version 5.1 (Life Technologies) and by blasting and comparing with the reference 
sequence to determine the derivation of the insertions.  
To identify the causative point mutations which activate intronic cryptic splice sites or create 
new intronic spice sites, the respective region was subsequently sequenced at the genomic 
level. 
Fragment 2 (pseudoexon 4a)  
The larger of two additional bands on fragment 2 found in five patients was sequenced. By 
manual analysis of the sequence, an insertion of 167 bp between exons 4 and 5 of the cDNA 
(pseudoexon 4a) was identified. By BLAST analysis it was found that the inserted sequence 
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originated from deep within intron 4 of the APC gene. Thus, the description of the mutation 
on RNA level is r.531_532ins532-1106_532-940. A base substitution was visible at the 
second to last basepair of pseudoexon 4a. Sequencing of the respective region of intron 4 
confirmed the heterozygous base substitution (c.532-941G>A) at the second to last base pair 
of the 3´ end of the inserted region (Figure 4.3 and 4.4).  
 
Figure 4.3. Sequencing patterns of the largest additional band excised from an agarose gel showing 
the junction of the 3’ end of the insert derived from intron 4 (pseudoexon 4a) and exon 5 (upper panel). 
Genomic DNA revealed a heterozygous substitution G>A at nucleotide position c.532-941 (reverse 
sequence) (lower panel). 
 
Figure 4.4. Diagram representing the pseudoexon 4a deep within intron 4 (top); boxes with numbers 
denote individual exons. The sequence of the pseudo-exon originating from intron 4 and the flanking 
intronic sequences with the cryptic splice sites (bold) are shown below. The germline mutation (G>A) 
is indicated by an arrow, and the predicted premature stop codon (TAA) within the pseudoexon is 
underlined. 
Fragment 4 (pseudoexon 10a) 
An additional band on fragment 4 from three patients was cut out from the gel, purified, re-
amplified, and sequenced. The sequences show the same insertion of 83 bp between exons 
10 and 11 of the cDNA (pseudoexon10a), originating from intron 10 of the APC gene 
(r.1408_1409ins1408+647_1408+729). The genomic DNA sequence of two patients (FAP64, 
FAP640) revealed a heterozygous base substitution (c.1408+731C>T) of intron 10 two 
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nucleotides downstream of the inserted region, which generates a new splice donor site with 
predicted high splice efficiency. Additionally, the genomic DNA sequence of FAP64 shows a 
heterozygous genotype for the SNP c.1458T>C; p.Tyr486 (rs2229992) in exon 11 (Figure 
4.5). The sequence of the excised wild-type band shows the C allele almost exclusively, 
indicating a very high splice efficiency of the new splice donor site (Figure 4.6). In addition, 
patient FAP 64 is heterozygous and patient FAP 640 is homozygous for the known SNP 
rs2545162 (c.1408+743A>G), located 12 bp downstream of the previously described 
mutation. Patient FAP1708 presents a heterozygous base substitution (c.1408+735A>T) six 
nucleotides downstream of the pseudoexon. However, given the length of the insertion, the 
same splice donor site as in the other two patients was used. 
 
Figure 4.5. (A) Sequencing pattern of the largest band (590 bp) on fragment 4 showing the junction 
of the 3’ end of pseudoexon 10a and exon 11. (B) Sequencing of corresponding genomic DNA of 
intron 10 reveals the heterozygous base substitution c.1408+731C>T together with the homozygous 
minor allele of SNP rs2545162 (FAP 640) and the heterozygous substitution c.1408+735A>T (FAP 
1708). (C) Sequencing of FAP64 revealed the heterozygosity of rs2229992 c.1458T>C; p.Tyr486 in 
exon 11 on the genomic DNA level and the almost exclusive presence of the C allele in the excised 
wild-type band of fragment 4. 
 
Figure 4.6. Diagram representing the pseudoexon 10/11 deep within intron 10 (top) and the sequence 
of the pseudoexon with the flanking intronic sequences. The cryptic splice sites are shown in bold, and 
both germline mutations are indicated by arrows.  
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4.1.3. In-silico analysis 
The splice prediction program NNSPLICE 0.9 from the Berkeley Drosophila Genome Project 
(BDGP, www.fruitfly.org/seq_tools/splice.html) was used for calculation of the splicing 
efficiencies of normal and mutant sequences. 
Pseudoexon 4a: This occurs in five patients and is flanked by already existing cryptic splice 
acceptor and donor sites predicted to have high splice efficiency. The substitution increases 
the splice efficiency of the splice donor site from 83% to 91%. The germline transition c.532-
941G>A obviously creates a more canonical splicing signal at the pseudoexon–intron 
boundary (pseudoexonic part: “AG,” intronic part: “GT”) (Faustino and Cooper 2003) and 
may thus enhance the efficiency of the splice donor site above a critical threshold. The 
insertion is predicted to result in a premature stop codon within the inserted region (c.532-
941G>A; r.531_532ins532-1106_532-940; p.Phe178Argfs*22).  
In comparison to the wildtype sequence, five instead of four A nucleotides were present at 
the 3´ end of the insert indicating an A base substitution or insertion at the second to last 
position. The variant c.532-941G>A is not recorded in dbSNP/1000Genomes and was not 
identified in 100 normal controls. Additionally, all five patients presented a heterozygous 
c.532-845A>G for the known SNP rs77939389 (dbSNP, 1000Genomes), located 94 bp 
downstream of the 3’ end of the insert, with minor allele frequency (MAF) of 0.8-2.0%. 
Pseudoexon 10a: A heterozygous base substitution adjacent to the 3´ end of pseudoexon 
10a in patients FAP64 and FAP640 (c.1408+731C>T) generates a new splice donor site with 
predicted high splice efficiency (99%). The pseudoexon 10a is predicted to result in a frame 
shift, which leads to a premature stop codon within exon 11 (c.1408+731C>T; 
r.1408_1409ins1408+647 _1408+729; p.Gly471Serfs*55). A putative cryptic splice acceptor 
site at the 5’ end is predicted to have a splice efficiency of 90% (consensus values according 
to Shapiro and Senapathy (1987)) or 97% (BDGP). The variant is not recorded in 
dbSNP/1000Genomes and was not found in 100 healthy blood donor controls. For patient 
FAP1708 who presents a heterozygous base substitution at six nucleotides downstream of 
the pseudoexon (c.1408+735A>T), in-silico analysis did not point to the generation of a new 
GT splice donor site secondary to the A>T substitution (splice efficiency 4%), while the CV 
predicts an increase in splice efficiency from 64% to 69% using the same splice donor region 
as in the other two patients.  
 
4.1.4. Haplotype analysis 
All five patients with pseudoexon 4a show a positive family history of polyposis disease. They 
have an attenuated colorectal phenotype consistent with the established genotype-
phenotype prediction in FAP. Haplotype analysis with a panel of seven microsatellite markers 
flanking the APC region was performed in these 5 patients and in seven relatives of three 
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patients where DNA was available. Testing of healthy relatives showed the wildtype 
sequence and the major SNP allele c.532-845A in a homozygous state. 
According to pedigree information, the five FAP families are unrelated; however, 
microsatellite analysis demonstrated that all affected members of the families shared the 
same disease-associated haplotype around the APC locus (Figure 4.7), which argues 
strongly for a founder mutation rather than a mutational hotspot. 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Haplotype analysis in the five families carrying the heterozygous germline mutation c.532-
941G>A deep within intron 4 of the APC gene using a panel of seven microsatellite markers flanking 
the APC region. All affected persons share the same haplotype marked with a black bar. The 
haplotypes of index patients FAP 715 and 1668 could not be determined, however, the allele 
distribution is consistent with the presence of the disease-associated haplotype. The alleles of marker 
D5S134 in patient FAP 1668 point to a previous recombination event. 
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4.2. CNV analysis 
Germline CNV analysis was performed to identify rare, high-penetrant microdeletions and 
microduplications in novel potentially causative genes. The analysis was carried out in 229 
unrelated patients with colorectal adenomatous polyposis (97 females, 132 males) in whom 
no underlying germline mutation in the known causative genes APC and MUTYH was 
identified by routine diagnostics (see section 3.5.1).  
 
4.2.1. Quality control of SNP array hybridization 
Average overall SNP call rate was calculated by the GenomeStudio Genotyping (GT) Module 
as 99.80% (range 99.19% – 99.90%), and the median was 99.81%. All 229 patients and 531 
controls passed quality control with Log R ratio deviation of less than 0.30 (mean 0.232; SD 
0.023). 
 
4.2.2. CNV calling 
QuantiSNP calculation was used for calling putative CNVs from two final reports. A total of 
296,178 CNVs were called in the control cohort (n = 531), and 103,028 CNVs and 29,473 
CNVs were called in the first and second group with181 and 48 patients, respectively. 
After QuantiSNP calculation was performed in all samples, eight patients were excluded from 
the study since in the meantime a pathogenic deep intronic APC mutation was identified by 
transcript analysis (see section 4.1). Thus, the number of included patients was reduced to 
221 (94 females, 127 males) and the total number of called CNVs in the patients was 
reduced to 127,979 (Table 4.2).  
Table 4.2. Number of putative CNVs called by the QuantiSNP program 
Lot Sample 
No. of 
Sample 
Total 
called 
CNVs 
Mean of 
CNVs/ 
sample 
SD Med 
Max 
No. of 
CNVs 
Min 
No. of 
CNVs 
CNVs smaller 
than 1 kb 
1
st
 Control 531 296178 558 57.31 559 662 359 79147 (26.7%) 
1
st
 Patient 181 103028 569 94.82 556 855 374 27338 (26.5%) 
2
nd
 Patient 48 29473 614 67.67 584 780 539 9151 (31%) 
Eight patients were excluded from the study because deep intronic APC mutations were identified. 
Combi
ned 
Patient 221 127979 579 92.76 568 855 374 35299 (27.6%) 
The average number of 579 CNVs per patient was not significantly different from that in 
controls (558 CNVs). The majority of patients (49.5%) and controls (65.2%) carried 501-600 
CNVs. Twenty-eight patients (12.6%) carried more than 700 CNVs whereas there was no 
control who presented more than 700 CNVs (Figure 4.8). The 28 patients with more than 700 
CNVs had no obvious specific clinical characteristics compared to patients with less than 700 
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CNVs. However, the mean number of CNVs ≥ 10 kb per individual was the same (109 CNVs) 
in both patient and control cohorts. 
 
Figure 4.8. Distribution of called CNVs in the patient (blue bars) and control (red bars) cohorts; the x-
axis presents the ranges of the number of CNVs called per individual and the y-axis shows the 
corresponding percentage of patients and controls.  
The smallest size of a called CNV was 1 bp and the largest size was 3,184 kb; the number of 
probes varied from 1 to 610 and the max log BF ranged from 0 to 1606.22. The number of 
CNVs with the same size was consistent between patients and controls. Around 27% of 
called CNVs were smaller than 1 kb, and defined as ‘indels’. The majority of CNVs (53.5%) in 
both groups were smaller than 10 kb (Table 4.3). The number of CNVs in each size range is 
shown in table 4.3. 
Table 4.3. The percentage of CNVs of each size in patients and controls 
Length Patients (%) Controls (%) 
< 1kb 27.58 26.72 
1 - 9.99 kb 53.57 53.73 
10 - 49.99 kb 13.73 13.97 
50 - 99.99 kb 2.72 2.84 
100 - 199.99 kb 1.57 1.79 
200 - 499.99 kb 0.63 0.74 
500 - 999.99 kb 0.17 0.19 
≥ 1 Mb 0.02 0.02 
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4.2.3. Survey of CNV in known candidate genes 
Before applying filtering steps, it was determined whether the putative CNVs cover known or 
established colorectal cancer (CRC) genes (Table 3.4) based on the genomic positions of 
the genes (NCBI build 36, hg 18). In 44 patients, deletions and/or duplications in the genes 
BMPR1A, CHD1, CTNNB1, EGFR, MAP2K4, and POLE4 were found (Table 4.4). 
Two CNVs carrying duplications of CTNNB1 and EGFR passed the filter criteria and were 
included in the study. Both genes function as oncogenes, thus, overexpression of the gene 
(gain of function mutation) due to the duplication would be in line with an oncogenic mutation 
and thus reasonable to be causative. 
All other CNVs failed the inclusion criteria because their size or max log BF did not fit the 
filter criteria, or the CNVs involved only an intronic region. Not only were filter criteria applied; 
the CNVs were also visually inspected on the Genome Viewer. 
The duplication (895-27270 bp) involving part of MAP2K4 showed a false positive pattern on 
the Genome Viewer. All seven probes inside the gene were CNV probes and assembled only 
within 895 bp. For the duplication (71395 bp) encompassing POLE4, the Log R Ratio (LRR) 
was higher than that of the flanking regions and its B allele frequency (BAF) showed loss of 
heterozygosity (Figure 4.9) instead of a duplication pattern. 
 
Figure 4.9. Genome viewer (Illumina GenomeStudio) demonstrating a duplication on chr2:75010111-
75081505 with 19 markers, max log BF 15.0471, involving the POLE4 gene. B allele frequency (BAF) 
represents no heterozygous probes and Log R Ratio (LRR) shows markers with intensity higher than 
zero. 
Results 
 
85 
Table 4.4. Known cancer predisposing genes found in the patient cohort. 
Gene Chro Postion 
No. 
of pt 
Type of CNV 
Part of 
disruption 
Size 
No. of 
probe 
Max log 
BF 
Remarks 
BMPR1A 10q22.3 
88506376-
88674925 
7 
Duplication - 5 5’UTR+exon 1  648-1697 12-13 0.5-6.2 
excluded because Max logBF failed 
the inclusion criteria 
Deletion - 2 partial gene 7429 2 4.1-7.1 
excluded because Max logBF failed 
the inclusion criteria 
CDH1 16q22.1 
67328696-
67328696 
1 Deletion intron 538 3 2.7 
excluded because Max logBF failed 
the inclusion criteria, and only an 
intronic region was involved 
CTNNB1 3p21 
41211405-
41256943 
1 Duplication whole gene 527160 187 305.322 included in further study 
EGFR 7p12 
55054219-
55242524 
6 
Duplication- 1 partial gene 338588 180 440.403 included in further study 
Deletion - 5 intron 193-810 4-12 5-37 
excluded because only an intronic 
region was involved 
MAP2K4 17p12 
11864866-
11987865 
28 Duplication 5’UTR+exon 1 895-27270 7-11 0.5-19.6 
excluded because Max logBF failed 
the inclusion criteria 
POLE4 2p12 
75039283-
75050366 
1 Duplication whole gene 71395 19 15.0471 
excluded because Max logBF failed 
the inclusion criteria 
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4.2.4. CNV filtering 
To search for rare, non-polymorphic CNVs, various filter criteria were applied. After filtering 
by the Cartagenia software according to size, number of probes, and max logBF, the 
number of putative CNVs was significantly reduced to 449 deletions and 510 duplications. 
These 959 CNVs were present in 215 patients. Only 6 patients did not carry any CNVs. The 
rest carried 1-11 CNVs but there was one patient with 25 CNVs. The majority of patients 
(60%) carried 2-5 CNVs. The length of CNVs, the number of consecutive probes, the max 
log BF, and the number of patients with CNVs are summarized in Table 4.5 and 4.6. Of the 
959 CNVs, 130 contained no gene. A further 105 CNVs involved only an intronic part of a 
gene. These CNVs were removed from the study. Therefore, the remaining CNVs consisted 
of 214 deletions and 461 duplications. 
On observation in the Database of Genomic Variants (DGV), by visual inspection with the 
Genome Viewer (Illumina GenomeStudio), and comparison with data from 531 healthy 
controls genotyped with the same array, it was revealed that 168 of the 214 deletions and 
353 of the 461 duplications are common CNVs (found in more than one control) and/or false 
positive CNVs. These CNVs were removed. Thus, 46 unique heterozygous deletion CNVs 
and 108 unique duplications (0.1% of all called CNVs) remained (Table 4.5).  
Table 4.5. Summary of number of CNVs after each filtering step 
Filter criteria Deletion Duplication 
CNV calling QuantiSNP 89,544 38,435 
CNV filtering (Cartagenia) 
≥ 10 kb, ≥ 5consecutive probes, max log BF ≥ 20 
≥ 20 kb, ≥ 7consecutive probes, max log BF ≥ 30 
 
449 
- 
 
785 
510 
Further manual CNV filtering 
CNVs without protein coding genes 
CNVs in an intronic region 
CNVs in segmental duplications 
Common CNVs (DGV, HNR cohort) and/or false 
positive CNVs in Genome Viewer 
CNVs in an outlier patient 
 
130 
105 
0 
168                    
    
0             
 
33 
16 
156 
197 
 
25 
Number of remaining CNVs 46 83 
The majority of patients carried only one CNV. However, two patients had considerably more 
CNVs: patient FAP257 carried 6 duplications located on chromosome 9. The CNVs involve 
two neighbouring genes separated by few normal markers and thus, they can be considered 
as one CNV (Figure 4.10). The other is patient FAP112 who carried 25 duplications, all of 
which showing a loss of heterozygosity (LOH) pattern on the Genome Viewer (Figure 4.11). 
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Figure 4.10. The six different CNVs (duplications) identified in one patient (FAP 257) according to the 
QuantiSNP algorithm. The first four CNVs are located in the GLIS3 gene and the last two CNVs 
involve parts of the SLC1A1 gene. Eventually, these CNVs were considered as one CNV. 
 
Figure 4.11. Genome Viewer illustrating a duplication on chr 20:20381027-20816315, composed of 
105 probes (max log BF 62), which involved the C29orf74 gene. The CNV was found in patient 
FAP112 who carried 25 duplications. BAF shows loss-of-heterozygosity (LOH) while it was unclear 
whether LRR was raised. 
The size of the included CNVs varied from 10 kb to 664 kb and 21 kb to 856 kb for deletions 
and duplications, respectively. Max log BF values were 50-1606 and 30-682, and number of 
probes were 8-353 and 11-610 for deletions and duplications, respectively. The 46 unique 
CNVs were present in 43 patients (19%); 40 of them carried only one CNV and the other 
three patients carried two deletions. The 83 duplications were present in 61 patients (28%) 
(Table 4.6).  
Table 4.6. Number of CNVs after filtering with the Cartagenia software and after excluding CNVs 
which failed additional filter criteria (see table 4.5) 
 After using Cartagenia filter After applying other filters 
 Deletion Duplication Deletion Duplication 
No. of CNV 449 510 46 unique 83 unique 
Length (kb) 10-1383 21-2050 10-664 21-856 
Max log BF 20-1606 30-996 50-1606 30-682 
No. of probe 7-353 10-610 8-353 11-610 
No. of patients 189 (86%) 198 (90%) 43 (19%) 61 (28%) 
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4.2.5. CNV validation by qPCR using SYBR Green I 
To validate the copy number of the 46 unique deleted CNVs identified by QuantiSNP, qPCR 
was applied. 43 of them were validated as deletions. The three unvalidated CNVs showed a 
normal copy number in exonic regions but a copy number of 1 (deletion) in intronic regions 
(Figure 4.12). The three false positive deletions were 13-16 kb in size with a max log BF 
below 40 and involved up to 19 probes. Of the validated 43 deletions, 33 were not present in 
controls, and 10 were found in one control. 
To validate the copy number of the duplications and multiplications, 83 CNVs present in 61 
patients were examined by qPCR. 82 of the 83 CNVs were validated and show a gain of 
copy number. The non validated CNV was located on chromosome X of a female patient. 
These 82 validated duplications were uniquely present in only one patient; 64 of them were 
not found in the control cohort, whereas 18 CNVs occurred in one control. 
In patient FAP112 with the 25 predicted rare duplications, 4 CNVs were randomly selected 
for qPCR validation. The Ct calculation showed a normal copy number in all four CNVs. Thus, 
this patient was excluded. 
In summary, a total of 125 confirmed CNVs were present in 93 patients (42%). Each patient 
carried 1-3 CNVs. Thirty-three CNVs were smaller than 50 kb whereas 62 CNVs were larger 
than 100 kb (Table A8 and A9). 
 
Figure 4.12. False positive CNV on chr3:194612501-194625470 (green frame). Three primers were 
put in two exons and one intron of ATP13A4 (orange arrows). The Ct calculation shows normal 
copy number in the first two probes and loss of copy number in the last probe, which means the two 
exons are not deleted but the intron is.  
 
4.2.6. Co-segregation analysis 
DNA samples of 10 affected and 7 healthy relatives of 5 unrelated index cases were 
available for examination whether they carry the CNV of the respective index patient. These 
5 probands contain a total of 9 CNVs (2 deletions, 7 duplications). Carrier testing was 
performed using qPCR with the same primers as used for the validation of the CNV in the 
index patient. From the segregation analysis, we found that none of the CNVs segregated 
with the phenotype in these five families (Figures 4.13 - 4.17).  
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Patient FAP003 
 
Figure 4.13. An affected male carried 3 duplications; two duplications were located on chromosome 
3q29 and the third was on chromosome 16p12.3. C3orf21, ACAP2, C3orf34, PIGX, PAK2, SENP5, 
NCBP2, PIGZ, ACSM2, and ACSM1 were involved. DNAs of two brothers (one healthy, one affected) 
and of one affected sister (diagnosed at 38 years old) were used to perform qPCR. The affected sister 
did not carry any CNV while the affected brother (diagnosed at 30 years old) carried a duplication on 
chromosome 16 and the healthy brother (44 years old when blood sample was collected) carried two 
CNVs on chromosome 3. The arrow indicates the index patient (study patient). 
Patient FAP132 
 
Figure 4.14. An affected female carried a duplication on Xq24 (SLC25A43, SLC25A5). DNA from an 
affected daughter (diagnosed at 20 years old) was available for copy number analysis. However, she 
did not carry this duplication. The arrow indicates the index patient (study patient). 
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Patient FAP020 
 
Figure 4.15. An affected man carried a deletion on chromosome 2q22.1 (THSD7B). A sister of the 
patient was also affected (diagnosed at 54 years old) but did not carry a deletion on chromosome 2 as 
in patient FAP020. The arrow indicates the index patient (study patient). 
Patient FAP197 
 
Figure 4.16. Patient FAP197 is female and carried two CNVs, a duplication on chromosome 5q35.5 
(BTNL9) and a deletion on chromosome 12p12.2 (SLCO1B3). A mother (unknown age) and healthy 
sons (16 and 14 years when blood samples were collected) of patient FAP197 were examined 
whether they carry the same CNVs as the patient. qPCR revealed that the mother carried the same 
CNVs as the proband and the first son carried a duplication on chromosome 5q35.5. The arrow 
indicates the index patient (study patient). 
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Patient FAP142 
 
Figure 4.17. Patient FAP142 is female and carried two duplications, one on chromosome 10p12.1 
(PTCHD3) and the other on chromosome 19q13.43 (ZSCAN5A, ZNF582, ZNF583, ZNF667, ZNF471, 
ZFP28, ZNF470, ZNF71, ZNF835). qPCR of the patient’s parents and siblings revealed that the 
patient’s affected brother (diagnosed at 58 years old) carried two duplications the same as the patient. 
However, the unaffected parents (81 and 80 years old when blood samples were collected) and 
brother (unknown age) also carried one of the two duplications. The arrow indicates the index patient 
(study patient). 
 
4.3. Candidate gene prioritization 
4.3.1. Genes covered by the validated CNVs 
The genes disrupted by the validated CNVs are annotated with RefSeq (hg18) definitions. 
The 43 deletions involve 68 genes; 66 of them are each deleted in one patient only, but 
THSD7B on chromosome 2q22.1 and SLCO1B3 on chromosome12p12 are deleted in two 
patients. Nevertheless, none of THSD7B and SLCO1B3 CNVs co-segregate with the 
phenotype in the family of patients FAP020 and FAP197 respectively.  
Careful checking with the Ensembl browser showed that 33 genes are completely deleted 
and 35 genes are partly deleted. In CHL1, HSH2D, LINGO2, and ZNF547, the deletion 
involved only an untranslated region (UTR). Twenty genes belong to the Olfactory Receptor 
(OR) gene family. The 20 OR genes are present in two CNVs, one on chromosome 1q44 
and the other on chromosome 12q13.2. 
The eighty-two validated duplications involved 168 genes. Fourteen of them failed the 
inclusion criteria because they are 1) duplicated only in an intronic region (HBE1, HBG2), 2) 
duplicated only in an UTR (KIF26A, P2RX1), 3) located in segmental duplication regions 
(ACSM2, CCDC74B, FAM128B, MYH7, NUP50, POTEF, SLC25A5, SMPD4, TUBA3E), and 
4) found in more than one control (PPEF1). Two genes on chromosome 11p15, affected by a 
whole gene duplication, belong to the OR family. Then 152 duplicated genes remained. 81 of 
them are partial duplications and 71 genes are whole gene duplications. Each duplicated 
gene was found in only one patient.  
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Candidates not fulfilling the inclusion criteria and belonging to the OR family were removed 
from the study (see discussion). Therefore, the number of candidate genes is reduced as 
summarized in table 4.7. 
Table 4.7. Number of genes involved in candidate CNVs 
Results Deletion Duplication 
No. of involved 
genes 
68 genes 168 genes 
No. of excluded 
genes 
24 genes 
- 4 genes deleted only UTR 
- 20 genes belong to Olfactory 
Receptor (OR) family 
  
 16 genes 
- 2 genes located in an intronic 
region 
- 2 genes duplicated only UTR 
- 9 genes located in segmental 
duplication region 
- 1 gene found in 7 controls 
- 2 genes belong to OR family   
No. of remaining 
genes 
44 genes 
- 42 genes presented in 1 pt 
- 2 genes presented in 2 pts 
152 genes (all in 1 pt only) 
- partial duplication (81 genes) 
- whole gene duplication (71 
genes) 
Beside THSD7B and SLCO1B3, which were found to be deleted in two patients, DOCK11 on 
chromosome Xq24 was also present in two patients, one being deleted and the other being 
partly duplicated. Since DOCK11 was affected by both a deletion and a duplication, the total 
number of the remaining candidate genes was 195 genes. 
 
4.3.2. Gene expression in human colon cDNA 
According to the expression data on the EST Profile UNIGENE database, 129 of 195 
candidate genes are expressed in the human intestine. Expression of the 66 genes reported 
to be unexpressed was examined by PCR with commercial human normal colon cDNA 
(Ambio). Agarose gel electrophoresis demonstrated that actually 51 of the 66 genes are 
expressed in colon mucosa by showing a clearly visible band on the gel. 15 of 66 genes did 
not show a band on the gel although a second primer pair was used for the test and/or a 
positive control showed expression (Figure 4.18). These 15 genes were removed from the 
list of 195 candidates.  
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Figure 4.18. Agarose gel electrophoresis of candidate genes reported as unexpressed in human 
intestine (EST Profiles, UNIGENE database). C refers to PCR product of commercial human colon 
cDNA (Ambio), while P, L, and T are known positive control tissues which express the candidate 
genes. For example, KRT1 is expressed in leukocyte cDNA but not in colon cDNA. The last lane is a 
negative control. GAPDH was used as an internal control to check the efficiency of the PCR reaction. 
 
4.3.3. Network and pathway analysis 
To further prioritize our candidate genes, a network and pathway analysis was performed 
twice in collaboration with the group of Prof. Fröhlich (Bonn-Aachen International Center for 
IT (B-IT), Algorithmic Bioinformatics, University of Bonn). For the first analysis, that is, 
protein-protein interaction, the candidates consisted of 142 genes affected by CNVs of 134 
patients and 8 genes from our GWAS analysis (unpublished preliminary results). In addition, 
17 established polyposis genes and 26 published candidate genes for CRC were included as 
anchor or reference genes, respectively. The most interesting candidates are DKK1 (whole 
gene duplication) and NFATC1 (partial gene duplication) (Figure 4.19). Other included CNV 
candidates which appear in the network are CDCA7L, CLU, CNTN6, DOCK11, DTNA, EGFR, 
FNBP1, GAB1, LDHA, MAPRE2, PTGES, RPRD1A, SLC39A6, and TFB2M.  
The second network analysis, the ‘Steiner tree’ algorithm, was performed with all 180 
candidate genes. The Steiner tree showed that 135 of the 180 included genes (26 deletions, 
61 partial gene duplications and 48 whole gene duplications) are present in the network 
(Figure 4.20, Table A10). UBC was identified in the center of the network. 
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Figure 4.19. Protein-protein interaction analysis. The first analysis of 142 candidate genes from 134 patients (red and blue circles indicate genes affected by 
heterozygous deletions and by duplications, respectively). Established polyposis genes, published candidate genes for colorectal cancer (black circles), and 
candidate genes from a polyposis GWAS (purple circles, unpublished data), were used to prioritize putative disease genes. The candidates from the CNV 
analysis most connected to known genes are DKK1 (whole gene duplication) and NFATC1 (partial gene duplication), indicated by red arrows. Thin lines 
present interaction of the genes: Green color is activating and red color is prohibiting the target gene (pointed by an arrow). Grey edges indicate an unknown 
mode of action.  
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Figure 4.20. Steiner Tree, the second analysis of 180 candidate genes. UBC was identified as a central candidate gene. Green colors represent the candidate 
genes and red colors indicate putative disease genes. 
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Subsequently, an enrichment analysis of KEGG pathways and GO terms was performed. The two established oncogenes CTNNB1, EGFR are 
involved in many cancer-related pathways. In total, 11 genes were involved in gene sets enriched for cancer related pathways (KEGG database) 
at p < 0.05 (Table 4.8) and 10 genes were part of a gene set enriched for GO term at p < 0.05 (Table 4.9). 
Table 4.8. Candidate genes from gene sets enriched for cancer related pathways (KEGG database) 
KEGG ID P-value Odds Ratio ExpCount Count Size Term Candidate gene* 
04310 0.000623 5.442095 2.376086 11 150 Wnt signaling pathway DKK1
w
, NFATC1
p
 
04520 0.002728 7.044397 1.156362 7 73 Adherens junction IQGAP1
 p
, YES1
 p
 
04110 0.043709988 3.938282648 1.964230966 7 124 Cell cycle TFDP2
 p
 
04510 0.04478684 3.134068811 3.168114461 9 200 Focal adhesion 
ARHGAP5
 p
, COL11A1
 p
, 
PAK2
 w
, CCDC148
d
 
* CTNNB1 and EGFR, being established oncogenes involved in many cancer related pathways, were not included in the table; 
d
 deletion; 
p
 partial duplication; 
w
 whole gene duplication 
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Table 4.9. Candidate genes from gene sets enriched for cancer related GO terms (Gene Ontology database) 
GOBPID P-value Odds Ratio ExpCount Count Size Term Candidate gene 
GO:2000060 0.002878 90.374603 0.103661 4 7 
positive regulation of protein ubiquitination involved 
in ubiquitin-dependent protein catabolic process 
CLU
p
 
GO:0051085 0.037736 28.903182 0.148087 3 10 
chaperone mediated protein folding requiring 
cofactor 
TOR1A
w
, 
TOR1B
w
, 
HSPH1
p
 
GO:0032880 0.040719 3.176820 4.400097 13 301 regulation of protein localization ADCYAP1
w
 
GO:0090090 0.040719 6.520819 1.017164 6 69 
negative regulation of canonical Wnt receptor 
signaling pathway 
DKK1
w
 
GO:0070940 0.040719 134.301887 0.044426 2 3 
dephosphorylation of RNA polymerase II C-terminal 
domain 
RPRD1A
w
, 
RPAP2
d
 
GO:0032436 0.045831 10.879234 0.427504 4 29 
positive regulation of proteasomal ubiquitin-
dependent protein catabolic process 
CLU
p
 
* CTNNB1 and EGFR, being established oncogenes, were not incluced in the table; 
d
 deletion; 
p
 partial duplication; 
w
 whole gene duplication 
Results 
 
99 
Ingenuity pathway analysis  
Another approach for further analysis of the genes obtained from the CNVs analysis was to 
use the Interaction pathway analysis tool (Ingenuity Pathway Analysis, IPA). According to 
the IPA, the 180 candidate genes were involved in 25 independent networks (Table A11). 
The top four networks consist of 25, 12, 11, and 10 candiate CNV genes (Table 4.10). Top 
functions of these networks are related to cancer, cellular development, cell death and 
survival, and cell cycle. The top first network with 25 candidate genes is presented in Figure 
4.21. 
Table 4.10. Top four networks of 180 candidate genes and the genes involved in the networks 
Net 
work 
Top functions Genes in network Score 
No. of 
candidate 
genes 
1 
Cancer, Cellular 
Development, 
Organismal Injury and 
Abnormalities 
ADCYAP1
w
, CLU
p
, CTDP1
p
, CTNNB1
 w
, DKK1
 w
, 
EGFR
p
, EPHB4
p
, GAB1
p
, GFI1
d
, GPR64
 w
,INHA
 w
, 
IQGAP1
p
, KDM5A
p
 (JARID1A), MAPRE2
p
, MICU1
 
d
 (CBARA1), PAK2
 w
, PDE4D
 d
, PHKA2
 w
, PTGES
 
w
, RPS6
 w
, SMYD3
p
, TFB2M
p
, USP20
 w
, YES1
p
, 
ZNF24
 w
 
46 25 
2 
Cellular Development, 
Hematological System 
Development and 
Function, Hematopoiesis 
ARHGAP5
p
, CMA1
 w
, COL11A1
p
, EVI5
 d
, HSPH1
p
, 
NFATC1
p
, PKD1L2
p
, PTGER3
 d
, SCD5
 d
, 
SLC1A1
p
, UTRN
p
, ZFP28
 w
 
17 12 
3 
Cell Cycle, Cancer, Cell 
Death and Survival 
ADAMTS17
p
, CAMKK1
 w
, CDCA7L
p
, DOCK11
 d
 *, 
DTNA
p
, ERC1
p
, LDHA
 w
, MOCOS
p
, NCBP2
 w
, 
TFDP2
p
, XRN1
p
 
15 11 
4 
Lipid Metabolism, 
Molecular Transport, 
Small Molecule 
Biochemistry 
DCP2
 d
, IL13RA1
 w
, MICALL2
 w
, NLRP1
 d
,   
NOXA1
 w
, PCNT
p
, PLIN2
 d
 (ADFP), SENP5
 w
, 
STX11
 w
, USP31
p
 
13 10 
* DOCK11 is both deleted and partially duplicated; 
d
 deletion; 
p
 partial duplication; 
w
 whole gene 
duplication 
By functional annotations of the 180 candidate genes, IPA showed the two established 
oncogenes CTNNB1 and EGFR, and in addition, DKK1, as the top three genes related to 
cancer (p = 1.67x10-5). Eleven candidate genes, ARHGAP5, CLU, CTNNB1, DNAH11, 
EGFR, EPHB4, FSTL5, GAL3ST2, KIF26B, ZNF24, and ZNF470, are related to colon 
carcinoma and adenocarcinoma (p < 0.01) (Table A12). 
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Figure 4.21. Top function network formed by the IPA software, relevant for cancer, cellular 
development, organismal injury and abnormalities. Of the 46 genes in this network, 25 were candidate 
genes from our CNV analysis. A simple straight line represents direct interaction, a dash line 
represents indirect interaction, an arrow head means action upon a gene. 
 
4.3.4. Data mining 
To further evaluate the pathogenic relevance of the candidates, various online databases 
were used for compiling all available information on the 180 candidate genes. 
Causative monogenic disease 
Twenty-seven genes have been reported in OMIM, DAVID, and GENATLAS as being 
causative for specific non tumor related autosomal dominant or autosomal recessive 
monogenic conditions (Table A13). These genes were removed from the list for further work 
up if the specific mode of inheritance, the characteristic sypmtoms, or the usual age at onset 
of the hereditary conditions argues against a causative role in colorectal tumor predisposition 
given the phenotype and family history of our patients. 
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GWAS Catalog 
Thirty-nine candidate genes (8 deletions, 19 partial duplications, 12 whole gene duplications) 
have been reported in the GWAS catalog. SNPs in several of them are associated with 
various cancers but not with CRC, as well as with complex neurodegenerative diseases, 
immune deficiency diseases, and other traits such as height and smoking behavior. However, 
since GWAS identify low-penetrant risk alleles, data from the GWAS catalog was not 
adequate to judge whether the candidate genes should be either included or excluded from 
the study. 
STRING 
Using the STRING database to see protein-protein interactions of our candidate genes with 
known somatically mutated cancer genes reported in COSMIC at or above medium 
confidence (0.4), we found that 54 candidate genes are somehow associated with those 
known cancer genes. Among the candidate genes found to be associated with known CRC 
genes are C10orf11, EDA2R, FSTL5, GFI1, and TESK2. All 54 candidate genes and the 
known somatically mutated cancer genes are presented in Table A14. However, a few of 
them, including C10orf11, cause specific phenotypes and were excluded from the study.  
Publications 
For 87 genes an association with cancer has been reported in original studies published in 
the PUBMED database. In addition to the two known oncogenes (CTNNB1, EGFR), several 
genes are notable such as DKK1, EDA2R, EPHB4, FOCAD, which are assumed to be 
candidate tumor suppressor genes. Additionally, several candidates are involved in pathways 
related to cancer. Particularly, RSPO4 is involved in the Wnt signaling pathway; NLRP1, 
TESK2 are involved in apoptosis; and EDA2R is involved in the p53 signaling pathway 
(Table A15). Twenty-five of them are up-regulated or down-regulated in CRC.  
By compiling relevant data, we were able to reduce the number of interesting candidates in 
several ways; we excluded genes causing other specific but non-tumor-related monogenic 
disorders; we comprehensively studied genes with functions unrelated to features relevant 
for tumorigenesis and/or genes expressed at very low levels in human adult colon cDNA; we 
also studied some genes not segregating with the phenotype in the family. Notably, more 
than one rule was applied to judge whether a gene should be excluded from the candidate 
list. On the other hand, we did not exclude genes which do not segregate with the phenotype 
but are present in more than one patient. The same rule was applied to genes of unknown 
function such as those belonging to the Zinc Finger Protein family.  
After applying these filtering steps, 97 genes derived from the CNV analysis (31 deletions, 45 
partial duplications, 22 whole gene duplications, [in DOCK11 both a deletion and a 
duplication were identified]) remained (Table A16). In addition, the UBC gene, which is 
centrally located in the network analysis, was included in the priority list. Besides two well-
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known oncogenes (CTNNB1, EGFR), 32 candidates are (i) related to known cancer 
pathways such as Wnt, ErbB, p53, TGF (C10orf11, CCDC148, DKK1, EDA2R, GAB1, 
NFATC1, RSPO4, STK11IP); (ii) reported as a putative TSG (DKK1, EPHB4, FOCAD, 
FSTL5, LZTFL1, PDE4D, SCARA3); (iii) involved in functions relevant for tumor development 
like cell cycle regulation, proliferation control, apoptosis, adherens junction, cell adhesion 
(ARHGAP5, CAMKK1, CCDC148, CNTN6, DOCK11, EDA2R, EVI5, GAB1, GFI1, IQGAP1, 
KIF26B, MAPRE2, MCM3AP, NLRP1, PIK3C2G, RPS6, TESK2, TFDP2, UBC, XRN1, 
YES1); (iv) related to CRC (ARHGAP5, CLU, CTNNB1, DNAH11, EGFR, EPHB4, FSTL5, 
GAL3ST2, KIF26B, ZNF24, ZNF470). FOCAD has been identified in early-onset cancer 
disease, and TESK2 is located upstream of MUTYH. 
To further evaluate the plausibility of the remaining 32 candidates, they were examined 
regarding (i) the occurrence of somatic mutations in colon tumor tissue (COSMIC database), 
(ii) the likelihood of haploinsufficiency according to the Haploinsufficiency score (Huang et al. 
2010), and (iii) their genetic intolerance to functional variation according to the Intolerance 
score (Petrovski et al. 2013). High frequencies (> 5%) of somatic mutations in colorectal 
tumors have been described in 9 of the above 32 genes (ARHGAP5, CNTN6, FOCAD, 
FSTL5, IQGAP1, MCM3AP, NLRP1, PIK3C2G, XRN1). A low value (< 25th percentile) on 
the intolerance score, indicating high sensitivity to genetic alterations, has been described in 
11 of the 32 genes (ARHGAP5, CAMKK1, CNTN6, EPHB4, IQGAP1, KIF26B, MCM3AP, 
NFATC1, PDE4D, SCARA3, UBC). The haploinsufficiency score, which indicates dosage-
sensitive genes, was very low (< 10%) for three genes (MAPRE2, TFDP2, YES1) and 
showed moderate sensitivity (< 40%) in another 12 genes (CAMKK1, CNTN6, DOCK11, 
EPHB4, EVI5, GAB1, GFI1, IQGAP1, KIF26B, NFATC1, TESK2, XRN1). In total, 9 of the 32 
genes showed significant scores in two of the three parameters (Table 4.11). CTNNB1, 
EGFR, and three genes not mentioned above (DMXL1, KDM5A, SLITRK6) exhibited 
significant values for all three parameters.  
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Table 4.11. Nine of the 32 candidate genes related to processes relevant for tumorigenesis, which are frequently affected by somatic mutations in colorectal 
tumors (> 5%), tend to be intolerant to functional variation (Intolerance score < 25
th
 percentile), and/or are likely to be haploinsufficient (Haploinsufficiency 
score < 40%). All are from partial duplications and present in one patient only. 
Gene Chr Part of gene Function & pathways/Literatures 
% of 
somatic 
mutation
a
 
Intolerance 
score
b
 
Haploinsuffi
ciency 
score
c
 
ARHGAP5 14q12 5'UTR + exon 1 Focal adhesion 7.9 20 44 
CAMKK1 17p13.2 whole gene 
involved in regulating cell apoptosis, 
promotes cell survival 
1.1 19 13 
CNTN6 * 3p26.3 exon 9-23 + 3'UTR cell adhesion, Notch signaling pathway 7.4 10 23 
EPHB4 7q22.1 exon 13-17 + 3'UTR acts as TSG, angiogenesis pathway 3.4 3 20 
IQGAP1 15q26.1 5'UTR + exon 1-2 Adherens junction, interacts with APC 5.9 5 17 
KIF26B * 1q44 2 exons positive regulation of cell-cell adhesion 4.5 18 26 
MCM3AP * 21q22.3 exon 21-28 + 3'UTR 
inhibits DNA replication and cell cycle 
progression 
5.5 1 60 
NFATC1 18q23 exon 12-13 + 3'UTR 
transcription factor, non-canonical Wnt 
signaling pathway 
3.8 2 38 
XRN1 3q23 exon 30-42 + 3'UTR 
involved in homologous recombination, 
meiosis, telomere maintenance, and 
microtubule assembly 
5.6 31 11 
* in these genes truncating germline mutations have been found in other patients in addition to the duplication identified in the index patient (see section 4.5.2); 
a 
COSMIC database; 
b
 Petrovski et al., 2013; 
c
 Huang et al., 2010.
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4.4. TaqMan® gene expression analysis of CTNNB1 and MUTYH 
Patient FAP5014 carried a whole gene duplication on chromosome 3p22.1 involving the 
canonical Wnt signalling oncogene CTNNB1, whereas patient FAP812 harbored a 
heterozygous deletion on chromosome 1p34, partly covering the TESK2 gene which is 
located 3.4 kb upstream of MUTYH. To examine whether the expression levels of CTNNB1 
and MUTYH were affected by these CNVs, TaqMan gene expression analysis using 
leukocyte RNA was performed in these two patients comparing them to ten healthy 
anonymous controls (5 males, 5 females).  
The average CTNNB1 expression level of patient FAP5104 (1.15  0.13) was slightly higher 
compared to those in the controls (1  0.62) and the average MUTYH expression level of 
patient FAP812 (0.64  0.01) was slightly lower compared to that in controls (1  0.61) 
(Figure 4.22). Although the mean expression levels of both genes were changed in the 
expected direction, there was no significant difference between cases and controls (p = 0.56 
and 0.54; Wilcoxon test). Notably, the gene expression levels varied markably among the 
controls. In patient FAP812, also no heterozygous MUTYH germline point mutation was 
identified by Sanger sequencing of the coding regions. 
 
Figure 4.22. Results of expression analysis of CTNNB1 in a patient carrying a duplication CNV 
encompassing the whole CTNNB1 gene (A) and MUTYH in a patient with a deletion CNV partly 
covering the TESK2 gene (B). The expression level of the target gene of each patient was compared 
to 10 anonymous healthy controls (5 males, 5 females). Results are shown as the means of three 
replicate reactions with standard deviations illustrated as vertical bars. The difference in expression 
between the control group and the patients was not significant. 
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4.5. Resequencing candidate genes 
To further evaluate the pathogenicity of the candidate genes, a mutation analysis was 
performed to look for germline point mutations in the most interesting ones. We were 
specifically looking for additional pathogenic germline point mutations in the respective genes 
assuming a dominant model of inheritance (heterozygous mutations in other patients) and a 
recessive model of inheritance (biallelic point mutations in other patients or a heterozygous 
point mutation in the same patient who carried a CNV in the respective gene). 
In this study, two methods were used for the mutation analysis. LZTFL1 was sequenced by 
Sanger sequencing while the remaining 97 genes were sequenced by high-throughput 
targeted NGS. 
 
4.5.1. Sanger sequencing of LZTFL1 
The Leucine zipper transcription factor-like 1 (LZTFL1) gene was selected for screening for 
pathogenic germline point mutations by Sanger sequencing. LZTFL1 is located on 3p21.3, 
which is a hotspot for putative TSG and has been reported as a candidate cancer gene 
(Sjoblom et al. 2006) and as a novel TSG, which may inhibit tumorigenesis by stabilizing E-
cadherin-mediated adherens junction formation and promoting epithelial cell differentiation 
(Wei et al. 2010). Forty-six variants of LZTFL1 have been reported in the Exome Variant 
Server (EVS) database. The majority of them are not in coding regions. Only one variant, 
reported in EVS, leads to a truncating mutation of the gene. 
The coding regions (10 exons) and the flanking intronic regions of the LZTFL1 gene were 
sequenced in 100 randomly selected polyposis patients of the study cohort. The SeqPilot® 
software (JSI medical systems GmbH, Germany) was used for the analysis of the sequence 
data. Three variations were detected in 13 patients.  
A heterozygous single base substitution located in exon 8, predicted to result in a missense 
mutation (c.736G>A;p.D246N), was found in eleven patients. The variant was reported in the 
dbSNP database (rs1129183) with a minor allele frequency (MAF) of 6%. By in-silico 
analysis using Mutation Taster and PolyPhen-2, the variant was predicted to be benign and 
possibly damaging, respectively.  
Another heterozygous single base substitution located in exon 8 and predicted to result in a 
missense mutation (c.625A>T;p.S209C) was found in one patient. The variant was reported 
in the dbSNP database (rs148560000) with no MAF data. By in-silico analysis using Mutation 
Taster and PolyPhen-2, the variant was predicted to be benign, suggesting a rare 
polymorphism. The last heterozygous single base substitution, located in the 5’UTR (c.-
147C>T), was predicted by Mutation Taster to be a polymorphism. The sequencing results 
are summarized in table 4.12.  
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Table 4.12. LZFTL1 variants found in 100 polyposis patients and the results of in-silico analysis 
No. of 
pt 
DNA 
change 
AA 
change 
Position 
dbSNP 
(MAF) 
Mutation Taster-
prediction 
PolyPhen-2 
11 c.736G>A p.D246N exon 8 
rs1129183 
(MAF=6%) 
polymorphism 
possibly 
damaging  
1 c.625A>T p.S209C exon 8 
rs148560000 
(N/A) 
polymorphism benign 
1 c.-147C>T - 5’UTR - polymorphism - 
 
4.5.2. High throughput resequencing of remaining candidate genes 
To validate the etiological relevance of the candidate genes by identifying point mutations in 
additional patients, the coding exons and adjacent intronic regions of all candidates were 
sequenced in 100 patients from the primary study cohort and in 92 patients from a second 
cohort (45 patients with adenomatous polyposis and 47 patients with Lynch syndrome-like 
phenotype) using targeted NGS (Table 3.1). Based on TruSeq Enrichment assays, all 97 
candidate genes, including UBC, consisted of 1497 targets and were covered by 2090 
probes. The overall performance of the enrichment and sequencing process is shown in 
table 4.13. 
Table 4.13. The overall performance of the enrichment and Next Generation Sequencing process * 
Target size 622657 
Number of target regions 2163 
Total reads 3.98 million (+/- 14%) 
Unique mapped reads 3.67 million (+/- 14%) 
GC drop out 2.2% (+/- 0.1) 
AT drop out 11.6% (+/- 1.5) 
Median library insert size 244 (+/- 6) 
Read length 2 x 101 (paired end) 
Mean coverage  304 (+/- 44) 
Covered at depths of 10× 97.7% 
Covered at depths of 20× 96.6% 
Covered at depths of 30× 95.6% 
* the enrichment assay included a total number of 140 genes, 97 of which are relevant for this study 
In total, 356 variants passed the filter criteria. The first analysis focused only on truncating 
mutations including frameshift mutations, nonsense mutations, and mutations at the 
canonical splice sites. In-frame and missense variants were not included. The sequence 
reads of all remaining 26 unique truncating mutations were visually inspected with the 
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VARBANK Read Browser (Figure 4.23). None of them were removed because the mutated 
reads were unlikely to be false positives. However, four variants showed a low read depth, 
only 8 reads each variant, and 2 of 8 reads showed a variation. Five variants were excluded 
from the study since they were reported in the dbSNP and EVS databases as frequent 
variants in the general population. 
 
Figure 4.23. Snapshot of the VARBANK Read Browser (Cologne Center for Genomics) showing NGS 
results of exon 13 of the CNTN6 gene. Red labeled positions (chr 3:1413999-1414000) indicate a 
heterozygous deletion (roughly 50% of reads are affected) of two bases (CG) which is predicted to 
result in a frameshift mutation and premature stop codon. Sanger sequencing confirmed the result as 
a true positive mutation. 
The remaining 21 variants were verified by Sanger sequencing. All except the four variants 
with low read depth were validated as true positive variations. 16 of the 17 true positive 
variants occurred in a single patient each, except for a frameshift mutation in PTGER3 
(c.1185delC; p.N395fs) that was found in 4 patients. However, the latter variant has 
frequently been reported in population-based controls (EVS database) with an MAF of 0.87% 
(A1A1=0/A1R=72/RR=4055). Another variant identified in the SDR39U1 gene and predicted 
to result in a frameshift (c.542delG;p.G181fs) is also frequently found in the European 
general population with an MAF of 0.50% (A1A1=2/A1R=36/RR=3908). Both variants were 
removed from the list of potential pathogenic germline point mutations (Table 4.14). 
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Table 4.14. Seventeen validated rare truncating mutations found in 192 patients by targeted NGS 
Genes Chro Positive 
Mutated 
exon 
(total 
No. of 
exon) 
Allele1 Allele2 cDNA Protein 
Number 
of pt. 
CNTN6 3 1269501 4 (23) G A c.183-1G>A CSS 1 
CNTN6 3 1363516 8 (23) A . c.944delA p.Y315Lfs*38 1 
CNTN6 3 1413981 13 (23) A T c.1493-2A>T CSS 1 
CNTN6 3 
1413999-
1414000 
13 (23) CG . c.1509_1510delCG p.V504Pfs*22 1 
FOCAD 9 20770046 10 (46) C T c.715C>T p.Q239* 1 
FOCAD 9 20929349 29 (46) T A c.3079-8T>A CSS 1 
HEXDC 17 
80400061-
80400062 
12 (12) CA . c.1353_1354delCA p.H451Qfs*66 1 
HSPH1 13 31719695 11 (18) C T c.1584+5G>A CSS 1 
KIF26B 1 245530424 3 (15) T . c.754delT p.C252Vfs*86 1 
MCM3AP 21 
47704082-
47704091 
1 (28) 
GTCAC
TTTCT 
. 
c.1110_1119delAGA
AAGTGAC 
p.E371Tfs*20 1 
PTGER3* 1 71418662 4 (4) G . c.1185delC p.N395Kfs*9 4 
PXDNL 8 52252210 21 (21) C A c.4120G>T p.E1374* 1 
SDR39U1* 14 24909629 6 (6) C . c.542delG p.G181Afs*22 1 
TESK2 1 45812650 8 (10) C A c.792+1G>T CSS 1 
ULK4 3 41439565 35 (37) C T c.3678+5G>A CSS 1 
YBEY 21 
47706876-
47706877 
2 (5) GC .  c.51_52delGC p.P18Tfs*4 1 
ZNF471 19 57035963 5 (5) G .  c.527delG p.S176Ifs*18 1 
* frequently found in population-based European controls; CSS, canonical splice site 
The remaining 15 heterozygous truncating point mutations (single base substitutions and 
small deletions or insertions of coding regions or canonical splice sites) were found in 11 
genes. No mutation was identified in the UBC gene. The 15 rare truncating mutations were 
present in 15 (8%) of the 192 patients.  
In these 11 genes, additional 66 unique missense variants were detected. 53 of 66 variants 
were found in one patient only while 13 variants were found in 2-31 patients. All 13 variants 
are frequently reported in the dbSNP and/or the EVS databases and are thus not regarded 
as high-penetrance mutations. The same was true for 26 of the 53 variants found only once 
in the patient cohort. The remaining 27 rare missense mutations, each present in a different 
patient, are listed in Table 4.15. In-silico analysis, using PolyPhen-2, MutationTaster, and 
SIFT online tools, partly resulted in inconclusive predictions regarding their pathogenic 
impact. However, 11 variants were predicted to be deleterious by all three tools (Table 4.16). 
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Table 4.15. Summary of putative pathogenic point mutations identified in 11 candidate genes 
Gene 
Type of 
CNV 
No. of 
truncating 
mutations 
No. of 
missense 
mutations 
No.of missense 
mutations 
predicted to be 
deleterious * 
Total no. 
of variants 
reported 
in EVS 
Truncating 
mutations 
reported in 
EVS 
CNTN6 
Partial 
duplication 
4 1 0 248 8 
FOCAD Deletion 2 1 0 441 11 
HEXDC 
Partial 
duplication 
1 2 0 160 4 
HSPH1 
Partial 
duplication 
1 1 1 161 1 
KIF26B 
Partial 
duplication 
1 9 5 363 3 
MCM3AP 
Partial 
duplication 
1 2 2 359 4 
PXDNL 
Partial 
duplication 
1 4 1 301 10 
TESK2 Deletion 1 2 0 119 3 
ULK4 
Partial 
duplication 
1 3 0 330 10 
YBEY 
Partial 
duplication 
1 0 0 19 0 
ZNF471 
Whole 
gene 
duplication 
1 2 2 85 8 
Total 15 27 11   
* predicted to be deleterious by all 3 in-silico tools (PolyPhen-2, Mutation Taster, SIFT) 
In total, 26 rare mutations (15 truncating mutations and 11 missense mutations predicted to 
be deleterious) in 11 genes were present in 22 patients. One patient had two variants in the 
same gene (HSPH1): however, the phase could not be determined since no DNA was 
available from relatives. The other patients had only one mutation per gene, and no patient 
carried both a point mutation and a CNV of the respective gene (Table 4.17). 
Among the 11 genes with a deletion or duplication and an additional point mutation, CNTN6, 
HSPH1, KIF26B, and MCM3AP are supposed to be intolerant against genetic variation (low 
intolerance score) and CNTN6, HSPH1, and KIF26B are predicted to be haploinsufficient. 
Three genes (CNTN6, FOCAD, MCM3AP) are frequently mutated in colorectal tumors (Table 
4.11). CNTN6 has the highest frequency of truncating mutations whereas KIF26B exhibits 
the highest frequency of variants overall and in MCM3AP only variants likely to be 
pathogenic have been identified.  
Since oncogenes are often affected by gain-of-function mutations such as specific activating 
missense mutations or amplifications, we also specifically looked for missense mutations in 
those genes, which were affected by whole gene duplications and which had been included 
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in the targeted sequence approach. We identified 23 missense mutations in CAMKK1, 
CTNNB1, DKK1, ELP2, GAL3ST2, KIAA1009, PTPN18, ZFP28, ZNF471, ZNF667, and 
ZNF835 (Table A17). Four of the 23 missense mutations were predicted by all 3 in-silico 
tools (PolyPhen-2, Mutation Taster, SIFT) to be disease causing. Two of the four are found in 
ZNF471, in which a frameshift mutation was found as well. The other two were found in 
CTNNB1 and PTPN18 (Table 4.16). 
Focusing on the 32 interesting candidates related to cancers from CNV analysis and the 13 
genes in which germline point mutations were identified, we found that seven patients are 
affected by more than one mutation in these predisposing genes (Table 4.17). 
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Table 4.16. List of 27 missense mutations in the 11 genes where truncating point mutations have been found and 2 missense mutations in genes affected by 
a whole gene duplication 
Gene Chro Position Exon Allele1 Allele2 cDNA Protein Predicted function (PP/MT/SIFT) 
CNTN6 3 1424677 18 T A c.2218T>A p.F740I benign/DC/damaging 
FOCAD 9 20923757 24 G A c.2951G>A p.G984E benign/polymorphism/tolerated 
HEXDC 17 80395185 8 C T c.845C>T p.A282V benign/DC/tolerated 
HEXDC 17 80397586 9 C T c.979C>T p.R327C benign/polymorphism/damaging 
HSPH1 13 31724312 8 A C c.916T>G p.F306V probably damaging/DC/damaging 
KIF26B 1 245530364 3 G A c.694G>A p.G232R benign/DC/damaging 
KIF26B 1 245530514 3 G A c.844G>A p.G282R probably damaging/DC/damaging 
KIF26B 1 245847612 11 T C c.2336C>T p.S779L probably damaging/DC/damaging 
KIF26B 1 245849362 12 C T c.3077C>T p.P1026L probably damaging/DC/damaging 
KIF26B 1 245849920 12 G A c.3635G>A p.S1212N probably damaging/DC/damaging 
KIF26B 1 245850019 12 C T c.3734C>T p.T1245M benign/polymorphism/tolerated 
KIF26B 1 245850064 12 C G c.3779C>G p.P1260R possibly damaging/DC/damaging 
KIF26B 1 245861578 13 C T c.5995C>T p.R1999C probably damaging/DC/torelated 
KIF26B 1 245865829 15 G A c.6248G>A p.R2083H probably damaging/DC/damaging 
MCM3AP 21 47662842 25 A G c.5300C>T p.A1767V probably damaging/DC/damaging 
MCM3AP 21 47692529 8 G A c.2411C>T p.A804V probably damaging/DC/damaging 
PXDNL 8 52284471 19 G A c.3863C>T p.P1288L probably damaging/DC/damaging 
PXDNL 8 52321668 17 T A c.2516A>T p.D839V probably damaging/DC/torelated 
PXDNL 8 52321834 17 C G c.2350G>C p.A784P possibly damaging/polymorphism/damage 
PXDNL 8 52336137 14 G A c.1793C>T p.T598M probably damaging/polymorphism/tolerated 
TESK2 1 45811588 10 C T c.958G>A p.E320K benign/DC/tolerated 
TESK2 1 45923396 2 T C c.62A>G p.E21G benign/polymorphism/damaging 
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Gene Chro Position Exon Allele1 Allele2 cDNA Protein Predicted function (PP/MT/SIFT) 
ULK4 3 41841779 20 G A c.1855C>T p.R619C probably damaging/DC/torelated 
ULK4 3 41925425 17 C T c.1597G>A p.V533I possibly damaging/polymorphism/tolerated 
ULK4 3 41937038 16 G A c.1549C>T p.H517Y possibly damaging/polymorphism/damaging 
ZNF471* 19 57036217 5 C T c.781C>T p.L261F probably damaging/DC/damaging 
ZNF471* 19 57036986 5 G A c.1550G>A p.C517Y probably damaging/DC/damaging 
CTNNB1*
$
 3 41266829 5 T G c.500T>G p.V167G probably damaging/DC/damaging 
PTPN18*
$
 2 131116862 3 A C c.259A>C p.I87L probably damaging/DC/damaging 
* genes affected by a whole gene duplication in the index patient; PP/MT/SIFT, Polyphen-2/Mutation Taster/SIFT; DC, disease causing; 
$
 no truncating 
mutation was identified 
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Table 4.17. Clinical and genetic details of patients with potentially deleterious mutations in at least two of the most promising candidate genes 
Patient 
ID 
Gene 
Mutation 
type 
Mutation Exon 
Age 
at Dx 
Phenotype 
No.of 
adenomas 
Develop 
CRC 
Extracolonic 
phenotype 
Family 
history 
F354 
CNTN6 frameshift 
c.1509_1510del CG; 
p.T503fs 
13 (23) 
27 attenuated 51-100 yes normal S/F 
KIF26B missense c.3635G>A;p.S1212N 12 (15) 
F1461 
KIF26B frameshift c.754delT; p.C252fs 3 (15) 
61 attenuated 21-50 no N/A S 
MCM3AP missense c.2411C>T;p.A804V 8 (28) 
F1520 
HSPH1 CSS c.1584+5G>A 11 (18) 
52 attenuated 11-20 no normal S/F 
HSPH1 missense c.916T>G;p.F306V 8 (18) 
F1735 
PDE4D CNV Deletion exon 1 
44 atypical 100-500 no N/A S 
NLRP1 CNV Deletion 
5'UTR + 
exon 1-3 
F1825 
MCM3AP CNV Partial duplication 
exon 21-28 
+ 3'UTR 
46 attenuated 21-50 yes N/A S 
YBEY CNV Partial duplication 
5'UTR + 
exon 1-3 
F1359 
HSPH1 CNV Partial duplication 
5'UTR + 
exon 1-4 
35 attenuated 51-100 yes normal S/F GFI1 CNV Deletion 
whole 
gene 
EVI5 CNV Deletion 
exon 18 + 
3'UTR 
F5014 
FOCAD stopgain c.715C>T;p.Q239* 10 (46) 
52 attenuated 51-100 yes normal S 
CTNNB1 CNV Whole gene duplication 
whole 
gene 
CNV: copy number variant; CSS: canonical splice site; S: sporadic case; F: familial; N/A: not applicable
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4.6. Screening for somatic point mutation 
From five patients who carried germline CNVs in candidate TSGs (DKK1, EDA2R, EPHB4, 
PDE4D, and FSTL5), Formalin-fixed paraffin embedded (FFPE) polyp tissue was available to 
screen for somatic “second hits” (point mutations, large deletions) in tumor DNA. The results 
are summarized in tables 4.18 and 4.19. 
Table 4.18. Candidate TSGs and results of screening for somatic point mutations in tumor DNA  
Patient ID CNV type CNV position 
Involved 
gene (TSG) 
Part of gene 
Sequence 
result 
FAP1576 duplication chr10:53735827-53798419 DKK1 whole gene No variation 
FAP1427 deletion chrx:65699679-65934932 EDA2R whole gene fail 
FAP1245 duplication chr7:100207480-100244080 EPHB4 
exon 13-17+ 
3‘UTR 
variant 
identified* 
FAP1735 deletion chr5:58578074-58734281 PDE4D exon 1 
variant 
identified* 
FAP764 deletion chr4:162981340-163113553 FSTL5 exon 4 No variation 
* for details see table 4.19 
Two variants identified in PDE4D are located in splice sites of exon 9 and 13; one is a known 
SNP (rs1553114), the other is g.1545822C>T which was predicted by MutationTaster to be a 
polymorphism and by BDGP to affect neither the splice acceptor nor the splice donor site of 
the respective exon. 
Four variants were detected in EPHB4, two of them are located in splice sites of exon 6 and 
were predicted to be polymorphisms and to affect neither the splice donor nor the acceptor 
site. The other two are located in exon 6 and 14; c.1272T>A;p.P424 is a mutation predicted 
to be synonymous while c.2372C>T;p.A791V is predicted to be a deleterious misense 
mutation by all three in-silico tools (MutationTaster, Polyphen-2, SIFT). 
Table 4.19. Somatic variants identified in the candidate TSGs 
Gene Position Variation Protein Mutation Taster 
PolyPhen-
2 
SIFT BDGP 
PDE4D g.1531323G>A  SS Polymorphism* n/a n/a - 
PDE4D g.1545822C>T  SS polymorphism n/a n/a 
No 
change  
EPHB4 g.7579C>T  SS polymorphism n/a n/a 
No 
change  
EPHB4 g.7918T>A c.1272T>A p.P424 disease causing n/a tolerated 
No 
change  
EPHB4 g.7958C>T  SS polymorphism n/a n/a 
No 
change  
EPHB4 g.20968C>T c.2372C>T p.A791V disease causing damaging damaging - 
* rs1553114; AA, amino acid; n/a, not applicable; SS, splice site 
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4.7. Replication of the GWAS performed in adenomatous polyposis 
To confirm new potential susceptibility loci identified in mutation-negative adenomatous 
polyposis patients by a genome-wide association study (GWAS) (unpublished data, not 
shown here), a replication study of the most promising 119 SNPs (top down approach using 
the most significantly associated SNPs) was performed in a large Dutch cohort of healthy 
controls and mutation-negative polyposis patients presenting with the same phenotype as 
the patients used for the original GWAS. 950 DNA samples (380 cases, 570 controls) were 
provided by our collaborator in the Netherlands. We excluded five patients (DNA provided in 
duplicate) and 24 controls (DNA likely contaminated). Therefore, 921 samples (375 cases, 
546 controls) remained for the genotyping. 
The Sequenom platform was used to genotype the 119 SNPs in the 921 samples. The assay 
design was able to include all but one SNP (rs10823418) in four plexes. However, one of the 
118 SNPs (rs11709614) failed genotyping on the Sequenom platform. Therefore, 
rs11709614 and rs10823418 were genotyped with the TaqMan SNP genotype assay.  
Of the 119 SNPs, 117 SNPs showed a call rate higher than 90% (mean call rate 98.4%) 
whereas rs1529017 (on plex 3) and rs10922106 (on plex 4) showed a mean call rate lower 
than 90%. In the four plexes, 11, 5, 10, and 5 samples failed genotyping, respectively. Of 921 
samples, 4 samples completely failed in all four plexes, 1 sample failed in 2 plexes, and 13 
samples each failed in one of the four plexes. Thus, 903 samples were successfully 
genotyped for all four plexes.  
A preliminary analysis was performed using logistic regression association analysis with call 
rate of 99% in which rs1529017 and rs10922106 were excluded. Two of the 117 SNPs 
(rs4236978 and rs797517) showed nominal significance (p = 0.004, and p = 0.008,) with an 
odd ratio of 1.29 and 1.38, respectively. However, after Bonferroni correction none of the 
SNPs showed a significant association with the phenotype anymore (Table A18). A 
comprehensive statistical analysis of the replication data will be performed in collaboration 
with the IMBIE at the University Hospital Bonn but has not yet been completed. 
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5. DISCUSSION 
5.1. Transcript analysis of the APC gene 
In recent years, pathogenic deep intronic point mutations leading to subsequent pseudoexon 
activation have been identified in a number of different genes and phenotypes including 
several hereditary tumor syndromes (Beroud et al. 2004; Clendenning et al. 2011; De Klein 
et al. 1998; Dehainault et al. 2007; Homolova et al. ; King et al. 2002; Nichols et al. 2005; 
Tuffery-Giraud et al. 2003; Tuohy et al. ; Zhang et al. 2008) and other monogenic conditions 
such as Becker muscular dystrophy, cystic fibrosis, or hemophilia (Bagnall et al. 1999; 
Beroud et al. 2004; Chillon et al. 1995; Highsmith et al. 1994; Tuffery-Giraud et al. 2003). 
These observations indicate that deep intronic splice mutations are more relevant than 
previously thought; however, to our knowledge this mutation type has so far not been 
described in FAP patients. 
In this study, we performed a transcript analysis in a large number of well characterized 
patients with clinically proven colorectal adenomatous polyposis, in whom no germline 
mutation in the APC or MUTYH genes were detected by routine procedures. By examination 
of reverse transcriptase (RT)-PCR products of five overlapping fragments spanning coding 
exons 1-15A of the APC gene, we identified a reproducible and intensive aberrant transcript 
pattern in 8 (6%) of the 125 cases pointing to an underlying intronic mutation on the genomic 
level. Sequencing of the aberrant bands revealed transcript insertions between two exons 
originating from exonized sequences (pseudoexons, cryptic exons) deep within the 
corresponding intron. All insertions are predicted to result in out-of-frame transcripts with 
subsequent premature stop codons, which strongly argue in favor of pathogenicity. 
Pesudoexon 4a: A 167 bp insertion originating from intron 4 was found in five apparently 
unrelated patients. The insert is flanked by pre-existing putative cryptic splice donor and 
acceptor sites with predicted high splice efficiency. The heterozygous germline transition 
c.532-941G>A at the penultimate position of the inserted sequence creates a canonical 
splicing signal at the pseudoexon-intron (Faustino and Cooper 2003) and thus might 
enhance the efficiency of the splice donor site over a critical threshold. The attenuated 
colorectal phenotype of the patients, which is in line with the established genotype phenotype 
prediction in FAP (Friedl and Lamberti 2001; Newton et al. 2011), and the segregation 
analyses in three families further suggest that the mutation is disease causing. Microsatellite 
analysis demonstrated that the alteration is a founder mutation, which originated on a 
haplotype shared by all affected persons in the families, rather than a mutational hotspot. 
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Pseudoexon 10a: A genomic transversion c.1408+735A>T at the less-conserved +6 
position of the cryptic splice donor site (GCAAGA to GCAAGT) obviously activates the splice 
site as well as a substitution c.1408+731C>T at the highly conserved +2 splice site position. 
The donor matrix of the GC–AG group (GCAAGT) shows a remarkable higher degree of 
conservation than compared with the canonical donor matrix of the GT–AG group (GTAAGT) 
at positions +3 to +6 (Burset et al. 2000). The sequence motif GCAAGA in APC intron 10 can 
be changed into a splice donor site with high splice efficiency by either a C>T transition at 
position +2 or an A>T transversion at position +6. The almost 100% splice efficiency of the 
activated splice donor site was demonstrated by sequencing the normal transcript, where 
only the wildtype sequence is detectable. The same mechanism has been described in 
genes underlying other hereditary tumor syndromes such as the MSH2 gene causing Lynch 
syndrome (Clendenning et al. 2011) and the RB1 gene causing familial retinoblastoma 
(Dehainault et al. 2007).  
Nontruncating single-base substitutions in the coding APC sequence or unique variants in 
less conserved intronic regions close to the splice sites have rarely been reported in FAP. 
Functional studies at the mRNA level have indicated that most of these APC variants are 
pathogenic due to aberrant splicing (Aretz et al. 2004; Kaufmann et al. 2009). In-silico 
analysis suggests that intronic sequences contain numerous putative splice donor and 
acceptor sites, which can result in pathogenic pseudoexon activation due to upstream or 
downstream mutations creating complementary splice sites (Clendenning et al. 2011). 
Regarding the observed transcript pattern and the segregation within families, these germline 
mutations are most likely disease causing. Our study points to the existence of a mutational 
hotspot region in intron 10 and a founder mutation in intron 4 of the APC gene. It will be 
interesting to see whether or not these mutations can also be identified in polyposis patients 
from other populations. 
 
5.2. Novel causative gene identification 
5.2.1. CNV analysis 
In patients with adenomatous polyposis, conventional methods including Sanger sequencing 
and MLPA are widely used for the detection of germline mutations in the APC and MUTYH 
genes. However, in up to 50% of the patients, APC and MUTYH mutations could not be 
identified by these methods. Nevertheless the presence of dozens or more colorectal 
adenomas argues in favour of an underlying genetic predisposition. There might be a few 
causes of unexplained polyposis due to unrecognized mutations in the extablished genes 
that may not be identified by routine molecular methods. The presence of deep intronic APC 
splice mutations (see previous section) emphasize that routine diagnostic tests are not 
sufficient to detect all causative mutations. Alternatively, mutations in other genes might be 
relevant, for example, in genes involved in the Wnt signaling pathway. Following the 
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discovery of MUTYH in 2002, it is reasonable to assume that there may still be un-identified 
causative genes awaiting discovery. Due to the clinical appearance and the pedigree pattern 
of mutation-negative patients, both monogenic subtypes and a more complex genetic 
etiology (multifactorial, polygenic cause) seem to be reasonable. 
Genomic structural variants, particularly copy number variants (CNVs), are thought to play an 
important role in human phenotypic variation. CNVs such as germline deletions and 
duplications are associated with inherited genetic disorders including familial cancer (Lucito 
et al. 2007). Several studies have explored the frequency of CNVs in well known high-
penetrant cancer predisposing genes, including MMR genes, APC, BRCA1, BRCA2, and 
VHL genes. These studies revealed that CNVs, in particular heterozygous deletions of single 
exons up to whole genes, occur in about 4–15% of the families, which has turned DNA 
dosage analysis such as MLPA into an essential component of mutation screening in 
patients with cancer predisposition syndromes (Aretz et al. 2007b; van Hattem et al. 2008; 
Venkatachalam et al. 2008). 
CNVs can predispose to disease by directly affecting the gene dosage of haploinsufficient 
genes, by unmasking a recessive mutation on the other allele, by changing gene expression 
due to the disturbance of regulatory regions or inducing epigenetic changes or position 
effects, or they may function in combination with other genetic and environmental factors 
(Feuk et al. 2006). Similar to SNPs, the more common CNVs may have no impact on cancer 
risk or act as low-penetrant risk factors (Shlien and Malkin 2010) while rare deletions and 
duplications may act as high-penetrant mutations. During the last years, several studies 
identified both common recurrent and rare heterogeneous germline CNVs as presumptive 
risk factors for sporadic solid malignancies (Diskin et al. 2009; Liu et al. 2009; Stadler et al. 
2012). In addition, it was shown that rare CNVs are collectively overrepresented in familial 
tumor syndromes compared to controls, and thus contribute to the yet missing heritability 
(Krepischi et al. 2012a; Pylkas et al. 2012; Shlien et al. 2008).  
Therefore, it is reasonable to assume that CNVs, particularly heterozygous deletions might 
be part of the mutation spectrum in yet unidentified genes responsible for colorectal 
adenomatous polyposis syndromes. In a mutation-negative FAP family, Thean et al. (2010) 
identified in all examined polyps a copy number loss at 3q26.1, which might regulate the 
expression of an upstream candidate TSG (PPMIL). However, the authors failed to identify a 
causative germline variant. De Voer et al. (2013) found a heterozygous microdeletion of 
BUB1 in a cohort of early-onset CRC, and subsequently additional point mutations in BUB1 
and BUB3. 
In the last few years, several calling algorithms have been developed to identify CNVs at the 
whole genome scale using high-resolution single nucleotide polymorphism (SNP) chips used 
to perform GWAS. SNP arrays have successfully been employed to identify CNVs in several 
phenotypes including familial CRC (Yang et al. 2013). These studies clearly demonstrate the 
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potential of high-resolution genomic copy number profiling for the discovery of new disease 
genes. 
Based on these notions, we performed a high resolution genome-wide SNP-based CNV 
analysis using Illumina Human Omni1-Quad Bead-arrays to search for novel predisposing 
genes in 221 well characterized unrelated adenomatous polyposis patients (94 females, 127 
males) in whom no mutations in the APC and MUTYH genes could be determined by routine 
diagnosis. The majority of patients are sporadic cases without extracolonic lesions and less 
than 100 colorectal adenomas. The clinical and family features of the patients are consistent 
with published data of other mutation-negative cohorts (Hes et al. 2014; Mongin et al. 2012; 
Thirlwell et al. 2007).  
We identified altogether 127979 CNVs (579 CNVs per patient). The average number of 
CNVs was similar in patients and controls. The majority of them carry 500-600 CNVs. Around 
27% of these called CNVs are smaller than 1 kb, which are defined as ‘indels’ and around 53% 
of the CNVs are smaller than 10 kb, which is in accordance with the size distribution of CNVs 
in the Database of Genomic Variants (DGV). 
Assuming a dominant or recessive mode of inheritance with high penetrance mutations as a 
monogenic etiology, the frequency of causative CNVs in the general population would be 
expected to be much lower than 1%. We used stringent filter criteria regarding size, number 
of probes, and max log BF, to reduce false positive results and to identify rare non-
polymorphic CNVs, which are not present in a large control cohort (531 population-based 
samples). By this approach, the proportion of called CNVs was reduced to less than 0.1% of 
total called CNVs. CNV deletions were less frequent than duplications (449 deletions, 785 
duplications). The number of duplications was further reduced to 510 CNVs when we used 
more stringent filter criteria. This is in contrast to case-control studies, where chromosomal 
deletions were more prevalent than duplications (Buizer-Voskamp et al. 2011; Dauber et al. 
2011).The number of CNVs was dramatically reduced after applying further filtering steps 
such as exclusion of CNVs in segmental duplication regions, exclusion of CNVs not 
encompassing coding genes, and exclusion of common CNVs reported in the DGV and/or 
found in more than one HNR control. Finally, 46 rare germline deletions and 108 rare 
germline duplications remained. We eventually validated 43 deletions and 82 duplications as 
true positives in 42% (93/221) of the patients. All these CNVs were non-recurrent and 
affected protein coding genes. 
CNV calling is a crucial step in CNV detection with genotyping arrays. PennCNV and 
QuantiSNP are the most popular CNV calling algorithms originally developed for the Illumina 
platform. Dellinger et al. (2010) reported that QuantiSNP outperforms six other algorithms 
(Circular Binary Segmentation (CBS), CNVFinder, CNVPartition, Gain and Loss Analysis of 
DNA (GLAD), Nexus algorithms, and PennCNV). However Xu et al. (2011) compared the 
calls generated by PennCNV (Wang et al. 2007) and QuantiSNP (Colella et al. 2007) and 
found that, for the Illumina Infinium 1Mduo chip, CNVs called by PennCNV are generally 
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shorter and more frequent than those called by QuantiSNP. Later on, Marenne et al. (2012) 
compared results from the Illumina Human 1M chip processed with CNV partition, PennCNV, 
and QuantiSNP. They reported that QuantiSNP and PennCNV provided a similar mean 
number of copy number changes that was higher than that provided by CNVPartition. 
Based on these studies and our own experience from previous CNV analyses (Herms et al. 
2013) we used QuantiSNP as the only algorithm in this study. Both QuantiSNP and 
PennCNV are based on the same HMM algorithm, showed a striking overlap of called CNVs 
and are known to have the best performance in the target size range of CNVs relevant for 
this study. An alternative approach would have included multiple algorithms to select either 
only those CNVs which were called by all tools or all CNVs detected by any of the 
programms. The former would have resulted in a high rate of true CNVs being missed and 
the latter procedure in a high rate of false positives (Jiang et al. 2013). 
Based on the observation that the validation rate of deletions is higher than that of 
duplications when the same filtering criteria are applied (Shaikh et al. 2009), we further 
adjusted the filtering criteria for duplications according to suggestions made by 
Venkatachalam et al. (2011) to avoid a high number of false positive CNVs. Consistent with 
Itsara et al. (2009), we found that the majority of deletions (401 of 449 CNVs = 89%) are 
smaller than 100 kb and more frequent than duplications, of which most are larger than 100 
kb (363 of 510 CNVs = 71%). Itsara et al. suggested that the relative enrichment of deletions 
smaller than 100 kb may reflect higher de novo occurrence rates of deletions. In contrast, the 
rather low numbers of large deletions may be due to their more deleterious effects compared 
with those of duplications of the same size. 
The vast majority of our patients harboured one CNV only, which is similar to published 
findings in familial and early-onset colorectal cancer (Venkatachalam et al. 2011) and breast 
cancer (Krepischi et al. 2012a). All CNVs in our study were smaller than 900 kb, consistent 
with the absence of intellectual disability or other syndromic features in this cohort. 
Many studies report CNVs of genes belonging to the olfactory receptor (OR) family. The OR 
genes are affected at a high frequency by stop mutations in the human population. However, 
these potential loss-of-function mutations obviously do not have any phenotypic 
consequences or cause clinical symptoms (Petrovski et al. 2013). Graubert et al. (2007) 
reported that CNVs of OR genes are involved in environmental response but are not 
associated with a disease phenotype. Additionally, Cooper et al. (2007) found that CNVs 
associated with segmental duplications are highly enriched in genes involved in sensory 
perception including olfactory receptors and components of the immune response. 
Duplicated regions can appear on the same or different chromosomes (Lander et al. 2001). 
Therefore, it is not possible to design specific primers to confirm CNVs within duplicated 
regions. Itsara et al. (2009) excluded segmental duplications from the analysis to avoid 
ascertainment bias in the results.  
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Taken together, OR genes seem to be tolerant against point mutations yet liable to a high 
degree of structural variability. Based on studies mentioned above and the associated 
methodical problems, we excluded CNVs spanning OR genes and also CNVs located in 
segmental duplication regions.  
In this study, one patient presented with an outlying number of CNV duplications. We 
randomly examined four CNVs by qPCR but we were unable to verify those CNVs. Together 
with the CNV pattern shown in the Genome Viewer, we concluded that these CNVs are 
actually copy-neutral LOH (see section 2.4.2) and thus, the patient was excluded.  
By qPCR we verified true positive CNVs in 43 of 46 deleted CNVs and 82 of 83 duplicated 
CNVs. These numbers indicate that the false positive rate of CNVs called by QuantiSNP is 
low once they passed our stringent filter criteria and visual inspection. The visual check, 
taking into account the pattern of LRR and BAF and the type of the consecutive probes of 
each CNV, could reduce the number of false positive CNVs significantly. The three deletions 
that could not be validated showed a normal copy number in the coding regions but loss of 
copy number in intronic parts. The invalidated duplication was on chromosome X of a female. 
This false calling might be caused by a disadvantage of hybridization-based technologies 
which include reliance on an accurate reference assembly, difficulty in precise delineation of 
CNV breakpoints due to noise inherent in measurement of fluorescence (Itsara et al. 2009). 
We performed a segregation analyses in 5 patients who carried 9 CNVs in total. However, 
none of the 9 CNVs co-segregated with the phenotype in the family. These CNVs might 
either not be causative or contribute to disease manifestation just as low or moderate 
penetrance risk factors. This is in line with genome-wide CNV studies in other familial tumor 
syndromes. Krepischi et al (2012b) even suggested that the vast majority of CNVs have 
moderate penetrance and contribute modestly to human diseases.  
From 125 rare germline CNVs, there are six overlapping CNVs in 3 regions (2 CNVs in each 
region). Two of the six CNVs do not co-segregate with the phenotype. Apart from the 3 pairs 
of overlaping CNVs, our work is consistent with the very few systematic genomewide CNV 
studies in unexplained hereditary tumor syndromes, which found as a characteristic feature 
almost only nonrecurrent CNVs and very little overlap of affected genes. Lucito et al. (2007), 
Venkatachalam et al. (2011), and Krepischi et al. (2012a) performed genome-wide CNV 
analysis in unrelated patients with pancreatic cancer, early-onset CRC, and early-onset 
breast cancer, respectively. In the study of familai pancreatic cancer, several disrupted 
genes formed a TP53 centered network and exhibited functions related to genomic integrity 
(Lucito et al. 2007). In other studies, the filtered genes were not functionally related. All rare 
CNVs are non-recurrent, and the results of segregation analysis are often inconclusive or 
argue against a high penetrant CNV contribution. An exception is a study of Yang et al. 
(2012) in a melanoma-prone family where a duplication, containing interesting candidate 
genes, segregates with the phenotype in three affected individuals. Recently, Yang et al 
(2013) found a deletion CNV on 12p12.3 in two of 384 familial CRC patients. Because of the 
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limited recurrence data obtained so far, it is impossible to state explicitly which of the variants 
contribute to cancer predisposition. Nevertheless, four of the genes or gene groups affected 
by CNVs in our study cohort (ARHGAP5, FOCAD, KIF26B, YBEY) have also been identified 
in the above mentioned CNV studies, which supports their pathogenic relevance for cancer 
predisposition. 
These and our non-recurrent results are in accordance with the observation that mutations in 
newly identified genes underlying inherited tumor predisposition syndromes are very rare. 
For example, germline mutations in RAD51C that cause hereditary breast and ovarian 
cancer have been found in less than 0.5% of 1,100 breast cancer families or in 1.3% of those 
480 families which presented with breast and ovarian cancer (Meindl et al. 2010), and 
mutations in the polymerase genes, POLD1 and POLE, have been observed in 0.3% of 
3,800 families with multiple colorectal adenomas and carcinomas (Palles et al. 2013). At 
least some of the unexplained tumor syndromes seem to be genetically extremely 
heterogeneous and large patient cohorts are needed to validate candidate genes by 
recurrent germline mutations.  
 
5.2.2. Candidate gene prioritization 
The 125 rare germline CNVs affect 68 deleted genes and 168 duplicated genes. By applying 
further rational filtering criteria at the gene level, we reduced the number of candidates using 
the same exclusion criteria for CNVs as for genes, that is, 1) occurring in intronic regions 
only; 2) located in segmental duplications; 3) belonging to the OR family; and 4) found in 
more than one control. Subsequently, we excluded genes, which are unexpressed in colonic 
mucosa. Thereby, the number of candidates was significantly reduced from 236 to 180 
genes. 
It is quite obvious that the deletion of a gene leads to a loss-of-function even though not all 
loss-of-function mutations are deleterious, some of them are even advantagous (Conrad et al. 
2010). Therefore, as a general rule, the loss of genomic material is more likely to be 
pathogenic rather than the gain of genomic material as the genome is thought to be more 
tolerant to duplications than deletions (Brewer et al. 1999). Regarding duplications, it is not 
unequivocally clear whether they lead to a gain-of-function (e.g. due to overexpression) or a 
reduction of the expression of the gene. 
Whole gene duplications are usually thought to act as gain of function mutations in the sense 
of an increased expression, and those mutations are unlikely to exist as germline mutations 
due to serious consequences. However, even if an overexpression can be confirmed, the 
functional relevance is difficult to validate. In contrast, partial gene duplications may result in 
deleterious loss-of-function effects depending on their genomic orientation and localization. A 
loss-of-function effect of a partial duplication was reported e.g. for the PTPRJ gene by Kuiper 
et al. (2010). They found that an intragenic duplication of PTPRJ encompassing the 
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transcriptional control elements and exons 1 to 11 resulted in allele-specific epigenetic 
silencing of the wild-type PTPRJ gene.  
In this CNV study, we found on chromosome 1p34 a heterozygous deletion of TESK2 which 
is located 3.4 kb upstream of MUTYH. The chromosomal region 1p34 is complex and 
rapidly evolving (Makalowska 2008). The TOE1 gene is located between, and shows partial 
overlap with, MUTYH and TESK2. Recent work has suggested that an equine SNP in exon 4 
of TOE1 may down-regulate MUTYH expression by affecting a transcription factor binding 
site (Brault et al. 2011). Long-range effects of CNVs on gene transcription due to disruption 
of regulatory regions or epigenetic modifications are well known (Ionita-Laza et al. 2009; 
Stranger et al. 2007). Kuiper et al. (2010) identified a disease-causing heterozygous deletion 
at the 3’ region of EPCAM located upstream of MSH2 gene in patients with Lynch syndrome 
and unexplained MSH2 loss in tumor tissue. This deletion resulted in a transcriptional read-
through of the EPCAM transcript and mono-allelic silencing of MSH2 due to cis 
hypermethylation of the MSH2 promoter. Jaeger et al. (Jager et al. 2012) identified a 
duplication spanning the 3′ end of the SCG5 gene and a region upstream of the GREM1 
which causes ectopic GREM1 expression, resulting in a mixed polyposis phenotype. 
Therefore, we hypothesized that the TESK2 deletion might decrease the MUTYH expression. 
We performed an expression analysis using RNA of the affected study patient. However, 
although the expression level of MUTYH in the patient with the TESK2 deletion was lower 
than that in controls, the difference was not statistically significant. Albeit CNVs may have a 
long-range regulatory effect on cancer gene transcription up to 1.2 Mb away from a gene 
(Stranger et al. 2007), this study could not confirm an effect of the upstream deletion on 
MUTYH expression. Moreover, no heterozygous MUTYH point mutation was identified in this 
patient, thus it is unlikely that in this case the CNV is the underlying cause of polyposis. 
Nevertheless, it cannot be ruled out that the TESK2 deletion might have an independent 
effect on the phenotype itself.  
Two well known oncogenes were identified in our study, CTNNB1 and EFGR. CTNNB1 (ß-
catenin) is an adherens junction protein and a central player of the canonical Wnt signaling 
pathway, in which it activates target genes for cell proliferation by interaction with 
transcription factors. As reported in the Cancer Gene Census (The Cancer Genome Project: 
CGP), it is involved in many types of cancer including adenomatous polyposis (IPA results). 
It is one of the most common initially altered genes in sporadic colorectal tumors (Pendas-
Franco et al. 2008). Consistent with the oncogenic properties of the protein, the whole gene 
duplication and a missense mutation found in our study would be in line with a gain-of-
function alteration leading to overexpression. However, gene expression analysis in the 
patient who carried the whole gene duplication of CTNNB1 gene showed no significant 
increase of the CTNNB1 expression. This is in consistent with the report of Stranger et al 
(2007) that 10% of all known duplication CNVs from the International HapMap project show a 
negative correlation to transcript expression. Furthermore, this patient also harbored a 
Discussion 
 
124 
mutation in FOCAD, a novel TSG (see section 5.2.3). Thus, this CNV is either unlikely to be 
the underlying cause or a high ranking candidate gene for adenomatous polyposis.  
The EGFR (epidermal growth factor receptor) signaling pathway is commonly activated in 
CRC, and EGFR-target therapies have improved the outcome for CRC patients. The copy 
number of EGFR is increased in human colorectal carcinogenesis and an upregulation of 
EGFR may correlate with malignant progression (Flora et al. 2012). In this study we identified 
in one patient a duplication, which partly involves EGFR. Assuming that the partial 
duplication disrupts the gene and thus has a loss of function effect, the expression of EGFR 
identified in our study should be decreased, which would not correspond to known oncogenic 
properties. On the other hand, if the duplication disrupts a silencer, the expression might be 
increased, and thus the result would be in line with the expected pathological effect. We did 
not further study the expression pattern of EGFR in the patient who carried the partial 
duplication since EGFR seems to be involved in tumor progression rather than initiation of 
tumorigenesis (Huang et al. 2013; Neumann et al. 2013; Zuo et al. 2013). 
The first run of a network analysis, performed by our collaborating colleagues, has shown 
two interesting candidates associated with known polyposis genes, DKK1 and NFATC1. 
DKK1 is also present in the IPA as one of the top three genes associated with cancer, next to 
CTNNB1 and EGFR. DKK1, or dickkopf homolog 1, on chromosome 10q11.2, acts as a 
tumor suppressor in human CRC cells harbouring endogenous mutations in the Wnt/beta-
catenin pathway (Pendas-Franco et al. 2008; Sato et al. 2007), so that loss of DKK1 may 
facilitate tumorigenesis. We found a whole gene duplication of DKK1 which is not in line with 
the expected inactivating (loss-of-function) mutations typical for TSGs. NFATC1, located on 
chromosome 18q23, is a transcription factor that regulates T-cell development, 
osteoclastogenesis, and macrophage function. Oikawa et al. (2013) reported that an 
expression of NFATC1 contributes to tumor progression due to an increase of invasive 
activity. This is likely to be a gain-of-function effect. However, in our study, we found a partial 
duplication of NFATC1. Assuming that a partial duplication rather leads to a loss than a gain 
of function, then the mutation in our patient is not consistent with previous study. 
Nevertheless, according to previous reports, NFATC1 is likely to be involved in tumor 
progression, rather than tumor inititation. 
To better understand if these genes are up- or down-regulated by a partial duplication, 
expression analyses could be performed. Nevertheless, since there were no recurrent CNVs 
and no germline truncating point mutations of NFATC1 and DKK1 were identified in the 
validation cohort, we did not perform functional studies. 
The second network analysis indicated that UBC, or Ubiquitin C is located in the center of the 
network (Steiner tree analysis). Ubiquitination is associated with protein degradation, DNA 
repair, cell cycle regulation, kinase modification, endocytosis, and regulation of other cell 
signaling pathways. Its function depends on Lysine (Lys) residue conjugation. UBC is 
involved in the Peroxisome proliferator-activated receptors (PPARs) signaling pathway and is 
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expressed in the human intestine. Since ubiquination is a very common and widespread 
mechanism, it might not be surprising that UBC appears in the center of this analysis as the 
lowest common denominator associated with the highest number of candidates. Together 
with the absence of a germline mutation in any of our patients, the gene was disregarded 
from further work-up. 
To summarize the network analysis, 3 notable candidates (DKK1, NFATC1, UBC) were 
identified in two analyses. However, after including all sources of information including 
patterns of expression and NGS results (see section 5.2.3), these three genes do not seem 
to be among the most interesting candidate genes for colorectal adenomatous polyposis. 
The data mining step was very helpful to reduce the number of candidate genes considerably 
from 180 to 98. Primarily, we excluded the candidate genes which cause other monogenic, 
early-onset diseases. If the type of mutation (e.g. truncating) in our patients was consistent 
with those reported in these disorders, then the study patients should be affected by these 
phenotypes in addition to the colorectal polyposis. Secondly, several genes were not 
included in our top candidate gene list because they are well known genes which are 
obviously not associated with tumorigenesis according to their functions and the pathways 
they are involved. Instead, data mining could help to select those genes as most interesting 
candidates whose functions and pathways have been reported to be related to cancer. In 
addition, we included a group of genes, most of whom belong to the zinc finger protein family, 
which have unknown functions and properties since genes of which nothing is known about 
cannot be excluded as causative genes in general. 
Literature review of genes predisposing to CRC using an exome sequencing approach 
demonstrates no overlap among new candidate genes in each study although the same 
phenotype was studied. Gylfe et al. (2013) identified rare germline truncating mutations in 11 
novel susceptibility genes (UACA, SFXN4, TWSG1, PSPH, NUDT7, ZNF490, PRSS37, 
CCDC18, PRADC1, MRPL3, and AKR1C4) in familial CRC cases. They are absent or rare 
(MAF  0.001) in the general population. Smith et al. (2013) identified 5 potential novel TSG 
which predispose to CRC; FANCM, LAMB4, LAMC3, PTCHD3, and TREX2, by seeking 
second hit (somatic) mutations in patients who carry germline truncating mutations. None of 
these novel candidates were found in our study.  
The data mining and pathway analyses revealed that 32 candidate genes are of special 
interest since they are related to well known cancer pathways, are discussed as potential 
TSG, or are involved in functions relevant for tumor development such as cell cycle 
regulation, proliferation control, apoptosis, or cell adhesion. Our finding is in line with a study 
of Fanciulli et al. (2010) which reported that germline copy number changes can affect 
several gene pathways, including the ERBB2, epidermal growth factor receptor (EGFR) and 
PI3K pathways in CRC.  
Discussion 
 
126 
Nonetheless, there are other possibilities to further evaluate clinical relevance such as the 
haploinsufficiency theory, the intolerance score, and frequency of somatic mutation in 
colorectal tumors.  
Assessment of haploinsufficiency (HI) by an HI score is an approach to identify genes, which 
are likely to be damaged by heterozygous loss-of-function mutations of one allele; i.e. the 
expression of one allele only (around 50% of the gene product) is not sufficient to maintain 
the physiological (normal) function (haploinsufficiency). The likelihood of haploinsufficiency of 
a gene helps to estimate the functional relevance of heterozygous loss of function mutations 
(deletion CNVs, truncating point mutations). Huang et al. (2010) reported that the most 
obvious pathogenic mechanism for heterozygous loss-of-function mutations (such as large 
rare deletions) is haploinsufficiency. Thus, many genes implicated in dominant diseases are 
supposed to be haploinsufficient. Several disorders are caused by heterozygous germline 
deletions at several haploinsufficient gene loci such as intellectual disability caused by 
haploinsufficiency of ARID1B (Hoyer et al. 2012). The tendency to delete one rather than 
both copies might be because critical genes nearby cannot be homozygously deleted 
(Greenman 2012). Chayka et al (2009) studied the role of clusterin in tumor development by 
using mouse models of neuroblastoma and they found that clusterin is a haploinsufficient 
TSG in neuroblastoma. For a haploinsufficient gene functioning as TSG, the loss of even one 
copy can initiate tumorigenesis instead of the more common haplosufficient TSG, in which a 
second mutational hit on the wildtype allele is needed to impair gene function (Lambertz et 
al. 2010; Vasanthakumar et al. 2013).  
Petrovski et al. (2013) found that genes responsible for Mendelian diseases are significantly 
less tolerant to functional genetic variation than genes not causing any known disease. For 
example, According to the intolerance score the APC gene (score 0.90) is intolerant against 
genetic variation while the tolerance for heterozygous mutations of the haplosufficient gene 
MUTYH, which causes a recessive disease is high (score 62.1). This is in line with their 
respective patterns of dominant and recessive inheritance models. The intolerance ranking 
system is helpful for ranking the candidate genes.  
Somatic mutations identified in tumor tissue are listed in the COSMIC databases. The higher 
the frequency of (specific) somatic mutations in a gene which are not present in the general 
population, the larger is the likelihood for them to be driver genes and relevant to 
tumorigenesis.  
By combining these three parameters (haploinsufficiency score, intolerance score, and 
number of somatic mutations) and all gathered data, we found that ARHGAP5, CNTN6, 
EPHB4, IQGAP1, KIF26B, MCM3AP, NFATC1, and XRN1 are the most interesting 
candidates in the group of 98 genes as they are related to tumorigenesis, involved in cancer 
pathways, likely to be huploinsufficient genes, frequently affected by somatic mutations, and 
they tend to be intolerant to functional variations. 
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Nevertheless, since all approaches mentioned above could not be sufficient to prove the 
causality of the candidate genes, mutation analysis was performed in parallel to look for 
recurrent mutations in patients to strengthen the causal relevance of the predisposing genes. 
 
5.2.3. Validation of the clinical relevance of the candidate genes 
To validate the clinical relevance of the most promising 97 candidate genes, which are either 
genes of unknown function or known genes with features related to CRC or other cancer 
types, we screened a large validation cohort (n = 192) for germline point mutations using an 
NGS-based targeted sequencing approach. Beforehand, the LZTFL1 gene was screened by 
Sanger sequncing in 100 polyposis patients. 
We identified 15 unique rare truncating mutations of 11 genes in 15 patients and were able to 
validate all of them by Sanger sequencing. In two genes, multiple mutations were found: 
CNTN6 showed a different truncating mutation in each of four patients and FOCAD showed 
a different mutation in two cases. All other truncating mutations were found only once. 
Subsequently, 11 missense mutations predicted to be deleterious were identified in these 11 
genes. Besides one patient with a putative compound-heterozygous HSPH1 mutation, no 
case with a biallelic point mutation or a heterozygous point mutation unmasked by a CNV 
was found, indicating that autosomal recessive inheritance is not frequent in genes affected 
by rare CNVs. 
Our strategy to select candidate genes based on truncating mutations is similar to that in 
other NGS studies (Gilissen et al. 2012). Truncating mutations introduce premature stop 
codons causing the dysfunction of the protein or nonsense-mediated decay whereas many 
missense mutations are variants of unknown significance (VUS), which means it is unclear 
whether they affect gene function or not. As a segregation analysis was possible in only five 
proband families, we were unable to prove whether the variants segregate with the 
phenotype and/or whether they are de novo events. 
Based on functions and pathways related to cancers, literature review, frequency of somatic 
mutations in colon tumors, haploinsufficiency score, and intolerance score, CNTN6 is as one 
of the 11 genes which most frequent found truncating mutations and fits into all criteria, same 
as KIF26B, MCM3AP, FOCAD, and HSPH1. 
CNTN6, or contactin6, is located on chromosome 3p26.3. It is a well-known gene involved in 
central nervous system development and functions as an axonal guidance during 
development maintenance of synaptic connections in adults. It is also involved in cell 
adhesion and the Notch signaling pathway, which is an essential pathway for maintaining the 
stem cell population as well as regulating cell lineage differentiation in the normal intestinal 
mucosa. Recently, Smith et al. (2013) identified a truncating mutation in NOTCH3 in one of 
50 CRC patients. So far, there have been no publications of CNTN6 as being related to CRC 
but a few studies have reported an association of CNTN6 with other cancers. Manderson et 
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al. (2009) detected LOH within chromosome 3p25.3-pter, including CNTN6, in epithelial 
ovarian cancers. Rokman et al. (2005) reported that chromosome 3p25-p26 is a 
susceptibility locus for prostate cancer. However, these authors cannot observe an exonic 
mutation or a change of the expression level of CNTN6. Further studies are needed to 
determine whether mutations of genes involved in the Notch signaling pathway have a 
significant causative role in adenomatous polyposis. 
KIF26B, or Kinesin family member 26B, is a member of the kinesin superfamily proteins 
(KIFs). It is known to be involved in the regulation of cell-cell adhesion. Several studies 
reported that abnormal expressions of different kinesins play a key role in development or 
progression of human cancers including CRC, partly by disturbing mitosis. Wang et al. (2013) 
reported that KIF26B is overexpressed in breast cancer tissue. Krepischi et al. (2012a) found 
a deletion in an early-onset familial case of breast cancer. In our study, KIF26B was affected 
by a partial duplication in one patient. However, the predominant mutation type in our cohort 
and in colorectal tumors is missense mutation. Germline missense mutations are outside the 
functional domain and cluster in exons 3 and 12. Nevertheless, this might be due to the 
length of the exons rather than pointing to mutational hotpots. Taken together, these results 
are not completely consistent and the impact of the different mutations has yet to be explored 
further. 
MCM3AP, acetylating minichromosome maintenance 3 (MCM3), or GANP, is an essential 
human DNA replication protein. It is a potential natural inhibitor of the initiation of DNA 
replication and, thus, functions to ensure the stability of human genomic DNA (Takei et al. 
2002). MCM3 acetylation has been suggested to be a novel pathway regulating DNA 
replication. We identified a partial duplication of the 3´ part of the gene, a frameshift mutation 
at the beginning, and two missense variants in the 3´and 5´parts, which are predicted to be 
deleterious and are compatible with the expectation of loss-of-function mutations. 
Another interesting candidate is FOCAD, previously known as KIAA1797. FOCAD is a large 
and highly conserved gene and has been reported in a few cancer types. So far, the 
germline deletions described in patients with unexplained familial tumor syndromes are not 
identical but partly overlap. Venkatachalam et al. (2011) found a heterozygous germline 
deletion (158 kb), which encompassed FOCAD exons 4-21 in one of 41 early-onset CRC 
patients. Krepischi et al. (2012a) identified a germline deletion CNV (136 kb), which 
encompassed FOCAD exons 3-13 in a patient with BRCA1/BRCA2 mutation-negative early-
onset (38 yrs) breast cancer. Recently, FOCAD was characterized as a novel component of 
the focal adhesion complex with tumor suppressor function, which was found to be disrupted 
by translocations or heterozygous or homozygous deletions in around half of glioblastomas 
(Brockschmidt et al. 2012). Focal adhesions influence growth control and are involved in 
cellular processes such as motility, proliferation, and differentiation (Dubash et al. 2009). Our 
study found a deletion of exons 20-30 and two truncating point mutations in the middle part 
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of the gene. These findings strengthen the pathogenic role in cancer predisposition of 
FOCAD as it might be a predisposing factor for a variety of different tumors.  
HSPH1 seems to be a haploinsufficient gene intolerant to variations. This is supported by the 
very low number (only 1) of truncating mutations reported in the EVS database. HSPH1 
belongs to the heat shock proteins (HSPs), which ensure the correct conformation of cellular 
proteins, and during stress, promote cell survival by maintaining protein homeostasis and 
inhibiting apoptosis (Lang et al. 2012). It suppresses H2O2-induced apoptosis by suppression 
of p38 MAPK signaling. Dai et al. (2012) reported that overexpression of HSPs in cancer 
cells reinforces oncogenic events. However, the pathogenicity of the two HSPH1 variants 
identified in our patient remains unclear. The patient presented an attenuated colorectal 
phenotype and a family history consistent with autosomal recessive inheritance (parents 
healthy, his brother had few colon polyps, his sister was diagnosed with breast cancer at 45 
years of age). Unfortunately, neither DNA nor RNA are available to confirm compound 
heterozygosity and aberrant splicing. 
For a whole gene duplication, it is assumed that a gain-of-function mutation of the gene 
would lead to tumorigenesis. Generally, a truncating mutation of the gene would lead to loss-
of-function whereas specific missense mutations are more likely to increase the function of 
the gene. For example, a missense mutation of KRAS oncogene, which change an amio acid, 
p.G12D, can promote the activation of RAS protein and leads pancreatic tumor (Pylayeva-
Gupta et al. 2011). Regarding this assumption, we looked for missense mutations of whole 
gene duplication candidates. 
In addition to the missense mutation in CTNNB1, we identified a missense mutation in 
PTPN18, which was found to be affected by a whole gene duplication in the CNV analysis. 
PTPN18 belongs to the protein tyrosine phosphatase (PTP) family. PTPs regulate a variety 
of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic 
transformation. PTPN18 regulates HER2, a member of the epidermal growth factor receptor 
(EGFR) family of receptor tyrosine kinases. Overexpression of PTPN18 inhibits HER2 
activity in breast cancer (Gensler et al. 2004; Lucci et al. 2010). The frequency of somatic 
mutations reported in COSMIC is very low whereas the haploinsufficieny score and 
intolerance score show that PTPN18 is likely to be haplosufficient and tolerated to variants.  
Gain of function of PTNP18 seems to inhibit tumor progression which is in contrast to 
concept of oncogenes. PTPN18 has been reported an association with not only breast 
cancer but also thyroid cancer (Guimaraes et al. 2006). However, there has been no report 
of PTPN18 being related to CRC so far. PTPN18 is rather a TSG than an oncogene, 
correspondingly, whole gene duplications and missense mutations do not represent the 
typical mutation spectrum of the TSG. Based on these pieces of information, it is unlikely to 
be a causative gene initiating adenomatous polyposis. 
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Loss of function of TSG is a recessive pattern and known as “two-hit” hypothesis (Knudson 
2001). Therefore, to prove the tumor suppressor activity of the candidate TSGs, identification 
of somatic mutation (second hit) could be helpful. This study performed somatic mutation 
analysis in five putative TSGs and found a missense somatic mutation in EPHB4, which 
predicted to be deleterious by in-silico tools, in the patient who carry a duplication CNV which 
partially involved EPHB4 (exon 13-17 and 3’UTR). EPHB4 is a candidate TSG (Dopeso et al. 
2009; Ronsch et al. 2011), involved in angiogenesis pathways and related to colorectal 
cancer (Guijarro-Munoz et al. 2013). Our finding is in line with the previous studies that 
EPHB4 has a tumor suppressor activity.  
This thesis provides support for the functional relevance of novel predisposing genes in 
unexplained adenomatous polyposis. To confirm the causality and phenotype spectrum of 
the predisposing genes, a larger sample size to identify recurrent mutations is needed as 
looking for mutations is less complicated than performing functional tests of each candidate 
gene.  
 
5.3. Limitations of the study 
Similar to other studies using a genome-wide CNV profiling approach, our work has some 
limitations. Since we used only one calling algorithm, we were unable to determine the 
sensitivity of false negative callings. Since not all protein-coding exons are equally covered 
by SNPs, a few CNVs might not be identified due to low SNP coverage of the region. 
Due to the stringent filtering process, some relevant genes might have been missed, in 
particular more frequent CNVs acting as moderately penetrant risk factors. Additionally, 
intronic CNVs, which may cause aberrant splicing and CNVs affecting regulatory regions, 
were excluded; however, in the context of Mendelian disease, the etiological impact of 
mutations in these regions is expected to be smaller compared to mutations in the coding 
regions.  
The parents of patients with attenuated polyposis are often deceased or inaccessible, and/or 
the colorectal phenotype cannot be clarified reliably, so we decided against a trio setting. 
Thus, the de novo occurrence of a CNV could not be proven systematically because DNA of 
patients’ parents was usually unavailable. However, although a high selection against 
de novo CNVs has been assumed in other phenotypes (Itsara et al. 2010; Stadler et al. 
2012), the rather attenuated clinical presentation in our patient cohort argues against strong 
purifying selection with a high frequency of de novo events.  
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6. SUMMARY 
In up to 50% of families with clinically verified adenomatous polyposis no germline mutations 
in the established genes APC and MUTYH can be identified during routine diagnostics 
although the presence of high numbers of colorectal adenomas strongly argues for an 
underlying genetic cause, either as a monogenic or genetically complex trait.  
Therefore, the aim of this study was (i) to identify cryptic germline mutations in the APC gene 
which were not detected by routine diagnostics; (ii) to identify novel causative genes of 
adenomatous polyposis by a genome-wide SNP-array based CNV analysis, and (iii) to 
further evaluate the pathogenic relevance of the candidate genes by additional experiments 
(segregation analysis, expression analysis, screening for germline point mutations, 
examination of tumor tissue to identify somatic mutations). 
Firstly, a functional study at the mRNA (transcript) level was carried out to look for deep 
intronic APC mutations. We identified aberrant transcript patterns in 8 (6%) of 125 unrelated 
patients. Five of them carried a founder germline mutation in intron 4 and three patients 
showed germline point mutations in intron 10, which lead to the inclusion of a pseudoexon 4 
and a pseudoexon 10 on transcript level. The pseudoexons are predicted to result in 
frameshift mutations and premature stop codons. The mutations segregated with the disease 
in those families where affected relatives could be examined. Based on the results of these 
experiments, the germline mutations were regarded as disease-causing.Thus, a few deep 
intronic mutations contribute substantially to the APC mutation spectrum and cDNA analysis 
and/or target sequencing of intronic regions should be considered as an additional mutation 
discovery approach in polyposis patients. 
To uncover novel causative genes in patients with unexplained adenomatous polyposis, a 
genome-wide analysis of germline copy number variants (CNV) using high-resolution SNP 
arrays was performed in 221 unrelated, well characterized APC and MUTYH mutation 
negative German patients. Putative CNVs were filtered according to stringent criteria, 
compared with those of 531 population-based German controls, and validated by qPCR. 125 
unique rare germline CNVs in 93 (42%) of 221 patients were identified. These CNVs involved 
68 deleted and 168 duplicated genes. The vast majority of patients harbor one CNV only. 
A segregation analysis was conducted for nine CNVs, however, no segregation with the 
phenotype was observed, indicating either a lack of causal relevance for the phenotype or, in 
particular for the two CNVs found two times each, a low to moderate penetrance. Two CNVs 
in or nearby established polyposis-related genes (CTNNB1, MUTYH) seemed to be 
interesting, however, expression analysis on RNA level showed no significant difference in 
the expression levels of the two patients compared to controls.  
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To further evaluate the pathogenic relevance of the candidate genes, additional filtering and 
prioritization steps on gene level including expression analysis in cDNA from human colon 
tissue, network analysis, enrichment analyses of genes and pathways, and data mining were 
performed. Ninety-eight candidate genes remained, 32 of which showed molecular and 
cellular functions related to tumorigenesis. Assessing the functional relevance of mutations in 
these 32 genes by using the frequency of somatic mutations in colorectal tumors, and two 
functional scores (intolerance score, haploinsufficiency score), resulted in the selection of 
ARHGAP5, CNTN6, EPHB4, IQGAP1, KIF26B, MCM3AP, NFATC1, and XRN1 as the most 
convincing candidates. 
To further explore the clinical relevance of the candidate genes in the absence of recurrent 
alterations and lack of segregation information, a germline point mutation analysis of all 
candidates was performed in a validation cohort using a targeted next generation sequencing 
(NGS) approach. Fifteen rare heterozygous truncating point mutations in 11 genes (CNTN6, 
FOCAD, HEXDC, HSPH1, KIF26B, MCM3AP, PXDNL, TESK2, ULK4, YBEY, and ZNF471) 
were identified in 15 patients. In these 11 genes, we found additional 27 rare missense 
mutations which were predicted to be deleterious. CNTN6 and FOCAD showed different 
truncating mutations in more than one patient whereas KIF26B has the highest frequency of 
potential deleterious mutations overall. The causative relevance of the two suggested tumor 
suppressor genes, FOCAD and EPHB4, was further underscored by the detection of somatic 
point mutations (“second hits”) in tumor tissue of the patients. 
By integrating all results and recent studies of early-onset colorectal and breast cancer, we 
selected CNTN6, EPHB4, KIF26B, MCM3AP, FOCAD, and HSPH1 as the most convincing 
predisposing genes for colorectal adenomatous polyposis. In addition, in the canonical Wnt 
pathway oncogene CTNNB1 (ß-catenin), two potential gain-of-function mutations were 
found. 
This thesis identified a group of rarely affected genes which are likely to predispose to 
colorectal adenoma formation and confirmed previously published candidates for tumor 
predisposition as etiologically relevant. Based on this work, rare CNVs are likely to contribute 
to the hereditary risk for colorectal tumors. However, the sporadic disease manifestation in 
most families, the often incomplete segregation of the genetic alterations, and the occurrence 
in the context of different tumor types indicate that at least some of the candidate genes act 
rather as moderate penetrant risk factors than highly penetrant mutations. The identification 
of six patients with di- or trigenic alterations is consistent with the assumption of a more 
oligogenic etiology. This approach generated no evidence for a high frequency of recessive 
subtypes. Similar to recent studies, the vast majority of the rare CNVs was non-recurrent. 
Our analysis demonstrated that the underlying genetic factors of unexplained colorectal 
polyposis are likely to be very heterogeneous, which makes clinical validation challenging. To 
further characterize the functional relevance of the selected genes, international 
collaborations with large patient cohorts and functional studies are needed. 
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7. OUTLOOK/PERSPECTIVE 
The transcript analysis of the APC gene pointed to the existence of deep intronic germline 
mutations, in particular a putative mutational hotspots in intron 10 and a founder mutation in 
intron 4. To further explore the frequency and distribution of pathogenic intronic mutations it 
will be interesting to examine additional patient cohorts and other polyposis forms. An 
extension of the routine germline mutation screening in FAP patients by sequencing of the 
regions around the identified hotspot and founder mutations should be considered a 
reasonable procedure. 
To further validate the causative relevance of the identified candidate genes of the CNV 
analysis it is important to identify recurrent mutations of the same mutation type in the 
respective genes. To achieve this, large collaborative studies including patient cohorts from 
several groups and the submission of all identified variants in locus-specific databases are 
needed. The already existing collaborations with several relevant groups are the basis to 
initiate such projects. 
In this study, we focus only on rare CNVs covering protein coding regions. In future studies, 
rare CNVs in intergenic and intronic regions might be considered as well. Such locations 
might be related to regulatory regions or might result in aberrant splicing, however, the 
consequences of such CNVs are difficult to predict. 
We used an approach assuming a monogenic bases of the polyposis disease. However, a 
major group of the phenotype might be better explained by oligogenic or genetically complex 
etiology. To address this, the data can be used to perform a CNV-based GWAS and a CNV-
based burden analysis. In addition, a SNP-based GWAS to look for low penetrance variants 
and a replication study have been performed recently, the statistical analyses are still 
ongoing. 
To identify genomic regions with potential causative disease loci it is also possible to look for 
shared haplotypes among the patients. The haplotype sharing statistic (HSS) compares the 
length of shared haplotypes between cases and controls. This approach might be even more 
powerful when large patient cohorts with the same ethnical background are included.  
The CNV approach identifies only large genomic deletions and duplications. To identify the 
whole mutational spectrum, a high-throughput sequencing of the coding regions of the 
genome (exome sequencing) or even the whole genome is needed. Currently, exome 
sequencing is regarded to be the most powerful tool to identify the causative genes of the still 
unexplained monogenic conditions. We have already started collaborative projects of exome 
sequencing in around 100 patients of the study cohort. 
Outlook / Perspective 
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The most interesting genes identified by these projects must be subject of functional studies 
to characterize the pathophysiological consequences of the mutations. Such studies may 
include expression analyses, interaction and pathway analyses performed in cell culture 
experiments, and mouse models. 
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Appendices  
 
Table A1. Forward and Reverse primers of 5 overlapping fragments of APC gene  
Frag
ment 
Size 
(bp) 
For primer (5’-3’) Location Rev primer (5’-3’) Location 
1 575 TCTGTACCACCCTCAGTTCTG 5’UTR AGAGAGGTCATTGCTTCTTGC Exon 3 
2 615 TCTGGAGAGTGCAGTCCTGTT Exon 3 CAAGTCATCTGGGAACCAAGG Exon 8 
3 665 GTGGGAGAAATCAACATGGCA Eon 7 GTGGACTGTGAAATGTATGGG Exon 11 
4 505 CAGATCTGTCCTGCTGTGTGT Exon 10 ATGTGCTGTAGATGGTGCACT Exon 14 
5 564 GACGTTGCGAGAAGTTGGAAG Exon 13 ATGTCTCCTGGCTCAAGCTTG Exon 15A 
 
 
 
Table A2. Primers used for Sanger sequencing of the inserted/deleted region on the genomic level 
Location For primer (5’-3’) Rev primer (5’-3’) 
Intron 4
#
 TTTATGTTGGGAAGCCAAGC CTTTTATTGCCTTTTGGGCA 
Intron 10 CAGCAGTGCACTCCATTTTT CCTATCCCCTCATCGTTTCA 
# 
only the reverse sequence was used  
 
 
Table A3. Primers used for the amplication of microsatellite markers and the expected size of the PCR 
products 
Marker Forward primer Reverse primer Size (bp) 
D5S134 ACATCTCCAATATACCCCCCTCTCTCTTTC TCCTCTGTGGTTGGTGAAATTGCACC 167-183 
D5S492 TTTCCCCAATACAACGTGA AACCAGCAAACTCAGAAGTG 248-260 
D5S1965 TGTCCCGTTGATAAAAATTACTGCG GTGTCTGGGATTTCCTACGCAATG 230-252 
D5S346 ACTCACTCTAGTGATAAATCGGG AGCAGATAAGACAGTATTACTAGTT 96-110 
D5S656 GCTAAGAAAATACGACAACTAAATG CATAATAAACTGATGTTGACACAC 185-203 
D5S2001 GCCAAGATGGTCTCGATCTC TCTGAACAGGTGATGGCAAC 255-273 
D5S421 TGGAAATAGAATCCAGGCTT TCTATCGTTAACTTTATTGATTCAG 152-170 
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Table A4. Primer sequences used for validating 46 deletion CNVs by qPCR with SYBR Green I 
Deletion CNVs 
Length 
(bp) 
No. 
Probes 
Max. 
Log BF 
Primer 
pair 
Forward primer sequence        
(5'-3') 
Reverse primer sequence     
(5'-3') 
chr1:45592076-45700435 108360 18 57.1361 1st  ACCCTTCAATGGTTCCCTTC AGAGCCCAGAGGAAAAGGAC 
  
   
2nd CAGAAGAGGGAAGGCTGTTG GAGCTGGGTTCCAAATCTCA 
  
   
3rd CGAAGATGGCCAAACTCTTC ACTATGGATCGGAGCAAACG 
chr1:71094328-71116548 22221 52 213.048 1st ATCCCAGGGTTAGGCAGATT TTCAACAGTGTGAAAGCAGGA 
  
   
2nd AACGGAAGGCAAAACAGAAG CCAGGACTTGGTGCAGTTCT 
  
   
3rd GCGTATGGCCAGCAAGTTAT AGAAAGCCCGGAAGTAAAGC 
chr1:92580922-92800950 220029 48 207.295 1st GCGGAATGGACTTTAATTGC TCCAAGGCAGTTTACAAAATCA 
  
   
2nd TAGCATTTCTACGCCCAAGG CGGAGTTTGAGGACTTCTGG 
  
   
3rd CTGGGATTACACGCAGGAAT CAAAATGTCCCTTGCAACCT 
chr1:246404335-246638006 233672 132 198.607 1st AACCGGAATGGAAGTTGAGA CTCTTCAGTGCTGGGAAGGT 
  
   
2nd AGACGATTGGAGAGGGGAAC CTGGAAACAGCTCACCAACA 
  
   
3rd GCCTCCCCTCTTTAACCCTA TGAGCCTCTCGGGTTTCTTA 
chr2:137473187-137569168 95982 33 122.085 1st CCCAGTGTGGTGATGACTGA GGTGGCCAGAAATTGTGATT 
  
   
2nd  TGTGTGCTTGTTCCTTACGC ACCACAGTTCGGTTCAGCTT 
  
   
3rd GCATGGGGCTTTCTTTATGA ACCCAGCAAGTTTGTGGAAC 
chr2:137484018-137615223 131206 51 193.92 1st CCCAGTGTGGTGATGACTGA GGTGGCCAGAAATTGTGATT 
  
   
2nd  TGTGTGCTTGTTCCTTACGC ACCACAGTTCGGTTCAGCTT 
  
   
3rd GCATGGGGCTTTCTTTATGA ACCCAGCAAGTTTGTGGAAC 
chr2:158813339-158905017 91679 51 196.779 1st TCCTGTCATCCCATCACGTA GGGCAGGAAAGTTTTAAGCA 
  
   
2nd CCAGTTCTGCCCATTCAACT AGAGGTGGGGAGTCAGGTTT 
  
   
3rd GAAGGAAAATGGGCTGTGAA AAGCTGGCTGAGATTGTGGT 
chr3:260287-291417 31131 32 82.4472 1st GAACTAGCTCCATGCCCTTG GCTTCTGAATGTCCCCAGAG 
  
   
2nd ATGTTCGGTGGATTGGATGT TGATGCAGTTGGCCATTAAA 
  
   
3rd GACCCCAAGTTCAAGCTGAG AGGAAAGGCCTCCCTGATAA 
chr3:41692118-41708287# 16170 20 28.2084 1st TGGGTAGGTCATGGGAAAAC AATTTGGAGGGAGCATGTGT 
  
   
2nd AGAGCAACCGCAAGCTAAAG CACCAGCAAGAATTGCATCA 
  
   
3rd AACCAGGAACATCAGGCAAC CGAGGAAGCTTCTGATCACC 
chr3:45839485-45852716 13232 8 20.4535 1st ATGGTTTCTGAAGGCCACAC TTGAGGGCTTCATTCTCACC 
  
   
2nd TAGCTGGTCCTGCAAATCCT GGCCTCACCTCAGTCAGAAG 
  
   
3rd TCCCCAGCTCATAGGTTGTC ATGCCAGAAATCAGGAAGGA 
chr3:176596105-176753724 157620 72 336.103 1st GACAAAGCCGATCAAACCTC GCTCTAGAGAGCTACACGCTTCAT 
  
   
2nd CCATCATCACACTGCACACA TCCTCCCCAAGAACAGAAAA 
  
   
3rd TTGGGTTTGGATTGGTGTTT GTTGTGTTGAAGGGCCTCAT 
chr3:194612501-194625470# 12970 19 40.0346 1st GGACATGTCTGTTCCCCTCT CTGGTTCTTGGGAACAATCAA 
  
   
2nd CCTCTGAACCAGGATGAAGC CCTAAGCTGGTGCCTTTCAG 
  
   
3rd ACCTGATGGCTTCTCCACTG TGTCCTTGTAGTGGGGGACT 
chr4:83794836-83805695 10860 9 32.9419 1st ACAGGGATTGGCAAAATGAA TGTAGGCCCAGAGGGTAATG 
  
   
2nd ACCAAGCCTCGCTGTTGTAT AGTCACCCTTCCCGGATTAC 
  
   
3rd TCTGGCACATCAGGCTCTAA GGGGTTGGGTCAATTAATCA 
chr4:91075998-91166816 90819 20 92.0585 1st TTTGAGACTCGGTTGCAAGA TTCCAACGCCTTAAATCTGG 
  
   
2nd AAGGAACAATTCCAGCCAAG AGCAGATGTGCAAGCAAAGA 
  
   
3rd TTGCAGTGGAGGGGACTAAA TCCAGAAGTGGGAAAGGGTA 
chr4:162981340-163113553 132214 38 97.0885 1st CAAAGAGGGTGGGTTAGCAA TGTACAACCAGCTCCCATCA 
  
   
2nd TCTCCGTCAGATCCACACAC GCCCTTTTGGATCTTGTGAA 
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Deletion CNVs 
Length 
(bp) 
No. 
Probes 
Max. 
Log BF 
Primer 
pair 
Forward primer sequence        
(5'-3') 
Reverse primer sequence     
(5'-3') 
chr4:162981340-163113553 132214 38 97.0885 3rd AATCTCCAGCACCTGACCAC CTGTCTTGGGCTTCTTCCAA 
chr4:172930640-172979152 48513 12 21.5379 1st GCCTCAGGAACTGCATTGTA GGGCTACATGTGCTTGAGGT 
  
   
2nd CCAAGCCTTTGCACTCTTTC GGCGTAGAGCGACATCTTTC 
  
   
3rd GGGGAGAGGAAAGGAATTTG TAAAGCCACCGTGAACAACA 
chr5:5229672-5280314 50643 46 182.73 1st TTCAAAAGAACCCAGGCATC GTCTGCCCTTTTGATGTGGT 
  
   
2nd ACATCCCCAGGTAGGGGTAG GAGAGATCCAGGCGTTTGAG 
  
   
3rd TGCTGTGAAAGCCACAGAAC GTCCACATTGCTGCAACATC 
chr5:58578074-58734281 156208 72 326.102 1st TCACAAAGCCTCGACATCAC GCCAAGATCCCGATCTACAA 
  
   
2nd GGGCCTAAGGCAGTTAAACA TTTTGTTTGGGATCCTCTGG 
chr5:112323863-112351637 27775 11 21.2786 1st CTTGTCATTGCTGCTTGGAA GCTGTGCTCCCTAGTGAAGG 
  
   
2nd TGCTGTGGGTCCTCATCAT GTCCGCGAAACTGAGAAAAC 
  
   
3rd TGGTCCCTTTTCTCAGTTGG CTTTCCTCGCTGGGAATATG 
chr5:119920805-120247470 326666 107 609.173 1st AGTGTGCTTGGTGTGTTCCA AGCCAGGTCTTCACAACAGC 
  
   
2nd TGACTGACAGCTCCAAAACG AGGACCGTGAGGATAGCAGA 
  
   
3rd TTGGGGCAGAGAGAGCTTAG TTGCCTTTTCATTTCGAGTG 
chr9:19101637-19117877 16241 12 48.4789 1st GCATTGCGGAACACTGAGTA ACTCAGCAGCTCCAGACCAC 
  
   
2nd GATCCAGGTTGGGAAAACAA ACTCAGGTGAGCTTGGGACA 
  
   
3rd ACCAGTCCCTTGACTTGCAT GAGATGGCAGAGAACGGTGT 
chr9:20856974-20934558 77585 30 122.794 1st CCCTCCTGGTCAGAATCAAA GGCGGAATCAGCCATACTTA 
  
   
2nd GGGCATGACTTTCTTCAAGC CCTGAACTCCCCACGTTTTA 
  
   
3rd GGCTTTGTCTCTCCTTGTGC GATTTGCACGGCTTGAGACT 
chr9:28465532-28493578 28047 16 61.4615 1st AATTGTTGGGCTCTTCATGC CCTTCTTGAAGCAAGCGAGT 
  
   
2nd GCAGTTCCAGAGGAAGATGG GCTTTCTTCCATCCAAGCAG 
  
   
3rd TGAAAGGAAGATGGCAAAGC GAGCAAAGAAAGCCAACAGG 
chr9:94670184-94740522 70339 24 60.0938 1st ACCCTAATGGTCCTGGCTCT ACAGGTGTGCCTAGGATTGG 
  
   
2nd TCTCCATAGCTCTCCCCAGA TTTTGGTCTTTGCCTTCCAG 
  
   
3rd CACAATTCAAGAGCCCAGGT CAGACTGTGTCCCCTCCATT 
chr10:73839878-73855644 15767 10 26.3311 1st TGGATGATTCCCTCTTCCTG AAGAATGGTGAGAGGCATGG 
  
   
2nd GTGCTTCTTGAGCTGCCTCT TCTGTTTCCCTCCCAGTTTG 
chr10:76856600-77074588 217989 50 117.305 1st TTCGCAAAGAGGCTTGATCT AAAGGACAACCCATGTGGAG 
  
   
2nd AATTTTGTCCCATCCATCCA GCACCTCCAAACTCAGGTTC 
  
   
3rd CCCAGGGCTTGTATTTGTGT GGCCATCTTGGTATTTGCAT 
chr11:44042462-44061557 19096 21 34.4747 1st GATTCAGCTGAGGAGGGCTA CTGGATGCTGCCTTATTGGT 
  
   
2nd CCTGGAACTGGTTCATCTTCA GCCACAGAGCTCACTTACCC 
  
   
3rd CAGAGGACCCATGTGATGTG CTGCAGGAAGAAGCACCCTA 
chr11:8116419-8185496 69078 52 217.569 1st CCCAAAACCGTAGATTGGAA TCGTTTCCAGAGGTCTCACC 
  
   
2nd TGGCCTGCTCTTACCTTCAG CTCCACAGTGCAGAGAGTCG 
  
   
3rd TGCCCACATACCTTTTCCTC CTCTCGGGCTCAGATCAAAC 
chr11:102695264-102848464 153201 64 209.884 1st TTCCAGAGGACGACAAACCT CTCCTTCAGGCTCACTAGCAA 
  
   
2nd GAAAGTGCCTCCTCCTAACG TTGCTGAGAGCAGCAAGAGA 
  
   
3rd ATGGCAGATCAGTGGCTTGT TGGAATCCAGCCCATAAAAC 
chr12:20897382-21303121 405740 353 1606.22 1st ATGTTCTTGGCAGCCCTGT CCAATTTCAAAGCTTCCATCA 
  
   
2nd AAGGCATCGGACAATGAAAG GCAATGTTAGTTGGCAGCAG 
  
   
3rd GACGGAAGCTTTGAAATTGG TTATTGCCAAATTGCCTGTG 
  
   
4th TCAATGTGGAATATCATGCAG CAGTTGTTGGTGGACCACTT 
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chr12:20908555-20927800 19246 23 90.009 1st AACACCATGATCCCTTTGGA TGCACAGAACATCAGCGTTA 
  
   
2nd CCACTGGGGCCTTAAAGTAA TTTGCTTTCGCAGATTAGAGG 
  
   
3rd TTGGGTCATGGTGAAGTCTG TGTGGTACCTCCTGTTGCAG 
chr12:53445641-54110181 664541 256 1432.03 1st CAAGGACTGAGGGTCTTCCA AGCAGCTGTTGTCGGATTCT 
  
   
2nd ATTTCTGCTGGGTGATGGAC CACCAATACGGAAACCCATC 
  
   
3rd TGGCTTGTAATCAGCTCCTG TGTGTCTGTGCAAGCAATCA 
chr12:80663903-80677221# 13319 16 27.5026 1st ACCAGGAAGCATACCTGTGG TCTAGACACCCTTCGGGAGA 
  
   
2nd AAGGGCTGTCAGGGCATAAT AATTTGGGATGTGCTGGTGT 
  
   
3rd ATTTCGGGTCCTTGCTTCTT TCTGAGCTGCCTTTCTCCTC 
chr13:84714710-85327835 613126 219 882.91 1st CTGGCAATTCTCAGTGGTGA GTGGCACAAGGGAAAGTGTC 
  
   
2nd TGTCTAATGGTGCCTTGCAG AATCCATCGTGCCATAGTCC 
  
   
3rd GTTGCGCTCCTGACAATGTA ACTACCCACCAAAGCACCAG 
chr14:87469000-87489111 20112 22 97.8503 1st TGGCTTCCACAAGAAAGTTG TGGCATGCTGAATGACAAGT 
  
   
2nd TCCATTTGCAAAAATCCAGA TTTTGCAGGACCAATCTGAC 
    
3rd TGACATTTCTGTGCCCTTTT CTTGGAAAAACATCCGAAAGA 
chr15:40160584-40195058 34475 28 92.5148 1st AAGCCTAGGATTGCAAACGA TGCTGAAGGGGTCCTATGAG 
  
   
2nd TCACACTTCCCAGAATGCAC CTAGCATGGAGAGCCTGTCA 
  
   
3rd GGAGTTCCAGGAATGGATCA CTTGTTTGCTGGGTGTTCTG 
chr16:3072198-3088992 16795 10 21.4463 1st ATGGACCTACCCACATTCCA TTCCGGCTCTGTAATCAAGG 
  
   
2nd AGCCACTTTGACCTCCAAAA GCAGAGTCCCAGGCAGATAG 
  
   
3rd AGCCTCTCCCTGGTAACGAT ATCCCCCATTCTGTACCACA 
chr17:5423583-5690836 267254 190 543.478 1st CCTGACGTTTCATCCAGAGG GTCTCCAAGCCAGGAGTCAC 
  
   
2nd CCAGGTATGGAGGGCTAGGT AGCTTCTGCTCGCCAATAAA 
chr17:29847372-30198038 350667 192 378.297 1st CAGTTGCCTTGCCTTCTAGG CCCAGCTTAGATTCCAGCAC 
  
   
2nd GTCAGAGGAGCTGGCCTATG CGCATGTAATTGTGCAGGTC 
  
   
3rd AGCCATATGGAGAGGTGGTG GGGTCCAAGAGACTGCAGAG 
chr18:14712857-14748540 35684 29 38.9638 1st CCTCCCTGTTTTGCTGAGAC GGCCTCTTCCCAGAGTAACC 
  
   
2nd AGCGAACGGGTCTACACTGA ACGGGCTTCTTCCCTACTGT 
  
   
3rd TTGCCATATGTGAAGGCTCA TAACTCCACAAGCAGCAGCA 
chr19:15931793-15964505 32713 12 23.4107 1st AGGACTGTGGCTGATCTGGT TCACGAATGGGACTGGTGTA 
  
   
2nd AACTGCACACCACAACCAAA TTCCGCATCCATTGTTATGA 
  
   
3rd CTCTGGGCTGCTTCAGTACC CAGGGATGTGGGAGATGAAC 
chr19:62581812-62597371 15560 10 39.1491 1st CACTGACCATTCCTCTGTGC TGATAGGTTCTGTGGCTTTGG 
  
   
2nd CGAAGACCTTCAAAGGGAAT ATGAGCCACTGTACCCACAA 
  
   
3rd ATTGGTGGCTCCACAGACAT CGAAACCACCTCACACTTCA 
chr19:62989408-63011738 22331 9 23.9233 1st TGTGATGCTGGAGACCTTGA GCCACAGTCCTGATGTGAGA 
  
   
2nd CAGTTTTGCAACAGGAGCAC TGCTAGCCAATCAGGACACA 
  
   
3rd CACCCGTAAGGCTTTTCTCC CCACAGCTCTACATTCCGTGT 
chrx:117506242-117629361 123120 30 181.128 1st CAAGCGAACAAACCCTGAAT CAAGCGAACAAACCCTGAAT 
  
   
2nd CCCTCCGAGATCTGCTTATG CCCTCCGAGATCTGCTTATG 
  
   
3rd CCTTTGAAGCTTTGCCTTTG ACATCACATTCCGGGATCAT 
chrx:126827482-127023260 195779 29 58.5965 1st TCACGTCAACTCTTCCCTGA TGGCAACATATTTCCAAGCA 
  
   
2nd CTGCGTGGGGTTCAGTAGTT CCTTGGTTCACTTGCTCTCC 
  
   
3rd TGACACAGGCAGAGGCATAG TTATGACCGAGCCCTCTTTG 
chrx:65699679-65934932 235254 23 150.713 1st TAGGAGGCAGAGCTGGAAAA CAGCTCGACTAGTGGCTTCC 
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chrx:65699679-65934932 235254 23 150.713 2nd GGCTGGTTCCTAAGATGCAA CCATGGATTGCCAAGAAAAT 
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chr1:54756695-54842677 85983 51 51.25 1st CCAGAATGTCGGAAATCACC TGGAGAGTGTGAGGAGATGC 
    
2nd GGCTTTCTTCTGCTGACACC AGAGGACCTTGAGGCAGGAG 
    
3rd AAGGTCTGTCCAGGTTGGAA TCCAGGACCACAAAGGTCAT 
chr1:103166045-103200900 34856 27 54.4936 1st CACCAGAAAACCTGGTGAGAA CTAGAGGACAGCAGGGGATG 
    
2nd ACGTGTACAGGGTAGCAGCA AGAACGTGGGTCAGCAGGTA 
    
3rd GGACCTGGATCACCCTAAAGA GCATTCCACCCAATATTCTCA 
chr1:243187849-243498562 310714 140 260.502 1st GTCGCACAAACAGGACAGG GGCCTAGCATGTTGCTTCA 
    
2nd TGTGGGGCTGAGGTATTTTC GGGTGACAAAAGCGAAAGTC 
    
3rd TGCTTAGCAAAACCGTACCC GTGTTTCCGAAAGGCTGAAA 
chr1:244601075-244774481 173407 108 189.364 1st GCGGTGCTTTTCAAACAAAT AAGTATGGTCCGTGGACAGG 
    
2nd TCTTCTTCCTCGCACACAGA TCACGTGAAGGTGTTTTGGA 
    
3rd ATAAATGAACCGCTCCACCA TGCACCCTCAAGACTTCAAA 
chr2:47985440-48507207* 521768 99 34.4042 1st CCCCCACCTACCACTAGAAA ACCCATCCCTTTGGCTTCT 
    
2nd GCTTGCTACCAGAACCCAGA GGAAAATGGTCCAGAATCCA 
    
3rd CATCATCCCAGTGCTGTACG CAGGGAAGACACGCTAGACC 
chr2:56247422-56277102 29681 20 52.1844 1st GCTTTTGTATTTGGGCTGGA ACCCAAAATTTGCAGTCAGC 
    
2nd AGGACCTGTCCAAAGTGTCG TGAGGTTGCTGTGGTCCAG 
    
3rd CCCATCACCGGAATGTCTAC CTAGCTAGCGCCTGCACTTT 
chr2:99205971-99283049 77079 29 68.9621 1st TTTTATGGCCCTCAAATCCA GCCTCCTGTGTAGCAGGAAC 
    
2nd TAACAGGAGGCAGCTGGAGT GACCCCTGACCAGTACCTGA 
    
3rd ATCCAGCCCAGAAATGTGAC AGAGCAGGAGACCATGCCTA 
chr2:130539728-130864578 324851 108 147.542 1st GTACCTGGTCAGCACCCCTA CCACGTCAAGCTTCCAGTCT 
    
2nd AAACAGGGCAAATGAACTGC CGACCCTGGGTAGGTAGGTT 
    
3rd ACTGCAGGTTTTGGAAATGG GGTGAGCAAGGGTTCTCAAA 
chr2:220068927-220112970 44044 25 42.6615 1st CGTGCTCAATGCTGATGTCT AGCTCTTGGGATCACCTCCT 
    
2nd ACCCAGAGCCTGACATGGTA TGGCAGAACTCACCACAGAG 
    
3rd GCTGCCACATAGTCGGAGTT CTTCTTTCCCATGCATTTCC 
chr2:220125968-220188031 62064 38 59.2593 1st AGCCTCGCAAGGTTAAGATG ACGTTCCGGTGTGAAGTCTC 
    
2nd CTTGGTCTCCCTCTGCTCTG GAAACTGGGAGGGTACACGA 
    
3rd TCCTGCTGGGTAGATTCCAG GGTCAAGGGCAGGACTTGTA 
chr2:242322777-242393086 70310 40 31.1488 1st ACACGGGCTATGACCTGAAG ACCCATCTCAAGGCACACAT 
    
2nd TGGTAACCTGCACCTCAATG AGGACGTCCCTCTTCCTGA 
    
3rd TTCAACATCATGTGCAACCA CCCCAAGCCTTACACTCCTT 
chr3:1285741-1575422 289682 236 382.449 1st GTGTTCAAGGTCCACCCACT ATTTGGCTCCACCAAACAAG 
    
2nd AGCACCCATTTTCTTTCCAT CTTGTGTCAGAGGCTGGAGA 
    
3rd TAAATGGCTCTCACCGGAAG GGAGGATGTCCCTGTTCTGA 
chr3:40985257-41512416 527160 187 305.322 1st ACGCTATCATGCGTTCTCCT CTCACGATGATGGGAAAGGT 
    
2nd ATGGCTGAGAGTGTGTGCTG GGAGAGCCTCAAGAATGCAG 
    
3rd GGCCTGGAACAGAGAGAAGA TTCCATCCTTGGGAACTGAG 
chr3:143289345-143568000 278656 75 85.1647 1st TGCTCAATCCATGTCAGCAT TCAGCTCTGTGATGCCAAGT 
    
2nd CTTTTCCCCACGAAACAAAA GATGTGTTGGAGTGGGATGA 
    
3rd AGCAGCACACACAAGTACACC GGGTGCAGTTCTACCTCAAGA 
chr3:196055397-196587456 532060 230 393.975 1st GGGACAATGTGCGTAGTGTG AAGCCAAAGGCTCTGACTGA 
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chr3:196055397-196587456 532060 230 393.975 2nd TAGGCCTCGAAGACGTCACT GGACCAGGACTTCTTCACCA 
    
3rd CGACCGAGAGGAAGAAGATG CATCTTCCACGATGTTGCTG 
    
4th TTGTTGCTGTCAGAATGTTGG AGATGCCAAGAAGCAATTCG 
chr3:197873977-198161806 287830 115 289.098 1st TTTCAAGCCTTTTTGCCTGT AAAACACTTGCAGCCCTCAC 
    
2nd TCCAGATTCGTCAAGCTCCT TGGCCAAGGAATCTTGAAAC 
    
3rd CTGGCTGAATGACCAGGTTAG CCTGGGGCAAGTAACCAGTA 
chr4:144333863-144496222 162360 37 118.866 1st GATCTTTCGCTTGCCTTTTG TTCTGAAGGACCGGGTACAG 
    
2nd TTTCCAACTCTTGGGTGAGG ACTTGCGGAGCTGGTTAAGA 
    
3rd CTCGCGTTCTGTTCAGGTTC GGCGAGAACCTAGCTCTCCT 
chr5:118487627-118649571 161945 57 104.324 1st TTGCTGACAACATCACACCA CTGCACTGGGATCCTGAAAT 
    
2nd CCCAGTCAGGGCTTACAGTC TTTAGAGGATGGGCCACAAT 
    
3rd TCAGCATTTACCTGCCATGA AAGCTGCCTCTGTTGTCGTT 
chr5:180379341-180448334 68994 38 34.7147 1st AGGCCACAACAGACTTCAGG GGAGACTGAGAGGTCCACCA 
    
2nd CCCTTCAGAAAAGCTGAGGA CGCTGGAATAAACCCTCGTA 
    
3rd CCTGGCTACAGCCCTATGAG CTTCAGACGGAGCAGGAGAG 
chr6:84547600-84691015 143416 39 118.216 1st GGAGGTGGGTGATAACTGGAT AGGCCTGTCACTCACCTGAC 
    
2nd GAGCAGCAGGATCAGATGGT GCCAATGCATCTGGAATTTA 
    
3rd CGTTTTGTCTTGAGGGATTTG CTTCCTGAACCTCATGGCTTA 
chr6:84847263-85138189 290927 89 210.706 1st CAAAGCTTGTCACCAGACCA TCACAAAGTTGGGGATGTCA 
    
2nd CATTTCCTCTCTGCCCTTTG CAATGAAGAACTGGCTGCAA 
    
3rd TCAACGGTGCACCAACATAC CGAAATCAACAGCCTTTTCC 
chr6:96654375-96715587 61213 27 52.6145 1st GATTGCACTGGCAAATGATG TGAGATTAGCCGCCTGTTGT 
    
2nd AGGAGGAATGCAGGCTACAA AAGCTGGGATTCCCTAAAGC 
    
3rd GCTTCTGGTACTCGGTGAGG TAGTTGCACTGGCTCACAGC 
chr6:144506912-144807770 300859 98 212.135 1st ATGACCAGCAGTTCCCAGAC CAGCAGCTGGTTTTCATCCT 
    
2nd GATGTCAAGCTGAACCATCG AATTCGTTCTGCCCATTGTC 
    
3rd CGCTGAGCTTCACTTCTGTG GCATGTACCCTTGTGGAACC 
chr7:1353711-1531935 178225 89 195.713 1st GACCATGATCACGTCATTGC GGGGTGAGAATCGAATGAGA 
    
2nd GCAGCTGCCTCTGTATCTCC TCCCCAGTCAGGGTGAGTAG 
    
3rd TGGGAGATTTCTGGTGAAGG CTCTTCACGCATCAGTCCAG 
chr7:21649161-21908645 259485 207 509.627 1st CCATAGTGGCCTACGAGGAA CTTCAGGGCTGTTTCGTAGC 
    
2nd TTTTGCTTTGCAGGTTGATG GCTGCAAAAGATTTGGTTCG 
    
3rd AGCATGTTGCTGCACTGTTC CGCTCAGCCCTGAGTTAGTT 
chr7:55095278-55433865 338588 180 440.403 1st TCGTGTGCATTAGGGTTCAA ACATAACCAGCCACCTCCTG 
    
2nd GGGCCATTCTAATAGCCTCA ATGAGGTACTCGTCGGCATC 
    
3rd TCCTAGAGGACGCTCTCTGC AGGTGGAGCTTCAGCCTCTT 
chr7:100207480-100244080 36601 31 51.5787 1st TCTCGTGAGGGAAGGAAAGA GCTGGGCATCATTAGTTCGT 
    
2nd CACTGGACACCGACTGATGT TGAGCAGAGCACAGATCCAG 
    
3rd TCTTTCTGCCAACAGTCCAG CCAGAGCTTCTTCCCCTCTT 
chr8:175887-277897 102011 81 67.1141 1st GCCTGTGGAGATTGAGAAGC CCTCCACACAAGCCTCCTAA 
    
2nd GGCAGAGATAGCCCTGTTTG GCTTTCTCTGGGATGTGTCC 
    
3rd TCAACACAAGGAAATTCACACC TTTCCCACACACACGACATT 
chr8:27522232-27652542 130311 60 108.328 1st CTGCTCAAGGGTAGGGAAGA GCGAGCAGAGCGCTATAAAT 
    
2nd CGGAAGACAGACGAGGAGAC GATGTTCTTGACCGCCTCTC 
    
3rd TGCCAACAATTCTGCCAATA ACTTCCTGATGGCCTTTCCT 
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chr8:52376255-52818072 441818 150 388.467 1st TTTCTAGCATCTTCACCCACA GCCTTGTACATGCCAAATGA 
    
2nd AACCCATGTCCATGCTCAGT ATTACTTTTGAGCCGCAGGA 
    
3rd GGGGGATGTCAAGCAAGTTA GCCTCGTTCTCCAACTGAAA 
chr9:3739196-3835784 96589 59 136.453 1st GCCCATGGATGTAGGGACTA ATGCTTGCGTTTCAGGATTT 
chr9:3931973-3995592 63620 47 83.717 2nd TGCGGATGATGGTATTGAAA CCTTTTTGGCACGGAAAGTA 
chr9:4011386-4196769 185384 168 396.494 3rd GAAAAGGGCTTCCAAACTCC TAAGCCCCAGGAGACAAATG 
chr9:4201589-4366397 164809 142 253.682 
   
chr9:4400854-4489426 88573 58 198.9 1st CTGCTGGTTCCTGCTCTACC GGTGCGGGATTAACAAAGAA 
chr9:4495544-4537288 41745 28 60.3107 2nd TCATGCCCTATTCCAACTCC AAGGTGGTAGAGGCAGCAGA 
    
3rd CTTGGTTCGAGAACACAGCA AAGGTACCTGTAATCATGCTGGA 
chr9:19316053-19376565 60513 37 82.1049 1st GCTCATAAATTGGCGAAGAGA TCATATGCCTGCTGAAGTGC 
    
2nd AATCCTCCCCCTGTTTCTGT CGAGGTTCCAGAAAATGATTG 
    
3rd GGGTTAAAGACGCAAATCCA TCTGAAGAAGCAGCGTACCA 
chr9:122779165-123328769* 549605 610 443.871 1st AGACACAGTTTGGCCTGGAG AGGAGGCTGCCAAAGTTTTA 
    
2nd CAAAACTGTCAAGCCCACCT AAGCAGATTTGGAGGCACAG 
    
3rd AGTCCCATAGCCGAAGCTCT CAATCACCTTCCCTGCCTTA 
chr9:131514006-131766096 252091 154 360.921 1st CCACCACAATCTGGAAGGAA TCTGCAGATCCTCTGGGAAG 
    
2nd TGTCCTGTGACTCGAGCAGT CTTCATCCGCTCCTTCTCAG 
    
3rd GAGAGCTTTGCACGTCCCTA AGCCCAGATGGCAGTTACAC 
chr9:139403162-139519804 116643 52 144.059 1st CCATCAGGCTCAGACTCACC TTCTGCAGATCCTCGTTCCT 
    
2nd GCTCCTCACCAAGTCTGAGC GGTGCCAGACGAATCTGACT 
    
3rd CGGCCTCACCTGTATATTGC CAGAATCATGCGGAAGCAG 
chr9:139973769-140061878 88110 29 31.916 1st TGTGAAGTCAGCGTCTGGAG AGAGCAGGCTGATGATGGAC 
    
2nd AGATCCTGACGGGAGAGGAC AGCCCCACAGAAGGATACAG 
    
3rd GTAACGTGGACCTGGAAAGC GTTGGTGGGGCTTAAACAGA 
chr9:140089674-140151812 62139 33 59.4435 1st CTTCCTGTGCTCCTTTCTGG GACATGGCCTGGATCAGAGT 
    
2nd CAGTGGGCGCATCAGTTAC GTTGCAGGGTCAGGGTCTAC 
    
3rd AAGCAGCGCTTCTACTCCTG GCCCTGACCTCTCCACCTAT 
chr10:27654698-27832689 177992 116 165.246 1st AGGCTGTCGATCTGGAGTGT ACATGTCACACATGCCCTTC 
    
2nd CCTTGGGTAGGTACAGGAAGC TGTCACACCGACTGCCTAGA 
    
3rd ACACAAACCCAGCAACAACA CCACAAAGTGGCTGTGCTAA 
chr10:28599898-28728684* 128787 75 38.7701 1st CAGTTCAGCAACTGCCAAGA GGAGACTTTTCGCCCACATA 
    
2nd GGAAGACAGCTGTGGAAACC TAGCTTCTCCAAGGCCAAAA 
    
3rd ATGGGAATGCCAGTGATTTC TCCCTCTTTGCAGGCTACAT 
chr10:53735827-53798419 62593 23 60.2727 1st CATCAGACTGTGCCTCAGGA CCACAGTAACAACGCTGGAA 
    
2nd GGAAAAGAGGTCCTGGGAAG CCTCTGGCTCTTGTTCCTCA 
    
3rd GGGGTTTTGGGGAGAAATAA CCTGTCATTCCTCAGCCTTC 
chr11:5359130-5388870 29741 42 99.1799 1st AAGGTGGTGCCACTTCTGTC AGAGTTGTGTGGGGATGAGC 
    
2nd ATCTGCCACCCTCTGAGGTA AAAGCCTTCAGGAGGAGGAC 
    
3rd CTGGATATCCGTCCCCTTCT CAACATGGCAAGGAAGAGGT 
chr11:18357549-18396314 38766 23 43.0579 1st TCACCCAGGAGAACCTGAAC GCTCCTCTCTTTGGCATGAG 
    
2nd TGTTCTGCTTCCACATCTGC AAAGTAGAGGGCACCCCATT 
    
3rd TCTGTACTGATTGCGCCAAG AAAGCAAGGCCCAGTCTACC 
chr11:108254505-108319661 65157 25 41.9953 1st CCCAACCGTAGCTGAGAGAG TAGCGGCTCTGGAATAGGAA 
    
2nd ATATCCATTGGGGTCTGCAA ACTCCAATCCAGAAAGGCTTC 
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chr11:108254505-108319661 65157 25 41.9953 3rd GCCAGGTGGGACACTTTAGA TGCCTACGCAGTCATAACCA 
chr12:95960-333509 237550 162 253.467 1st CCTCTCTGTCCTCGTCCTTG TTGCGGATTTTCTCGAAGTT 
    
2nd GACTCACCCTCAAGCTCCTG CGTTCTCCTGGGACTGGATA 
    
3rd CCTTTTCTTCCCATCGTTCA TCAGATCCGCAACAAGTCAC 
chr12:1071807-1311398 239592 78 125.37 1st TGAAACAGGAGCTGTCCAGA CCCTCTGCTCCTTAGCAGTC 
    
2nd TCATTGTTTGGGACATGGTTT CCAAGTGCTGTATTCGGTCA 
    
3rd TCAATGTGTTCCTGCGTCTC GGCCATCAGTAACTCCTCCA 
chr12:18459223-18485035 25813 11 35.4792 1st CCTTATGCACTGGGGGTAGA TGTTGAACTGCCACTTTACGA 
    
2nd TTCTACTCCACCGCTCCTTG TCCTCTAAAGCTGCCCCATA 
    
3rd GGTGATCAGACGGTGACTTG CTCAGTCAGAGCCACACTGG 
chr12:51330003-51442331 112329 109 120.634 1st GGATGACGTTGGTGTCAGTG AGGGTCTGCGTTTCCCTTAT 
    
2nd GGCTCTAGGAGGCTCTGGTT CTTTGGAGGAGGTGGTTTTG 
    
3rd CAGTTGCAAAAGGTCCCAAT AGTTCCTCAAAGCCCAGGAT 
chr13:24169434-24228338 58905 22 52.948 1st ACTGAACCATCCCCACTTTG GCTGAAATGATCCCCACACT 
    
2nd CATGGTCTGCTGGGTGTATG GAGGCCATAGGAGAGGATCA 
    
3rd CCAAGGCTCTACTGCTGGAC AAGCTGTGCGTTCCTTCAAT 
chr13:30626847-30772444 145598 47 53.1348 1st TCTTGGGTCCCCACACTAAG GCTCGCAGAGCTGCTACAT 
    
2nd TGCAGCTGCTTAAAAATGAGC CCAAACCAAAAGCTGGAAAA 
    
3rd TGTGCCAGTGATTGTCACCT AGGAATTCCCAAATCCACAG 
chr14:22925866-22953123 27258 32 43.1433 1st GGGTGGTGAAATCATTGAGG TCACCCTTCCTGTCTTGCTT 
    
2nd CTCTCCCTGAGACACGAAGG CCCTCCCTTTCCCAACTCTA 
    
3rd CTCGGTTTCAGCAATGACCT ACCTCCGCAAGTCAGAGAAG 
chr14:23985223-24057519 72297 34 44.7893 1st CAGGAGACCATGCCTGAGAT TCCAGGCCATGTTCTTTGAT 
    
2nd AGGGCATTCTTTGAATGTGG ACTCCTGGCTGTTGAGAGGA 
    
3rd TTTTGTCTTCCTGGGATTGC CTGGGGAAGAACAGGTGTGT 
chr14:31579294-31628653 49360 19 64.3384 1st GCAACTACCCGATTGAGGAA ATCATGCATTTGGGAGAAGG 
    
2nd GATCCACGTCTTGGCTTCTC CCCAGAAGACGAAACTCCAC 
    
3rd TTCCACCTGGAAAGGGTACA GAAGAGAACCCAGGGAGGAG 
chr14:68992305-69046721 54417 13 33.1456 1st GCCGGGACATTTCTTTATGT GATGAGAGGGATGAGGCAAC 
    
2nd ACAAGGGGATGCTGTCTGAG CAGGCATTTGGATGTGTGAC 
    
3rd ACAGTGCTTGCTTGGGACTT GCAGCTGATGACACTTTGGA 
chr14:103716079-103873344 157266 69 71.4027 1st GGAGTGGGACTTACCTGCAC ATGGATCTGCGTTGAGAACC 
    
2nd CATCTCCTCGTGTTGCAGAA TGTAATGGTGCCCGTCTGTA 
    
3rd AGGTGTGTCTTGGGAGGATG CAGAGCAGATAGGCCTTTGG 
chr15:88664833-88752520 87688 40 60.2516 1st CACAGCCCTGTCACGAATC CCCTCCTTGAATCACTCACC 
    
2nd CGGAAGCCACACCTCATAAT GTGTGGGTCCTCTGGTGAGT 
    
3rd CGTCAGAACGTGGCTTATGA CCACTGTGTTCAGCCTCAAA 
chr15:98367631-98710098 342468 217 312.989 1st AAGTCGCCCTTCACCAAGT ATGAGGCCCTCTGGTTCTTT 
    
2nd CTGACATGATGTGGGACCTG AGCACCAGGAACTGGAAATG 
    
3rd CACGTCGGCTTCTTCTTTTC GCCTGTCGAGACTGACCACT 
chr16:20465942-20630271 164330 48 71.4004 1st TTGGGGCTGTTTGTTACCTC AACTGCAGCAGCATGTCAAG 
    
2nd TTTGCTGATAGGGGAAGGTG CTGTCGGACTCAGGATGGAT 
    
3rd ATCTTGGGGCTCCAAATTCT TGAGGACTGTTTCACCATGC 
chr16:22980334-23025207 44874 19 52.6576 1st CTGAAAATCGGGATGGAGAA GTGAGAAGTGTCCAGCGTCA 
    
2nd TGAGCAACCAAGAAATGCTG CCTGATGCAGAAAGTGTTCG 
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chr16:22980334-23025207 44874 19 52.6576 3rd GGTGGCATTATGGAAACAGG ACGACCTGGAAACAGTCCAT 
chr16:79757966-79888598 130633 127 256.56 1st CTGACTTCAGAGGCCAGCTT CTGACTTCAGAGGCCAGCTT 
    
2nd ATACCAGCAACTGCCCTCTG CAGAATCCCCATTTCTGCAC 
    
3rd AGCCTGTGCAGACCAAGTTT GTTCAGGTTGGCCAGGTAGA 
chr17:3708409-3747829 39421 35 69.2656 1st TGTTGATCCCTCCAGAAAGG AGACAAGAATCCCGAGACGA 
    
2nd CGAGAAGGGCTTGTCACAG GACTCATGTGGGCACAGGTT 
    
3rd ACGTGAGCACACAACACACA CCGTCCTCGAACTTTCTGAC 
chr17:77925586-77986847 61262 26 49.3379 1st CATCGTGCTGCTCTTCTGG TAGGTGAGGCAGGTGGTCA 
    
2nd TTATGCGGGAGAAGAAGGTG ACGGCTATTGTGTCCTCTGC 
    
3rd CTCTCCAGCCCCTCTGAAAT TGGCACCAGGTAACTTCCAT 
chr18:723474-929338 205865 79 162.859 1st TCAAATTGTGCTCTGGTTGTG TTCACCCAGGTGCTTATTCC 
    
2nd TGAACTTGGCACCACTGAAA TGTCACCATGTCCGTCATCT 
    
3rd GGGATCTTCACGGACAGCTA AGCTGGTAACCCATCGCTAC 
chr18:9066995-9126155 59161 23 52.5421 1st TATGAGAAGCCACCCTCTGC CCTGACGGCCTCTAAAATCA 
    
2nd GGGAAGACATGTAAGGAATTTG GGATTTACCCCAATTTCCAAG 
    
3rd CAGGGCCAAGGTATGCTTTA CCAAAGCTCCTACCAATTCC 
chr18:30679496-30915415 235920 78 129.858 1st TCCCTGAAGGTTCAAGAAGAA CCTCCATGATGAGCAGACAA 
    
2nd GCTTGAAGTGGCATGACTGA ACTGCTTGAAATGGCCTAGC 
    
3rd AGGGATTGACAGCAGAGGTG CGGTGGCCATAAACTCCTTA 
chr18:31152359-32009041 856683 279 470.034 1st TGGAAGGCTCTAGACAGCTCA TGCCTTCAATTCAAGCACTC 
    
2nd GCCAATAGGCCATTTCAGAG TGATTCGTTTCCACATTTCG 
    
3rd TGTGCAGTGAACATCCTTGC TCTCACTGGCTGCTGTAGGA 
chr18:32045011-32098386 53376 24 55.0338 1st TAGGCTGGTCATGTCTGTGG GTGCAGGCGAGTGTCTATGA 
    
2nd GAGGTGCCTCTTGAGGAAAA TTACCCTCTTCCCCCTCTGT 
    
3rd GCCATCCTCCCCCTACTTAC CTTCAAAAGCCCTTTTTCCA 
chr18:75342653-75507409 164757 136 198.576 1st TGCCTGATCACACTCATTCG GGACTTAACCCCTGGCTCAC 
    
2nd TAGTCGGGGGTTGTTGAAAG ATAAGCCCCACGTGTTTCTG 
    
3rd GTTGGATGCCTATGGCACTT ATCCCAATGCTAACCACTGC 
chr18:75515931-75559025 43095 20 64.4395 1st TCCTGGGTTATGGAATCGTC GCTGAGGGAGTTAGCAGGTG 
    
2nd CGGTCCTGGAAATAAGGACA GGCGTCAACAGGGAAGAATA 
    
3rd AGCTGAACAGCTGGGAAGAG CGACATCTGCTGACAGTGCT 
chr19:61150873-61219157 68285 67 92.4029 1st CAGAAATTGCCTGGGTCTGT CGAGAGAGGGACATTTCAGC 
    
2nd CTCCGCAAAAACCAACATCT CCCGGTGGAGACTTACAAAA 
    
3rd CGCTCACCTTTTCCAGCTAC ACGTTGGCATTCTCGATTTC 
chr19:61413858-61898207 484350 298 316.716 1st TGGAAGAGCCTTCACTCAAAG CCAATGTTCAATCAGGGAAGA 
    
2nd AAAACCTTCAGCTCGGGTTC TTGATGCTGAGTGAGTGATGC 
    
3rd CAGGGCTCGATATGGTTCTT CAGGAAAACCAGGAAAGCTG 
chr20:828964-979043 150080 166 183.098 1st GTTGGAGTCCCTGGAGACCT CACCATGTCTGTGGCTCAAC 
    
2nd AGCCACGTACTTTTGCACCT CAGCAGAGGCTCTTCCTGTT 
    
3rd CTGACCATGCGGCTACTACA CCTCCAGACGAGTCTCAACC 
chr20:5352295-5718919 366625 149 272.438 1st GTTTTCCGGGAATTTCTGCT GCACGTAGTTCAGGGTGATG 
    
2nd TCAGTGACCTGCCACTTCAG TACAGGCGAATGCCACTATG 
    
3rd CGAGGCTTTCAGTTCTTTGG ATCACACACCCGTATTGCTG 
chr21:46515232-46536901 21670 20 44.2269 1st CTTTGGAATTTGCGTGGATT GGACTACCTGGTGACCCAGA 
    
2nd AAGCAGAAGTGCTTGGGAAA TGTTGGACCCTTTTCTGGAC 
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chr21:46515232-46536901 21670 20 44.2269 3rd TTTGCCTTGGGATTAACCAG GAAAATCAGGCTGGGGAAAT 
chr21:46540022-46625020 84999 34 121.771 1st CCTTCCTTCCAGATGTTCCA GTCCCGCTTTCAGAAGGAA 
    
2nd TTCCTGACCGTTGAGTAGGG GCTAATCACCTGGCTGTTCC 
    
3rd CCAGAGTCTTGGGTCTGGAA TCATGCTGCAACTTCCCATA 
chr22:28615613-28885216* 269604 80 52.359 1st GGGTAGGGAGGAAGCAGTTC ACTGTCCACGTTTGGTCCTC 
    
2nd CACCTCCGTTGTTTTTCCAG GGAAACAGGCCCCTTAGGTA 
    
3rd AACGTGCAAGTGGGATTTGT ATGGGCGATCTCAGTAGTGC 
chr22:43955895-44001348 45454 40 43.1688 1st ACCACGAGAGAGGCTTTTGA CCCGGTTCATTTGGTAACAG 
    
2nd AGAGCTGGCTGTGAGAAGGT GCTGAACAGAGCAGATGGAA 
    
3rd GCGCACATAGAAAAGCATGT CGTCCTTCCTCACTCCTGTC 
chrX:6016157-6169284 153128 37 87.8562 1st GATGATGGTGCCTTGATCCT TGGCTAAGTGATGCATTCCA 
    
2nd CAAGGAGACAAAGCCCAGAG AGAAAACGGCTGTGCTTGTT 
    
3rd GCGAGACAGATGGGAGAAAG TTGACTTGCAGCAAAGGATG 
chrx:18689860-19105471 415612 72 85.1306 1st TCCCAATCGGTACAATCGTT TCCCTGAGAGAAGATTCATGC 
    
2nd TTACTGAGCATGGTGCGACT GCCCTCGACAATGAGATGAT 
    
3rd TTGAGGCTTGTTGTTTCAACC CCTCCTCCAATGGTACTCCA 
chrx:46443751-46604442 160692 24 33.1653 1st GGTGCTTGAAGAGCCAGATG ATGGAGGAGCTCGCTACTGA 
    
2nd GGCTGCTTCTTCTCCAAGAG GCGGCTACACGACTTTCATT 
    
3rd CCAGAAGATGCTGTGGTTCA TCGCTGCTCTTCTGTCTCTG 
chrX:117664921-117848187 183267 41 35.3568 1st GCCAAAGAGCTTGATCCAAA AAGGGGCCTCAAAAACAAAT 
    
2nd AACTCAGCCACCTGTGACAA TTGTTTGTCGCCAAAATGAC 
    
3rd GACGACTCCGATGAGGATGT GGGAATCAATGACCAGCACT 
chrx:118311796-118492016 180221 36 71.2488 1st CGGCCCATACCATATTTCTG TGACGGACACGAAGCAGTTA 
    
2nd TTGGGGATATCGTGCTTCTC CCTGCACAAGGTTTTCCTGT 
    
3rd CACCCAGGCTCTTAACTTCG CACAAAACACAGGGATGTGG 
chrX:152871559-152945374# 73816 31 30.7141 1st GACAGAGATGGGGCTCTTCA TCTACCCGCCCTATCATCAC 
    
2nd TCTGTGACGTGCTCCAGTTC GTCATCGGTTTTCAGCAGGT 
    
3rd GGTAGAAGAAGGGGCTGGAG CCTGCCTCTCACTGGTGTCT 
 
 
 
  
 164 
Table A6. Primer sequences of reference genes used for CNV validation 
 
 
  
Reference 
Gene 
For Primer (5’ – 3’) Rev Primer (5’ – 3’) 
Product size 
(bp) 
BNC1 TCAGTGCTTTGTCCAACAGG GCAGATGTCACACTGGAAGC 125 
CFTR GGAGATGCTCCTGTCTCCTG GGGAGTCTTTTGCACAATGG 138 
RPP38 CTGCCATGATCACCTCACAC GAACGCCAAGGCTAGAACAC 128 
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Table A7. Primers used in Sequenom analysis. The SNPs were divided into plexes 1 through 4 
containing 37, 34, 30 and 17 SNPs, respectively. 
PLEX 1 
SNP ID Forward PCR primer Reverse PCR primer UEP primer 
rs10823418 ACGTTGGATGGTTGGAGACAAATGTGGAGC ACGTTGGATGGCAGATACCCAAGTTCTTCC agGCTCACCAACTCTTGT 
rs1512414 ACGTTGGATGGGAGGGAGATAGGATCTCTA ACGTTGGATGTACCCTACAGTGCCTGAAAC AACCGTCACCATGAG 
rs1799932 ACGTTGGATGGATGCTGTGGATGTCATGG ACGTTGGATGATGAGTCCCTCCCCACCCT ttcCCTTGGGGCACTTCA 
rs2112613 ACGTTGGATGCTGCTTACATGGGCCTTGTG ACGTTGGATGAGAAGCTATGAGCACATGCC GCCCTTTCACATCCTA 
rs292488 ACGTTGGATGCTCTGGTCAACACCCTTTTC ACGTTGGATGAGAGAGAACAGGTGGGCAAG GGTCAGCAAAGACAGA 
rs667808 ACGTTGGATGAGGGAGAGAAGCAGGAATCG ACGTTGGATGACTGGTGAGTCATCCTCTTG gTTGGGGACTTGGCCAC 
rs7727544 ACGTTGGATGAGTGGCTCAGGGCACGATG ACGTTGGATGAAGAGCACAGTGACTTCTCC AGACCTGGCTGCATA 
rs7920199 ACGTTGGATGTCCTGGAATGACTTCCTCCG ACGTTGGATGTCCTCGCAAACATTCCTCAC ccTTCAGCTTCCCGCAC 
rs8098464 ACGTTGGATGCTACAAAAATCCATCCTAAAG ACGTTGGATGCATGGAAGAAGTGTACTGAC AGTGTACTGACCTACCT 
rs10848666 ACGTTGGATGCATTGCTCACCCAGGCAGT ACGTTGGATGGAAGCAGGAGGACAGATGAG ACAGATGAGAGATGGAGA 
rs11645638 ACGTTGGATGCAGAATTTCAGTAACCAAGAG ACGTTGGATGAAGAAAATAAAGCCTGGCCC aTGGCCCATGCAATTTGAA 
rs17151639 ACGTTGGATGACCTGAGAGATGGGAGAAAC ACGTTGGATGCGTGCCTTATCAGAATGGAC agCCTGTTATACTGGCAGTTC 
rs1887432 ACGTTGGATGGAAGGCAGAGCCATTCCCAT ACGTTGGATGTTTTGACAAAGGGCTGCCTC cccccGTTGGGCCTTGTTCT 
rs2158641 ACGTTGGATGTCATACACAGTGGCTACACG ACGTTGGATGCTTTCCTACCTGTTTTTCCC TTCCCTGGCACTTCTATAGC 
rs2274170 ACGTTGGATGCAATCATTATGTGATAATGT ACGTTGGATGAAAAGTACCTGGGAGTGTTG agGGGAGTGTTGCCAAGC 
rs2304644 ACGTTGGATGCAGAGAAGAAATGTGGCAAG ACGTTGGATGCTCCATAAAGTAACAGCAAC AAGTGAAAAGGAGCCTAGTT 
rs6884552 ACGTTGGATGCACTGCGCCCAGCCTAATT ACGTTGGATGCTGCAGAGCTGAGAAAATTC tttgGGCATGTAAGGACAGA 
rs7191411 ACGTTGGATGCCCCGCCCCATAAAAGAATG ACGTTGGATGTCATGGAGAAGAACGCTCCT ACGCTCCTAAAATGTATGTAT 
rs12139641 ACGTTGGATGGAATAAGTTGGAGACTTCCC ACGTTGGATGTTCCCACACCTGAGCTCTG ggggCACCTGAGCTCTGCGTTGT 
rs16957347 ACGTTGGATGCACAAATACACCCTTGGGTC ACGTTGGATGAGACATAAAACGTGTTGCCC aatcTGCCCAAACCAGTTAATAA 
rs17346550 ACGTTGGATGTCACATGGTATGTAAAGTGC ACGTTGGATGGGAGAGTCCATCCATGTATT ttcTTGTTGCATGTTCCCTACC 
rs2089855 ACGTTGGATGTATATGCTCACGCACAGAGG ACGTTGGATGAACCTCCTCCTTCTCATGTG tggGAAAGGCCAGATCCACACGCT 
rs330297 ACGTTGGATGACTTCTGAATTCCTGGACCC ACGTTGGATGCAGGGTACTACTTCTGATCC agacCCCTGGGACCAAGGGATT 
rs6475895 ACGTTGGATGCCTATAACATACTCATCCCG ACGTTGGATGGTGAGAAAATAACATACTC ACTACTGTAACAAACACTATGTC 
rs6981465 ACGTTGGATGACTGATTGCAGACTCTTCCG ACGTTGGATGGCGGAATCATGATGCCATAG cccccGCAGCCATTTTTCTTTAGC 
rs7997539 ACGTTGGATGGGATAATGAAGATATTAGC ACGTTGGATGACAGGTAGTCTACAAAGGTG cttCAGGCCTAAAAAATAAGAGAT 
rs942876 ACGTTGGATGGTCTGAGGCTCTTCTCTTCA ACGTTGGATGTCCTCAAAAACTGGGAAGAG GGGAAGAGTTTTATAAAGGAA 
rs11629255 ACGTTGGATGTTCTGCTGTACCCAGTTACC ACGTTGGATGATGTGGGGTGTGTATATAGG ctatGAATACCTCTTCTTCCAGAGA 
rs11730575 ACGTTGGATGCCAGGTTGTCAACCCAAAAC ACGTTGGATGTGGTGCTAGACTTGGCAATG cccccTGGCAATGGGATTAGCATATT 
rs2400940 ACGTTGGATGCAGAGGTTATGTCTCTCTTTC ACGTTGGATGCCTTTAGCTAACGTGATCAAG gacgTTAGCTAACGTGATCAAGAAAAGC 
rs389557 ACGTTGGATGAGCAACATTGGAAGCAACCC ACGTTGGATGAGTATTCCCTTGCAGGATGG gttgGCAGGATGGTACATTTATTTA 
rs4860701 ACGTTGGATGAAGAGTATAAGGAATCCTC ACGTTGGATGAAACAAGGATGATGATCACG tcttcTGATTGTTTTTGGAGCTGAGTGA 
rs544276 ACGTTGGATGGTCCCAACACTCTGTGTTTG ACGTTGGATGTGATTTCGGAGGCCTGTACT gcaaTGAAATTATTGGATTGAGTCT 
rs60455014 ACGTTGGATGGCTTTGAGCTTTGAAGTAATC ACGTTGGATGGACAGGGAAAATAAAGGAGT CAGGGAAAATAAAGGAGTTAAAAGTT 
rs6997421 ACGTTGGATGGTTTCTAAGATACATTGTC ACGTTGGATGCCCTCACATTAAAAGAAGCC gaagCAAAAGAGGAAATGTATCACAGA 
rs731326 ACGTTGGATGCAAAAGGTAAGTTGAGGCCC ACGTTGGATGAGAAGTGTATCCATACTGAC tAAGTGTATCCATACTGACTACTTAAT 
rs927596 ACGTTGGATGCCTTGCTTTTGGAGCAAACG ACGTTGGATGAATGGCGGGAAGGACATTAA GACAGTGATAGAAATGACTATTACTTA 
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PLEX 2 
SNP ID Forward PCR primer Reverse PCR primer UEP primer 
rs11012878 ACGTTGGATGTGCAAACTAGTCTGCTGCTG ACGTTGGATGGAGGGTAAATTTACCTCAAG ggCTCAAGAGTCTTGGGC 
rs11158362 ACGTTGGATGATGAAAGCACTCAGCAAGCC ACGTTGGATGGAGTGAAAATTGTCAGGAGC ACTTCCTGCCACCCC 
rs12935619 ACGTTGGATGCGAAAAAAATATGAACTCTG ACGTTGGATGGTTATTCCTGGTACAGGTTG TGCAAAATGCTCAGAAC 
rs4392152 ACGTTGGATGACCAGCTTTTTGGACATGCC ACGTTGGATGCATGCCCATGTCCTTCAATC TGCTCAAACCTGCAA 
rs4789409 ACGTTGGATGTGGATAAACCGAAGAGGGTC ACGTTGGATGAGGCATTGCTGACATCCTTC AAAGGTTGGAAGAGGAG 
rs624350 ACGTTGGATGGGCTGAATTGTTTGTTCTCC ACGTTGGATGAAAGCCTCAGTCCCAAGAAC tCAAGAACTGCTCCCCCT 
rs798379 ACGTTGGATGTCACAGTCCTCCCCAAACAG ACGTTGGATGGAAGAATGGAATCCAGGGTC CAGGGTCATGTGTAGG 
rs9805437 ACGTTGGATGTGTTGCTGTGAGGACTGACC ACGTTGGATGTTAAAATGTACCCAGCACCC CCAGCACCCTGTATGA 
rs10065787 ACGTTGGATGTCCAGCTGCACCTGCATCTT ACGTTGGATGACCTTTCTGGGTGACTCAAG cggtCCACCGTGTGTTGAAT 
rs2169123 ACGTTGGATGGGAATGGAGAAACTCCAGAC ACGTTGGATGCTTCAAGAATGAAACCACTG ATGAAACCACTGACCCTTA 
rs2275199 ACGTTGGATGACATCACCCTGTTTCCCCTC ACGTTGGATGTTTCCATGGTGTGACCTGGC gAGGATCAGATGTCGCAG 
rs2965228 ACGTTGGATGGTCCATCCTGGAGAATATGC ACGTTGGATGACGGAAAGAAAACTGCACCC tttaGCACCCAGCAAAAAC 
rs3111779 ACGTTGGATGGCAACAAGAAGGAATGAGGG ACGTTGGATGTCAGATGCCCTGGATCCTTC ccctTTTCAGACACTCTGACG 
rs4236978 ACGTTGGATGAATGGTAGATGTACCATGT ACGTTGGATGTACCTACATTTCTTGGTTG GGTTGAATACACTGAAACTAA 
rs4968046 ACGTTGGATGTCAGGTGTTGCATTTTTCCG ACGTTGGATGCAAGATGAGGGAACATGAGC gggtGGCATCGTGGAGCTT 
rs6061772 ACGTTGGATGGACAGGAAGAATCCCATGGT ACGTTGGATGGCATCCAACGCTGTAATCTC ctCTGTAATCTCACATCCTCA 
rs1329428 ACGTTGGATGGAGTGCCCTAACTTTTACAAC ACGTTGGATGATTTTGTGCCCTCTACTCCC ggaaTCTACTCCCAGAACTAAGAG 
rs13419910 ACGTTGGATGGATTTATTCTACAACATCCCC ACGTTGGATGCCTGAGTTGTTATCAAAGAGC gAAGAGCAGAATTTTCCAGATCAT 
rs16931374 ACGTTGGATGTGCTGGATTTAACAGCTGAG ACGTTGGATGGGCAATGAATCGGAAGTATC ATCGGAAGTATCTGTCTCTGTG 
rs2828064 ACGTTGGATGACATAAATACCAAGTTGAG ACGTTGGATGCAGCAGCACCTCAAACAAAC aAGCACCTCAAACAAACTTTAAG 
rs6570786 ACGTTGGATGGTAGAGTTGTTACAGATTTG ACGTTGGATGGTTGTGCCCCTTCACTTTTG ccttCCCCTTCACTTTTGGATAAC 
rs7521700 ACGTTGGATGACTCTAGGGCAGGAAAAGAC ACGTTGGATGGGTGCTCAGTAAATGCTAGG agAGGAGTTATTTCTGACTAGG 
rs797517 ACGTTGGATGGAGACTTCATATCTTGAATC ACGTTGGATGTGCAGACATAGTTTCTCTCC cccgAGTTTCTCTCCTTTCCATAG 
rs9984896 ACGTTGGATGTAGTTATTAACAGAGAGCG ACGTTGGATGTCTGGTTTAGGCTACCCAAC catcTGTTGGCCTGGTTTCCTT 
rs10153396 ACGTTGGATGAGTTGACTAGTTTGTACTC ACGTTGGATGCAGATATCTTAGACCGCATC ctccGATATCTTAGACCGCATCAATTTG 
rs11161353 ACGTTGGATGGAAGGGCATGCCAAGGAATC ACGTTGGATGCGCAACCTCTCTGTTCAAAC ccccAACCCTGCAATGGCCATGTATTC 
rs13357903 ACGTTGGATGCTGAATCCACACCACTGTAG ACGTTGGATGGAGAACAGGCTGTAAGAAATC agaATTAGGAGGTAGATACTTCAGTCC 
rs158896 ACGTTGGATGTCAGAGAGTTAGAGGAGGTG ACGTTGGATGTGCAAAACCAGGAGTTGATG ggacAACCAGGAGTTGATGGTAGAA 
rs16931326 ACGTTGGATGGGCATTAAAAAAATCTGCAC ACGTTGGATGTTCTTCAATGACCCTTCCAC CAGTATTTATCATGTGTTAAAGTCAT 
rs16932506 ACGTTGGATGGAATGTCCACCACAGTAGTC ACGTTGGATGAGGAGAAGGACATTGTCATC cTTGTCATCTTCATTAGATTGTTTAT 
rs17835866 ACGTTGGATGAGACCCGGAATTGTCCCAG ACGTTGGATGACTCAGCTGATCAGCTTTGG ggcgGATCAGCTTTGGTTTGATGTT 
rs2918006 ACGTTGGATGAAATCCCAAAAGTGGTGTGC ACGTTGGATGTGGCAAGGGTTCTGTGAAAC tcacCCAGTCACCAATATGCTAGTA 
rs443685 ACGTTGGATGACCTTGGACATGACTGTGCG ACGTTGGATGGTGAAGACAGAGAAAATCTAC gggcAGACAGAGAAAATCTACCATACT 
rs7569783 ACGTTGGATGGCTGACAAGTTCTGTATTGG ACGTTGGATGCCCAGATGTCACATCATGTC ccTCATGTCAGTGATTTTTAAATTGTCC 
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PLEX 3 
SNP ID Forward PCR primer Reverse PCR primer UEP primer 
rs1864262 ACGTTGGATGTAAGGGTGGAACACTGAGAG ACGTTGGATGGTAGTTCCTTTTTGGTTGTC ATCTCCAACCCCCTA 
rs195656 ACGTTGGATGGAGTAGGAGCTGTGGTGCAT ACGTTGGATGAAGCCACCATTGCCTGTTAC CCTGTTACTGTGGTCA 
rs2073167 ACGTTGGATGGGCAGGACGAGAAACAAAAG ACGTTGGATGCCAGGAGATGAGTCTCCTTC TCTCCTTCTCTTCACCA 
rs4858100 ACGTTGGATGCTAGACACCTTACCTGCCTC ACGTTGGATGCTTTGCACATGCTGTGATCC TGATCCCATCTAGGACA 
rs6089491 ACGTTGGATGCCCTTCCAGAGAAGCATATC ACGTTGGATGATGCACCATGCACATTTCCC CCTTGGGGCAGTGTT 
rs6536530 ACGTTGGATGGCCAGCAGAAAGAATCTGAC ACGTTGGATGTCAACATATAGCCTAAGCAC ATCCTCAGCAAGCCT 
rs912284 ACGTTGGATGACCCAAATCACCAACTACCG ACGTTGGATGCTGAATGCAAAGCCAAGAGC cAGCAGCAATACCGACCT 
rs11578307 ACGTTGGATGCATGCAAGTGGCCAGTGTTG ACGTTGGATGTTCTCCACCTGAATCCCAGT GGCAGGGGAGCTATGCCTCA 
rs11955347 ACGTTGGATGTGCCTTGACCACTCTATGAC ACGTTGGATGATGTTTAAGGCCCCAGCTTG GCCTACAGGAAAAAACCTT 
rs12597756 ACGTTGGATGGGGAGGTATAAGACATCAATC ACGTTGGATGCATCACCCCTGCCTTTCCG CAAACCAATGTTTTTCTTCAA 
rs1351805 ACGTTGGATGAGAGAGGGTGAAACTTGAGC ACGTTGGATGTTCCTCCACTGACTCATTCC CCAAAGCAACTGTTTTCAA 
rs234434 ACGTTGGATGCTCAGCTGAGCTAGACCATA ACGTTGGATGGAGGTAAAAGCATTGCTGGG AAGGGTTCGATAAGTGAT 
rs8192120 ACGTTGGATGCCCTCCATCTTTGTAGTTAC ACGTTGGATGCCTTCTCTCCTAAGCATA CTCTCCTAAGCATATCCTAC 
rs822431 ACGTTGGATGGACCCTTGGATGCACTCTTG ACGTTGGATGTGGAGGGCTTCCTCGCCAC GTGCAGTATCAGATGCAGTTC 
rs1020430 ACGTTGGATGGATGAGTTCAAAGGCCATGC ACGTTGGATGTCTTACTCTCTTTGCTTCTC ACTCTCTTTGCTTCTCATGAAGTG 
rs10770675 ACGTTGGATGAGAAACGGAAACTGGCAAGC ACGTTGGATGTTTCAGGTTGCCGTTCTTAC ggCTTACACCATACCCATATTTC 
rs1244229 ACGTTGGATGGCTTCCGGAAAAACTGTTTG ACGTTGGATGTTTCTTCTTCTCCTTTTTG aCTTTTTCTTTTCTTTCTCCTTC 
rs149476 ACGTTGGATGGGCTGCTGGGGATTGTAGTT ACGTTGGATGTTGTAGTCCACCTGCACAAC agGCCAGAGAGCGGGGCCTCACGA 
rs330295 ACGTTGGATGGGGTCTCTGGGGCCACCCT ACGTTGGATGAAACCTGAGGGTAGCCATAC CATACGAACCTTTGAATATGTA 
rs35407548 ACGTTGGATGAGGAACCAAGGAATTTGGGC ACGTTGGATGTCTCCTTGGAGGCACTAGGG AATCTATTTCCTTGTGTTTTTCT 
rs8192166 ACGTTGGATGCATGTGGACTGATGTCAACG ACGTTGGATGAGTGTTGATCTGTCATGAG TGTTGATCTGTCATGAGATTTTA 
rs10501538 ACGTTGGATGCTTCAGCTTTTAAGTTTCTGC ACGTTGGATGGTTAAGAGACACCTAGTAAG cTAAGAGACACCTAGTAAGAGCTCAAC 
rs12015040 ACGTTGGATGGATTCTATCCCAGTGACGCC ACGTTGGATGGAGTTCATTGGGTTTCATAG gaATTGGGTTTCATAGTATGGCAGTG 
rs1354876 ACGTTGGATGTGATGTAGACTTTTGCACAC ACGTTGGATGTGAGATATTTGCTCACCCAG ggCTCTAGTTCTTTAGTTCTCTTCT 
rs1529017 ACGTTGGATGGGCATTAGGCAAAGTCCATC ACGTTGGATGATGTCCATGCAGGAAAAAGG cTTGTCTTTTTTTGGCCAAATGCCT 
rs292489 ACGTTGGATGTTAGTGGTAGCAGCCGTTAG ACGTTGGATGTACAGAGACAGTTCCGACCG GAATATTTGAATAAACAAAAGAATGAAT 
rs4344834 ACGTTGGATGTGTGATGACATTGGGAGGTG ACGTTGGATGAGCATTGGTCCGTTTGTGAG aGTTTGTGAGCACAGAGTCCTCATTA 
rs6025931 ACGTTGGATGAAGTCTACGAAGCACTGAGC ACGTTGGATGATGAATTTTGGGAGGGACAC gggTTTTGGGAGGGACACTATCTT 
rs7156868 ACGTTGGATGCTCATTTTTCATTTTTAAAC ACGTTGGATGAACTCATCTGAGATGTTGGC CCAAAATGATCTCACATTCCAACAAGA 
rs9521265 ACGTTGGATGACCTGGCCAAACATAACCTC ACGTTGGATGGTCTGAATTCATTTTTTCTC gCATTTTTTCTCATGTATGTTGTTAAGA 
 
  
 168 
PLEX 4 
SNP ID Forward PCR primer Reverse PCR primer UEP primer 
rs1006286 ACGTTGGATGATCACCAACTATGGTTTCCG ACGTTGGATGAACACCGTGTTCACATCAGG ATCAGGCCAGGATCTCC 
rs16943226 ACGTTGGATGGTCACCAGAAAAATGCCTCC ACGTTGGATGTGTTTATTGTGCTGGTTGGG GGAGAAGGTGAACCC 
rs2822757 ACGTTGGATGCCCAAATTTAGAGTCTTCTC ACGTTGGATGGTGGTTCAGACAAAGGAACG AACGGCCCAGTTGACTT 
rs2883645 ACGTTGGATGAGATTAATGCCTGCTCCCTC ACGTTGGATGTACAGGAGAGTTCTGGTTGG AGTGCCCTTCTGGTA 
rs1407467 ACGTTGGATGGTCGTAACTACTCAACTTGTC ACGTTGGATGGGAACAGAGCTACAACTATTC ACATGTTATCGATGGTTGC 
rs17151653 ACGTTGGATGCAACTCCGAGGCTTGCTTTA ACGTTGGATGATCAGCTGATGCCGTATTGC CAGCACAGGTGGGGAGC 
rs35806 ACGTTGGATGATGTGTTAAGCCCCACAGAG ACGTTGGATGCCAGATACATCTGCCCAGTG ATCTGCCCAGTGGCCTCCC 
rs6133535 ACGTTGGATGCTTAAAGGAAATGAGGAAGC ACGTTGGATGCTGCCCCAAACTCTTTCATC CTGTCTCTCCAAAGATAGC 
rs1708759 ACGTTGGATGTGTGAATCCGCAACATTGGG ACGTTGGATGAAATAAAAAATAGCTTCGTG AAAATAGCTTCGTGTTTTGGTC 
rs17237765 ACGTTGGATGAAGCATTGCTACCCATGTCC ACGTTGGATGTGAGGCTGCAGCCATGAGAA AGAAGGCCTGGCTGAGGAGCCCT 
rs292482 ACGTTGGATGGTTGGAAGGTAGAATTTATC ACGTTGGATGTCTTACCCACACCTTCCTTG TTTTTTTTTTTCTGCATATCTGAA 
rs4596920 ACGTTGGATGTACCTACTGTGTGAACTACC ACGTTGGATGTCCTTGTAGAATGTAGTCTC TGTGTCAAATTGTCTTTGTCC 
rs10189158 ACGTTGGATGGCCATTTCAATAAGAACCA ACGTTGGATGGAGCCTACCTTATTTCCAAG ATTTCCAAGATCTTGAACTCTGAAAT 
rs10922106 ACGTTGGATGAGATTAGTTCATATTTATTG ACGTTGGATGTCTTCATTTATGAAGTTTAG TCATTTATGAAGTTTAGTTTAGCA 
rs12674544 ACGTTGGATGAAACATGATGACCCTAAAA ACGTTGGATGCCCATGAATCATTAAATGGT TATTTTGAATGAAATACAAAATAAACAA 
rs12928389 ACGTTGGATGTCACCTCAATTTGCCGACAG ACGTTGGATGACGAGTCTAAATCTGGCACG TAAATCTGGCACGCAGGTTAAGGAT 
rs202916 ACGTTGGATGCTTCCTGCTATTCAGTTTAG ACGTTGGATGAGTGCCACCATAATCCACTC AAGAGGAATATAATTCAAGAAACAGT 
 
 
  
 169 
Table A8. Genomic positions (NCBI build36/hg18), size, number of probes, max log BF, and affected 
genes of 43 rare heterozygous germline deletions. Each CNV is present in only one patient. 
Chro 
region 
Position 
Length 
(bp) 
No. of 
probes 
Max. 
Log BF 
Involved genes 
1p34.1 chr1:45592076-45700435 108360 18 57.1361 TESK2 
1p31.1 chr1:71094328-71116548 22221 52 213.048 PTGER3 
1p22.1 chr1:92580922-92800950 220029 48 207.295 RPAP2, GFI1, EVI5 
1q44 chr1:246404335-246638006
#
 233672 132 198.607 
OR2M2, OR2M3, OR2M4, 
OR2T33, OR2T12, OR2M7, 
OR14C36, OR2T4, OR2T6, 
OR2T1 
2q22.1
$
 chr2:137473187-137569168 95982 33 122.085 THSD7B 
2q22.1 chr2:137484018-137615223 131206 51 193.92 THSD7B 
2q24.1 chr2:158813339-158905017 91679 51 196.779 CCDC148 
3p26.3 chr3:260287-291417 31131 32 82.4472 CHL1-UTR 
3p21.3 chr3:45839485-45852716 13232 8 20.4535 LZTFL1 
3q26.31 chr3:176596105-176753724 157620 72 336.103 NAALADL2 
4q21.22 chr4:83794836-83805695
#
 10860 9 32.9419 SCD5 
4q22 chr4:91075998-91166816 90819 20 92.0585 MMRN1 
4q32.2 chr4:162981340-163113553 132214 38 97.0885 FSTL5 
4q34.1 chr4:172930640-172979152 48513 12 21.5379 GALNTL6 
5p15.32 chr5:5229672-5280314 50643 46 182.73 ADAMTS16 
5q11.2 chr5:58578074-58734281 156208 72 326.102 PDE4D 
5q22.2 chr5:112323863-112351637 27775 11 21.2786 DCP2 
5q23.1 chr5:119920805-120247470 326666 107 609.173 PRR16 
9p22.1 chr9:19101637-19117877
#
 16241 12 48.4789 ADFP 
9p21.3 chr9:20856974-20934558 77585 30 122.794 FOCAD 
9p21.2 chr9:28465532-28493578
#
 28047 16 61.4615 LINGO2-UTR 
9q22.31 chr9:94670184-94740522 70339 24 60.0938 ZNF484 
10q22.1 chr10:73839878-73855644 15767 10 26.3311 CBARA1 
10q22.3 chr10:76856600-77074588 217989 50 117.305 C10orf11 
11p15.4 chr11:8116419-8185496 69078 52 217.569 RIC3 
11p11.2 chr11:44042462-44061557 19096 21 34.4747 ACCS 
11q22.3 chr11:102695264-102848464
#
 153201 64 209.884 DYNC2H1 
11p11.2 chr11:44042462-44061557 19096 21 34.4747 ACCS 
11q22.3 chr11:102695264-102848464
#
 153201 64 209.884 DYNC2H1 
12p12 chr12:20897382-21303121 405740 353 1606.22 SLCO1B3, SLCO1B1 
12p12.2
$
 chr12:20908555-20927800 19246 23 90.009 SLCO1B3 
12q13.2 chr12:53445641-54110181
#
 664541 256 1432.03 
MUCL1, KIAA0748, 
NEUROD4, OR9K1P, OR9K2, 
OR10A7, OR6C74, OR6C6, 
OR6C1, OR6C3, OR6C75, 
OR6C65, OR6C76 
13q31.1 chr13:84714710-85327835 613126 219 882.91 SLITRK6 
14q31 chr14:87469000-87489111
#
 20112 22 97.8503 GALC 
15q15.1 chr15:40160584-40195058 34475 28 92.5148 PLA2G4D 
16p13.3 chr16:3072198-3088992 16795 10 21.4463 ZSCAN10 
17p13.2 chr17:5423583-5690836 267254 190 543.478 NLRP1 
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Chro 
region 
Position 
Length 
(bp) 
No. of 
probes 
Max. 
Log BF 
Involved genes 
17q12 chr17:29847372-30198038 350667 192 378.297 C17orf102, TMEM132E 
18p11.21 chr18:14712857-14748540
#
 35684 29 38.9638 ANKRD30B 
19p13.12 chr19:15931793-15964505 32713 12 23.4107 HSH2D-UTR 
19q13.43 chr19:62581812-62597371 15560 10 39.1491 ZNF547-UTR, ZNF548 
19q13.43 chr19:62989408-63011738 22331 9 23.9233 ZNF586, ZNF552 
Xq12 chrx:65699679-65934932
#
 235254 23 150.713 EDA2R 
Xq24 chrx:117506242-117629361
#
 123120 30 181.128 DOCK11 
Xq25 chrx:126827482-127023260 195779 29 58.5965 ACTRT1 
#
 was found in 1 control; $ DNA from relatives of the index patient was available for co-segregation 
analysis. The CNV does not co-segregate with the phenotype. 
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Table A9. Genomic positions (NCBI build36/Hg18), size, number of probes, max log BF, and affected 
genes of 82 rare germline duplications 
Chro 
region 
Position 
Length 
(bp) 
No. of 
probes 
Max. 
Log BF 
Involved genes 
1p32.3 chr1:54756695-54842677 85983 51 51.25 ACOT11 
1p21.1 chr1:103166045-103200900 34856 27 54.4936 COL11A1 
1q44 chr1:243187849-243498562 310714 140 260.502 EFCAB2, KIF26B 
1q44 chr1:244601075-244774481 173407 108 189.364 SMYD3, TFB2M 
2p16.1 chr2:56247422-56277102 29681 20 52.1844 CCDC85A 
2q11.2 chr2:99205971-99283049 77079 29 68.9621 LYG2, LYG1 
2q21.1 chr2:130539728-130864578 324851 108 147.542 
POTEF, CCDC74B, SMPD4, 
FAM128B, TUBA3E, CCDC115, 
IMP4, PTPN18 
2q35 chr2:220068927-220112970 44044 25 42.6615 GMPPA, ACCN4, CHPF 
2q35 chr2:220125968-220188031 62064 38 59.2593 OBSL1, INHA, STK11IP 
2q37.3 chr2:242322777-242393086 70310 40 31.1488 D2HGDH, GAL3ST2 
3p26.3 chr3:1285741-1575422 289682 236 382.449 CNTN6 
3p21.3 chr3:40985257-41512416 527160 187 305.322 CTNNB1, ULK4 
3q23 chr3:143289345-143568000 278656 75 85.1647 TFDP2, GK5, XRN1 
3q29
$
 chr3:196055397-196587456 532060 230 393.975 C3orf21, ACAP2 
3q29
$
 chr3:197873977-198161806 287830 115 289.098 
C3orf34, PIGX, PAK2, SENP5, 
NCBP2, PIGZ 
4q31.21 chr4:144333863-144496222 162360 37 118.866 USP38, GAB1 
5q23.1 chr5:118487627-118649571 161945 57 104.324 DMXL1 
5q35.3
$
 chr5:180379341-180448334 68994 38 34.7147 BTNL9 
6q14.2 chr6:84547600-84691015 143416 39 118.216 RIPPLY2, CYB5R4 
6q14.3 chr6:84847263-85138189 290927 89 210.706 MRAP2, KIAA1009 
6q16 chr6:96654375-96715587 61213 27 52.6145 FUT9 
6q24.2 chr6:144506912-144807770 300859 98 212.135 STX11, UTRN 
7p22.3 chr7:1353711-1531935 178225 89 195.713 MICALL2, INTS1 
7p21 chr7:21649161-21908645 259485 207 509.627 DNAH11, CDCA7L 
7p11.2 chr7:55095278-55433865 338588 180 440.403 EGFR, LANCL2 
7q22.1 chr7:100207480-100244080 36601 31 51.5787 ZAN, EPHB4 
8p21.1 chr8:175887-277897 102011 81 67.1141 ZNF596 
8p21.1 chr8:27522232-27652542 130311 60 108.328 CLU, SCARA3, CCDC25 
8q11.2 chr8:52376255-52818072 441818 150 388.467 PXDNL 
9p24.2 chr9:3739196-3835784 96589 59 136.453 GLIS3 
9p24.2 chr9:3931973-3995592 63620 47 83.717 GLIS3 
9p24.2 chr9:4011386-4196769 185384 168 396.494 GLIS3 
9p24.2 chr9:4201589-4366397 164809 142 253.682 GLIS3 
9p24 chr9:4400854-4489426 88573 58 198.9 SLC1A1 
9p24 chr9:4495544-4537288 41745 28 60.3107 SLC1A1 
9p22.1 chr9:19316053-19376565 60513 37 82.1049 DENND4C, RPS6 
9q34.11 chr9:131514006-131766096 252091 154 360.921 
PRRX2, PTGES, TOR1B, 
TOR1A, C9orf78, USP20, FNBP1 
9q34.3 chr9:139403162-139519804 116643 52 144.059 
EXD3, NOXA1, ENTPD8, NELF, 
PNPLA7 
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Chro 
region 
Position 
Length 
(bp) 
No. of 
probes 
Max. 
Log BF 
Involved genes 
9q34 chr9:139973769-140061878 88110 29 31.916 CACNA1B 
9q34 chr9:140089674-140151812 62139 33 59.4435 CACNA1B 
10p12.1
$
 chr10:27654698-27832689 177992 116 165.246 PTCHD3 
10q11.2 chr10:53735827-53798419 62593 23 60.2727 DKK1 
11p15.4 chr11:5359130-5388870 29741 42 99.1799 HBG2, HBE1, OR51M1, OR51J1 
11p15.1 chr11:18357549-18396314 38766 23 43.0579 LDHA, LDHC 
11q22.3 chr11:108254505-108319661 65157 25 41.9953 DDX10 
12q13.13 chr12:95960-333509 237550 162 253.467 
IQSEC3, SLC6A12, SLC6A13, 
KDM5A 
12p13.33 chr12:1071807-1311398 239592 78 125.37 ERC1 
12p12 chr12:18459223-18485035 25813 11 35.4792 PIK3C2G 
12q13.13 chr12:51330003-51442331 112329 109 120.634 KRT2, KRT1, KRT77 
13q11 chr13:24169434-24228338 58905 22 52.948 ATP12A 
13q12.3 chr13:30626847-30772444 145598 47 53.1348 HSPH1, B3GALTL 
14q11.2 chr14:22925866-22953123 27258 32 43.1433 MYH6, MYH7 
14q12 chr14:23985223-24057519 72297 34 44.7893 SDR39U1, CMA1 
14q12 chr14:31579294-31628653 49360 19 64.3384 ARHGAP5, C14orf128 
14q24.1 chr14:68992305-69046721 54417 13 33.1456 SLC39A9 
14q32.33 chr14:103716079-103873344 157266 69 71.4027 KIF26A 
15q26.1 chr15:88664833-88752520 87688 40 60.2516 ZNF774, IQGAP1 
15q26.3 chr15:98367631-98710098 342468 217 312.989 ADAMTS17 
16p12.3
$
 chr16:20465942-20630271 164330 48 71.4004 ACSM2, ACSM1 
16p12.3 chr16:22980334-23025207 44874 19 52.6576 USP31 
16q23.2 chr16:79757966-79888598 130633 127 256.56 PKD1L2, BCMO1 
17p13.2 chr17:3708409-3747829 39421 35 69.2656 CAMKK1, P2RX1 
17q25.3 chr17:77925586-77986847 61262 26 49.3379 UTS2R, C17orf101, HEXDC 
18p11 chr18:723474-929338 205865 79 162.859 YES1, ADCYAP1 
18p11.22 chr18:9066995-9126155 59161 23 52.5421 NDUFV2 
18q12 chr18:30679496-30915415 235920 78 129.858 DTNA, MAPRE2 
18q12 chr18:31152359-32009041 856683 279 470.034 
ZNF24, ZNF396, INO80C, 
GALNT1, C18orf21, RPRD1A, 
SLC39A6, ELP2 
18q12 chr18:32045011-32098386 53376 24 55.0338 MOCOS 
18q23 chr18:75342653-75507409 164757 136 198.576 NFATC1 
18q23 chr18:75515931-75559025 43095 20 64.4395 CTDP1 
19q13.43 chr19:61150873-61219157 68285 67 92.4029 NLRP8, NLRP5 
19q13.43
$
 chr19:61413858-61898207 484350 298 316.716 
ZSCAN5A, ZNF582, ZNF583, 
ZNF667, ZNF471, ZFP28, 
ZNF470, ZNF71, ZNF835 
20p13 chr20:828964-979043 150080 166 183.098 ANGPT4, RSPO4 
20p12.3 chr20:5352295-5718919 366625 149 272.438 C20orf196 
21q22.3 chr21:46515232-46536901 21670 20 44.2269 MCM3AP, YBEY 
21q22.3 chr21:46540022-46625020 84999 34 121.771 YBEY, C21orf58, PCNT 
22q13.31 chr22:43955895-44001348 45454 40 43.1688 NUP50, KIAA0930 
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Chro 
region 
Position 
Length 
(bp) 
No. of 
probes 
Max. 
Log BF 
Involved genes 
Xp22.33 chrX:6016157-6169284 153128 37 87.8562 NLGN4X 
Xp22 chrx:18689860-19105471 415612 72 85.1306 PPEF1, PHKA2, GPR64 
Xp11.23 chrx:46443751-46604442 160692 24 33.1653 SLC9A7, RP2 
Xq24 chrX:117664921-117848187 183267 41 35.3568 DOCK11, IL13RA1, ZCCHC12 
Xq24
$
 chrx:118311796-118492016 180221 36 71.2488 SLC25A43, SLC25A5 
#
 was found in 1 control; 
$
 DNA from relatives of the index patient was available for co-segregation 
analysis. The CNV does not co-segregate with the phenotype. 
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Table A10. The list of candidate genes present in the Steiner tree (second network analysis) (see 
Figure 4.20) 
Type of 
aberration 
Genes 
No. of 
gene 
Deletion 
ACCS, ADFP, CBARA1, DCP2, DOCK11, DYNC2H1, EDA2R, EVI5, GFI1, KIAA0748, 
FOCAD, LZTFL1, MMRN1, NAALADL2, NLRP1, PDE4D, PRR16, RIC3, RPAP2, SCD5, 
TESK2, THSD7B, ZNF484, ZNF548, ZNF552, ZNF586 
26 
Partial gene 
duplication 
ACAP2, ADAMTS17, ANGPT4, ARHGAP5, B3GALTL, C20orf196, YBEY, KIAA0930, 
CACNA1B, CCDC25, CCDC85A, CDCA7L, CHPF, CLU, COL11A1, CTDP1, D2HGDH, 
DDX10, DENND4C, DMXL1, DNAH11, DOCK11, DTNA, EGFR, EPHB4, ERC1, EXD3, 
FNBP1, GAB1, GLIS3, HEXDC, HSPH1, IQGAP1, KDM5A, KIF26B, KRT2, LANCL2, 
LDHC, MAPRE2, MCM3AP, MOCOS, MYH6, NFATC1, NLGN4X, OBSL1, PCNT, 
PIK3C2G, PXDNL, RP2, SDR39U1, SLC1A1, SLC9A7, SMYD3, STK11IP, TFB2M, 
TFDP2, ULK4, USP31, USP38, XRN1, YES1 
61 
Whole gene 
duplication 
ADCYAP1, C17orf101, C18orf21, C21orf58, C3orf21, C3orf34, C9orf78, CCDC115, 
CTNNB1, DKK1, ELP2, GALNT1, GK5, GMPPA, IL13RA1, IMP4, INHA, INO80C, INTS1, 
KIAA1009, LDHA, MICALL2, NCBP2, NDUFV2, NELF, NOXA1, PAK2, PHKA2, PIGX, 
PTCHD3, PTPN18, RPRD1A, RPS6, SCARA3, SENP5, SLC25A43, SLC39A6, STX11, 
TOR1A, TOR1B, USP20, ZCCHC12, ZFP28, ZNF24, ZNF396, ZNF471, ZNF667, ZNF71 
48 
CNTN6 and PTGES are present in the 1
st
 network but not in the 2
nd
 network analysis 
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Table A11. Twenty-five networks of 180 candidate genes (bold) and the genes involved in the 
networks as given by Ingenuity pathway analysis 
Net 
work 
Top functions Genes in network Score 
No. of 
candidate 
genes 
1 
Cancer, Cellular Development, 
Organismal Injury and 
Abnormalities 
ADCYAP1, Akt, CLU, CTDP1, CTNNB1, DKK1, 
EGFR, EPHB4, ERK, ERK1/2, GAB1, GFI1, GPR64, 
Histone h3, INHA, IQGAP1, KDM5A (JARID1A), Lh, 
MAPRE2, Mek, MICU1 (CBARA1), NFkB(complex), 
PAK2, PDE4D, PHKA2, PI3K(complex), PTGES, 
RNA polymeraseII, RPS6, SMYD3, TFB2M, USP20, 
Vegf, YES1, ZNF24 
46 25 
2 
Cellular Development, 
Hematological System 
Development and Function, 
Hematopoiesis 
ADD2, ARHGAP5, CCND1, CD44, CMA1, 
COL11A1, CSF1, DSE, EVI5, Focal adhesion kinase, 
GLI1, HDAC2, HNRNPA2B1, HSPH1, IDS, MAPK1, 
MEST, MNS1, MTMR1, NFATC1, NTS, PDLIM3, 
PGM2L1, PHACTR2, PKD1L2, PTBP3, PTGER3, 
RGS10, SBDS, SCD5, SLC1A1, TLE1, UTRN, VIL1, 
ZFP28 
17 12 
3 
Cell Cycle, Cancer, Cell Death 
and Survival 
ABLIM1, ADAMTS17, AMOTL2, ARHGEF2, ARPC4, 
CAMKK1, CDCA7L, CPSF3, CSTF2, DHCR7, 
DOCK11*, DTNA, E4F1, ERC1, F Actin, FDFT1, 
FSH, HMGCS1, LDHA, LSS, MAMLD1, MGEA5, 
MLH1, MOCOS, NCBP2, PFKM, RASAL2, RB1, 
RGS12, SH3BP4, TFDP2, TP53, TPD52L1, XRN1, 
YWHAG 
15 11 
4 
Lipid Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry 
AKAP12, ATPBD4, DCP2, DIDO1, EPG5, EXTL2, 
FABP5, GRB2, GTF2H5, HNRNPM, IGF2BP3, IL8, 
IL13RA1, KAT5, LBR, MICALL2, MYO1E, NLRP1, 
NOP58, NOX3, NOXA1, NOXO1, NUPR1, PCNT, 
PF4, PLIN2 (ADFP), PPARG, RUVBL2, SENP5, 
SRF, STX11, STXBP2, TUBGCP2, USP31, XRN2 
13 10 
5 
Cardiac Hypertrophy, 
Cardiovascular Disease, Cellular 
Compromise 
ALOX15, PRRX2 2 1 
6 
Cancer, Cell Cycle, Cell Death 
and Survival 
CDH1, SLC39A6 2 1 
7 
Developmental Disorder, 
Hereditary Disorder, Cellular 
Development 
INO80C, MLL 2 1 
8 
Cancer, Cell Death and Survival, 
Neurological Disease 
TGM2, TOR1B 2 1 
9 
Cell Cycle, Cellular Function and 
Maintenance, Cell-To-Cell 
Signaling and Interaction 
CHRNA7, RIC3 2 1 
10 
Cellular Development, Cellular 
Function and Maintenance, 
Developmental Disorder 
GLIS3, SUFU 2 1 
11 
Cell Cycle, Embryonic 
Development, Cellular 
Development 
CCDC85A, NANOG 2 1 
12 
Cancer, Cellular Movement, 
Connective Tissue Development 
and Function 
KIF26B, NQO1 2 1 
13 
Molecular Transport, RNA 
Trafficking, Cell Death and 
Survival 
RAE1, ZNF552 2 1 
14 
Organ Morphology, Cancer, 
Endocrine System Disorders 
CLDN7, XXYLT1 (C3orf21) 2 1 
15 
Cancer, Carbohydrate 
Metabolism, Cardiovascular 
System Development and 
Function 
KIT, PTPN18 2 1 
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Net 
work 
Top functions Genes in network Score 
No. of 
candidate 
genes 
16 
Tissue Morphology, Cancer, Cell 
Morphology 
Mir-10, STK11IP 2 1 
17 
Cancer, Cell Morphology, 
Cellular 2Response to 
Therapeutics 
MCM3AP, TP73 2 1 
18 
Gene Expression, RNA Post-
Transcriptional Modification, Cell 
Death and Survival 
SCARA3, SYVN1 2 1 
19 
Cellular Assembly and 
Organization, RNA Post-
Transcriptional Modification, 
Hereditary Disorder 
NDUFV2, RBM5 2 1 
20 
Hereditary Disorder, Ophthalmic 
Disease, Neurological Disease 
KHSRP, RP2 2 1 
21 
Cancer, Cell Cycle, Cellular 
Development 
CEBPA, MMRN1 2 1 
22 
Cellular Movement, Skeletal and 
Muscular System Development 
and Function, Hair and Skin 
Development and Function 
BARX2, DMXL1 2 1 
23 
RNA Post-Transcriptional 
Modification, Embryonic 
Development, Organismal 
Development 
INTS1, POLR2C 2 1 
24 
Connective Tissue Disorders, 
Dermatological Diseases and 
Conditions, Hematological 
System Development and 
Function 
DENND4C, TLR7 2 1 
25 
Cardiac Arrythmia, Cardiac 
Hypertrophy, Cardiovascular 
Disease 
MYH6, MYOCD 2 1 
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Table A12. The functional annotations by Ingenuity pathway analysis (IPA) of candidate genes 
associated with colorectal cancer 
Functional annotation 
No.of 
candidate 
gene 
Candidate genes p-value 
Cancer 91 
ACAP2, ACCS, ACSM1, ADAMTS16, ADAMTS17, 
ANGPT4, ANKRD30B, ARHGAP5, ASIC4, BCMO1, 
C21orf58, CACNA1B, CAMKK1, CCDC85A, CDCA7L, 
CHPF, CLU, CNTN6, COL11A1, CTNNB1, DKK1, 
DMXL1, DNAH11, DOCK11, DTNA, DYNC2H1, EDA2R, 
EGFR, ELP2, EPHB4, EVI5, FSTL5, GAL3ST2, GALC, 
GFI1, GK5, HEXDC, HSPH1, IQGAP1, KDM5A, 
KIAA0930, KIAA1009, KIF26B, KRT2, LDHA, LDHC, 
MCM3AP, MMRN1, MOCOS, MYH6, NAALADL2, 
NDUFV2, NLGN4X, NLRP1, PAK2, PDE4D, PIGX, 
PIK3C2G, PKD1L2, PLIN2, PRR16, PRRX2, PTCHD3, 
PTGER3, PTGES, PXDNL, RPS6, RSPO4, SCD5, 
SLC39A6, SLC9A7, SLCO1B3, SLITRK6, STX11, 
TESPA1, TFB2M, TFDP2, THSD7B, TMEM132E, 
TOR1A, ULK4, USP31, UTRN, XRN1, YES1, ZNF24, 
ZNF470, ZNF484, ZNF667, ZNF835, ZSCAN5A 
1.67 x 10
-2
 
Colon cancer 14 
ARHGAP5, CLU, CTNNB1, DNAH11, EGFR, EPHB4, 
FSTL5, GAL3ST2, KIF26B, PTGES, SLCO1B3, YES1, 
ZNF24, ZNF470 
2.31 x 10
-2
 
Colon carcinoma 11 
ARHGAP5, CLU, CTNNB1, DNAH11, EGFR, EPHB4, 
FSTL5, GAL3ST2, KIF26B, ZNF24, ZNF470 
5.73 x 10
-3
 
Colon adenocarcinoma 10 
ARHGAP5, CLU, CTNNB1, DNAH11, EGFR, EPHB4, 
FSTL5, GAL3ST2, KIF26B, ZNF470 
2.25 x 10
-3
 
Colorectal adenoma 2 CLU, CTNNB1 1.11 x 10
-2
 
Adenomatous polyposis coli 1 CTNNB1 4.67 x 10
-2
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Table A13. Twenty-seven genes causing specific phenotype, reported in OMIM, DAVID, and 
GENATLAS. 
Genes Chro Type of CNV  Descriptions Mutation type 
ADAMTS17 15q26.3 
partial gene 
duplication 
Weill-Marchesani-like syndrome (AR) 
FS-DEL, FS-
INS, SS 
B3GALTL 13q12.3 
partial gene 
duplication 
Peters-plus syndrome (PpS) (AR) FS-DEL, CSS 
BCMO1 16q23.2 
whole gene 
duplication 
Hypercarotenemia and vitamin A deficiency (AD) 
(DAVID) 
MS 
COL11A1 1p21.1 
partial gene 
duplication 
Stickler syndrome; Marshall syndrome SS 
CTDP1 18q23 
partial gene 
duplication 
Congenital cataract, Facial dysmorphism neuropathy 
syndrome (AR) 
MS 
D2HGDH 2q37.3 
partial gene 
duplication 
D-2-hydroxyglutaric aciduria (AR) MS, SS 
DNAH11 7p21 
partial gene 
duplication 
Ciliary dyskinesia, primary, 7, with or without situs 
inversus 
FS-INS, SS 
DTNA 18q12 
partial gene 
duplication 
Noncompaction of left ventricular myocardium with 
congenital heart defects, Muscle dystrophies (AD) 
MS 
DYNC2H1 11q22.3 deletion Asphyxiating thoracic dystrophy type 3 (ATD3)(AR) MS 
GALC 14q31 deletion Globoid cell leukodystrophy (Krabbe disease) (AR) MS 
GFI1 1p22 deletion Autosomal dominant severe congenital neutropenia unknown 
KRT2 12q13.13 
partial gene 
duplication 
Epidermal ichthyosis bullosa of Siemens MS 
LDHA 11p15.1 
whole gene 
duplication 
Glycogen storage disease XI with loss-of-function 
mutations. Exertional myoglobinuria due to deficiency 
of LDH-A (DAVID) 
MS, FS-DEL 
MOCOS 18q12 
partial gene 
duplication 
Xanthinuria type 2 MS 
MYH6 14q11.2 
partial gene 
duplication 
Atrial septal defect 3, hypertrophic cardiomyopathy, 
familial, 6 
MS 
NDUFV2 18p11.22 
whole gene 
duplication 
Mitochondrial complex I deficiency; Hypertrophic 
cardiomyopathy with encephalopathy 
MS, FS-DEL 
NELF 9q34.3 
whole gene 
duplication 
Hypogonadotropic hypogonadism 9 with or without 
anosmia (AD) 
MS 
OBSL1 2q35 
partial gene 
duplication 
Gloomy face syndrome 2; 3M syndrome type 2 (AR) MS, FS-DEL 
PCNT 21q22.3 
partial gene 
duplication 
Microcephalic osteodysplastic primordial dwarfism, 
type II, truncating mutation; early onset (AR) 
FS-DEL, NS 
PDE4D 5q11.2 deletion Acrodysostosis 2 (AD) MS 
PHKA2 Xp22 
whole gene 
duplication 
Glycogen storage disease type 9A (GSD9A) also 
known asX-linked liver glycogenosis (XLG) 
NS, MS, CSS 
PKD1L2 16q23.2 
partial gene 
duplication 
Conduct disorder and ADHD unknown 
RP2 Xp11.23 
partial gene 
duplication 
Retinitis pigmentosa-2, Xp11.3 deletion syndrome, unknown 
RSPO4 20p13 
whole gene 
duplication 
Congenital anonychia (AR) MS 
SLCO1B3 12p12 deletion Hyperbilirubinemia (AR) NS, DEL 
STX11 6q24.2 
whole gene 
duplication 
Familial hemophagocytic lymphohistiocytosis (AR) 
MS, FS-DEL, 
NS, DEL 
TOR1A 9q34.11 
whole gene 
duplication 
Dystonia 1, idiopathic torsion (AD) IF-DEL, MS 
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AD, autosomal dominant disease; AR, autosomal recessive disease; CSS, canonical splice site 
mutation; DEL, deletion; FS-DEL, frameshift deletion; FS-INS, frameshift insertion; IF-DEL, in-frame 
deletion; MS, missense mutation; NS, nonsense mutation, SS, splice site mutation  
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Table A14. The list of 54 from 180 candidate genes shown in STRING associated with known somatic 
mutated cancer genes reported in COSMIC database  
Genes Chro Type 
Known somatically mutated cancer 
gene (COSMIC) 
ADFP 9p22.1 deletion ARNT 
C10orf11* 10q22.3 deletion CTNNB1 
EDA2R Xq12 deletion TP53 
FSTL5 4q32.2 deletion BCR 
GFI1 1p22 deletion MYC 
FOCAD 9p21.3 deletion ASPSCR1 
LZTFL1 3p21.3 deletion CDH1 
PDE4D 5q11.2 deletion PDE4DIP 
PRR16 5q23.1 deletion TAL1 
SLITRK6 13q31.1 deletion NTRK1 
TESK2 1p34.1 deletion MUTYH 
ZSCAN10 16p13.3 deletion SOX2, POU5F1 
ARHGAP5 14q12 partial gene duplication ras homolog (RHO) family 
CCDC25 8p21.1 partial gene duplication SOS1-KRAS 
CDCA7L 7p15.3 partial gene duplication PHOX2B 
CNTN6 3p26.3 partial gene duplication NOTCH1, NOTCH2 
CTDP1* 18q23 partial gene duplication TCEA1 
CYB5R4 6q14.2 partial gene duplication DDIT3 
D2HGDH 2q37.3 partial gene duplication IDH1, IDH2 
DDX10 11q22.3 
partial gene duplication HOXD13, WHSC1L1, RAP1GDS1, NUP98, 
HOXA9 
EGFR 7p11.2 partial gene duplication ERBB2, CBL 
EPHB4 7q22.1 partial gene duplication HOXA9, PIK3R1, PIK3CA 
FNBP1* 9q34 partial gene duplication DNM2 
GAB1 4q31.21 partial gene duplication EGFR, MET, PTPN11, PIK3R1 
GLIS3 9p24.2 partial gene duplication WWTR1 
IQGAP1 15q26.1 partial gene duplication CTNNB1, CDH1, KDR 
KDM5A 12p13.33 partial gene duplication RB1, SUZ12, ERCC2 
LANCL2 7q31 partial gene duplication EGFR, PPARG 
MAPRE2 18q12.1 partial gene duplication APC, RBM15 
NFATC1 18q23 partial gene duplication JUN, IL2 
PCNT* 21q22.3 partial gene duplication AKAP9 
PIK3C2G 12p12 partial gene duplication PTEN 
PRRX2 9q34.11 partial gene duplication JAK1, NUP98 
SMYD3 1q44 partial gene duplication MET, SET 
STK11IP 2q35 partial gene duplication STK11 
TFDP2 3q23 partial gene duplication RB1 
YES1 18p11 partial gene duplication CBLB, IL7R, KDR, EGFR, PDGFRB 
CTNNB1 3p21.3 whole gene duplication 
GSK3B, TCF7L2, AXIN1, CDH2, CTNNA1, 
APC, CDH1 
DKK1 10q11.2 whole gene duplication TP53, CTNNB1 
GALNT1 18q12.1 whole gene duplication MUC1 
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Genes Chro Type 
Known somatically mutated cancer 
gene (COSMIC) 
IL13RA1 Xq24 whole gene duplication JAK1, JAK2, JAK3 
INO80C 18q12.2 whole gene duplication MLL 
LDHA* 11p15.1 whole gene duplication CREB1, MYC, SETD2, EP300, ARNT 
MICALL2 7p22.3 whole gene duplication HRAS 
NELF* 9q34.3 whole gene duplication FGFR1 
RIPPLY2 6q14.2 whole gene duplication CTNNB1, NOTCH1, NOTCH2 
RPRD1A 18q12.2 whole gene duplication CCND1, CCNE1 
SCARA3 8p21 whole gene duplication CD79A 
SENP5 3q29 whole gene duplication NPM1 
SLC39A6 18q12.2 whole gene duplication GATA3 
USP20 9q34.11 whole gene duplication VHL, ERG 
ZCCHC12 Xq24 whole gene duplication CTNNB1, PML, CREB1, TCF7L2 
ZNF24 18q12 whole gene duplication FANCA 
ZNF667 19q13.43 whole gene duplication SDHC 
* causes specific phenotype   
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Table A15. The list of candidate genes reported to be associated with colorectal cancer.  
Gene Chro Type Descriptions 
ADFP 
(PLIN2) 
9p22.1 deletion 
Adipophilin, product of this gene, is increased in CRC patients and it can be used 
as a plasma biomarker for the detection of early-stage CRC (Matsubara et al. 
2011). 
EDA2R Xq12 deletion 
EDA2R (XEDAR) is a member of the TNFR superfamily and a putative tumor 
suppressor gene (Tanikawa et al. 2009). It functions as a direct p53 target and 
downregulated in CRC tissues (Tanikawa et al. 2010). 
GFI1 1p22 deletion 
GFI binding site is affected by a 2-bp GA deletion rs67491583. This variant is 
identified as a functional variant in CRC-associated enhancer MYC-335 
(Tuupanen et al. 2012). 
FOCAD 
(KIAA1797) 
9p21.3 deletion 
FOCAD is presented in candidate predisposing CNVs in familial and early-onset 
CRC patients (Venkatachalam et al. 2011). Not only repoted in CRC but also 
reported as a potential additional driver of breast cancers (Natrajan et al. 2012) 
and a novel focal adhesion protein with tumor suppressor function in gliomas 
(Brockschmidt et al. 2012). 
PTGER3 1p31.1 deletion 
PTGER3 is a member of the G-protein coupled receptor family. This protein is one 
of four receptors identified for prostaglandin E2 (PGE2). Changes in PGE2 
receptors and synthesis in cell populations of precancerous familial adenomatous 
polyposis (FAP) colonic mucosa is defined by in situ and in vitro techniques 
(Takafuji et al. 2001). It plays an important role in suppression of cell growth and 
its down-regulation enhances colon carcinogenesis at a later stage (Shoji et al. 
2004). 
SLCO1B3 12p12 deletion 
SLCO1B3 or OATP1B3 is frequent overexpressed in colorectal adenocarcinomas, 
it’s overexpression reduces transcription activity of p53 (Lee et al. 2008). 
CLU 
8p21-
p12 
partial gene 
duplication 
Clusterin (CLU) is a pleiotropic protein, plays an oncogenic role in colorectal 
tumorigenesis and progression (Xie et al. 2005). sCLU (a form of CLU) is 
overexpressed in CRC (Rodriguez-Pineiro et al. 2006). It could be a molecular 
marker for colon cancer screening (Chen et al. 2003; Mazzarelli et al. 2009). 
COL11A1 1p21.1 
partial gene 
duplication 
COL11A1 is up-regulated in most sporadic colorectal carcinomas (Fischer et al. 
2001; Kim et al. 2010). Suceveanu et al. (2009) found mutation in COL11A1 (exon 
54) in colorectal tumor samples. 
EGFR 7p11.2 
partial gene 
duplication 
EGFR is commonly overexpressed in CRC (Moran et al. 2004), activates in 
colorectal tumor (Hayashi et al. 1994; Karameris et al. 1993), and is one of drug 
target for CRC treatment (Bertotti et al. 2011; Prenen et al. 2013). EGFR copy 
number increases progressively in human colorectal carcinogenesis (Flora et al. 
2012). 
EPHB4 7q22.1 
partial gene 
duplication 
Inactivation of a single allele of EphB4 results in higher proliferation in both the 
normal epithelium and intestinal tumors (Dopeso et al. 2009). This gene functions 
as a TSG (Dopeso et al. 2009; Ronsch et al. 2011). 
GAB1 4q31.21 
partial gene 
duplication 
Overexpression of GAB1 stimulates tumor progression in colorectal cancer cells 
(Moran et al. 2004; Seiden-Long et al. 2008).  
IQGAP1 15q26.1 
partial gene 
duplication 
IQGAP1 is a multifunctional protein involved in actin cytoskeleton assembly and E-
cadherin-mediated cell adhesion (Shimao et al. 2002) and shows an over-
expression in colorectal carcinoma tissues (Nabeshima et al. 2002). It plays a 
critical role in colon cancer cell invasion and it’s high expression predicts poor 
prognosis in patients with colorectal carcinoma (Hayashi et al. 2010). 
MAPRE2 18q12.1 
partial gene 
duplication 
MAPRE2 or RP1 is homolog to adenomatous polyposis coli-binding EB1-like gene 
family.Members of the EB1-like gene family may not only be involved in the 
tumorigenesis of colorectal cancers but may also play a role in the proliferative 
control of normal cells (Renner et al. 1997). 
PCNT 21q22.3 
partial gene 
duplication 
PCNT aberration is found by array CGH in American African CRC patients (Brim 
et al. 2012). 
SMYD3 1q44 
partial gene 
duplication 
SMYD3 is overexpressed in CRC and validated as a biomarker for colorectal 
cancer (Xi et al. 2008). It has been reported the over-expression in colorectal 
tumor without KRAS mutation (Watanabe et al. 2011). This gene is also related to 
Wnt signaling pathway and other cancers (Hamamoto et al. 2004). 
YES1 18p11 
partial gene 
duplication 
Increasing of c-YES activity may promote cancer spread and metastasis rather 
than tumor growth in colorectal carcinogenesis (Barraclough et al. 2007). 
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Gene Chro Type Descriptions 
ADCYAP1 18p11 
whole gene 
duplication 
ADCYAP1 or PACAP not only acts as a neurotransmitter/neuromodulator but also 
plays a protective role in inflammatory bowel disease (IBD) and IBD-associated 
colorectal cancer in mice. PACAP knock out mice developed colorectal tumors 
with an aggressive-appearing pathology (Nemetz et al. 2008). PACAP is 
expressed in human colonic adenocarcinoma cell lines (Lelievre et al. 1998) and 
might play a role in the regulation of colon cancer growth via the Fas-R/Fas-L 
apoptotic pathway (Le et al. 2002).  
BCMO1 16q23.2 
whole gene 
duplication 
Down regulation of BCMO1 increases ALDH1A expression which activates 
PPARA pathway. The PPARA pathway influences oxidative damage and alters 
the expression of tumor suppressors which may contribute to intestinal 
tumorigenesis (Leclerc et al. 2013). 
CTNNB1 3p21.3 
whole gene 
duplication 
CTNNB1, or Beta-Catenin, is a known cancer gene involves in many types of 
cancers reported in Cancer Gene Cencus (The Cancer Genome Project: CGP). It 
is one of the most common initially altered in sporadic colorectal tumors (Pendas-
Franco et al. 2008). It functions as a key downstream oncogene, an 
overexpression of the gene could lead to tumorigenesis (Christie et al. 2013; Priolli 
et al. 2013). 
DKK1 10q11.2 
whole gene 
duplication 
all known DKK genes were frequently silenced in colorectal cancer (CRC) cells but 
not in normal colon mucosa and that loss of DKKs may facilitate tumorigenesis 
through beta-catenin/T-cell factor-independent mechanisms (Sato et al. 2007). 
DKK1 up-regulation acts as TSG (Pendas-Franco et al. 2008). 
GAL3ST2 2q37.3 
whole gene 
duplication 
GAL3ST2 is down-regulated in non-mucinous adenocarcinoma (Seko et al. 2002). 
LDHA 11p15.1 
whole gene 
duplication 
LDHA is up-regulated in colorectal cell lines (Rutzky and Siciliano 1982) and in 
metastatic colorectal cancer (mCRC) patients with high serum lactate 
dehydrogenase (LDH) (Azuma et al. 2007). 
NOXA1 9q34.3 
whole gene 
duplication 
NOXA1 functions in the production of reactive oxygen species (ROS) and highly 
expressed in colon (Gianni et al. 2010). It activates NOX1 which highly expressed 
in human colon carcinoma cell lime (Gianni et al. 2008). 
PAK2 3q29 
whole gene 
duplication 
PAK2 upregulation indicates acquisition of motility of human colon cancer C85 
cells (Dabrowska et al. 2011). 
ZNF24 18q12 
whole gene 
duplication 
ZNF24 is located in chromosomal region that has been deleted in colorectal 
neoplasia (Rousseau-Merck et al. 1991). 
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Table A16. List of remaining 98 candidate genes after prioritization, for the point mutation screening 
No Gene Chr. Type Affected part of gene 
No.of 
patient 
No. of 
control 
Functions and pathways/Literature 
No. of tumor 
with somatic 
mutations/total 
no. of tumors 
(%) ** 
Intolerance 
score
$
  
(percentile) 
Haplo-
insufficiency 
score (%) 
$$
 
Heterozygous deletions 
1 ACCS 11p11.2 DEL 5'UTR + exons 1-13 1 0 catalytic activity 19/636 (3.0) 72 75 
2 ADAMTS16 5p15.32 DEL exons 4-11 1 0 
upregulated in esophageal squamous cell 
carcinoma and breast cancer  
37/635 (5.8) 85 62 
3 C10orf11 10q22.3 DEL 5'UTR + exons 1-2 1 0 Wnt/beta-catenin signalling pathway  4/610 (0.7) 66 81 
4 CBARA1 10q22.1 DEL exon 10 1 0 key regulator of mitochondrial calcium uptake  7/610 (1.2) 24 46 
5 CCDC148 2q24.1 DEL exons 5-10 1 0 
pathways in cancer, focal adhesion, related to 
GI disease  
16/599 (2.7) 91 80 
6 DCP2 5q22.2 DEL 5'UTR + exons 1-2 1 0 RNA degradation  10/610 (1.6) 10 92 
7 DOCK11 Xq24 
DEL/D
UP 
whole gene/exon 41-53 
+ 3’UTR 
2 1 DEL 
regulate cell growth and differentiation, gene 
family (DOCK1-11) involved in cancer 
29/610 (4.7) 47 26 
8 EDA2R Xq12 DEL whole gene 1 1 DEL 
involved in cell differentiation, apoptosis, tumor 
necrosis factor-mediated signaling pathway 
8/611 (1.3) 79 99 
9 EVI5 1p22.1 DEL exon 18 + 3'UTR 1 0 regulator of cell cycle progression 23/634 (3.6) 66 35 
10 
FOCAD 
(KIAA1797) 
9p21.3 DEL exons 20-30 1 0 
potential TSG in glioma/related to early-onset 
CRC?  
38/610 (6.2) 39 89 
11 FSTL5 4q32.2 DEL exon 4 1 0 potential TSG?/calcium-ion binding  43/636 (6.7) 81 53 
12 GALNTL6 4q34.1 DEL 5'UTR + exon 1 1 0 
transferase activity/Mucin type O-Glycan 
biosynthesis  
23/635 (3.6) 11 n/a 
13 GFI1 1p22 DEL whole gene 1 0 
involved in regulation as a transcription 
repressor of G1/S phase of mitotic cell cycle 
16/610 (2.6) 73 30 
14 KIAA0748 12q13.2 DEL whole gene 1 1 DEL 
positive regulation of T cell receptor signaling 
pathway 
16/599 (2.6) 95 45 
15 LZTFL1 3p21.3 DEL exons 3-10 + 3'UTR 1 0 
candidate cancer gene, located on a hotspot 
for TSG 
5/610 (0.8) 80 74 
16 MMRN1 4q22 DEL exons 6-8 + 3'UTR 1 0 
hemostasis, platelet degranulation, platelet 
activation  
25/610 (4.1) 74 66 
17 NAALADL2 3q26.31 DEL exons 5-8 1 0 unknown  12/599 (2) 94 49 
18 NLRP1 17p13.2 DEL 5'UTR + exons 1-3 1 0 
induction of apoptosis/NOD-like receptor 
signaling  
33/635 (5.2) 99 92 
19 PDE4D 5q11.2 DEL 5'UTR + exons 1 1 0 novel TSG in esophageal adenocarcinoma  11/611 (1.8) 4 50 
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No Gene Chr. Type Affected part of gene 
No.of 
patient 
No. of 
control 
Functions and pathways/Literature 
No. of tumor 
with somatic 
mutations/total 
no. of tumors 
(%) ** 
Intolerance 
score
$
  
(percentile) 
Haplo-
insufficiency 
score (%) 
$$
 
20 PLA2G4D 15q15.1 DEL 5'UTR + exons 1-11 1 0 
play a critical role in inflammation in psoriatic 
lesions  
14/634 (2.2) 96 75 
21 PRR16 5q23.1 DEL exon 3 + 3'UTR 1 0 unknown  9/599 (1.5) 81 55 
22 PTGER3 1p31.1 DEL exons 6-7 + 3'UTR 1 0 colorectal cancer metastasis signaling  17/611 (2.7) 63 35 
23 RPAP2 1p22.1 DEL exons 12-13 + 3'UTR 1 0 RNA polymerase II-associated protein  10/610 (1.6) 18 81 
24 SLITRK6 13q31.1 DEL whole gene 1 0 unknown  35/634 (5.5) 13 28 
25 TESK2 1p34.1 DEL exons 2-3 1 0 
Serin/Threonin-Proteinkinase, 4 kb upstream 
of MUTYH 
15/665 (2.2) 68 39 
26 THSD7B 2q22.1 DEL exons 3-5 2 0 unknown  51/599 (8.5) n/a 32 
27 TMEM132E 17q12 DEL whole gene 1 0 unknown  24/599 (4.0) 62 30 
28 ZNF484 9q22.31 DEL exons 1-2 1 0 
unknown, may be involved in transcriptional 
regulation 
13/610 (2.1) 54 77 
29 ZNF552 19q13.43 DEL exon 3 + 3'UTR 1 0 
unknown, may be involved in transcriptional 
regulation 
13/610 (2.1) 62 75 
30 ZNF586 19q13.43 DEL exons 2-3 + 3'UTR 1 0 
unknown, may be involved in transcriptional 
regulation 
6/610 (1.0) 60 98 
31 ZSCAN10 16p13.3 DEL whole gene 1 0 
Embryonic stem (ES) cell-specific transcription 
factor 
12/611 (1.9) 17 22 
Partial duplications 
32 ARHGAP5 14q12 DUP 5'UTR + exon 1 1 0 Focal adhesion 48/610 (7.8) 20 44 
33 C20orf196 20p12.3 DUP 5'UTR + exons 1-2 1 0 unknown  3/610 (0.5) 87 90 
34 C22orf9 22q13.31 DUP exons 2-9 + 3'UTR 1 0 unknown  7/610 (1.1) 9 58 
35 CACNA1B 9q34 DUP exons 32-44 + 3'UTR 1 1 DUP regulation of calcium ion transport 58/634 (9.1) n/a 25 
36 CCDC25 8p21.1 DUP exon 9 + 3'UTR 1 0 unknown  2/610 (0.3) 55 82 
37 CCDC85A 2p16.1 DUP 5'UTR + exons 1-2 1 0 candidate imprinted gene 9/599(1.5) 57 73 
38 CDCA7L 7p15.3 DUP exon 10 + 3'UTR 1 0 
inhibits monoamine oxidase A, prevent cell 
apoptosis 
13/610 (2.1) 7 31 
39 CLU 8p21-p12 DUP 5'UTR + exons 1-3 1 0 unknown but expression increases in CRC 18/611 (2.9) 65 68 
40 CNTN6 3p26.3 DUP exons 9-23 + 3'UTR 1 1 DEL cell adhesion, Notch signaling pathway 47/636 (7.4) 10 23 
41 CYB5R4 6q14.2 DUP 5'UTR + exons 1-10 1 0 plays a critical role in insulin production  22/636 (3.4) 71 47 
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No Gene Chr. Type Affected part of gene 
No.of 
patient 
No. of 
control 
Functions and pathways/Literature 
No. of tumor 
with somatic 
mutations/total 
no. of tumors 
(%) ** 
Intolerance 
score
$
  
(percentile) 
Haplo-
insufficiency 
score (%) 
$$
 
42 D2HGDH 2q37.3 DUP exons 2-10 + 3'UTR 1 1 DUP 
cellular protein metabolic process, small 
molecule metabolic process 
7/599 (1.1) 49 39 
43 DDX10 11q22.3 DUP exons 17-18 + 3'UTR 1 1 DUP 
NUP98-DDX10 fusion increases proliferation 
and self-renewal of primary human CD34+ cells 
13/637 (2.0) 22 20 
44 DENND4C 9p22.1 DUP exons 9-26 + 3'UTR 1 1 DUP unknown  23/610 (3.7) 9 27 
45 DMXL1 5q23.1 DUP exons 12-43 + 3'UTR 1 0 unknown  37/610 (6.0) 12 11 
46 EGFR 7p11.2 DUP exons 2-28 + 3'UTR 1 1 DEL 
involved in cancer pathways, cell 
proliferation, cell adhesion 
182/3467 (5.2) 1 0 
47 EPHB4 7q22.1 DUP exons 13-17 + 3'UTR 1 0 act as TSG, angiogenesis pathway  22/641 (3.4) 3 20 
48 EXD3 9q34.3 DUP exon 22 + 3'UTR 1 0 unknown  13/610 (2.1) 99 n/a 
49 GAB1 4q31.21 DUP 5'UTR + exons 1-2 1 0 
ErbB signaling pathway, cellular growth 
response, transformation and apoptosis 
26/637 (4.1) 54 13 
50 GLIS3 9p24.2 DUP 
5'UTR + exons 1-2 + 2 
exons + exons 10-11 + 
3'UTR 
1 0 transcription activator & repressor 25/610 (4.1) 52 15 
51 HEXDC 17q25.3 DUP 5'UTR + exons 1-4 1 1 DUP carbohydrate metabolic process 15/610 (2.4) 81 62 
52 HSPH1 13q12.3 DUP 5'UTR + exons 1-4 1 0 positive regulation of NK T cell activation 11/610 (1.8) 19 6 
53 IQGAP1 15q26.1 DUP 5'UTR + exons 1-2 1 0 Adherens junction, interact with APC 36/610 (5.9) 5 17 
54 
KDM5A 
(JARID1A) 
12p13.33 DUP exons 8-28 + 3'UTR 1 0 transcriptional regulation, chromatin modification 33/611 (5.4) 14 14 
55 KIF26B 1q44 DUP 5'UTR + exons 1-2 1 0 positive regulation of cell-cell adhesion 27/599 (4.5) 18 26 
56 LANCL2 
7q31.1-
q31.33 
DUP 5'UTR + exons 1-3 1 0  involved in negative regulation of transcription 12/610 (1.9) 50 75 
57 LYG1 2q11.2 DUP exons 4-8 + 3'UTR 1 0 peptidoglycan catabolic process  7/599 (1.1) 50 93 
58 MAPRE2 18q12.1 DUP 5'UTR + exons 1-2 1 0 
play a role in proliferative control of normal 
cells 
7/611 (1.1) 38 6 
59 MCM3AP 21q22.3 DUP exons 21-28 + 3'UTR 1 0 
inhibits DNA replication and cell cycle 
progression 
35/637 (5.5) 1 60 
60 NFATC1 18q23 DUP exons 12-13 + 3'UTR 1 0 
transcription factor, non-canonical Wnt 
signaling pathway 
24/637 (3.7) 2 38 
61 PIK3C2G 12p12 DUP exons 16-17 1 0 
play roles in signaling pathways involved in cell 
proliferation, oncogenic transformation 
32/611 (5.2) 83 61 
62 PNPLA7 9q34.3 DUP exons 10-35 + 3'UTR 1 0 regulation of adipocyte differentiation  24/610 (3.9) 65 79 
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No Gene Chr. Type Affected part of gene 
No.of 
patient 
No. of 
control 
Functions and pathways/Literature 
No. of tumor 
with somatic 
mutations/total 
no. of tumors 
(%) ** 
Intolerance 
score
$
  
(percentile) 
Haplo-
insufficiency 
score (%) 
$$
 
63 PRRX2 9q34.11 DUP exons 2-4 + 3'UTR 1 0 play a role in fetal skin development  3/610 (0.5) n/a 22 
64 PXDNL 
8q11.21-
q11.22 
DUP 5'UTR + exons 1-21 1 0 
oxidation-reduction process, hydrogen peroxide 
catabolic process  
21/610 (3.4) 99 99 
65 SDR39U1 14q12 DUP 5'UTR + exon 1 1 0 catalytic activity  8/599 (1.3) 95 n/a 
66 STK11IP 2q35 DUP 5'UTR + exons 1-23 1 0 
TGFB1 signaling pathway/reported related to 
Peutz-Jaghers syndromes 
10/669(1.5) 37 74 
67 TFDP2 3q23 DUP 5'UTR + exons 1-3 1 1 DUP 
cell cycle progression, involved in G1 phase 
of mitotic cell cycle 
8/599 (1.3) 43 2 
68 ULK4 3p21.3 DUP exons 33-37 + 3'UTR 1 0 unknown  9/630 (1.4) 96 72 
69 USP31 16p12.3 DUP exons 4-16 + 3'UTR 1 0 
may be involved in ubiquitin-dependent protein 
catabolism  
26/611 (4.2) 49 32 
70 USP38 4q31.1 DUP exons 4-10 + 3'UTR 1 0 
involved in ubiquitin-dependent protein 
catabolism  
24/611 (3.9) 5 65 
71 UTRN 6q24.2 DUP 5'UTR + exons 1-13 1 0 positive regulation of cell-matrix adhesion 54/610 (8.8) 3 51 
72 XRN1 3q23 DUP exons 30-42 + 3'UTR 1 0 
involved in homologous recombination, 
meiosis, telomere maintenance, and 
microtubule assembly 
34/610 (5.5) 31 11 
73 
YBEY 
(C21orf57) 
21q22.3 DUP 5'UTR + exons 1-3 1 0 putative metalloprotease or ribonuclease activity 5/610 (0.8) 54 62 
74 YES1 18p11 DUP 5'UTR + exons 1-10 1 0 
adherens junction, involved in G2/M 
progression and cytokinesis   
13/641 (2.0) 39 3 
75 ZNF596 8p23.3 DUP exons 2-6 + 3'UTR 1 0 
transcription, DNA-dependent, regulation of 
transcription, DNA-dependent 
10/610 (1.6) 72 63 
Whole gene duplications 
76 CAMKK1 17p13.2 DUP whole gene 1 0 
involved in regulating cell apoptosis, promotes 
cell survival 
7/641 (1.1) 19 13 
77 CCDC115 2q21.1 DUP whole gene 1 0 unknown 2/610 (0.3) 35 76 
78 CTNNB1 3p21.3 DUP whole gene 1 0 Wnt signaling pathway, known cancer gene 380/6059 (6.2) 18 0.1 
79 
DKK1 10q11.2 DUP whole gene 1 0 
act as TSG, play a role in Wnt signaling 
pathway 
11/611 (1.8) 77 43 
80 
ELP2 18q12.2 DUP whole gene 1 0 
may have a role in chromatin structure and 
transcription 
14/637 (2.2) 93 18 
81 GAL3ST2 2q37.3 DUP whole gene 1 0 involved in tumor metastasis process 14/610 (2.3) n/a 91 
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No Gene Chr. Type Affected part of gene 
No.of 
patient 
No. of 
control 
Functions and pathways/Literature 
No. of tumor 
with somatic 
mutations/total 
no. of tumors 
(%) ** 
Intolerance 
score
$
  
(percentile) 
Haplo-
insufficiency 
score (%) 
$$
 
82 
GALNT1 18q12.1 DUP whole gene 1 0 
Mucin type O-Glycan biosynthesis, metabolism 
of proteins 
5/610 (0.8) 26 25 
83 
INO80C 18q12.2 DUP whole gene 1 1 DEL 
involved in transcriptional regulation, DNA 
replication and probably DNA repair 
3/610 (0.5) 64 n/a 
84 
KIAA1009 6q14.3 DUP whole gene 1 1 DEL 
functions in cell division regulating chromosome 
segregation and mitotic spindle assembly 
29/610 (4.8) 92 29 
85 PTPN18 2q21.1 DUP whole gene 1 0 proetin stability pathway 9/611 (1.5) 37 89 
86 
RIPPLY2 
(C6orf59) 
6q14.2 DUP whole gene 1 0 ossification, somitogenesis 4/610 (0.7) 51 n/a 
87 
RPS6 9p22.1 DUP whole gene 1 1 DUP 
 plays an essential role in cell growth and 
proliferation, mTOR signaling pathway 
6/610 (1.0) 30 n/a 
88 RSPO4 20p13 DUP whole gene 1 0 
Wnt receptor signaling pathway, activator of 
the beta-catenin signaling cascade 
5/610 (0.8) 72 51 
89 SCARA3 8p21-p12 DUP whole gene 1 0 response to oxidative stress, potential TSG 3/611 (0.5) 6 56 
90 
ZFP28 19q13.43 DUP whole gene 1 0 
plays a role in embryonic development, 
regulation of transcription 
26/610 (4.3) 58 49 
91 
ZNF470 19q13.43 DUP whole gene 1 0 
unknown, may be involved in transcriptional 
regulation 
16/610 (2.6) 79 52 
92 
ZNF471 19q13.43 DUP whole gene 1 0 
unknown, may be involved in transcriptional 
regulation 
22/636 (3.5) 93 47 
93 
ZNF582 19q13.43 DUP whole gene 1 1 DUP 
unknown, may be involved in transcriptional 
regulation 
14/634 (2.2) 27 61 
94 
ZNF583 19q13.43 DUP whole gene 1 0 
unknown, may be involved in transcriptional 
regulation 
23/610 (3.8) 36 64 
95 
ZNF667 19q13.43 DUP whole gene 1 0 
unknown, may be involved in transcriptional 
regulation 
19/611 (3.1) 62 57 
96 
ZNF71 19q13.43 DUP whole gene 1 0 
unknown, may be involved in transcriptional 
regulation 
12/610 (2.0) 63 43 
97 
ZNF835 19q13.43 DUP whole gene 1 0 
unknown, may be involved in transcriptional 
regulation 
27/599 (4.5) 79 n/a 
Other 
98 UBC 12q24.3 identified by network analysis 0 0 
DNA repair, cell cycle regulation, protein 
degradation, 
12/610 (1.9) 12 n/a 
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* present both as deletion and duplication; ** tumors of the large intestine, COSMIC database; 
$
 Petrovski et al., 2013; 
$$,
 Huang et al., 2010; DEL, 
deletion; DUP, duplication; n/a, not available 
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Table A17. Twenty-three missense mutations identified in a group of whole gene duplications 
Gene Chro Position Exon Allele1 Allele2 cDNA Protein dbSNP 
CAMKK1 17 3776716 12 A C c.1151T>G p.F384C  
CAMKK1 17 3788648 2 G A c.334C>T p.H112Y rs140915354 
CTNNB1* 3 41266829 5 T G c.500T>G p.V167G  
DKK1 10 54074755 2 G A c.316G>A p.A106T rs141115379 
DKK1 10 54076088 3 G A c.440G>A p.R147Q rs371367754 
ELP2 18 33716276 3 C G c.224C>G p.S75C rs74438152 
ELP2 18 33747114 18 A G c.1990A>G p.S664G rs151280482 
ELP2 18 33750104 17 G A c.1945G>A p.V649M  
GAL3ST2 2 242716387 1 G A c.17G>A p.G6D rs117755329 
GAL3ST2 2 242743565 4 C G c.1181C>G p.P394R  
KIAA1009 6 84862387 23 A G c.3506T>C p.V1169A  
KIAA1009 6 84913772 7 G A c.614C>T p.P205L  
PTPN18* 2 131116862 3 A C c.259A>C p.I87L  
ZFP28 19 57065068 8 A T c.914A>T p.H305L rs149264851 
ZFP28 19 57065202 8 G A c.1048G>A p.A350T  
ZFP28 19 57066595 8 A T c.2441A>T p.N814I  
ZNF471 19 57035935 5 T G c.499T>G p.C167G  
ZNF471 19 57036139 5 G A c.703G>A p.A235T rs377656535 
ZNF471* 19 57036217 5 C T c.781C>T p.L261F  
ZNF471* 19 57036986 5 G A c.1550G>A p.C517Y rs143533715 
ZNF667 19 56953108 7 T C c.1256A>G p.E419G  
ZNF667 19 56954077 7 G A c.287C>T p.P96L  
ZNF835 19 57174975 2 G A c.1592C>T p.P531L  
* missense mutations predicted to be disease causing by all 3 in-silico tools (PolyPhen-2, Mutation 
Taster, SIFT) 
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Table A18. Logistic regression association of 117 SNPs from the replication GWAS study 
SNP Chr Position 
Ref 
allele 
No. of 
sample 
OR SE L95 U95 p-value 
Bonferroni 
correction 
rs4236978 8 56381051 T 895 1.375 0.112 1.105 1.711 0.004 0.501 
rs797517 13 50128852 C 900 1.299 0.099 1.070 1.578 0.008 0.978 
rs7156868 14 96898501 G 895 0.784 0.107 0.635 0.967 0.023 2.693 
rs10501538 11 82464338 A 899 0.460 0.345 0.234 0.905 0.024 2.857 
rs10823418 10 71109197 T 897 0.798 0.106 0.649 0.981 0.032 3.785 
rs7727544 5 131618433 C 900 0.818 0.096 0.677 0.988 0.037 4.293 
rs1354876 18 71820641 G 900 1.412 0.169 1.014 1.968 0.041 4.824 
rs4858100 3 24057780 T 901 0.825 0.096 0.683 0.997 0.046 5.424 
rs234434 14 96890773 G 895 0.818 0.105 0.666 1.004 0.055 6.431 
rs17835866 14 96903431 A 898 0.817 0.107 0.662 1.008 0.060 6.971 
rs9984896 21 36857539 C 898 1.240 0.122 0.976 1.576 0.078 9.149 
rs1351805 14 96877218 C 898 0.833 0.105 0.678 1.023 0.082 9.537 
rs9805437 13 101634297 G 902 1.493 0.250 0.914 2.439 0.109 12.776 
rs2089855 5 131601428 C 900 1.166 0.097 0.964 1.410 0.113 13.268 
rs10153396 18 29687410 A 901 1.235 0.135 0.948 1.608 0.117 13.736 
rs798379 2 16755670 G 902 1.461 0.247 0.902 2.369 0.124 14.473 
rs1708759 4 57539472 T 901 0.624 0.306 0.342 1.138 0.124 14.485 
rs4344834 18 28400665 T 899 0.868 0.093 0.724 1.040 0.125 14.672 
rs11955347 5 131595823 A 902 1.160 0.097 0.959 1.404 0.127 14.801 
rs2400940 14 100294675 G 900 1.200 0.121 0.948 1.520 0.130 15.187 
rs544276 9 112680289 C 899 1.205 0.128 0.939 1.548 0.144 16.790 
rs4789409 17 72547423 A 899 0.854 0.109 0.690 1.056 0.145 16.965 
rs330295 18 28403845 G 902 0.874 0.092 0.730 1.048 0.146 17.035 
rs10848666 12 2479535 A 901 1.220 0.138 0.930 1.599 0.151 17.655 
rs2965228 19 58442297 C 902 0.868 0.101 0.712 1.059 0.162 18.989 
rs6061772 20 59738235 A 893 0.878 0.098 0.725 1.064 0.185 21.598 
rs13357903 5 144235338 C 902 0.868 0.107 0.704 1.071 0.187 21.867 
rs2304644 15 38532886 G 902 0.680 0.294 0.382 1.211 0.191 22.289 
rs11578307 1 24325350 A 902 1.142 0.102 0.936 1.394 0.192 22.429 
rs16943226 12 112717990 A 900 0.815 0.161 0.594 1.118 0.204 23.845 
rs667808 10 78835668 G 901 0.883 0.101 0.724 1.075 0.215 25.108 
rs60455014 14 7000655 C 900 1.422 0.298 0.794 2.548 0.236 27.659 
rs17151639 7 127425052 G 894 0.880 0.109 0.711 1.089 0.238 27.893 
rs2828064 21 23618125 G 900 0.873 0.116 0.695 1.096 0.242 28.349 
rs11730575 4 178888021 A 901 0.876 0.115 0.699 1.098 0.250 29.262 
rs1329428 1 194969433 A 902 0.895 0.100 0.736 1.088 0.264 30.900 
rs11158362 14 61362431 G 902 0.694 0.336 0.359 1.340 0.277 32.351 
rs2275199 1 155176319 A 902 0.870 0.132 0.672 1.127 0.293 34.246 
rs624350 11 77501205 C 896 0.897 0.104 0.731 1.099 0.294 34.351 
rs12674544 8 65857939 T 901 1.266 0.226 0.812 1.973 0.298 34.808 
rs11629255 14 71670705 G 901 0.902 0.101 0.739 1.100 0.307 35.861 
rs8192120 5 6685320 A 900 0.905 0.101 0.742 1.103 0.321 37.604 
rs16932506 12 6272601 C 894 0.870 0.142 0.659 1.149 0.328 38.376 
rs2274170 6 147227544 C 891 1.098 0.096 0.910 1.324 0.330 38.563 
rs202916 22 33011163 C 901 0.913 0.096 0.756 1.102 0.342 40.026 
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SNP Chr Position 
Ref 
allele 
No. of 
sample 
OR SE L95 U95 p-value 
Bonferroni 
correction 
rs443685 1 232629683 C 902 1.103 0.104 0.900 1.352 0.345 40.365 
rs330297 18 28411147 T 902 1.098 0.099 0.904 1.334 0.346 40.482 
rs2112613 5 114839566 G 890 0.903 0.109 0.729 1.118 0.347 40.611 
rs11709614 3 24056776 A 898 0.914 0.097 0.756 1.105 0.353 41.266 
rs10770675 12 20649080 A 900 0.899 0.114 0.719 1.125 0.353 41.278 
rs9521265 13 108710327 A 891 1.107 0.109 0.894 1.370 0.353 41.278 
rs389557 20 17763664 A 901 0.914 0.097 0.755 1.106 0.354 41.371 
rs17151653 7 127433088 G 901 0.905 0.109 0.731 1.120 0.359 42.026 
rs10065787 5 131464385 T 902 1.090 0.095 0.905 1.312 0.365 42.728 
rs927596 13 99334817 T 900 1.125 0.132 0.869 1.456 0.371 43.372 
rs35806 10 78835836 G 902 0.916 0.100 0.754 1.114 0.380 44.402 
rs12139641 1 155152391 G 899 0.893 0.132 0.690 1.155 0.388 45.396 
rs7997539 13 103627451 G 857 1.097 0.108 0.888 1.356 0.391 45.794 
rs912284 13 99335233 T 901 1.116 0.131 0.862 1.443 0.405 47.362 
rs292488 5 168041837 A 902 0.910 0.120 0.720 1.151 0.432 50.579 
rs1020430 2 133409885 T 901 0.888 0.156 0.654 1.205 0.445 52.007 
rs822431 1 155168905 G 902 0.907 0.128 0.707 1.165 0.447 52.276 
rs16931374 8 65749351 T 901 1.184 0.234 0.749 1.872 0.469 54.873 
rs8098464 18 28516811 G 849 0.901 0.147 0.676 1.201 0.477 55.751 
rs2073167 22 40121482 C 890 0.937 0.096 0.776 1.130 0.495 57.915 
rs1244229 10 8047566 T 872 1.075 0.110 0.867 1.334 0.509 59.600 
rs4860701 4 66266097 T 896 1.068 0.099 0.879 1.297 0.511 59.799 
rs4968046 16 22985890 T 902 0.923 0.125 0.723 1.179 0.521 60.969 
rs16957347 16 10496762 T 901 0.897 0.172 0.640 1.256 0.525 61.472 
rs10189158 2 175746125 A 902 1.147 0.223 0.742 1.775 0.537 62.771 
rs942876 13 23512951 A 901 1.062 0.097 0.877 1.285 0.540 63.122 
rs292489 5 167949578 T 901 0.936 0.110 0.754 1.161 0.546 63.835 
rs4596920 1 159189375 T 902 1.063 0.102 0.871 1.297 0.548 64.093 
rs12935619 16 23035790 T 901 0.928 0.125 0.727 1.186 0.552 64.584 
rs2883645 15 22514468 T 901 1.065 0.111 0.856 1.324 0.572 66.924 
rs7521700 1 168069384 G 901 1.056 0.098 0.872 1.279 0.576 67.369 
rs7569783 2 5780740 C 902 1.064 0.118 0.845 1.340 0.600 70.153 
rs3111779 2 231501259 T 901 1.077 0.145 0.811 1.431 0.610 71.323 
rs11012878 10 22481893 C 902 0.922 0.160 0.673 1.262 0.610 71.370 
rs17346550 1 171582248 C 894 0.949 0.105 0.772 1.166 0.616 72.107 
rs1512414 6 13384394 T 900 0.946 0.117 0.752 1.191 0.638 74.646 
rs149476 5 167939278 A 864 0.954 0.109 0.770 1.181 0.665 77.817 
rs6536530 4 161790521 A 900 1.042 0.097 0.862 1.259 0.671 78.519 
rs6025931 20 55968066 C 901 0.962 0.094 0.800 1.156 0.677 79.151 
rs292482 5 167989258 T 891 0.954 0.114 0.763 1.193 0.678 79.268 
rs12928389 16 10533623 C 902 1.074 0.172 0.767 1.504 0.678 79.303 
rs7191411 16 10529441 A 896 1.073 0.173 0.765 1.505 0.682 79.771 
rs12597756 16 10381318 A 902 0.933 0.179 0.657 1.324 0.697 81.549 
rs1887432 9 36721326 G 902 0.948 0.144 0.715 1.258 0.712 83.304 
rs6089491 20 59730129 T 899 0.966 0.098 0.797 1.170 0.720 84.193 
rs6133535 20 7986649 G 902 1.069 0.193 0.733 1.560 0.727 85.106 
rs2822757 21 14831122 C 902 1.036 0.107 0.840 1.279 0.739 86.510 
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SNP Chr Position 
Ref 
allele 
No. of 
sample 
OR SE L95 U95 p-value 
Bonferroni 
correction 
rs1864262 2 5777922 G 898 0.971 0.093 0.808 1.166 0.750 87.703 
rs8192166 5 6695356 T 897 1.032 0.100 0.848 1.255 0.754 88.241 
rs731326 23 13438391 C 898 0.974 0.086 0.822 1.153 0.755 88.370 
rs158896 5 167915925 T 900 0.967 0.111 0.779 1.201 0.764 89.341 
rs13419910 2 5757137 G 899 1.028 0.101 0.844 1.254 0.781 91.412 
rs1006286 10 119509000 C 901 0.949 0.205 0.635 1.418 0.798 93.343 
rs195656 16 69604985 A 893 0.964 0.143 0.728 1.277 0.799 93.448 
rs1799932 22 40241471 T 899 0.977 0.095 0.811 1.177 0.806 94.349 
rs6570786 6 147395785 T 900 0.977 0.098 0.806 1.185 0.814 95.180 
rs11161353 15 21655245 T 901 1.033 0.146 0.777 1.374 0.822 96.127 
rs35407548 1 171593970 C 895 0.980 0.106 0.797 1.206 0.851 99.544 
rs2918006 2 231492535 G 901 1.026 0.137 0.784 1.343 0.851 99.567 
rs7920199 10 134078268 G 901 1.022 0.130 0.792 1.317 0.869 101.720 
rs6884552 5 6714966 T 902 1.016 0.100 0.834 1.236 0.877 102.574 
rs2169123 15 21677404 A 902 1.021 0.142 0.774 1.348 0.882 103.136 
rs6981465 8 65612808 T 901 1.021 0.150 0.760 1.370 0.892 104.341 
rs12015040 23 13437789 C 902 0.989 0.086 0.836 1.171 0.897 104.972 
rs6475895 9 26443356 G 897 0.980 0.166 0.708 1.356 0.902 105.569 
rs6997421 8 65643604 A 901 1.026 0.216 0.673 1.566 0.905 105.827 
rs16931326 8 65657887 A 901 0.983 0.225 0.633 1.527 0.939 109.851 
rs2158641 7 48891030 G 891 0.992 0.102 0.812 1.213 0.941 110.085 
rs4392152 18 73915669 C 901 0.993 0.097 0.820 1.202 0.942 110.226 
rs1407467 9 7958906 G 901 1.004 0.096 0.832 1.213 0.964 112.788 
rs11645638 16 77517824 T 901 0.996 0.094 0.828 1.198 0.966 112.999 
rs17237765 6 147378663 0 902 NA NA NA NA NA NA 
NA, not application; OR, odd ratio; SE, standard error 
 
